```
=>  file registry
FILE 'REGISTRY' ENTERED AT 14:03:58 ON 19 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 FEB 2008  HIGHEST RN 1004360-55-7
DICTIONARY FILE UPDATES:  18 FEB 2008  HIGHEST RN 1004360-55-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 14:04:02 ON 19 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 19 Feb 2008  VOL 148 ISS 8
FILE LAST UPDATED: 18 Feb 2008  (20080218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L60
L51           4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  EVERTSSON E?/AU
L52          34 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  INGHARDT T?/AU
L53         536 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LINDBERG J?/AU
L54          23 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LINUSSON A?/AU
L55          30 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  GIORDANETTO F?/AU
L56           3 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L51 AND (L52 OR L53 OR L54 OR
```

```
                L55)
L57           10 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L52 AND (L53 OR L54 OR L55)
L58            4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L53 AND (L54 OR L55)
L59            2 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L54 AND L55
L60           10 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  (L56 OR L57 OR L58 OR L59)


=> d stat que L61
L2           196 SEA FILE=REGISTRY ABB=ON  PLU=ON  (100-46-9/BI OR 1000417-94-6/
                 BI OR 1000490-56-1/BI OR 10102-94-0/BI OR 106792-38-5/BI OR
                 1192-58-1/BI OR 1215-59-4/BI OR 131237-81-5/BI OR 132706-12-8/B
                 I OR 13523-92-7/BI OR 13669-42-6/BI OR 141-82-2/BI OR 141-97-9/
                 BI OR 143679-80-5/BI OR 147-71-7/BI OR 154737-90-3/BI OR
                 156496-64-9/BI OR 1578-96-7/BI OR 15861-36-6/BI OR 171919-36-1/
                 BI OR 17380-18-6/BI OR 175202-93-4/BI OR 175204-81-6/BI OR
                 1810-72-6/BI OR 18529-12-9/BI OR 19012-03-4/BI OR 1953-54-4/BI
                 OR 20507-53-3/BI OR 233-88-5/BI OR 2338-71-8/BI OR 238756-47-3/
                 BI OR 238756-48-4/BI OR 2388-32-1/BI OR 25016-12-0/BI OR
                 25233-47-0/BI OR 271-29-4/BI OR 271-63-6/BI OR 271241-24-8/BI
                 OR 271241-25-9/BI OR 272-49-1/BI OR 27257-15-4/BI OR 274-76-0/B
                 I OR 27421-51-8/BI OR 27643-15-8/BI OR 276862-85-2/BI OR
                 29969-57-1/BI OR 30198-01-7/BI OR 3385-21-5/BI OR 349447-08-1/B
                 I OR 371-40-4/BI OR 372-19-0/BI OR 3779-27-9/BI OR 4002-83-9/BI
                  OR 40053-37-0/BI OR 406204-74-8/BI OR 43192-31-0/BI OR
                 439095-43-9/BI OR 441715-30-6/BI OR 444683-23-2/BI OR 455-14-1/
                 BI OR 477848-00-3/BI OR 477886-95-6/BI OR 482585-36-4/BI OR
                 498-62-4/BI OR 501-53-1/BI OR 50634-05-4/BI OR 50890-83-0/BI
                 OR 5170-68-3/BI OR 52173-35-0/BI OR 52606-02-7/BI OR 52771-21-8
                 /BI OR 536-90-3/BI OR 541-41-3/BI OR 542-92-7/BI OR 5467-57-2/B
                 I OR 5652-13-1/BI OR 58630-07-2/BI OR 6041-50-5/BI OR 6188-43-8
                 /BI OR 6340-55-2/BI OR 636-61-3/BI OR 645400-43-7/BI OR
                 645400-44-8/BI OR 645400-49-3/BI OR 645400-50-6/BI OR 67509-84-
                 6/BI OR 67999-51-3/BI OR 6953-22-6/BI OR 703-61-7/BI OR
                 79-44-7/BI OR 79200-56-9/BI OR 814-68-6/BI OR 827-01-0/BI OR
                 83783-33-9/BI OR 860296-28-2/BI OR 860296-29-3/BI OR 860296-30-
                 6/BI OR 860296-31-7/BI OR 860296-32-8/BI OR 860296-33-9/BI OR
                 860296-34-0/BI OR 860296-35-1/BI OR 860296-37-3/BI OR 860296-39
                 -5/BI OR 860296-41-9/BI OR 860296-42-0/BI OR 860
L3               STR
```




```
Structure attributes must be viewed using STN Express query preparation:
Uploading l3.str
```



ring nodes :
1 2 3 4 5 6 7 8 9 10
ring/chain nodes :
11 12 13
chain bonds :
9-11
ring/chain bonds :
11-13 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
9-11 11-13 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS

L5 STR



Structure attributes must be viewed using STN Express query preparation:
Uploading L5.str



ring nodes :
1 2
ring bonds :
1-2
exact bonds :
1-2

Match level :
1:Atom 2:Atom

L7 8933 SEA FILE=REGISTRY SSS FUL L3 AND L5
L8 STR



Structure attributes must be viewed using STN Express query preparation:
Uploading L8.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-13 11-15 12-16 12-14
13-14 15-16
exact/norm bonds :
9-11
exact bonds :
11-13 11-15 12-16 12-14 13-14 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
isolated ring systems :
containing 11 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom

```
L10         3365 SEA FILE=REGISTRY SUB=L7 SSS FUL L8
L18              STR
```



Structure attributes must be viewed using STN Express query preparation:
Uploading L18.str




```
chain nodes :
16  17
ring nodes :
1  2  3  4  5  6  7  8  9  10
ring/chain nodes :
11  12  13
chain bonds :
9-11  12-16  16-17
ring/chain bonds :
11-13  12-13
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10
exact/norm bonds :
9-11  11-13  12-13  12-16  16-17
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS  16:CLASS  17:Atom
```

```
L20         3929 SEA FILE=REGISTRY SUB=L7 SSS FUL L18
L21         2293 SEA FILE=REGISTRY ABB=ON  PLU=ON  L20 NOT L10
L24           39 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND L2
L25            2 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L24
L51            4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  EVERTSSON E?/AU
```

```
L52          34 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  INGHARDT T?/AU
L53         536 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LINDBERG J?/AU
L54          23 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LINUSSON A?/AU
L55          30 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  GIORDANETTO F?/AU
L61           2 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  (L51 OR L52 OR L53 OR L54 OR
                 L55) AND L25


=> d stat que L63
L3              STR
```




```
Structure attributes must be viewed using STN Express query preparation:
Uploading L3.str
```




```
ring nodes :
1  2  3  4  5  6  7  8  9  10
ring/chain nodes :
11  12  13
chain bonds :
9-11
ring/chain bonds :
11-13  12-13
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10
exact/norm bonds :
9-11  11-13  12-13
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS



L5              STR
```



Structure attributes must be viewed using STN Express query preparation:
Uploading L5.str



ring nodes :
1 2
ring bonds :
1-2
exact bonds :
1-2

Match level :
1:Atom 2:Atom

L7 8933 SEA FILE=REGISTRY SSS FUL L3 AND L5
L29 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading L29.str







chain nodes :
11 13 14 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 33 34
35 36 38 39 40 41 43 45 46 47 49 50 52 53 54 67
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
9-67 11-13 13-16 14-16 14-17 18-19 19-20 20-21 22-23 23-24 24-25 26-27
27-28 29-30 30-31 31-33 33-34 35-36 36-38 38-39 40-41 41-43 43-45 46-47
47-49 50-52
53-54
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
9-67 11-13 13-16 14-16 14-17 19-20 20-21 22-23 23-24 29-30 30-31 31-33
33-34 35-36 36-38 38-39 40-41 41-43 43-45 46-47 47-49 50-52 53-54
exact bonds :
18-19 24-25 26-27 27-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

G1:CH2,O

G2:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 14:CLASS 16:Atom 17:CLASS 18:CLASS 19:Atom 20:CLASS
21:CLASS 22:CLASS 23:CLASS
24:Atom 25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 31:Atom

```
33:CLASS  34:CLASS
35:CLASS  36:Atom  38:CLASS  39:CLASS  40:CLASS  41:CLASS  43:Atom  45:CLASS
46:CLASS  47:Atom
49:CLASS  50:Atom  52:CLASS  53:Atom  54:CLASS  67:CLASS
Generic attributes :
31:
Number of Hetero Atoms : Exactly 1
36:
Number of Hetero Atoms : Exactly 1
43:
Number of Hetero Atoms : Exactly 1
47:
Number of Hetero Atoms : Exactly 1
50:
Type of Ring System    : Polycyclic
53:
Type of Ring System    : Polycyclic

Element Count :
Node 31: Limited
    O,O1

Node 36: Limited
    O,O1

Node 43: Limited
    O,O1

Node 47: Limited
    O,O1

Node 50: Limited
    N,N1
    C,C2-9

Node 53: Limited
    N,N1
    C,C2-9




L31        1356 SEA FILE=REGISTRY SUB=L7 SSS FUL L29
L32          85 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L31
L33          17 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  MCH ANTAGONIST/TI
L34           4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L32 AND L33
L36             TRANSFER  PLU=ON  L34 1- RN :    3820 TERMS
L37        3820 SEA FILE=REGISTRY ABB=ON  PLU=ON  L36
L38        1043 SEA FILE=REGISTRY ABB=ON  PLU=ON  L37 AND L31
L39         313 SEA FILE=REGISTRY ABB=ON  PLU=ON  L31 NOT L38
L41          81 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L39
L42          42 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L32 AND P/DT
L43          43 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L32 NOT L42
L44          36 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L43 AND PY<2005
L45          25 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L42 AND PD<20040107
L46          33 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L42 AND PRD<20040107
L47          27 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L42 AND AD<20040107
L48          70 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  (L44 OR L45 OR L46 OR L47)
```

```
L49          67 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L41 AND L48
L51           4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  EVERTSSON E?/AU
L52          34 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  INGHARDT T?/AU
L53         536 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LINDBERG J?/AU
L54          23 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LINUSSON A?/AU
L55          30 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  GIORDANETTO F?/AU
L63           1 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  (L51 OR L52 OR L53 OR L54 OR
                L55) AND L49


=> s L60 or L61 or L63
L64         10 L60 OR L61 OR L63

=> d ibib abs hitstr L64 1-10

L64  ANSWER 1 OF 10  ZCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2007:746464  ZCAPLUS  Full-text
DOCUMENT NUMBER:          147:314167
TITLE:                    Discovery of cyclopentane- and cyclohexane-trans-1,3-
                          diamines as potent melanin-concentrating hormone
                          receptor 1 antagonists
AUTHOR(S):                Giordanetto, Fabrizio; Karlsson, Olle; Lindberg,
                          Jan; Larsson, Lars-Olof; Linusson, Anna;
                          Evertsson, Emma; Morgan, David G. A.; Inghardt, Tord
CORPORATE SOURCE:         Lead Generation, Computational Chemistry, AstraZeneca
                          R&D Moelndal, Moelndal, SE-431 83, Swed.
SOURCE:                   Bioorganic & Medicinal Chemistry Letters (2007),
                          17(15), 4232-4241
                          CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER:                Elsevier Ltd.
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
OTHER SOURCE(S):          CASREACT 147:314167
AB    The authors herein report the optimization of cyclopentane- and cyclohexane-
      1,3-diamine derivs. as novel and potent MCH-R1 antagonists. Structural
      modifications of the 2-amino-quinoline and thiophene moieties found in the
      initial lead compound served to improve its metabolic stability profile and
      MCH-R1 affinity, and revealed unprecedented SAR when compared to other 2-
      amino-quinoline-containing MCH-R1 antagonists.
IT    860296-65-7 860296-66-8
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
         (discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as
         potent melanin-concentrating hormone receptor 1 antagonists)
RN    860296-65-7  ZCAPLUS
CN    Bicyclo[2.2.1]heptane-2,6-diamine, N6-(6-methoxy-4-methyl-2-quinolinyl)-N2-
      (3-thienylmethyl)-, (1S,2S,4R,6S)-  (CA INDEX NAME)

Absolute stereochemistry.
```



RN 860296-66-8 ZCAPLUS
CN Bicyclo[2.2.1]heptane-2,6-diamine, N6-(6-methoxy-4-methyl-2-quinolinyl)-N2-(3-thienylmethyl)-, (1R,2S,4S,6S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L64 ANSWER 2 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:87243 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:184498
TITLE: Thienoheterocycles, processes for preparing them, pharmaceutical compositions containing them, and their use in the treatment of obesity, psychiatric and neurological disorders
INVENTOR(S): Giordanetto, Fabrizio; Inghardt, Tord
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 34pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007011286	A1	20070125	WO 2006-SE880	20060713

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: SE 2005-1690 A 20050715
SE 2005-1877 A 20050824
OTHER SOURCE(S): MARPAT 146:184498
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. I, processes for preparing them, pharmaceutical compns. containing them, and their pharmaceutical use. Compds. I are used as MCHr1 (melanin-concentrating hormone receptor 1) antagonists, useful in treating obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurol. disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease and pain related disorders. In compds. I, A, B, D, and E represent C or N; XY represents N=C, C=N, NH-CO, or N=N; Z represents NH, NMe, NHC(O), S, SO, SO2, CH2, or O; R1 and R2 independently represent H, C1-3 (fluoro)alkyl(oxy), Cl, or F; R3 represents H, F, Cl, OH, (un)substituted C1-3 alkyl(oxy); R4 and R5 independently represent H, oxo, F, OH, CH2OH, C1-3 (alk|acyl)oxy; both R4 and R5 are not H; m is 1 or 2; including tautomers, optical isomers, racemates, and pharmaceutically acceptable salts. For instance, hydrolysis of Me 3-amino-5-(4-chlorophenyl)thiophene-2-carboxylate (II) (98%) followed by condensation with 1-[2-(4-amino-2- methoxyphenoxy)ethyl]pyrrolidin-3-ol (III) (48%) and heterocyclization in the presence of sodium nitrite (67%) gave the invention compound IV. Compds. I had an IC50 of ≤ 100 nM in a human MCHr1 binding assay, and preferred compds. had an activity of ≤ 20 nM (e.g., an IC50 value of 1.0 nM was obtained for compound IV). Compound IV also had IC50 > 5 μM in an hERG assay, indicating greater selectivity for MCHr1. I were active in a diet-induced obesity mouse model, inducing significant decrease in body weight, with the major effect being via a reduction in fat mass (no data).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L64 ANSWER 3 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:86227 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:184480
TITLE: Preparation of thieno[3,2-d]pyrimidin-4(3H)-one derivatives as MCH agonists
INVENTOR(S): Giordanetto, Fabrizio; Inghardt, Tord; Nordberg, Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 44pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007011284	A1	20070125	WO 2006-SE878	20060713

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: SE 2005-1688 A 20050715
SE 2005-1879 A 20050824

SE 2005-2568 A 20051123

OTHER SOURCE(S): MARPAT 146:184480

GI



I



II

AB Title compds. represented by the formula I [wherein A, B, C, D = independently C or N; X-Y = N=C, C=N, N=N or X = NH and Y = C=O; R1, R2 = independently H, alkyl, alkoxy, Cl or F; R3 = H, F, Cl, CN, etc.; R4, R5 = independently H, oxo, OH, etc.; m = 0 or 1; and their tautomers, optical isomers and racemates thereof as well as pharmaceutically acceptable salts or solvates thereof] were prepared as MCH (Melanin concentrating hormone) agonists. For example, II was provided in a multi-step synthesis starting from Me 3-amino-5-(4-chlorophenyl)thiophene-2-carboxylate. The biol. assay for MCHr1 receptor radioligand binding was described, and II had an IC50 exceeding 5 μM in the abovementioned assay. Thus, I and their pharmaceutical compns. are useful for the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurol. disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L64 ANSWER 4 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:83866 ZCAPLUS Full-text

DOCUMENT NUMBER: 146:163147

TITLE: Benzimidazolyl-substituted thienoheterocycles, processes for preparing them, pharmaceutical compositions containing them, and their use in the treatment of obesity, psychiatric and neurological disorders

INVENTOR(S): Giordanetto, Fabrizio; Inghardt, Tord

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 30pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2007011285	A1	20070125	WO 2006-SE879	20060713

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: SE 2005-1689 A 20050715
SE 2005-1878 A 20050824

OTHER SOURCE(S): MARPAT 146:163147
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. I, processes for preparing them, pharmaceutical compns. containing them, and their pharmaceutical use. Compds. I are used as MCHr1 (melanin-concentrating hormone receptor 1) antagonists, useful in treating obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurol. disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease and pain related disorders. In compds. I, A and B represent C or N; XY represents C=N, NHCO, or N=N; R1 and R2 independently represent H, C1-3 (fluoro)alkyl(oxy), Cl, or F; R3 represents H or (un)substituted C1-3 alkyl; R4 and R5 independently represent H or (un)substituted C1-3 alkyl; or NR4R5 represents (un)substituted pyrrolidino, piperidino, piperazino, or morpholino; including tautomers, optical isomers, racemates, and pharmaceutically acceptable salts. For instance, alkaline hydrolysis of Me 3-amino-5-(4-chlorophenyl)thiophene-2-carboxylate (II) (98%) followed by condensation with N2,N2,1-trimethyl-1H-benzimidazole-2,6-diamine (III) (69%) and heterocyclization in the presence of sodium nitrite (39%) gave the invention compound IV. Compds. I had an IC50 of ≤ 100 nM in a human MCHr1 binding assay, and preferred compds. had an activity of ≤ 20 nM (e.g., an IC50 value of 2 nM was obtained for compound IV). Compound IV also had IC50 > 5 μM in an hERG assay, indicating greater selectivity for MCHr1. I were active in a diet-induced obesity mouse model, inducing significant decrease in body weight, with the major effect being via a reduction in fat mass (no data).

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L64 ANSWER 5 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:859323 ZCAPLUS Full-text
TITLE: Discovery of novel and potent melanin-concentrating hormone receptor 1 antagonists through structure-based design
AUTHOR(S): Giordanetto, Fabrizio; Lindberg, Jan; Karlsson, Olle; Inghardt, Tord
CORPORATE SOURCE: Medicinal Chemistry, AstraZeneca R&D Molndal, Moelndal, SE-43183, Swed.
SOURCE: Abstracts of Papers, 232nd ACS National Meeting, San

Francisco, CA, United States, Sept. 10-14, 2006 (2006) , COMP-410. American Chemical Society: Washington, D. C.
CODEN: 69IHRD
DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)
LANGUAGE: English
AB High-throughput screening (HTS) identified several hits against the Melanin-concentrating Hormone Receptor 1 (MCH-1R). Homol. modeling coupled to docking and scoring was employed to retrospectively analyze the HTS data and to assess the value of structure-based virtual screening (VS) in the context of a G-protein-coupled receptor (GPCR). A number of interesting observations on the importance of protein flexibility and scoring emerged from the retrospective VS study. Following its successful validation, docking was used extensively during the idea generation and compound prioritisation steps of the discovery phase. Here, custom-made, interaction-based scoring functions and post-docking filters proved particularly helpful. As a result, the initial hits were optimized into metabolically stable, single-digit nanomolar MCH-1R antagonists.

L64 ANSWER 6 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:631401 ZCAPLUS Full-text
DOCUMENT NUMBER: 145:103568
TITLE: Preparation of heterocycles as melanin concentrating hormone receptor 1 (MCHR1) antagonists.
INVENTOR(S): Egner, Bryan; Giordanetto, Fabrizio; Inghardt, Tord
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006068594	A1	20060629	WO 2005-SE1966	20051219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1831194	A1	20070912	EP 2005-819128	20051219
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2007DN04514	A	20070831	IN 2007-DN4514	20070613
CN 101124216	A	20080213	CN 2005-80048470	20070820
PRIORITY APPLN. INFO.:			SE 2004-3119 A	20041221
			SE 2005-1686 A	20050715
			WO 2005-SE1966 W	20051219

OTHER SOURCE(S): MARPAT 145:103568
GI



I

AB Title compds. [I; A = N, (substituted) alkyl, alkenyl, cycloalkyl, adamantyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyridinyl, etc.; X = bond, NR3; R1, R2 = H, (substituted) alkyl, alkenyl, cycloalkyl, carbamoyl, Ph, naphthyl, heterocyclyl; Y = NR3, CR5R6, bond; R3, R5, R6 = H, alkyl; R4 = H, F; D, E = null, CH2; Z = (substituted) thienyl, furyl, pyrrolyl; W = (substituted) Ph, pyridyl; with provisos], were prepared for the treatment of obesity, type II diabetes, metabolic syndrome, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, and related conditions. Thus, 1-[[1-[4- (trifluoromethyl)phenyl]-1H-pyrrol-3-yl]methyl]piperidin-4-amine (preparation given), Ph2CHCO2H, K2CO3, and EDC were stirred in CH2Cl2/H2O for 18 h at room temperature to give 2,2-diphenyl-N-[1-[[1-[4-(trifluoromethyl)phenyl]-1H- pyrrol-3-yl]methyl]piperidin-4-yl]acetamide. The latter showed IC50 = 0.042 μM in a MCHr1 functional assay.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L64 ANSWER 7 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1042233 ZCAPLUS Full-text
DOCUMENT NUMBER: 143:326221
TITLE: Preparation of 4-amido-N-substituted piperidine derivatives as CCR3 modulators and melanin concentrating hormone receptor 1 (MCH1r) ligands
INVENTOR(S): Brickmann, Kay; Egner, Bryan J.; Giordanetto, Fabrizio; Inghardt, Tord; Linusson Jonsson, Anna; Ponten, Fritiof
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090330	A1	20050929	WO 2005-SE411	20050321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005223727	A1	20050929	AU 2005-223727	20050321
CA 2558058	A1	20050929	CA 2005-2558058	20050321

EP 1730136	A1	20061213	EP 2005-722252		20050321
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU					
CN 1934099	A	20070321	CN 2005-80009157		20050321
BR 2005008952	A	20070814	BR 2005-8952		20050321
JP 2007530533	T	20071101	JP 2007-504912		20050321
IN 2006DN05015	A	20070427	IN 2006-DN5015		20060831
MX 2006PA10754	A	20061215	MX 2006-PA10754		20060920
KR 2007007341	A	20070115	KR 2006-721670		20061019
NO 2006004752	A	20061120	NO 2006-4752		20061020
PRIORITY APPLN. INFO.:			SE 2004-718	A	20040322
			SE 2004-2780	A	20041112
			WO 2005-SE411	W	20050321

OTHER SOURCE(S): CASREACT 143:326221; MARPAT 143:326221

GI



I



II

AB Title compds. I [X = Ph, naphthyl, pyrrolyl, etc.; Y = alkoxy, thioalkoxy, etc.; R1 = H, alkyl; A, B = (CH2)0-1; R2 = H or when A, B are identical represents CH2, R2 = H, F; Z = Ph, thienyl, furyl, pyridyl, etc.; W = Ph, thienyl, furyl, pyridyl, etc.] are prepared For instance, 2-(3-chlorophenoxy)-N-[1-[(1-phenyl-1H-pyrrol-3-yl)methyl]piperidin-4- yl]acetamide (II) is prepared from 2-(3-chlorophenoxy)-N-(piperidin-4- yl)acetamide and 1-phenyl-1H-pyrrole-3-carboxaldehyde (CH2Cl2, NaHB(OAc)3). Example compds. exhibited activity in the melanin concentrating hormone receptor assay with IC50 less than 1 μM. I are useful in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurol. disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L64 ANSWER 8 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:696888 ZCAPLUS Full-text

DOCUMENT NUMBER: 143:194018

TITLE: Preparation of substituted diaminoquinazolines as MCH1

receptor ligands for use in the treatment of neurological disorders

INVENTOR(S): Evertsson, Emma; Inghardt, Tord; Lindberg, Jan; Linusson, Anna

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070902	A1	20050804	WO 2005-SE10	20050105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1706388	A1	20061004	EP 2005-704684	20050105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1906176	A	20070131	CN 2005-80001883	20050105
JP 2007517869	T	20070705	JP 2006-549186	20050105
IN 2006DN03552	A	20070831	IN 2006-DN3552	20060620
US 2007185119	A1	20070809	US 2006-596995	20061122

PRIORITY APPLN. INFO.: GB 2004-193 A 20040107
WO 2005-SE10 W 20050105

OTHER SOURCE(S): CASREACT 143:194018; MARPAT 143:194018

GI



I

AB Title compds. I [R1 = alkoxy, alkyl, halo, etc.; n = 0-3; R2 = H, CN, alkyl, etc.; R3 = H, alkyl; L1 = (alkyl)cycloalkyl with provisions; R4 = H, alkyl; L2 = alkylene, etc.; R5 = Ph, naphthyl, heterocyclyl, etc.] are prepared For instance, trans-2-[[3-((benzothiophen-3- yl)amino)cyclohexyl]amino]-4-(dimethylamino)quinazoline is prepared from trans-2-[[3-aminocyclohexyl]amino]-4-(dimethylamino)quinazoline (preparation given) and benzo[b]thiophene-3-carboxaldehyde (MeOH, NaBH3CN). Compds. of the invention exhibit IC50 < 2 μM for the melanin concentrating hormone receptor 1. I are useful in the treatment of obesity, psychiatric disorders, cognitive

disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurol. disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L64 ANSWER 9 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:638850 ZCAPLUS Full-text
DOCUMENT NUMBER: 143:172772
TITLE: Preparation of quinoline derivatives as MCH modulators
INVENTOR(S): Evertsson, Emma; Ingbardt, Tord; Lindberg, Jan; Linusson, Anna; Giordanetto, Fabrizio
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005066132	A1	20050721	WO 2005-SE4		20050105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1706384	A1	20061004	EP 2005-704678		20050105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1906169	A	20070131	CN 2005-80001921		20050105
JP 2007517868	T	20070705	JP 2006-549184		20050105
IN 2006DN03548	A	20070817	IN 2006-DN3548		20060620
US 2007185079	A1	20070809	US 2006-596994		20061122
PRIORITY APPLN. INFO.:			GB 2004-196	A	20040107
			GB 2004-25209	A	20041116
			WO 2005-SE4	W	20050105

OTHER SOURCE(S): CASREACT 143:172772; MARPAT 143:172772
GI



I



II

AB Title compds. I [R1 = (un)substituted alkoxy, alkyl, NRaRb, etc.; R2 = (un)substituted alkoxy, alkyl, NRaRb, etc.; Ra and Rb independently = H, alkyl or Ra and Rb together with the nitrogen to which they are attached from a 3-7 membered heterocycle optionally including O; n = 0-3; m = 0-1; R3 = H or alkyl; L1 = (CH2)pcycloalkyl(CH2)q with provisions; p and q independently = 0-1; R4 = H or (un)substituted alkyl; L2 = (un)substituted (CH2)x or 5-6 membered carbocycle fused to R5; x = 1-3; R5 = (un)substituted Ph, naphthyl, heterocycle, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as melanin concentrating hormone (MCH) modulators. Thus, e.g., II was prepared by palladium catalyzed coupling of benzyl[(1R,2S,4S,6S)-6-aminobicyclo[2.2.1]hept-2- yl]benzylcarbamate (preparation given) with 2-chloro-6-methoxy-4- methylquinoline followed by deprotection and subsequent reductive alkylation with thiophene-3-carbaldehyde. The activity of I was evaluated in MCH1 receptor radioligand binding assays and it was revealed that compds. of the invention displayed IC50 values of less than 2 μM. I as MCH modulator should prove useful in the treatment of obesity, anxiety and depression. Pharmaceutical compns. comprising I are disclosed.

IT 860296-34-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinoline derivs. as MCH modulators)

RN 860296-34-0 ZCAPLUS

CN 1,3-Cyclohexanediamine, N-(6-chloro-2-quinolinyl)-N'-(3-thienylmethyl)-(9CI) (CA INDEX NAME)



IT 860296-28-2P 860296-29-3P 860296-30-6P
860296-31-7P 860296-32-8P 860296-33-9P
860296-35-1P 860296-37-3P 860296-41-9P

860296-42-0P 860296-43-1P 860296-44-2P
860296-46-4P 860296-47-5P 860296-53-3P
860296-55-5P 860296-57-7P 860296-58-8P
860296-59-9P 860296-60-2P 860296-62-4P
860296-63-5P 860296-64-6P 860296-65-7P
860296-66-8P 860296-67-9P 860296-68-0P
860296-69-1P 860296-70-4P 860296-71-5P
860296-72-6P 860296-73-7P 860296-74-8P
860296-75-9P 860296-76-0P 860296-77-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline derivs. as MCH modulators)

RN 860296-28-2 ZCAPLUS
CN 4-Quinolinecarboxamide, N,N-dimethyl-2-[[3-[[[5-(2-pyridinyl)-2-thienyl]methyl]amino]cyclohexyl]amino]- (CA INDEX NAME)



RN 860296-29-3 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(6-chloro-4-methyl-2-quinolinyl)-N'-[(1-methyl-1H-indol-3-yl)methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-30-6 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(6-fluoro-4-methyl-2-quinolinyl)-N'-(3-thienylmethyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 860296-31-7 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(6-fluoro-4-methyl-2-quinolinyl)-N'-(3-thienylmethyl)-, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 860296-32-8 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(6-fluoro-4-methoxy-2-quinolinyl)-N'-(3-thienylmethyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-33-9 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-fluoro-4-methyl-2-quinolinyl)-N'-[(1-methyl-1H-indol-3-yl)methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-35-1 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(6-chloro-2-quinolinyl)-N'-[(1-methyl-1H-pyrrol-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 860296-37-3 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(6-chloro-2-quinolinyl)-N'-(3-quinolinylmethyl)-(9CI) (CA INDEX NAME)



RN 860296-41-9 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-[(4-chloro-1-methyl-1H-pyrazol-3-yl)methyl]-N'-(6-methoxy-4-methyl-2-quinolinyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-42-0 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)-N'-(1,2,3-thiadiazol-4-ylmethyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-43-1 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)-N'-[[5-(2-pyridinyl)-2-thienyl]methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-44-2 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-[[1-[(2-chloro-5-thiazolyl)methyl]-1H-indol-3-yl]methyl]-N'-(6-methoxy-4-methyl-2-quinolinyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-46-4 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)-N'-[[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-47-5 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-([2,2'-bithiophen]-5-ylmethyl)-N'-(6-methoxy-4-methyl-2-quinolinyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-53-3 ZCAPLUS
CN 3-Azabicyclo[3.2.1]octan-8-amine, 3-(6-methoxy-4-methyl-2-quinolinyl)-N-methyl-N-(3-thienylmethyl)- (CA INDEX NAME)



RN 860296-55-5 ZCAPLUS
CN 2-Quinolinamine, 6-methoxy-4-methyl-N-[[(1R,2S)-2-[[(1-methyl-1H-indol-3-yl)methyl]amino]cyclopentyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-57-7 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-fluoro-4-methyl-2-quinolinyl)-N'-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-58-8 ZCAPLUS
CN 1H-Indole-6-carbonitrile, 3-[[[(1S,3S)-3-[(7-methoxy-4-methyl-2-quinolinyl)amino]cyclopentyl]amino]methyl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-59-9 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-fluoro-4-methyl-2-quinolinyl)-N'-[(1-methyl-1H-indol-2-yl)methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-60-2 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-fluoro-4-methyl-2-quinolinyl)-N'-[[1-[3-(trifluoromethyl)-2-pyridinyl]-1H-indol-3-yl]methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-62-4 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(7-methoxy-4-methyl-2-quinolinyl)-N'-[[1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-63-5 ZCAPLUS
CN 1H-Indole-5-carbonitrile, 3-[[[(1S,3S)-3-[(7-methoxy-4-methyl-2-quinolinyl)amino]cyclopentyl]amino]methyl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-64-6 ZCAPLUS
CN 1,3-Cyclopentanediamine, N1-[[5-(difluoromethoxy)-1-methyl-1H-indol-3-yl]methyl]-N3-(7-methoxy-4-methyl-2-quinolinyl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-65-7 ZCAPLUS
CN Bicyclo[2.2.1]heptane-2,6-diamine, N6-(6-methoxy-4-methyl-2-quinolinyl)-N2-

(3-thienylmethyl)-, (1S,2S,4R,6S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-66-8 ZCAPLUS
CN Bicyclo[2.2.1]heptane-2,6-diamine, N6-(6-methoxy-4-methyl-2-quinolinyl)-N2-(3-thienylmethyl)-, (1R,2S,4S,6S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-67-9 ZCAPLUS
CN Bicyclo[2.2.1]heptane-2,6-diamine, N-(7-methoxy-4-methyl-2-quinolinyl)-N'-[(1-methyl-1H-indol-3-yl)methyl]-, (1S,2S,4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-68-0 ZCAPLUS
CN 2-Quinolinamine, 6-methoxy-4-methyl-N-[(1S,2R)-2-[[[(1-methyl-1H-indol-3-yl)methyl]amino]methyl]cyclopentyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-69-1 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(7-methoxy-4-methyl-2-quinolinyl)-N'-[(1-methyl-1H-pyrrolo[3,2-h]quinolin-3-yl)methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-70-4 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-fluoro-4-methyl-2-quinolinyl)-N'-[(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-71-5 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(7-methoxy-4-methyl-2-quinolinyl)-N'-[(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-72-6 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-fluoro-4-methyl-2-quinolinyl)-N'-(imidazo[1,2-a]pyridin-3-ylmethyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-73-7 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(7-methoxy-4-methyl-2-quinolinyl)-N'-[[1-methyl-5-(phenylmethoxy)-1H-indol-3-yl]methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-74-8 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(7-methoxy-4-methyl-2-quinolinyl)-N'-[[3-(trifluoromethoxy)phenyl]methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-75-9 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(2,1,3-benzothiadiazol-4-ylmethyl)-N'-(7-methoxy-4-methyl-2-quinolinyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-76-0 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-N'-(7-methoxy-4-methyl-2-quinolinyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860296-77-1 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-[(2-bromo-4-methoxyphenyl)methyl]-N'-(7-methoxy-4-methyl-2-quinolinyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 860297-37-6P 860297-41-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoline derivs. as MCH modulators)
RN 860297-37-6 ZCAPLUS
CN Carbamic acid, [(1R,2S,4S,6S)-6-[(6-methoxy-4-methyl-2-quinolinyl)amino]bicyclo[2.2.1]hept-2-yl](phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860297-41-2 ZCAPLUS
CN Carbamic acid, [(1R,2S,4S,6S)-6-[(7-methoxy-4-methyl-2-quinolinyl)amino]bicyclo[2.2.1]hept-2-yl](phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L64 ANSWER 10 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:41275 ZCAPLUS Full-text
DOCUMENT NUMBER: 140:93940
TITLE: Preparation of N-(cycloalkyl, aryl or

heteroaryl)-N'-(quinolin-2-yl)alkyldiamines as melanin concentrating hormone receptor 1 (MCH1R) antagonists

INVENTOR(S): Ray, Asim Kumar; Sigfridsson, Emma Margareta; Linusson, Anna Stina Maria; Sandberg, Pernilla Marie; Inghardt, Tord; Svensson, Anette Marie; Brickmann, Kay

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004726	A1	20040115	WO 2003-GB2884	20030704 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491835	A1	20040115	CA 2003-2491835	20030704 <--
AU 2003281194	A1	20040123	AU 2003-281194	20030704 <--
BR 2003012312	A	20050412	BR 2003-12312	20030704 <--
EP 1528924	A1	20050511	EP 2003-740771	20030704 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1665502	A	20050907	CN 2003-816074	20030704 <--
JP 2006501186	T	20060112	JP 2004-518963	20030704 <--
NO 2004005528	A	20050404	NO 2004-5528	20041217 <--
IN 2004DN04072	A	20050401	IN 2004-DN4072	20041221 <--
ZA 2005000030	A	20051111	ZA 2005-30	20050103 <--
US 2006247439	A1	20061102	US 2005-520372	20050104 <--
MX 2005PA00336	A	20050331	MX 2005-PA336	20050105 <--
PRIORITY APPLN. INFO.:			SE 2002-2134 A	20020708 <--
			WO 2003-GB2884 W	20030704 <--

OTHER SOURCE(S): MARPAT 140:93940

GI



I

AB The title compds. (I) [R1, R2 = optionally fluorinated C1-4 alkoxy or C1-4 alkyl; m, n = 0, 1; R3 = H, C1-4 alkyl group; L1 = (CH2)r (wherein r = 2, 3); L1 = a cyclohexyl group wherein the two nitrogens bearing R3 and R4, resp., are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of

the cyclohexyl group; or L1 = a cyclopentyl group wherein the two nitrogens bearing R3 and R4, resp., are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group and addnl. when R5 = 9, 10-methanoanthracen-9(10H)-yl the group -L1-N(R4)- together represents a piperidyl ring which is linked to L2 through the piperidinyl nitrogen and to N-R3 via the 4 position of the piperidyl ring with the proviso that when R5 = 9,10-methanoanthracen-9(10H)-yl then r = only 2; R4 = H, (un)substituted C1-4 alkyl; L2 = a bond, (un)substituted (CH2)s (s = 1, 2, 3) wherein the alkylene chain is optionally substituted by one or more of the following] as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof are prepared These compds., e.g. N-(9,10-Methanoanthracen-9(10H)-ylmethyl)-N-(quinolin-2-yl)-1,2- ethanediamine, N-(6-Methoxy-4-methyl-2-quinolinyl)-N'-(3-thienylmethyl)- 1,3-propanediamine, and N-[(1-Acetyl-1H-indol-3-yl)methyl]-N'-(6-methoxy-4- methyl-2-quinolinyl)-1,3-propanediamine, are useful for the treatment of obesity, psychiatric disorders, anxiety, anxio-depressive disorders, depression, bipolar disorder, attention deficit hyperactivity disorder (ADHD), cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurol. disorders and pain related disorders.

IT 645400-39-1P, N-Quinolin-2-ylcyclohexane-1,4-diamine
645400-40-4P, N-Quinolin-2-ylcyclohexane-1,3-diamine
645400-45-9P, N-(6-Methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine 645400-46-0P, N-(4-Methylquinolin-2-yl)cyclohexane-1,3-diamine 645400-49-3P 645400-50-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of N-(cycloalkyl, aryl or heteroaryl)-N'-(quinolinyl)alkyldiamines as melanin concentrating hormone receptor 1 (MCH1R)
antagonists for treatment of prophylaxis of MCH1R-related diseases)

RN 645400-39-1 ZCAPLUS
CN 1,4-Cyclohexanediamine, N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 645400-40-4 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 645400-45-9 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 645400-46-0 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(4-methyl-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 645400-49-3 ZCAPLUS
CN Carbamic acid, [(1S,3S)-3-[(6-methoxy-4-methyl-2-quinolinyl)amino]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645400-50-6 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 645399-85-5P 645399-87-7P 645399-89-9P
645399-98-0P 645400-09-5P, N-[(3,4-Dichlorophenyl)methyl]-N'-(2-quinolinyl)-1,4-cyclohexanediamine
645400-14-2P 645400-26-6P 645400-27-7P
645400-28-8P 645400-29-9P 645400-30-2P

645400-31-3P 645400-32-4P 645400-33-5P
645400-34-6P 645400-35-7P 645400-36-8P
645400-37-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(cycloalkyl, aryl or heteroaryl)-N'-(quinolinyl)alkyldiamines as melanin concentrating hormone receptor 1 (MCH1R)
antagonists for treatment of prophylaxis of MCH1R-related diseases)

RN 645399-85-5 ZCAPLUS
CN 1,4-Cyclohexanediamine, N-(9,10-methanoanthracen-9(10H)-ylmethyl)-N'-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 645399-87-7 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(9,10-methanoanthracen-9(10H)-ylmethyl)-N'-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 645399-89-9 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-2-quinolinyl-N'-(3-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 645399-98-0 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-[(3,4-dichlorophenyl)methyl]-N'-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 645400-09-5 ZCAPLUS
CN 1,4-Cyclohexanediamine, N-[(3,4-dichlorophenyl)methyl]-N'-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 645400-14-2 ZCAPLUS
CN 1,4-Cyclohexanediamine, N-2-quinolinyl-N'-(3-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 645400-26-6 ZCAPLUS
CN 1H-Indole-3-methanamine, 1-acetyl-N-[3-(2-quinolinylamino)cyclohexyl]- (9CI) (CA INDEX NAME)



RN 645400-27-7 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)-N'-(3-thienylmethyl)-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645400-28-8 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)-N'-[(1-methyl-1H-indol-3-yl)methyl]-, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645400-29-9 ZCAPLUS
CN 1H-Indole-3-methanamine, 1-acetyl-N-[3-[(6-methoxy-4-methyl-2-quinolinyl)amino]cyclohexyl]- (9CI) (CA INDEX NAME)



RN 645400-30-2 ZCAPLUS

CN 1,3-Cyclohexanediamine, N-(1H-indol-3-ylmethyl)-N'-(6-methoxy-4-methyl-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 645400-31-3 ZCAPLUS

CN 1,3-Cyclohexanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)-N'-(3-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 645400-32-4 ZCAPLUS

CN 1,3-Cyclohexanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)-N'-[(1-methyl-1H-indol-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 645400-33-5 ZCAPLUS

CN 1,3-Cyclohexanediamine, N-(2-benzofuranylmethyl)-N'-(6-methoxy-4-methyl-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 645400-34-6 ZCAPLUS

CN 1,3-Cyclohexanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)-N'-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 645400-35-7 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(4-methyl-2-quinolinyl)-N'-(3-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 645400-36-8 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)-N'-(3-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 645400-37-9 ZCAPLUS
CN 1,3-Cyclopentanediamine, N-(6-methoxy-4-methyl-2-quinolinyl)-N'-[(1-methyl-1H-indol-3-yl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file registry
FILE 'REGISTRY' ENTERED AT 14:05:10 ON 19 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 FEB 2008  HIGHEST RN 1004360-55-7
DICTIONARY FILE UPDATES:  18 FEB 2008  HIGHEST RN 1004360-55-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 14:05:16 ON 19 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 19 Feb 2008  VOL 148 ISS 8
FILE LAST UPDATED: 18 Feb 2008  (20080218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L25
L2          196 SEA FILE=REGISTRY ABB=ON  PLU=ON  (100-46-9/BI OR 1000417-94-6/
                BI OR 1000490-56-1/BI OR 10102-94-0/BI OR 106792-38-5/BI OR
                1192-58-1/BI OR 1215-59-4/BI OR 131237-81-5/BI OR 132706-12-8/B
                I OR 13523-92-7/BI OR 13669-42-6/BI OR 141-82-2/BI OR 141-97-9/
                BI OR 143679-80-5/BI OR 147-71-7/BI OR 154737-90-3/BI OR
```

156496-64-9/BI OR 1578-96-7/BI OR 15861-36-6/BI OR 171919-36-1/BI OR 17380-18-6/BI OR 175202-93-4/BI OR 175204-81-6/BI OR 1810-72-6/BI OR 18529-12-9/BI OR 19012-03-4/BI OR 1953-54-4/BI OR 20507-53-3/BI OR 233-88-5/BI OR 2338-71-8/BI OR 238756-47-3/BI OR 238756-48-4/BI OR 2388-32-1/BI OR 25016-12-0/BI OR 25233-47-0/BI OR 271-29-4/BI OR 271-63-6/BI OR 271241-24-8/BI OR 271241-25-9/BI OR 272-49-1/BI OR 27257-15-4/BI OR 274-76-0/BI OR 27421-51-8/BI OR 27643-15-8/BI OR 276862-85-2/BI OR 29969-57-1/BI OR 30198-01-7/BI OR 3385-21-5/BI OR 349447-08-1/BI OR 371-40-4/BI OR 372-19-0/BI OR 3779-27-9/BI OR 4002-83-9/BI OR 40053-37-0/BI OR 406204-74-8/BI OR 43192-31-0/BI OR 439095-43-9/BI OR 441715-30-6/BI OR 444683-23-2/BI OR 455-14-1/BI OR 477848-00-3/BI OR 477886-95-6/BI OR 482585-36-4/BI OR 498-62-4/BI OR 501-53-1/BI OR 50634-05-4/BI OR 50890-83-0/BI OR 5170-68-3/BI OR 52173-35-0/BI OR 52606-02-7/BI OR 52771-21-8/BI OR 536-90-3/BI OR 541-41-3/BI OR 542-92-7/BI OR 5467-57-2/BI OR 5652-13-1/BI OR 58630-07-2/BI OR 6041-50-5/BI OR 6188-43-8/BI OR 6340-55-2/BI OR 636-61-3/BI OR 645400-43-7/BI OR 645400-44-8/BI OR 645400-49-3/BI OR 645400-50-6/BI OR 67509-84-6/BI OR 67999-51-3/BI OR 6953-22-6/BI OR 703-61-7/BI OR 79-44-7/BI OR 79200-56-9/BI OR 814-68-6/BI OR 827-01-0/BI OR 83783-33-9/BI OR 860296-28-2/BI OR 860296-29-3/BI OR 860296-30-6/BI OR 860296-31-7/BI OR 860296-32-8/BI OR 860296-33-9/BI OR 860296-34-0/BI OR 860296-35-1/BI OR 860296-37-3/BI OR 860296-39-5/BI OR 860296-41-9/BI OR 860296-42-0/BI OR 860

L3 STR



Structure attributes must be viewed using STN Express query preparation:
Uploading L3.str



ring nodes :
1 2 3 4 5 6 7 8 9 10
ring/chain nodes :
11 12 13
chain bonds :
9-11
ring/chain bonds :
11-13 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :
9-11 11-13 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS

L5 STR



Structure attributes must be viewed using STN Express query preparation:
Uploading L5.str



ring nodes :
1 2
ring bonds :
1-2
exact bonds :
1-2

Match level :
1:Atom 2:Atom

L7 8933 SEA FILE=REGISTRY SSS FUL L3 AND L5
L8 STR



Structure attributes must be viewed using STN Express query preparation:

Uploading L8.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-13 11-15 12-16 12-14
13-14 15-16
exact/norm bonds :
9-11
exact bonds :
11-13 11-15 12-16 12-14 13-14 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
isolated ring systems :
containing 11 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom

L10 3365 SEA FILE=REGISTRY SUB=L7 SSS FUL L8
L18 STR



Structure attributes must be viewed using STN Express query preparation:
Uploading L18.str




```
chain nodes :
16  17
ring nodes :
1  2  3  4  5  6  7  8  9  10
ring/chain nodes :
11  12  13
chain bonds :
9-11  12-16  16-17
ring/chain bonds :
11-13  12-13
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10
exact/norm bonds :
9-11  11-13  12-13  12-16  16-17
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS  16:CLASS  17:Atom



L20         3929 SEA FILE=REGISTRY SUB=L7 SSS FUL L18
L21         2293 SEA FILE=REGISTRY ABB=ON  PLU=ON  L20 NOT L10
L24           39 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND L2
L25            2 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L24


=> s L25 not L64
L65           0 L25 NOT L64
```

```
=> file registry
FILE 'REGISTRY' ENTERED AT 14:05:54 ON 19 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 FEB 2008  HIGHEST RN 1004360-55-7
DICTIONARY FILE UPDATES:  18 FEB 2008  HIGHEST RN 1004360-55-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 14:05:59 ON 19 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 19 Feb 2008  VOL 148 ISS 8
FILE LAST UPDATED: 18 Feb 2008  (20080218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L50
L3              STR
```



Structure attributes must be viewed using STN Express query preparation:
Uploading L3.str



ring nodes :
1 2 3 4 5 6 7 8 9 10
ring/chain nodes :
11 12 13
chain bonds :
9-11
ring/chain bonds :
11-13 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
9-11 11-13 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS

L5 STR



Structure attributes must be viewed using STN Express query preparation:
Uploading L5.str



ring nodes :
1 2
ring bonds :
1-2
exact bonds :
1-2

Match level :
1:Atom 2:Atom

L7 8933 SEA FILE=REGISTRY SSS FUL L3 AND L5
L29 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading L29.str







chain nodes :
11 13 14 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 33 34
35 36 38 39 40 41 43 45 46 47 49 50 52 53 54 67
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
9-67 11-13 13-16 14-16 14-17 18-19 19-20 20-21 22-23 23-24 24-25 26-27

```
27-28  29-30  30-31  31-33  33-34  35-36  36-38  38-39  40-41  41-43  43-45  46-47
47-49  50-52
53-54
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10
exact/norm bonds :
9-67  11-13  13-16  14-16  14-17  19-20  20-21  22-23  23-24  29-30  30-31  31-33
33-34  35-36  36-38  38-39  40-41  41-43  43-45  46-47  47-49  50-52  53-54
exact bonds :
18-19  24-25  26-27  27-28
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10


G1:CH2,O

G2:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  13:CLASS  14:CLASS  16:Atom  17:CLASS  18:CLASS  19:Atom  20:CLASS
21:CLASS  22:CLASS  23:CLASS
24:Atom  25:CLASS  26:CLASS  27:Atom  28:CLASS  29:CLASS  30:CLASS  31:Atom
33:CLASS  34:CLASS
35:CLASS  36:Atom  38:CLASS  39:CLASS  40:CLASS  41:CLASS  43:Atom  45:CLASS
46:CLASS  47:Atom
49:CLASS  50:Atom  52:CLASS  53:Atom  54:CLASS  67:CLASS
Generic attributes :
31:
Number of Hetero Atoms : Exactly 1
36:
Number of Hetero Atoms : Exactly 1
43:
Number of Hetero Atoms : Exactly 1
47:
Number of Hetero Atoms : Exactly 1
50:
Type of Ring System    : Polycyclic
53:
Type of Ring System    : Polycyclic

Element Count :
Node 31: Limited
    O,O1

Node 36: Limited
    O,O1

Node 43: Limited
    O,O1

Node 47: Limited
    O,O1

Node 50: Limited
    N,N1
    C,C2-9

Node 53: Limited
    N,N1
```

C,C2-9

```
L31        1356 SEA FILE=REGISTRY SUB=L7 SSS FUL L29
L32          85 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L31
L33          17 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  MCH ANTAGONIST/TI
L34           4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L32 AND L33
L36             TRANSFER  PLU=ON  L34 1- RN :    3820 TERMS
L37        3820 SEA FILE=REGISTRY ABB=ON  PLU=ON  L36
L38        1043 SEA FILE=REGISTRY ABB=ON  PLU=ON  L37 AND L31
L40           4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L38
L42          42 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L32 AND P/DT
L43          43 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L32 NOT L42
L44          36 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L43 AND PY<2005
L45          25 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L42 AND PD<20040107
L46          33 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L42 AND PRD<20040107
L47          27 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L42 AND AD<20040107
L48          70 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  (L44 OR L45 OR L46 OR L47)
L50           3 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L40 AND L48


=> d ibib abs hitind fhitstr L50 1-3

L50  ANSWER 1 OF 3  ZCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:875033  ZCAPLUS  Full-text
DOCUMENT NUMBER:          141:332214
TITLE:                    Preparation of quinoline, tetrahydroquinazoline, and
                          pyrimidine derivatives as MCH antagonist for treatment
                          of CNS disorders
INVENTOR(S):              Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera,
                          Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han,
                          Sangdon; Casper, Martin; Kramer, Bryan A.; Semple,
                          Graeme; Zou, Ning
PATENT ASSIGNEE(S):       Taisho Pharmaceutical Co. Ltd., Japan
SOURCE:                   Eur. Pat. Appl., 586 pp.
                          CODEN: EPXXDW
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   3
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
     EP 1464335            A2    20041006    EP 2004-7651           20040330 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
     EP 1464335            A2    20041006    EP 2004-7651           20040330 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
PRIORITY APPLN. INFO.:                        US 2003-458530P     P  20030331 <--
                                              US 2003-495911P     P  20030819 <--
                                              US 2003-510186P     P  20031009 <--
                                              US 2003-530360P     P  20031216 <--
                                              EP 2004-7651        A  20040330
GI
```



AB Title compds. I, II, and III [wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide IV•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data). This is part III of three in a series covering the patent.

IC ICM A61K031-4709
ICS C07D401-12; C07D403-12; C07D405-12; C07D409-12; C07D413-12; C07D417-12; C07D417-14; C07D215-38; A61K031-506; A61P003-04

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 769177-03-9P 769177-12-0P 769177-41-5P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2,4-difluorobenzamide 769178-07-6P, N-[cis-4-[(4-Dimethylaminopyrimidin-2-yl)amino]cyclohexyl]-4-fluorobenzamide 769178-58-7P, 5-Bromo-N-[cis-4-[(4-dimethylaminopyrimidin-2-yl)amino]cyclohexyl]nicotinamide 769179-30-8P, N-[[cis-4-[(4-Dimethylaminopyrimidin-2-yl)amino]cyclohexyl]methyl]-3,4-difluorobenzamide 769179-45-5P 769181-46-6P, N-[[cis-4-[(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-yl)amino]cyclohexyl]methyl]-3,4-difluorobenzamide 769184-42-1P 769184-44-3P 769185-80-0P 771543-21-6P, 1-(2,3-Dichlorophenyl)-3-[[cis-4-[(4-dimethylamino-5,6,7,8-tetrahydroquinazolin-2-yl)amino]cyclohexyl]methyl]urea 771543-38-5P, 4-Cyano-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 771543-40-9P, 3-Fluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 771543-42-1P, 3,5-Difluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 771543-46-5P, 2-(3,4-Difluorophenyl)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide 771543-48-7P, 2-(2-Bromo-4,5-dimethoxyphenyl)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide 771543-54-5P, 2-(4-Fluorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 771543-56-7P, 2-(4-Chlorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 771543-58-9P, 2,6-Dimethoxy-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 771543-64-7P, cis-N-(3,5-Dimethoxybenzyl)-N'-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine 771543-66-9P, cis-N-(3,5-Dichlorobenzyl)-N'-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine 771544-28-6P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide 771544-37-7P, 5-Bromofuran-2-carboxylic acid [cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]amide 771544-72-0P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide 771544-76-4P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-bis(trifluoromethyl)benzamide 771545-13-2P, 2-(3,4-Dichlorophenoxy)-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 771545-15-4P, 2-(2,3-Dichlorophenoxy)-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 771545-17-6P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771545-22-3P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide 771545-26-7P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-2-furancarboxamide 771545-30-3P, 2-[[cis-4-[(3-Bromobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6-dimethylpyrimidine 771545-36-9P, 1-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]cyclobutanecarboxamide 771545-38-1P, 2-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-methylpropanamide 771545-44-9P, 1-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]cyclopropanecarboxamide 771545-46-1P, 1-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]cyclobutanecarboxamide 771545-48-3P, 1-(2,4-Dichlorophenyl)-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]cyclopropanecarboxamide 771545-53-0P 771545-68-7P 771545-85-8P, N-[cis-4-[[4-[Ethyl(methyl)amino]-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide 771546-04-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(4-fluorophenoxy)nicotinamide 771546-17-9P, N-(3,4-Difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-

methylurea 771551-36-1P 771551-38-3P 771551-40-7P 771551-42-9P 771551-44-1P 771551-46-3P 771551-48-5P 771551-50-9P 771556-51-5P, N-[cis-4-[(4-Dimethylaminopyrimidin-2-yl)amino]cyclohexyl]-2-[ethyl(phenyl)amino]acetamide dihydrochloride 771557-10-9P, N-[1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl]-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 771557-15-4P, cis-N-[1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl]-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771557-24-5P, 2-[(2-Chlorophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 771557-33-6P 771557-35-8P 771557-38-1P 771557-44-9P, N-(3,4-Difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 771557-47-2P, N-(4-Chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-ethylurea 771557-49-4P, N-[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-[[2-(trifluoromethyl)pyrimidin-4-yl]oxy]acetamide 771557-51-8P, 2,2-Difluoro-N-[cis-4-[[4-methyl-6-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-1,3-benzodioxole-5-carboxamide 773140-48-0P, 1-(4-Chlorophenyl)-2-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]ethanone 773140-49-1P, 1-(3,4-Difluorophenyl)-2-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]ethanone 773140-50-4P, 1-(4-Bromophenyl)-2-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]ethanone 773140-51-5P, N-[1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl]-N'-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773140-52-6P, N-[1-(4-Chlorophenyl)-1-methylethyl]-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773140-53-7P, N-[1-(4-Chlorophenyl)-1-methylethyl]-N'-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773140-54-8P, N-[1-(4-Chlorophenyl)cyclopropyl]-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773140-55-9P, N-[1-(4-Chlorophenyl)cyclopropyl]-N'-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773140-56-0P, N-[1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl]-N'-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methylurea 773140-57-1P, N-[1-(4-Chlorophenyl)-1-methylethyl]-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methylurea 773140-58-2P, N-[1-(4-Chlorophenyl)-1-methylethyl]-N'-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methylurea 773140-59-3P, N-[1-(4-Chlorophenyl)cyclopropyl]-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methylurea 773140-60-6P, N-[1-(4-Chlorophenyl)cyclopropyl]-N'-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methylurea 773140-61-7P, cis-N-[1-(4-Chlorophenyl)-1-methylethyl]-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 773140-62-8P, cis-N-[1-(4-Chlorophenyl)-1-methylethyl]-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 773140-63-9P, cis-N-[1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl]-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 773140-64-0P, 4-Chloro-N-[cis-4-[(4-methoxy-5-methylpyrimidin-2-yl)amino]cyclohexyl]benzamide 773140-65-1P, N-[cis-4-[(4-Methoxy-5-methylpyrimidin-2-yl)amino]cyclohexyl]-4-(trifluoromethoxy)benzamide 773140-66-2P, 3,4-Dichloro-N-[cis-4-[(4-methoxy-5-methylpyrimidin-2-yl)amino]cyclohexyl]benzamide 773140-67-3P, 3,5-Dichloro-N-[cis-4-[(4-methoxy-5-methylpyrimidin-2-yl)amino]cyclohexyl]benzamide 773140-68-4P, N-[cis-4-[(4-Methoxy-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide 773140-69-5P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(4-fluorophenyl)sulfonyl]nicotinamide 773140-70-8P, 2-[(4-

Chlorophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773140-71-9P, 2-[(3-Chlorophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773140-72-0P, 2-[(2-Chlorophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773140-73-1P, 2-[(3-Bromophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773140-74-2P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(4-methoxyphenyl)sulfonyl]nicotinamide 773140-75-3P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[[3-(trifluoromethyl)phenyl]sulfonyl]nicotinamide 773140-76-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(4-methylphenyl)sulfonyl]nicotinamide 773140-77-5P, 2-[(4-Bromophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773140-78-6P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(2-methyl-3-furyl)sulfonyl]nicotinamide 773140-79-7P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[[4-(trifluoromethyl)phenyl]sulfonyl]nicotinamide 773140-80-0P 773140-81-1P 773140-82-2P 773140-83-3P 773140-84-4P 773140-85-5P 773140-86-6P 773140-87-7P 773140-88-8P 773140-89-9P 773140-90-2P 773140-91-3P 773140-92-4P 773140-93-5P 773140-94-6P 773140-95-7P 773140-96-8P 773140-97-9P 773140-98-0P 773140-99-1P 773141-00-7P 773141-01-8P 773141-02-9P 773141-03-0P 773141-04-1P 773141-05-2P 773141-06-3P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N'-(2-methoxyphenyl)urea 773141-07-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N'-(3-methoxyphenyl)urea 773141-08-5P, N-(3,4-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-09-6P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N'-(2-fluorophenyl)urea 773141-10-9P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N'-(3-fluorophenyl)urea 773141-11-0P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N'-(4-fluorophenyl)urea 773141-12-1P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N'-[3-(trifluoromethyl)phenyl]urea 773141-13-2P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N'-[4-(trifluoromethyl)phenyl]urea 773141-14-3P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N'-[2-(trifluoromethoxy)phenyl]urea 773141-15-4P, N-(3-Chloro-4-fluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-16-5P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N'-[4-fluoro-3-(trifluoromethyl)phenyl]urea 773141-17-6P, N-(4-Chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-18-7P, N-[3,5-Bis(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-19-8P, N-(4-Bromophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-20-1P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N'-(2-methylphenyl)urea 773141-21-2P, N-(3,4-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-22-3P, N-(2,4-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-23-4P, N-(3,5-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-24-5P, N-(3-Chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-25-6P, N-Benzyl-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-26-7P, N-(2,5-Dichlorophenyl)-N'-[cis-4-

[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-27-8P, N-(2',3-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-28-9P, N-[2-Chloro-6-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea 773141-29-0P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N'-(2,4,6-trichlorophenyl)urea 773141-30-3P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-(2-fluorophenyl)-N-methylurea 773141-31-4P, N-(2-Chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methylurea 773141-32-5P, N-(2,4-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methylurea 773141-33-6P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-ethyl-N-[2-(trifluoromethoxy)phenyl]urea 773141-34-7P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-ethyl-N-phenylurea 773141-35-8P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-ethyl-N-[4-(trifluoromethoxy)phenyl]urea 773141-36-9P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methyl-N-[2-(trifluoromethoxy)phenyl]urea 773141-37-0P, N-[3,5-Bis(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-ethylurea 773141-38-1P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-ethyl-N-(3-methylphenyl)urea 773141-39-2P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]acetamide 773141-40-5P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[[6-(trifluoromethyl)pyrimidin-4-yl]oxy]acetamide 773141-41-6P, 4-Chloro-N-[cis-4-[[4-methyl-6-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide 773141-42-7P, 2-(3,4-Dichlorophenoxy)-N-[cis-4-[[4-methyl-6-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 773141-43-8P, N-[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]acetamide 773141-44-9P, N-[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-[[6-(trifluoromethyl)pyrimidin-4-yl]oxy]acetamide 773141-45-0P, N-[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-[[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]oxy]acetamide 773141-46-1P, N-[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-[[5-(trifluoromethyl)-1H-pyrazol-3-yl]oxy]acetamide 773141-47-2P, 3,4-Difluoro-N-[cis-4-[[(4-methylquinolin-2-yl)methyl]amino]cyclohexyl]benzamide 773141-48-3P, 3-Chloro-N-[cis-4-[[(4-methylquinolin-2-yl)methyl]amino]cyclohexyl]benzamide 773141-49-4P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(4-fluorophenyl)sulfonyl]nicotinamide 773141-50-7P, 2-[(3-Chlorophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773141-51-8P, 2-[(4-Chlorophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773141-52-9P, 2-[(2-Bromophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773141-53-0P, 2-[(3-Bromophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773141-54-1P, 2-[(4-Bromophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773141-55-2P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(2-methylphenyl)sulfonyl]nicotinamide 773141-56-3P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(3-methylphenyl)sulfonyl]nicotinamide 773141-57-4P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(4-methylphenyl)sulfonyl]nicotinamide 773141-58-5P, N-[cis-4-[[4-

(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(2-methoxyphenyl)sulfonyl]nicotinamide 773141-59-6P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(3-methoxyphenyl)sulfonyl]nicotinamide 773141-60-9P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(4-methoxyphenyl)sulfonyl]nicotinamide 773141-61-0P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[[2-(trifluoromethyl)phenyl]sulfonyl]nicotinamide 773141-62-1P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-4-(trifluoromethoxy)benzamide 773141-63-2P, 4-Chloro-N-[cis-4-[(4-dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-3-fluorobenzamide hydrochloride 773141-64-3P, 3-Chloro-N-[cis-4-[(4-dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-5-fluorobenzamide hydrochloride 773141-65-4P, N-[cis-4-[(4-Dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-3,4,5-trifluorobenzamide hydrochloride 773141-66-5P, 3-Chloro-4-fluoro-N-[cis-4-[(5-methyl-4-methylaminopyrimidin-2-yl)amino]cyclohexyl]benzamide hydrochloride 773141-67-6P, 4-Chloro-N-[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3-fluorobenzamide hydrochloride 773141-68-7P, 3-Chloro-N-[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-5-fluorobenzamide hydrochloride 773141-69-8P , N-[cis-4-[(4-Dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,4,5-trifluorobenzamide hydrochloride 773141-70-1P, N-[cis-4-[(4-Dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,5-difluorobenzamide hydrochloride 773141-71-2P, 2-(3,4-Difluorophenyl)-N-[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]acetamide hydrochloride 773141-72-3P, N-[cis-4-[(4-Amino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3-chloro-4-fluorobenzamide hydrochloride 773141-73-4P, 2-(3,4-Dichlorophenoxy)-N-[cis-4-[(4-dimethylaminopyrimidin-2-yl)amino]cyclohexyl]acetamide hydrochloride 773141-74-5P, N-[cis-4-[(4-Dimethylaminopyrimidin-2-yl)amino]cyclohexyl]-2-(3-methoxyphenoxy)acetamide hydrochloride 773141-75-6P, 5-Chloro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 773141-78-9P, 5-Fluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 773141-79-0P, 3-Chloro-N-[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-4-fluorobenzamide methanesulfonate 773141-80-3P, 2-[[cis-4-[[2-(4-Bromo-2-trifluoromethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 773141-81-4P, 2-[[cis-4-[(4-Bromo-2-trifluoromethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 773141-82-5P, 2-[[cis-4-[(4-Bromo-2-trifluoromethoxybenzyl)amino]cyclohexyl]amino]-4-(methylamino)quinoline 773141-83-6P, 2-[[4-[[2-(4-Bromo-2-trifluoromethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(methylamino)quinoline 773141-84-7P, 4-(Methylamino)-2-[[cis-4-[[(2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]quinoline 773141-85-8P, 2-[[cis-4-[[(4-Bromo-2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 773141-86-9P 773141-87-0P, 3,4-Difluoro-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773141-88-1P, 2-Phenoxy-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide 773141-89-2P 773141-90-5P, 3-Methyl-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773141-91-6P, 3-Chloro-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773141-92-7P, 5-Nitrothiophene-3-carboxylic acid [cis-4-[(quinolin-2-yl)amino]cyclohexyl]amide 773141-93-8P, 5-Nitrothiophene-3-carboxylic acid [cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]amide 773141-94-9P, 3-Chloro-4-fluoro-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773141-95-0P, 3,5-Dimethoxy-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773141-96-1P, 3,4-Dichloro-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide

773141-97-2P, Benzo[2,3,1]oxadiazole-5-carboxylic acid [cis-4-[(quinolin-2-yl)amino]cyclohexyl]amide 773141-98-3P, 1-Methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis-4-[(quinolin-2-yl)amino]cyclohexyl]amide 773141-99-4P, 9H-Xanthene-9-carboxylic acid [cis-4-[(quinolin-2-yl)amino]cyclohexyl]amide 773142-00-0P, 5-(4-Chlorophenyl)furan-2-carboxylic acid [cis-4-[(quinolin-2-yl)amino]cyclohexyl]amide 773142-01-1P, 3-Nitro-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773142-02-2P, 4-Fluoro-3-methyl-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773142-03-3P, 3-Bromo-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773142-04-4P, 2-(2-Bromophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-05-5P, 3-Cyano-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773142-06-6P 773142-07-7P, N-[cis-4-[(4-Chloroquinolin-2-yl)amino]cyclohexyl]-3,4-difluorobenzamide 773142-08-8P, 3,4-Dichloro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-09-9P, 4-Fluoro-3-methyl-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-10-2P, 1-Methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]amide 773142-11-3P, 9H-Xanthene-9-carboxylic acid [cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]amide 773142-12-4P, N-[cis-4-[(Quinolin-2-yl)amino]cyclohexyl]-2-(m-tolyloxy)acetamide 773142-13-5P, 2,2-Diphenyl-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide 773142-14-6P, 5-Bromofuran-2-carboxylic acid [cis-4-[(quinolin-2-yl)amino]cyclohexyl]amide 773142-15-7P, Benzo[2,3,1]oxadiazole-5-carboxylic acid [cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]amide 773142-16-8P, 3-Bromo-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-17-9P 773142-18-0P, 2-(4-Fluorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-19-1P, 2-(3,4-Difluorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-20-4P, 2-(3,4-Difluorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-21-5P, N-[cis-4-[(Quinolin-2-yl)amino]cyclohexyl]-2-(p-tolyloxy)nicotinamide 773142-22-6P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-2-(p-tolyloxy)nicotinamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

IT 773142-23-7P, 2-(4-Chlorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-24-8P, 2-(4-Bromophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-25-9P, 2-(4-Bromophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-26-0P, 2-(4-Methoxyphenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-27-1P, 2-(4-Methoxyphenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-28-2P, 2-(3-Chloro-4-fluorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-29-3P, 2-(3-Chloro-4-fluorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-30-6P, N-[cis-4-[(Quinolin-2-yl)amino]cyclohexyl]-2-(m-tolyloxy)nicotinamide 773142-31-7P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-2-(m-tolyloxy)nicotinamide 773142-32-8P, 2-(3-Chlorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide 773142-33-9P, 2-(3-Chloro-4-fluorophenoxy)-N-[cis-4-[(4-

methylquinolin-2-yl)amino]cyclohexyl]acetamide 773142-34-0P, 2-(3,4-Dichlorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide 773142-35-1P, 2-[Methyl(phenyl)amino]-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide 773142-36-2P, 2-(3,4-Dichlorophenylamino)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide 773142-37-3P, 2-(3-Methoxyphenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide 773142-38-4P, 2-(3-Chlorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide 773142-39-5P, 2-(3-Chloro-4-fluorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide 773142-40-8P, 2-(3,4-Dichlorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide 773142-41-9P, 2-[Methyl(phenyl)amino]-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide 773142-42-0P, 2-(3,4-Dichlorophenylamino)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide 773142-43-1P, 3-Hydroxy-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773142-44-2P, N-[cis-4-[(Quinolin-2-yl)amino]cyclohexyl]-3-trifluoromethoxybenzamide 773142-45-3P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-3-trifluoromethoxybenzamide 773142-46-4P, N-[cis-4-[(4-Aminoquinolin-2-yl)amino]cyclohexyl]-3,4-difluorobenzamide 773142-47-5P, 2-[Ethyl(phenyl)amino]-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide 773142-48-6P, 2-[Ethyl(phenyl)amino]-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide 773142-49-7P, 3-Hydroxy-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-50-0P, 2-Amino-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-51-1P, 2,3-Difluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-52-2P, 2,4-Difluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-53-3P, 2,5-Difluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-54-4P, 2,6-Difluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-55-5P 773142-56-6P, 4-Chloro-3-fluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-57-7P, 2-Fluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-58-8P, 4-Chloro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-59-9P, 3,5-Difluoro-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773142-60-2P, 4-Chloro-3-fluoro-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]benzamide 773142-61-3P 773142-62-4P, 6-Dimethylamino-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 773142-63-5P, 3-Hydroxymethyl-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-64-6P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]isophthalamide 773142-65-7P, 3-Chloro-5-fluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-66-8P, 3,4,5-Trifluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 773142-67-9P, Pyridine-2-carboxylic acid [cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]amide 773142-68-0P, 4-Chloropyridine-2-carboxylic acid [cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]amide 773142-69-1P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-6-trifluoromethylnicotinamide 773142-70-4P, 3,4-Difluoro-N-[[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]methyl]benzamide 773142-71-5P 773142-72-6P, 3,4-Difluoro-N-[[cis-4-[(quinolin-2-yl)amino]cyclohexyl]methyl]benzamide 773142-73-7P, 2-Phenoxy-N-[[cis-4-[(quinolin-2-yl)amino]cyclohexyl]methyl]nicotinamide 773142-74-8P, N-(2,3-Dichlorophenyl)-N'-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]urea 773142-75-9P, 1-(2,3-Dichlorophenyl)-3-[[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]methyl]urea

773142-76-0P, 2-[[cis-4-[[2-(4-Bromo-2-trifluoromethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 773142-77-1P, 2-[[cis-4-[[2-(4-Bromo-2-trifluoromethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(methylamino)-5,6,7,8-tetrahydroquinazoline 773142-78-2P, 2-[[cis-4-[[(4-Bromo-2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(methylamino)-5,6,7,8-tetrahydroquinazoline 773142-79-3P, 2-[[cis-4-[[(4-Bromo-2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 773142-80-6P, 4-(Methylamino)-2-[[cis-4-[[(2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 773142-81-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(naphth-1-yl)urea 773142-82-8P, 2-[[4-[(4-Bromo-2-trifluoromethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 773142-83-9P, 2-[[cis-4-[[2-(4-Bromo-2-trifluoromethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 773142-84-0P, 2-[[cis-4-[[(4-Bromo-2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 773142-85-1P, N-[cis-4-[(4-Dimethylaminopyrimidin-2-yl)amino]cyclohexyl]-2-(4-fluorophenoxy)nicotinamide 773142-86-2P, N-[cis-4-[(4-Dimethylaminopyrimidin-2-yl)amino]cyclohexyl]-2-[ethyl(phenyl)amino]acetamide 773142-87-3P 773142-88-4P, 2-(3,4-Difluorophenyl)-N-[cis-4-[(4-dimethylaminopyrimidin-2-yl)amino]cyclohexyl]acetamide 773142-89-5P, 4-Chloro-N-[cis-4-[(4-dimethylaminopyrimidin-2-yl)amino]cyclohexyl]-3-fluorobenzamide 773142-90-8P, 3-Chloro-4-fluoro-N-[cis-4-[(4-methylaminopyrimidin-2-yl)amino]cyclohexyl]benzamide 773142-91-9P, 3-Chloro-N-[cis-4-[(4-dimethylaminopyrimidin-2-yl)amino]cyclohexyl]-5-fluorobenzamide 773142-92-0P, N-[cis-4-[(4-Dimethylaminopyrimidin-2-yl)amino]cyclohexyl]-3,4,5-trifluorobenzamide 773142-93-1P, 2-(3,4-Dichlorophenoxy)-N-[cis-4-[(4-dimethylaminopyrimidin-2-yl)amino]cyclohexyl]acetamide 773142-94-2P, N-[cis-4-[(4-Dimethylaminopyrimidin-2-yl)amino]cyclohexyl]-2-(3-methoxyphenoxy)acetamide 773142-95-3P, N-[3-(Cyclopentyl)-4-methoxyphenyl]-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 773142-96-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide 773142-97-5P, 2-(4-Bromophenoxy)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773142-98-6P, 2-(4-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773142-99-7P, 2-(2-Bromophenoxy)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773143-00-3P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide 773143-01-4P, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 773143-02-5P 773143-03-6P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(isopropylthio)nicotinamide 773143-04-7P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(propylthio)nicotinamide 773143-05-8P, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 773143-06-9P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide 773143-07-0P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide 773143-08-1P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 773143-09-2P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide 773143-10-5P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide 773143-12-7P 773143-14-9P 773143-16-1P, 4-Chloro-N-[cis-4-[(4-

dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-3-fluorobenzamide 773143-17-2P, 3-Chloro-N-[cis-4-[(4-dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-5-fluorobenzamide 773143-19-4P, N-[cis-4-[(4-Dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-3,4,5-trifluorobenzamide 773143-20-7P, 3-Chloro-4-fluoro-N-[cis-4-[(5-methyl-4-methylaminopyrimidin-2-yl)amino]cyclohexyl]benzamide 773143-21-8P, 4-Chloro-N-[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3-fluorobenzamide 773143-22-9P, 3-Chloro-N-[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-5-fluorobenzamide 773143-23-0P, N-[cis-4-[(4-Dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,4,5-trifluorobenzamide 773143-24-1P, N-[cis-4-[(4-Dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,5-difluorobenzamide 773143-25-2P, 2-(3,4-Difluorophenyl)-N-[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]acetamide 773143-28-5P, 1-(2,3-Dichlorophenyl)-3-[[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]methyl]urea 773143-29-6P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzenesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

IT 14394-70-8P, (2-Chloro-5-methylpyrimidin-4-yl)amine 56864-96-1P, N-(2-Chloro-5-methylpyrimidin-4-yl)methylamine 773141-76-7P, 5-Bromo-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide 773141-77-8P, 5-Amino-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinolines, quinazolines, and pyrimidines as MCH antagonist for treatment of CNS disorders)

IT 403-17-8, 4-Chloro-3-fluorobenzoic acid 1780-31-0, 2,4-Dichloro-5-methylpyrimidine 20826-04-4, 5-Bromonicotinic acid 34171-43-2, 2-Chloro-4-dimethylamino-5-methylpyrimidine 771543-35-2 771543-91-0, 2-[(cis-4-Aminocyclohexyl)amino]-5-methyl-4-(dimethylamino)pyrimidine 771543-97-6, 2-[(cis-4-Aminocyclohexyl)amino]-6-methyl-4-(dimethylamino)pyrimidine 771556-87-7, N-(cis-4-Aminocyclohexyl)-3-chloro-4-fluorobenzamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinolines, quinazolines, and pyrimidines as MCH antagonist for treatment of CNS disorders)

IT 769177-03-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

RN 769177-03-9 ZCAPLUS
CN Benzamide, 3-chloro-N-[[cis-4-[[4-(dimethylamino)-2-quinolinyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



L50 ANSWER 2 OF 3 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:875032 ZCAPLUS Full-text
DOCUMENT NUMBER: 141:350191
TITLE: Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders
INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.; Semple, Graeme; Zou, Ning
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co. Ltd., Japan
SOURCE: Eur. Pat. Appl., 586 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1464335	A2	20041006	EP 2004-7651	20040330 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
EP 1464335	A2	20041006	EP 2004-7651	20040330 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.:			
US 2003-458530P	P	20030331	<--
US 2003-495911P	P	20030819	<--
US 2003-510186P	P	20031009	<--
US 2003-530360P	P	20031216	<--
EP 2004-7651	A	20040330	

GI



AB Title compds. I, II, and III [wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide IV•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data). This is part II of three in a series covering the patent.

IC ICM A61K031-4709
ICS C07D401-12; C07D403-12; C07D405-12; C07D409-12; C07D413-12; C07D417-12; C07D417-14; C07D215-38; A61K031-506; A61P003-04

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 331-40-8P, (3-Chloro-4-fluorophenoxy)acetic acid 535-89-7P, 2-Chloro-4-dimethylamino-6-methylpyrimidine 588-22-7P, (3,4-Dichlorophenoxy)acetic acid 588-32-9P, (3-Chlorophenoxy)acetic acid 703-61-7P, 2,4-Dichloroquinoline 1202-22-8P, 6-Chloro-N,N,N',N'-

tetramethylpyrimidine-2,4-diamine 1780-32-1P, 2,4-Dichloro-5,6-dimethylpyrimidine 2088-24-6P, (3-Methoxyphenoxy)acetic acid 2145-85-9P, Ethyl (3,4-difluorophenyl)carbamate 2806-29-3P, 2-Chloro-4-trifluoromethylquinoline 3569-33-3P, N-(2-Chloro-6-methylpyrimidin-4-yl)methylamine 4157-47-5P, trans-2-(4-Chlorophenyl)cyclopropanecarboxylic acid 4295-09-4P, 2-Chloro-4-methoxyquinoline 4295-16-3P, 2-Chloroquinoline-4-carboxylic acid amide 5652-13-1P, (2-Chloroquinolin-4-yl)dimethylamine 6041-50-5P, (4-Chloroquinolin-2-yl)dimethylamine 14108-81-7P 14394-70-8P, (2-Chloro-5-methylpyrimidin-4-yl)amine 20150-91-8P 20151-42-2P, (4-Chloroquinolin-2-yl)amine 21911-74-0P, [Methyl(phenyl)amino]acetic acid ethyl ester 23631-02-9P, (4-Chloropyrimidin-2-yl)dimethylamine 31058-81-8P, (2-Chloropyrimidin-4-yl)dimethylamine 34171-40-9P, 2,4-Dichloro-5-ethylpyrimidine 34171-43-2P, 2-Chloro-4-dimethylamino-5-methylpyrimidine 34916-68-2P, 2-Chloro-4,5-dimethylpyrimidine 35042-48-9P, 5,6,7,8-Tetrahydroquinazoline-2,4-diol 40105-30-4P, 4-Methylquinoline-2-carboxaldehyde 40643-55-8P, [Methyl(phenyl)amino]acetic acid 51362-37-9P, 2-(4-Chlorophenoxy)nicotinic acid 52094-98-1P, (3-Chlorophenoxy)acetic acid ethyl ester 54629-13-9P, 2-(4-Fluorophenoxy)nicotinic acid 54629-14-0P, 2-(m-Tolyloxy)nicotinic acid 54629-15-1P, 2-(p-Tolyloxy)nicotinic acid 56864-96-1P, N-(2-Chloro-5-methylpyrimidin-4-yl)-N-methylamine 57054-86-1P, (5-Bromo-2-chloropyrimidin-4-yl)dimethylamine 61532-37-4P, 2-(4-Bromophenoxy)nicotinic acid 62855-72-5P, (3,4-Dichlorophenoxy)acetic acid ethyl ester 65051-17-4P, (3,4-Dichlorophenylamino)acetic acid 66131-68-8P, N-(2-Chloropyrimidin-4-yl)-N-methylamine 71406-68-3P, 4-Chloro-2-dimethylamino-5-methylpyrimidine 76781-03-8P, (2-Chloro-5,6,7,8-tetrahydroquinazolin-4-yl)dimethylamine 77200-07-8P, (2-Chloropyrimidin-4-yl)ethylmethylamine 80947-25-7P, (2-Chloroquinolin-4-yl)amine 82815-86-9P, (3-Methoxyphenoxy)acetic acid ethyl ester 83164-85-6P, 2-(3-Chloro-4-fluorophenoxy)nicotinic acid 83164-88-9P, 2-(3,4-Difluorophenoxy)nicotinic acid 86443-51-8P, N-(2-Chloropyrimidin-4-yl)ethylamine 86575-65-7P, N-(4-Chloropyrimidin-2-yl)ethylamine 117077-93-7P, (2,6-Dichloropyrimidin-4-yl)dimethylamine 135292-35-2P, 2-Chloro-4-methoxy-5-methylpyrimidine 138563-54-9P, N-(3,4-Difluorophenyl)-N-methylamine 149423-70-1P, (cis-4-Aminocyclohexyl)carbamic acid benzyl ester 223131-01-9P, (cis-4-Hydroxymethylcyclohexyl)carbamic acid tert-butyl ester 247570-24-7P, (cis-4-Aminocyclohexyl)carbamic acid tert-butyl ester 355829-23-1P, (2-Chloro-5-fluoropyrimidin-4-yl)dimethylamine 488098-44-8P, 1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethylamine 509142-45-4P, [cis-4-[(Benzyloxycarbonyl)amino]cyclohexyl]carbamic acid benzyl ester 509142-53-4P, [cis-4-[[(Benzyloxycarbonyl)amino]methyl]cyclohexyl]carbamic acid tert-butyl ester 509142-55-6P, [(cis-4-Aminocyclohexyl)methyl]carbamic acid benzyl ester 509143-03-7P, cis-[4-[(tert-Butoxycarbonyl)amino]cyclohexyl]carbamic acid benzyl ester 667437-18-5P, (3-Chloro-4-fluorophenoxy)acetic acid ethyl ester 749908-65-4P, 2-[(2-Chloropyrimidin-4-yl)(methyl)amino]ethanol 769175-46-4P, 2-[(cis-4-Aminocyclohexyl)amino]-4-(dimethylamino)quinoline 769175-49-7P, [[cis-4-(4-Dimethylaminoquinolin-2-ylamino)cyclohexyl]methyl]carbamic acid benzyl ester 769175-50-0P, 2-[(cis-4-Aminomethylcyclohexyl)amino]-4-(dimethylamino)quinoline 769175-59-9P, 2-[(cis-4-Aminocyclohexyl)amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769175-66-8P, [cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester 769175-67-9P, 2-[(cis-4-Aminocyclohexyl)amino]-4-(dimethylamino)pyrimidine 769175-69-1P, [[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]methyl]carbamic acid benzyl

ester 769175-70-4P, 2-[(cis-4-Aminomethylcyclohexyl)amino]-4-(dimethylamino)pyrimidine 769175-71-5P, 2-[(cis-4-Aminomethylcyclohexyl)amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 771543-34-1P, cis-[4-(4-Methylquinolin-2-ylamino)cyclohexyl]carbamic acid benzyl ester 771543-35-2P, cis-N-(4-Methylquinolin-2-yl)cyclohexane-1,4-diamine 771543-36-3P, 3,4-Difluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide 771543-80-7P, 3-Methoxy-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide 771543-82-9P, cis-[4-(3-Methoxybenzoylamino)cyclohexyl]carbamic acid tert-butyl ester 771543-83-0P, cis-N-(4-Aminocyclohexyl)-3-methoxybenzamide 771543-90-9P, cis-[4-(4-Dimethylamino-5-methylpyrimidin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester 771543-91-0P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanamine 771543-96-5P, cis-[4-(4-Dimethylamino-6-methylpyrimidin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester 771543-97-6P, cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanamine 771543-99-8P, cis-4-(4-Dimethylamino-6-methylpyrimidin-2-ylamino)cyclohexanecarboxylic acid ethyl ester 771544-00-4P, cis-4-(4-Dimethylamino-6-methylpyrimidin-2-ylamino)cyclohexanecarboxylic acid 771544-02-6P, cis-[4-(3-Nitrobenzylcarbamoyl)cyclohexyl]carbamic acid tert-butyl ester 771544-03-7P 771544-04-8P, cis-4-(4-Dimethylamino-5-methylpyrimidin-2-ylamino)cyclohexanecarboxylic acid 3-nitrobenzylamide 771544-05-9P, cis-4-(4-Dimethylamino-5-methylpyrimidin-2-ylamino)cyclohexanecarboxylic acid 3-aminobenzylamide 771544-14-0P, [cis-4-[(3-Nitrobenzoylamino)methyl]cyclohexyl]carbamic acid tert-butyl ester 771544-15-1P, cis-N-(4-Aminocyclohexylmethyl)-3-nitrobenzamide hydrochloride 771544-16-2P, cis-N-[[4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-nitrobenzamide 771544-69-5P, cis-N-(4-Aminocyclohexyl)-3,5-bis(trifluoromethyl)benzamide 771544-70-8P 771544-71-9P, [cis-4-[[3,5-Bis(trifluoromethyl)benzoyl]amino]cyclohexyl]carbamic acid tert-butyl ester 771544-72-0P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide 771544-75-3P 771544-76-4P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-bis(trifluoromethyl)benzamide 771544-79-7P, N-[[cis-4-(4-Dimethylamino-5-methylpyrimidin-2-ylamino)cyclohexyl]methyl]carbamic acid benzyl ester 771544-80-0P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]amine 771544-85-5P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]amine 771544-88-8P, N-[[cis-4-(4-Dimethylamino-6-methylpyrimidin-2-ylamino)cyclohexyl]methyl]carbamic acid benzyl ester 771544-89-9P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]amine 771544-91-3P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxylic acid ethyl ester 771544-92-4P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxylic acid 771545-19-8P, (2-Chloro-5,6-dimethylpyrimidin-4-yl)dimethylamine 771545-20-1P, cis-[4-(4-Dimethylamino-5,6-dimethylpyrimidin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester 771545-21-2P, cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexanamine 771545-53-0P 771545-70-1P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-bromoacetamide 771545-73-4P 771545-74-5P 771545-77-8P 771545-81-4P, 2-Chloro-4-dimethylamino-5-ethylpyrimidine 771545-82-5P, N-(cis-4-Aminocyclohexyl)-3,4-difluorobenzamide 771545-84-7P, 2-Chloro-4-[(ethyl)(methyl)amino]-5-methylpyrimidine 771545-85-8P, N-[cis-4-[[4-[Ethyl(methyl)amino]-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide 771545-88-1P, 2-Chloro-4-(dimethylamino)-5-(trifluoromethyl)pyrimidine 771545-89-2P, cis-[4-(4-Dimethylamino-5-

trifluoromethylpyrimidin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester 771545-90-5P, cis-N-(4-Dimethylamino-5-trifluoromethylpyrimidin-2-yl)cyclohexane-1,4-diamine 771545-94-9P, [(3-Trifluoromethylphenyl)sulfanyl]acetic acid ethyl ester 771545-95-0P 771545-96-1P 771545-97-2P, (3-Trifluoromethylphenylsulfinyl)acetic acid 771545-98-3P 771546-01-1P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[[3-(trifluoromethyl)phenyl]sulfonyl]acetamide 771546-03-3P, 2-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 771546-04-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(4-fluorophenoxy)nicotinamide 771546-10-2P, 2-(tert-Butylthio)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 771546-15-7P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[(3,4-difluorophenyl)sulfanyl]nicotinamide 771546-16-8P, 2-[(3,4-Difluorophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 771546-21-5P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-bis(trifluoromethyl)benzamide 771546-23-7P, cis-1-(6-Chloropyrazin-2-ylamino)-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexane 771546-25-9P, cis-1-[[6-(3,4-Difluorophenylsulfonyl)pyrazin-2-yl]amino]-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexane 771553-05-0P, [cis-4-[[1-(3,4-Difluorophenyl)methanoyl]amino]cyclohexyl]carbamic acid tert-butyl ester 771553-12-9P 771553-16-3P, cis-N-(Quinolin-2-yl)cyclohexane-1,4-diamine 771553-62-9P, 2-(4-Fluorophenoxy)nicotinic acid ethyl ester 771553-78-7P, 2-(4-Methoxyphenoxy)nicotinic acid 771554-11-1P, (cis-4-Aminomethylcyclohexyl)(quinolin-2-yl)amine 771554-87-1P, (cis-4-Aminomethylcyclohexyl)(4-methylquinolin-2-yl)amine 771555-21-6P, 2-Chloroquinolin-4-ol 771555-68-1P, (2-Chloro-5-phenylpyrimidin-4-yl)dimethylamine 771555-72-7P, (2,5-Dichloropyrimidin-4-yl)dimethylamine 771555-98-7P, N-[cis-4-(Quinolin-2-ylamino)cyclohexyl]isophthalamic acid methyl ester 771556-26-4P, N-[cis-4-(4-Methylquinolin-2-ylamino)cyclohexyl]isophthalamic acid methyl ester 771556-76-4P, [cis-4-(4-Methylaminopyrimidin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester 771556-78-6P, 2-[(cis-4-Aminocyclohexyl)amino]-4-(methylamino)pyrimidine 771556-83-3P, (4-Chloropyrimidin-2-yl)ethylmethylamine 771556-85-5P, 2-[(4-Chloropyrimidin-2-yl)(methyl)amino]ethanol 771556-87-7P, N-(cis-4-Aminocyclohexyl)-3-chloro-4-fluorobenzamide 771556-91-3P, (2-Chloro-6-ethylpyrimidin-4-yl)dimethylamine 771556-92-4P, (6-Chloro-2-ethylpyrimidin-4-yl)dimethylamine 771556-94-6P, 2-Chloro-N,N,N',N'-tetramethylpyrimidine-4,6-diamine 771557-04-1P, 3-Chloro-4-fluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide 771557-19-8P, N-[cis-4-(4-Methoxy-5-methylpyrimidin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester 771557-20-1P, cis-4-(4-Methoxy-5-methylpyrimidin-2-ylamino)cyclohexan-1-amine 771557-26-7P 771557-28-9P 771557-31-4P, 1-(4-Methylquinolin-2-yl)ethane-1,2-diol 771557-37-0P, cis-4-(4-Methylquinolin-2-ylamino)cyclohexanecarboxylic acid 771557-40-5P, trans-3-(4-Chlorophenyl)-N-methoxy-N-methyl-2-propenamide 771557-41-6P, N-Methoxy-N-methyl-trans-2-(4-chlorophenyl)cyclopropanecarboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating hormone antagonist for treatment of CNS disorders)

IT 771546-27-1P 771555-97-6P, N-[cis-4-(Quinolin-2-ylamino)cyclohexyl]isophthalamic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(melanin-concentrating hormone antagonist; preparation of quinolines, quinazolines,
and pyrimidines as melanin-concentrating hormone antagonist for treatment of
CNS disorders)

IT 771537-44-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(5-phenyl-2-thienyl)urea 771537-46-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(6-fluoro-4H-1,3-benzodioxin-8-yl)urea 771537-47-4P, Benzyl 4-[[[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]carbonyl]amino]piperidine-1-carboxylate 771537-48-5P, N-[4-(Dimethylamino)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]urea 771537-49-6P, N-(2,6-Dichloropyridin-4-yl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]urea 771537-50-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3,5-dimethylisoxazol-4-yl)urea 771537-51-0P, N-(3-Acetylphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-52-1P, N-(4-Acetylphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-53-2P, N-[3,5-Bis(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-54-3P, N-Benzyl-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-55-4P, N-(3-Bromophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-56-5P, N-Butyl-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-57-6P, N-Cyclohexyl-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-58-7P, N-Cyclopentyl-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-59-8P, N-(3-Chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-60-1P, N-(4-Chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-61-2P, N-(2,5-Difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-62-3P, N-(2,5-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-63-4P, N-(3,4-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-64-5P, N-(2,6-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-65-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-ethoxyphenyl)thiourea 771537-66-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2-furylmethyl)thiourea 771537-67-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-fluorophenyl)thiourea 771537-68-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-hexylthiourea 771537-69-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-(trans-4-propylcyclohexyl)phenyl]thiourea 771537-70-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-isobutylthiourea 771537-71-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-methoxybiphenyl-3-yl)thiourea 771537-72-5P, N-(1,3-Benzodioxol-5-ylmethyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-

tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-73-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3-methylphenyl)thiourea 771537-74-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-(methylthio)phenyl]thiourea 771537-75-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-methoxyphenyl)thiourea 771537-76-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2-methylprop-2-en-1-yl)thiourea 771537-77-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-methylthiourea 771537-78-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3-nitrophenyl)thiourea 771537-79-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-nitrophenyl)thiourea 771537-80-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(1,1,3,3-tetramethylbutyl)thiourea 771537-81-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-phenylthiourea 771537-82-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-propylthiourea 771537-83-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[3-(trifluoromethyl)phenyl]thiourea 771537-84-9P 771537-85-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-methylphenyl)thiourea 771537-86-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2-methylphenyl)thiourea 771537-87-2P, N-(tert-Butyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-88-3P, N-(Adamant-1-yl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-89-4P, N-(2-Bromophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-90-7P, N-(2-Chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-91-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2-phenylethyl)thiourea 771537-92-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-ethylphenyl)thiourea 771537-93-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[2-(methylthio)phenyl]thiourea 771537-94-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[2-(trifluoromethoxy)phenyl]thiourea 771537-95-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[2-(trifluoromethyl)phenyl]thiourea 771537-96-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2,3,4-trifluorophenyl)thiourea 771537-97-4P, N-(2,3-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-98-5P, N-(2,4-Difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771537-99-6P, N-(2,5-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-00-2P, N-(2,6-Difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-01-3P, N-(2-Chloro-4-nitrophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-02-4P, N-[2-(Difluoromethoxy)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-03-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]thiourea

771538-04-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2-fluorophenyl)thiourea 771538-05-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2-iodophenyl)thiourea 771538-06-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[3-[(trifluoromethyl)thio]phenyl]thiourea 771538-07-9P, N-(3,5-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-08-0P, N-(3,5-Difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-09-1P, N-(3-Cyanophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-10-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3-fluorophenyl)thiourea 771538-11-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3-iodophenyl)thiourea 771538-12-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3-methoxyphenyl)thiourea 771538-13-7P, N-[4-(Difluoromethoxy)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-14-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-(trifluoromethoxy)phenyl]thiourea 771538-15-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-(trifluoromethyl)phenyl]thiourea 771538-16-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-[(trifluoromethyl)thio]phenyl]thiourea 771538-17-1P, N-(4-Bromo-2-fluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-18-2P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-19-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-fluoro-3-(trifluoromethyl)phenyl]thiourea 771538-20-6P, N-(5-Chloro-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-21-7P, tert-Butyl [4-[[[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]phenyl]carbamate 771538-22-8P, N-[2-(3,4-Dimethoxyphenyl)ethyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-23-9P, N-[2-(4-Chlorophenyl)ethyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-24-0P 771538-25-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2,4,5-trichlorophenyl)thiourea 771538-26-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2,4,6-trifluorophenyl)thiourea 771538-27-3P, N-(2,6-Diisopropylphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-28-4P, N-[2-Chloro-5-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-29-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[3-(methylthio)phenyl]thiourea 771538-30-8P, N-(3,4-Dichlorobenzyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-31-9P, N-(3,5-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-32-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3,5-dimethylphenyl)thiourea 771538-33-1P, N-[3-(Benzyloxy)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-34-2P,

3-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]benzoic acid 771538-35-3P, N-(3-Chloro-4-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-36-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3-phenylpropyl)thiourea 771538-37-5P, N-[4-(Diethylamino)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-38-6P, Ethyl 4-[[[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]benzoate 771538-39-7P 771538-40-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-fluorobenzyl)thiourea 771538-41-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-isopropylphenyl)thiourea 771538-42-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-methoxy-2-nitrophenyl)thiourea 771538-43-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-methoxybenzyl)thiourea 771538-44-4P, Methyl 4-[[[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]benzoate 771538-45-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-methyl-2-nitrophenyl)thiourea 771538-46-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-methylbenzyl)thiourea 771538-47-7P, N-(4-Butylphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-48-8P, N-(5-Chloro-2-methoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-49-9P 771538-50-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(diphenylmethyl)thiourea 771538-51-3P, N-Cyclododecyl-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-52-4P, N-(Cyclohexylmethyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-53-5P, N-Cyclooctyl-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-54-6P, N-Cyclopropyl-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-55-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2,2-diphenylethyl)thiourea 771538-56-8P, N-(2,4-Dichlorobenzyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-57-9P, N-(2,5-Dibromophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-58-0P, N-[2-(2,5-Dimethoxyphenyl)ethyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-59-1P, N-(2-Chloro-5-nitrophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-60-4P, N-(2-Cyanophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-61-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2-fluorobenzyl)thiourea 771538-62-6P, N-[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]carbonothioyl]-2-furancarboxamide 771538-63-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2-methoxy-5-nitrophenyl)thiourea 771538-64-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2-methylbenzyl)thiourea 771538-65-9P, N-(3,4-Dimethoxybenzyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-66-0P,

N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3-ethylphenyl)thiourea 771538-67-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3-fluorobenzyl)thiourea 771538-68-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3-methoxybenzyl)thiourea 771538-69-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3-methylbenzyl)thiourea 771538-70-6P, N-(4-Bromo-3-chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-71-7P, N-(4-Bromo-3-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-72-8P, N-(4-Decylphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-73-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-(4-nitrophenoxy)phenyl]thiourea 771538-74-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]thiourea 771538-75-1P, 4-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]benzenesulfonamide 771538-76-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[2-(4-methylphenyl)ethyl]thiourea 771538-77-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-phenoxyphenyl)thiourea 771538-78-4P, N-(2,3-Dihydro-1H-inden-5-yl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-79-5P, N-Cycloheptyl-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-80-8P 771538-81-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-(piperidin-1-ylsulfonyl)phenyl]thiourea 771538-82-0P 771538-83-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2,5-dimethylphenyl)thiourea 771538-84-2P, N-(2-Bromo-4-isopropylphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-85-3P, N-(2-Bromo-5-fluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-86-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(2-methoxybenzyl)thiourea 771538-87-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3,4-dimethylphenyl)thiourea 771538-88-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(4-phenylbutyl)thiourea 771538-89-7P, N-(4-tert-Butylphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-90-0P, N-(5-Chloro-2-fluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-91-1P, N-(Cyclopropylmethyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-92-2P, Ethyl 2-[[[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate 771538-93-3P, N-(2-Bromo-4-fluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-94-4P, N-(3-Chloro-4-fluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-95-5P, N-[4-(Dimethylamino)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-96-6P, N-[3-(Diethylamino)propyl]-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771538-97-7P, N-[cis-4-[[4-(Dimethylamino)-

5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[2-(morpholin-4-yl)ethyl]thiourea 771538-98-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-(phenanthro[9,10-d]oxazol-2-yl)phenyl]thiourea 771538-99-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(pyridin-3-yl)thiourea 771539-00-5P 771539-01-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[3-(morpholin-4-yl)propyl]thiourea 771539-02-7P, N-(4-Chlorobenzyl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771539-03-8P 771539-04-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[2-(piperidin-1-yl)ethyl]thiourea 771539-05-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-(1H-pyrazol-1-yl)phenyl]thiourea 771539-06-1P, N-(2,1,3-Benzothiadiazol-4-yl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771539-07-2P, N-(2,1,3-Benzothiadiazol-5-yl)-N'-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiourea 771539-08-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(3,5-dimethylisoxazol-4-yl)thiourea 771539-09-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[4-(1,3-oxazol-5-yl)phenyl]thiourea 771539-10-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-[6-(morpholin-4-yl)pyridin-3-yl]thiourea 771539-11-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-N'-(6-phenoxypyridin-3-yl)thiourea 771539-12-9P, N-(2-Chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-13-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2,6-dimethylphenyl)urea 771539-14-1P, N-(2,4-Difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-15-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-ethyl-6-methylphenyl)urea 771539-16-3P 771539-17-4P, N'-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(4-fluorophenyl)urea 771539-18-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-[4-(methylthio)phenyl]urea 771539-19-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-[2-(trifluoromethyl)phenyl]urea 771539-20-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-mesitylurea 771539-21-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-methylphenyl)urea 771539-22-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2,4,6-trichlorophenyl)urea 771539-23-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2,4,6-tribromophenyl)urea 771539-24-3P, N-(2,4-Dibromo-6-fluorophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-25-4P, N-(2,6-Diethylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-26-5P, N-[2-Chloro-6-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-27-6P, N-(2-Chloro-6-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-28-7P, N-(2-Chlorobenzyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-29-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-ethyl-6-isopropylphenyl)urea 771539-30-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-ethylphenyl)urea 771539-31-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-iodophenyl)urea 771539-32-3P, N-[cis-4-[[4-

(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-isopropyl-6-methylphenyl)urea 771539-33-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-isopropylphenyl)urea 771539-34-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-methyl-3-nitrophenyl)urea 771539-35-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-propylphenyl)urea 771539-36-7P, N-(2-tert-Butyl-6-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-37-8P, N-(2-tert-Butylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-38-9P, N-(3-Chloro-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-39-0P, N-(4-Bromo-2,6-difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-40-3P, N-[4-Chloro-2-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-41-4P, N-(4-Cyanophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-42-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(diphenylmethyl)urea 771539-43-6P, N-(4-Bromo-2,6-dimethylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-44-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea 771539-45-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea 771539-46-9P, N-(2-Bromophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-47-0P, N-(Biphenyl-2-yl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-48-1P, N-Butyl-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-49-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2,3-dimethylphenyl)urea 771539-50-5P, Ethyl 3-[[[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]carbonyl]amino]benzoate 771539-51-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-[1-(3-isopropenylphenyl)-1-methylethyl]urea 771539-52-7P 771539-53-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(naphth-1-yl)urea 771539-54-9P 771539-55-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(4-phenoxyphenyl)urea 771539-56-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-pentylurea 771539-57-2P 771539-58-3P 771539-59-4P 771539-60-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2,3,5,6-tetrachlorophenyl)urea 771539-61-8P, N-(2,4-Dibromophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-62-9P, N-(2,4-Dichlorobenzyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-63-0P, N-(2,4-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-64-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-ethoxyphenyl)urea 771539-65-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-fluorobenzyl)urea 771539-66-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-methyl-4-nitrophenyl)urea 771539-67-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-methyl-5-nitrophenyl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(melanin-concentrating hormone antagonist; preparation of quinolines,

quinazolines,
and pyrimidines as melanin-concentrating hormone antagonist for treatment of
CNS disorders)

IT 771539-68-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-methylbenzyl)urea 771539-69-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-nitrophenyl)urea 771539-70-9P, N-(Benzodioxol-5-yl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-71-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(3,4,5-trimethoxyphenyl)urea 771539-72-1P, N-(3,4-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-73-2P, N-(3-Chloro-4-methoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-74-3P, N-[4-Bromo-2-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-75-4P, N-(4-Bromobenzyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-76-5P, N-(4-Chloro-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-77-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(4-fluorobenzyl)urea 771539-78-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(4-methoxy-2-methylphenyl)urea 771539-79-8P, N-(5-Chloro-2,4-dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-80-1P 771539-81-2P, N-(4-Bromo-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-82-3P 771539-83-4P, N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-84-5P, N-(2,6-Dibromo-4-isopropylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-85-6P, N-[3-(Cyclopentyloxy)-4-methoxyphenyl]-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-86-7P, N-(3,4-Dihydro-2H-1,5-benzodioxepin-7-yl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-87-8P, N-(4-Butyl-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]urea 771539-88-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(5-methyl-3-phenylisoxazol-4-yl)urea 771539-89-0P, N-(4-Bromophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771539-90-3P, N-(4-Cyanophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771539-91-4P, N-(2,4-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771539-92-5P, N-(2,4-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771539-93-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2,6-dimethylphenyl)thiourea 771539-94-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-ethyl-6-isopropylphenyl)thiourea 771539-95-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-methoxyphenyl)thiourea 771539-96-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(naphth-1-yl)thiourea 771539-97-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(3,4,5-trimethoxyphenyl)thiourea 771539-98-1P, N-(3,4-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771539-99-2P, N-[4-(Dimethylamino)naphth-1-yl]-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea

771540-00-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-ethylphenyl)thiourea 771540-01-3P, N-(2-Chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-02-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2,6-dimethylphenyl)urea 771540-03-5P, N-(2,4-Difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-04-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-ethyl-6-methylphenyl)urea 771540-05-7P 771540-06-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(4-fluorophenyl)urea 771540-07-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-[4-(methylthio)phenyl]urea 771540-08-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-[2-(trifluoromethyl)phenyl]urea 771540-09-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-mesitylurea 771540-10-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-methylphenyl)urea 771540-11-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2,4,6-trichlorophenyl)urea 771540-12-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2,4,6-tribromophenyl)urea 771540-13-7P, N-(2,4-Dibromo-6-fluorophenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-14-8P, N-(2,6-Diethylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-15-9P, N-[2-Chloro-6-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-16-0P, N-(2-Chloro-6-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-17-1P, N-(2-Chlorobenzyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-18-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-ethyl-6-isopropylphenyl)urea 771540-19-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-ethylphenyl)urea 771540-20-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-iodophenyl)urea 771540-21-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-isopropyl-6-methylphenyl)urea 771540-22-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-isopropylphenyl)urea 771540-23-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-methyl-3-nitrophenyl)urea 771540-24-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-propylphenyl)urea 771540-25-1P, N-(2-tert-Butyl-6-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-26-2P, N-(2-tert-Butylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-27-3P, N-(3-Chloro-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-28-4P, N-(4-Bromo-2,6-difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-29-5P, N-[4-Chloro-2-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-30-8P, N-(4-Cyanophenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-31-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(diphenylmethyl)urea 771540-32-0P, N-(4-Bromo-2,6-dimethylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-33-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea 771540-34-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea 771540-35-3P, N-(2-Bromophenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-36-4P, N-(Biphenyl-2-yl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-37-5P, N-Butyl-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-38-6P,

N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2,3-dimethylphenyl)urea 771540-39-7P, Ethyl 3-[[[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]amino]benzoate 771540-40-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-[1-(3-isopropenylphenyl)-1-methylethyl]urea 771540-41-1P 771540-42-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(naphth-1-yl)urea 771540-43-3P 771540-44-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(4-phenoxyphenyl)urea 771540-45-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-pentylurea 771540-46-6P 771540-47-7P 771540-48-8P 771540-49-9P 771540-50-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2,3,5,6-tetrachlorophenyl)urea 771540-51-3P, N-(2,4-Dibromophenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-52-4P, N-(2,4-Dichlorobenzyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-53-5P, N-(2,4-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-54-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-ethoxyphenyl)urea 771540-55-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-fluorobenzyl)urea 771540-56-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-methyl-4-nitrophenyl)urea 771540-57-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-methyl-5-nitrophenyl)urea 771540-58-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-methylbenzyl)urea 771540-59-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-nitrophenyl)urea 771540-60-4P, N-(Benzodioxol-5-yl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-61-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(3,4,5-trimethoxyphenyl)urea 771540-62-6P, N-(3,4-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-63-7P, N-(3-Chloro-4-methoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-64-8P, N-[4-Bromo-2-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-65-9P, N-(4-Bromobenzyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-66-0P, N-(4-Chloro-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-67-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(4-fluorobenzyl)urea 771540-68-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(4-methoxy-2-methylphenyl)urea 771540-69-3P, N-(5-Chloro-2,4-dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-70-6P 771540-71-7P, N-(4-Bromo-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-72-8P 771540-73-9P, N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-74-0P, N-(2,6-Dibromo-4-isopropylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-75-1P, N-[3-(Cyclopentyloxy)-4-methoxyphenyl]-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-76-2P, N-(3,4-Dihydro-2H-1,5-benzodioxepin-7-yl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-77-3P, N-(4-Butyl-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]urea 771540-78-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(5-methyl-3-phenylisoxazol-4-yl)urea 771540-79-5P, N-(4-Bromophenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771540-80-8P, N-(4-Cyanophenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771540-81-9P, N-(2,4-Dichlorophenyl)-N'-[cis-4-[[4-

(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771540-82-0P, N-(2,4-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771540-83-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2,6-dimethylphenyl)thiourea 771540-85-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-ethyl-6-isopropylphenyl)thiourea 771540-86-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-methoxyphenyl)thiourea 771540-88-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(naphth-1-yl)thiourea 771540-90-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(3,4,5-trimethoxyphenyl)thiourea 771540-92-2P, N-(3,4-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771540-94-4P, N-[4-(Dimethylamino)naphth-1-yl]-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771540-96-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-ethylphenyl)thiourea 771540-98-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-methoxy-4-nitrophenyl)thiourea 771541-00-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-methoxy-5-methylphenyl)thiourea 771541-02-7P, N-(4-Bromo-2-chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-04-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(4-iodophenyl)thiourea 771541-06-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2,4,6-tribromophenyl)thiourea 771541-08-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2,4,6-trichlorophenyl)thiourea 771541-09-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-mesitylthiourea 771541-10-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2,4-dimethylphenyl)thiourea 771541-12-9P , N-(2,6-Diethylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-13-0P, N-(2-Bromo-4-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-14-1P, N-(2-Chlorobenzyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-15-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-ethyl-6-methylphenyl)thiourea 771541-16-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-isopropylphenyl)thiourea 771541-17-4P , Methyl 3-[[[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]benzoate 771541-18-5P, N-(4-Bromo-2,6-dimethylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-19-6P, N-(4-Bromo-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-20-9P, N-[4-Bromo-2-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-21-0P, N-(4-Chloro-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-22-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(naphth-1-ylmethyl)thiourea 771541-23-2P , N-(2,3-Dimethoxybenzyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-24-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2,4,5-trimethylphenyl)thiourea 771541-25-4P, N-(Biphenyl-2-yl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-26-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-methyl-4-nitrophenyl)thiourea 771541-27-6P, N-(3-Chlorobenzyl)-N'-[cis-4-[[4-

(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-28-7P, Ethyl 3-[[[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]benzoate 771541-29-8P, N-[4-Chloro-2-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-30-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(4-fluoro-2-methylphenyl)thiourea 771541-31-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(4-methoxy-2-methylphenyl)thiourea 771541-32-3P, N-(5-Chloro-2,4-dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-33-4P 771541-34-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2,3-dimethylphenyl)thiourea 771541-35-6P, N-(2,4-Dibromo-6-fluorophenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-36-7P, N-(2,4-Dichloro-6-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-37-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-ethoxyphenyl)thiourea 771541-38-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(2-isopropyl-6-methylphenyl)thiourea 771541-39-0P, N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-40-3P, N-(Benzodioxol-5-yl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-41-4P, N-(3-Chloro-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-42-5P, N-[4-Bromo-2-(trifluoromethoxy)phenyl]-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-43-6P, N-(4-Chloro-2,5-dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-44-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-N'-(5-methyl-3-phenylisoxazol-4-yl)thiourea 771541-45-8P

, Methyl 3-[[[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]-4-methylthiophene-2-carboxylate 771541-46-9P, Methyl 3-[[[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]thiophene-2-carboxylate 771541-47-0P, N-(4-Butyl-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiourea 771541-48-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-methoxy-4-nitrophenyl)thiourea 771541-49-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-methoxy-5-methylphenyl)thiourea 771541-50-5P, N-(4-Bromo-2-chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-51-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(4-iodophenyl)thiourea 771541-52-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2,4,6-tribromophenyl)thiourea 771541-53-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2,4,6-trichlorophenyl)thiourea 771541-54-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-mesitylthiourea 771541-55-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2,4-dimethylphenyl)thiourea 771541-56-1P, N-(2,6-Diethylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-57-2P, N-(2-Bromo-4-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-58-3P, N-(2-Chlorobenzyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-59-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-ethyl-6-

methylphenyl)thiourea 771541-60-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-isopropylphenyl)thiourea 771541-61-8P, Methyl 3-[[[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]benzoate 771541-62-9P, N-(4-Bromo-2,6-dimethylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-63-0P, N-(4-Bromo-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-64-1P, N-[4-Bromo-2-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-65-2P, N-(4-Chloro-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-66-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(naphth-1-ylmethyl)thiourea 771541-67-4P, N-(2,3-Dimethoxybenzyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-68-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2,4,5-trimethylphenyl)thiourea 771541-69-6P, N-(Biphenyl-2-yl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-70-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-methyl-4-nitrophenyl)thiourea 771541-71-0P, N-(3-Chlorobenzyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-72-1P, Ethyl 3-[[[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]benzoate 771541-73-2P, N-[4-Chloro-2-(trifluoromethyl)phenyl]-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-74-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(4-fluoro-2-methylphenyl)thiourea 771541-75-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(4-methoxy-2-methylphenyl)thiourea 771541-76-5P, N-(5-Chloro-2,4-dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-77-6P 771541-78-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2,3-dimethylphenyl)thiourea 771541-79-8P, N-(2,4-Dibromo-6-fluorophenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-80-1P, N-(2,4-Dichloro-6-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-81-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-ethoxyphenyl)thiourea 771541-82-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(2-isopropyl-6-methylphenyl)thiourea 771541-83-4P, N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-84-5P, N-(Benzodioxol-5-yl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-85-6P, N-(3-Chloro-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-86-7P, N-[4-Bromo-2-(trifluoromethoxy)phenyl]-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-87-8P, N-(4-Chloro-2,5-dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-88-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-N'-(5-methyl-3-phenylisoxazol-4-yl)thiourea 771541-89-0P, Methyl 3-[[[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]-4-methylthiophene-2-carboxylate 771541-90-3P, Methyl 3-[[[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]amino]carbonothioyl]amino]thiophene-2-carboxylate 771541-91-4P, N-(4-Butyl-2-methylphenyl)-N'-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiourea 771541-92-5P, N-(2-Chlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771541-93-6P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2,6-dimethylphenyl)urea 771541-94-7P, N-(2,4-Difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea

771541-95-8P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-ethyl-6-methylphenyl)urea 771541-96-9P 771541-97-0P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(4-fluorophenyl)urea 771541-98-1P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-[4-(methylthio)phenyl]urea 771541-99-2P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-[2-(trifluoromethyl)phenyl]urea 771542-00-8P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-mesitylurea 771542-01-9P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methylphenyl)urea 771542-02-0P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2,4,6-trichlorophenyl)urea 771542-03-1P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2,4,6-tribromophenyl)urea 771542-04-2P, N-(2,4-Dibromo-6-fluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-05-3P, N-(2,6-Diethylphenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-06-4P, N-[2-Chloro-6-(trifluoromethyl)phenyl]-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-07-5P, N-(2-Chloro-6-methylphenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-08-6P, N-(2-Chlorobenzyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-09-7P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-ethyl-6-isopropylphenyl)urea 771542-10-0P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-ethylphenyl)urea 771542-11-1P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-iodophenyl)urea 771542-12-2P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-isopropyl-6-methylphenyl)urea 771542-13-3P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-isopropylphenyl)urea 771542-14-4P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methyl-3-nitrophenyl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(melanin-concentrating hormone antagonist; preparation of quinolines, quinazolines,
and pyrimidines as melanin-concentrating hormone antagonist for treatment of
CNS disorders)

IT 771542-15-5P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-propylphenyl)urea 771542-16-6P, N-(2-tert-Butyl-6-methylphenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-17-7P, N-(2-tert-Butylphenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-18-8P, N-(3-Chloro-2-methylphenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-19-9P, N-(4-Bromo-2,6-difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-20-2P, N-[4-Chloro-2-(trifluoromethyl)phenyl]-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-21-3P, N-(4-Cyanophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-22-4P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-

yl]amino]cyclohexyl]methyl]-N'-(diphenylmethyl)urea 771542-23-5P , N-(4-Bromo-2,6-dimethylphenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-24-6P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea 771542-25-7P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea 771542-26-8P, N-(3,5-Dichlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-27-9P, N-(2,3-Dichlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-28-0P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(4-methylphenyl)urea 771542-29-1P, N-(2,6-Diisopropylphenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-30-4P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2,3-dimethyl-6-nitrophenyl)urea 771542-31-5P, N-(2,6-Dibromo-4-fluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-32-6P, N-(2,6-Dichlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-33-7P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methoxy-5-methylphenyl)urea 771542-34-8P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methyl-6-nitrophenyl)urea 771542-35-9P, N-(3,4-Difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-36-0P, N-(3,5-Difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-37-1P, N-(3-Chloro-4-fluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea 771542-38-2P, N-(2-Chlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-39-3P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2,6-dimethylphenyl)urea 771542-40-6P, N-(2,4-Difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-41-7P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2-ethyl-6-methylphenyl)urea 771542-42-8P 771542-43-9P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(4-fluorophenyl)urea 771542-44-0P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-[4-(methylthio)phenyl]urea 771542-45-1P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-[2-(trifluoromethyl)phenyl]urea 771542-46-2P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-mesitylurea 771542-47-3P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methylphenyl)urea 771542-48-4P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2,4,6-trichlorophenyl)urea 771542-49-5P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2,4,6-tribromophenyl)urea 771542-50-8P, N-(2,4-Dibromo-6-fluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-51-9P, N-(2,6-Diethylphenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-52-0P, N-[2-Chloro-6-(trifluoromethyl)phenyl]-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-53-1P, N-(2-Chloro-6-methylphenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-54-2P, N-(2-Chlorobenzyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-55-3P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2-ethyl-6-isopropylphenyl)urea 771542-56-4P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-

yl]amino]cyclohexyl]methyl]-N'-(2-ethylphenyl)urea 771542-57-5P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2-iodophenyl)urea 771542-58-6P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2-isopropyl-6-methylphenyl)urea 771542-59-7P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2-isopropylphenyl)urea 771542-60-0P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methyl-3-nitrophenyl)urea 771542-61-1P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2-propylphenyl)urea 771542-62-2P, N-(2-tert-Butyl-6-methylphenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-63-3P, N-(2-tert-Butylphenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-64-4P, N-(3-Chloro-2-methylphenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-65-5P, N-(4-Bromo-2,6-difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-66-6P, N-[4-Chloro-2-(trifluoromethyl)phenyl]-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-67-7P, N-(4-Cyanophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-68-8P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(diphenylmethyl)urea 771542-69-9P, N-(4-Bromo-2,6-dimethylphenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-70-2P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea 771542-71-3P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea 771542-72-4P, N-(3,5-Dichlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-73-5P, N-(2,3-Dichlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-74-6P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(4-methylphenyl)urea 771542-75-7P, N-(2,6-Diisopropylphenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-76-8P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2,3-dimethyl-6-nitrophenyl)urea 771542-77-9P, N-(2,6-Dibromo-4-fluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-78-0P, N-(2,6-Dichlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-79-1P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methoxy-5-methylphenyl)urea 771542-80-4P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methyl-6-nitrophenyl)urea 771542-81-5P, N-(3,4-Difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-82-6P, N-(3,5-Difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-83-7P, N-(3-Chloro-4-fluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]urea 771542-84-8P, N-(2-Chlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771542-85-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2,6-dimethylphenyl)urea 771542-86-0P, N-(2,4-Difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771542-87-1P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-ethyl-6-methylphenyl)urea 771542-88-2P 771542-89-3P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(4-fluorophenyl)urea 771542-90-6P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-

yl]amino]cyclohexyl]methyl]-N'-[4-(methylthio)phenyl]urea 771542-91-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-[2-(trifluoromethyl)phenyl]urea 771542-92-8P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-mesitylurea 771542-93-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methylphenyl)urea 771542-94-0P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2,4,6-trichlorophenyl)urea 771542-95-1P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2,4,6-tribromophenyl)urea 771542-96-2P, N-(2,4-Dibromo-6-fluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771542-97-3P, N-(2,6-Diethylphenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771542-98-4P, N-[2-Chloro-6-(trifluoromethyl)phenyl]-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771542-99-5P, N-(2-Chloro-6-methylphenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-00-1P, N-(2-Chlorobenzyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-01-2P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-ethyl-6-isopropylphenyl)urea 771543-02-3P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-ethylphenyl)urea 771543-03-4P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-iodophenyl)urea 771543-04-5P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-isopropyl-6-methylphenyl)urea 771543-05-6P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-isopropylphenyl)urea 771543-06-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methyl-3-nitrophenyl)urea 771543-07-8P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-propylphenyl)urea 771543-08-9P, N-(2-tert-Butyl-6-methylphenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-09-0P, N-(2-tert-Butylphenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-10-3P, N-(3-Chloro-2-methylphenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-11-4P, N-(4-Bromo-2,6-difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-12-5P, N-[4-Chloro-2-(trifluoromethyl)phenyl]-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-13-6P, N-(4-Cyanophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-14-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(diphenylmethyl)urea 771543-16-9P, N-(4-Bromo-2,6-dimethylphenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-18-1P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea 771543-19-2P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea 771543-20-5P, N-(3,5-Dichlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-21-6P, N-(2,3-Dichlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-22-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-

yl]amino]cyclohexyl]methyl]-N'-(4-methylphenyl)urea 771543-23-8P, N-(2,6-Diisopropylphenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-24-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2,3-dimethyl-6-nitrophenyl)urea 771543-25-0P, N-(2,6-Dibromo-4-fluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-26-1P, N-(2,6-Dichlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-27-2P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methoxy-5-methylphenyl)urea 771543-28-3P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-N'-(2-methyl-6-nitrophenyl)urea 771543-29-4P, N-(3,4-Difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-30-7P, N-(3,5-Difluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-31-8P, N-(3-Chloro-4-fluorophenyl)-N'-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]urea 771543-33-0P, 2,3,4-Trifluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide trifluoroacetate 771543-37-4P, 3,4-Difluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide trifluoroacetate 771543-39-6P, 4-Cyano-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide trifluoroacetate 771543-41-0P, 3-Fluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide trifluoroacetate 771543-43-2P, 3,5-Difluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide trifluoroacetate 771543-45-4P 771543-47-6P 771543-49-8P 771543-51-2P, 4-(Benzyloxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide trifluoroacetate 771543-53-4P 771543-55-6P, 2-(4-Fluorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide trifluoroacetate 771543-57-8P, 2-(4-Chlorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide trifluoroacetate 771543-59-0P, 2,6-Dimethoxy-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide trifluoroacetate 771543-61-4P 771543-63-6P 771543-65-8P 771543-67-0P 771543-69-2P 771543-71-6P, N-(3,5-Difluorophenyl)-N'-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]urea trifluoroacetate 771543-73-8P, N-[3,5-Bis(trifluoromethyl)phenyl]-N'-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]urea trifluoroacetate 771543-75-0P, N-(3-Chlorophenyl)-N'-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]urea trifluoroacetate 771543-77-2P, N-(3,4-Dichlorophenyl)-N'-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]urea trifluoroacetate 771543-79-4P, N-(3-Methoxyphenyl)-N'-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]urea trifluoroacetate 771543-81-8P, 3-Methoxy-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide trifluoroacetate 771543-85-2P, 3-Methoxy-N-[cis-4-[[4-(trifluoromethyl)quinolin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate 771543-87-4P
, 3-Methoxy-N-[cis-4-[(quinolin-2-ylmethyl)amino]cyclohexyl]benzamide trifluoroacetate 771543-89-6P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methylbenzamide trifluoroacetate 771543-92-1P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide hydrochloride 771543-93-2P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride 771543-95-4P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide trifluoroacetate 771543-98-7P, cis-4-[[4-(Dimethylamino)-

6-methylpyrimidin-2-yl]amino]-N-[3-(trifluoromethyl)benzyl]cyclohexanecarboxamide 771544-01-5P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-N-[3-(propionylamino)benzyl]cyclohexanecarboxamide 771544-06-0P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-N-[3-(isobutyrylamino)benzyl]cyclohexanecarboxamide 771544-07-1P 771544-08-2P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-N-[3-[(2,2-dimethylpropanoyl)amino]benzyl]cyclohexanecarboxamide 771544-09-3P, cis-N-[3-[(Cyclobutylcarbonyl)amino]benzyl]-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-10-6P, cis-N-[3-[(Cyclopentylcarbonyl)amino]benzyl]-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-11-7P, cis-N-[3-[(Cyclohexylcarbonyl)amino]benzyl]-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-12-8P, cis-N-[3-[(Cyclopropylcarbonyl)amino]benzyl]-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-13-9P 771544-17-3P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-(propionylamino)benzamide 771544-18-4P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-(isobutyrylamino)benzamide 771544-19-5P, 3-[(Cyclopropylcarbonyl)amino]-N-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771544-20-8P, 3-[(Cyclobutylcarbonyl)amino]-N-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771544-21-9P, 3-[(Cyclopentylcarbonyl)amino]-N-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771544-22-0P, 3-[(Cyclohexylcarbonyl)amino]-N-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771544-23-1P, 3-Methyl-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 771544-24-2P, 4-Methyl-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 771544-25-3P, 4-Fluoro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 771544-26-4P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-3-(trifluoromethyl)benzamide 771544-27-5P, 3-Chloro-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 771544-28-6P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide 771544-29-7P, 3-Methoxy-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 771544-30-0P, 3-Cyano-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 771544-31-1P, 2-(4-Chlorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide 771544-32-2P, 3,4,5-Trimethoxy-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 771544-33-3P, 3,5-Dimethoxy-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]benzamide 771544-34-4P, 2-(3-Methoxyphenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide 771544-35-5P 771544-36-6P, 2-[(3-Methylphenyl)oxy]-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide 771544-37-7P, 5-Bromo-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]-2-furancarboxamide 771544-38-8P, N-[4-(Benzyloxy)phenyl]-N'-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]urea 771544-39-9P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-N'-(4-phenoxyphenyl)urea 771544-40-2P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-N'-(3-phenoxyphenyl)urea 771544-41-3P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-N'-(2-phenoxyphenyl)urea 771544-42-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 771544-43-5P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methoxybenzamide 771544-44-6P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methoxybenzamide 771544-45-7P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-

methylbenzamide 771544-46-8P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771544-47-9P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771544-48-0P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide 771544-49-1P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide 771544-50-4P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 771544-51-5P, cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]-N-(3-iodobenzyl)cyclohexanecarboxamide 771544-52-6P, cis-N-(2,4-Dichlorobenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-53-7P, cis-N-(2,5-Dichlorobenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-54-8P, cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]-N-(4-methylbenzyl)cyclohexanecarboxamide 771544-55-9P, cis-N-(3,5-Dichlorobenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-56-0P, cis-N-(3,5-Dimethoxybenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-57-1P, cis-N-(3-Chlorobenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-58-2P, cis-N-[3,5-Bis(trifluoromethyl)benzyl]-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-59-3P, cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]-N-(3-methoxybenzyl)cyclohexanecarboxamide 771544-60-6P, cis-N-(4-Chlorobenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-61-7P, cis-N-(3,4-Dichlorobenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-62-8P, cis-N-(2,4-Difluorobenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-63-9P, cis-N-(2,5-Difluorobenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-64-0P, cis-N-(2,3-Difluorobenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-65-1P, cis-N-(4-Bromo-2-fluorobenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771544-66-2P, cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]-N-(3-methylbenzyl)cyclohexanecarboxamide 771544-67-3P, cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]-N-[2-(trifluoromethoxy)benzyl]cyclohexanecarboxamide 771544-68-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771544-73-1P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771544-77-5P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-(trifluoromethoxy)benzamide 771544-78-6P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-(trifluoromethoxy)benzamide trifluoroacetate 771544-81-1P, 3,5-Dichloro-N-[cis-4-[[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]benzamide 771544-82-2P, 3,5-Dichloro-N-[cis-4-[[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]benzamide trifluoroacetate 771544-84-4P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide trifluoroacetate 771544-86-6P, 4-Chloro-N-[[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771544-87-7P, 4-Chloro-N-[[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide trifluoroacetate 771544-90-2P 771544-95-7P, 2,2-Difluoro-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-1,3-benzodioxole-5-carboxamide trifluoroacetate 771544-97-9P,

5-Bromo-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-furancarboxamide trifluoroacetate 771544-99-1P, 3,5-Dibromo-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate 771545-01-8P, 3-Fluoro-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-(trifluoromethyl)benzamide trifluoroacetate 771545-03-0P, N-[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide trifluoroacetate 771545-04-1P, N-[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771545-06-3P 771545-08-5P, 3,4-Difluoro-N-[cis-4-[[4-(isopropylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate 771545-10-9P 771545-12-1P, 3,4-Difluoro-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate 771545-14-3P 771545-16-5P 771545-18-7P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate 771545-23-4P 771545-25-6P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-2-hydroxynicotinamide trifluoroacetate 771545-27-8P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-2-furancarboxamide trifluoroacetate 771545-29-0P 771545-31-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(melanin-concentrating hormone antagonist; preparation of quinolines, quinazolines,
and pyrimidines as melanin-concentrating hormone antagonist for treatment of
CNS disorders)

IT 771545-33-6P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-N'-(3-methoxyphenyl)urea trifluoroacetate 771545-35-8P, N-(3,5-Difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]urea trifluoroacetate 771545-37-0P, 1-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]cyclobutanecarboxamide trifluoroacetate 771545-39-2P 771545-41-6P 771545-43-8P 771545-45-0P, 1-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]cyclopropanecarboxamide trifluoroacetate 771545-47-2P, 1-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]cyclobutanecarboxamide trifluoroacetate 771545-49-4P, 1-(2,4-Dichlorophenyl)-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]cyclopropanecarboxamide trifluoroacetate 771545-51-8P 771545-52-9P 771545-54-1P 771545-55-2P 771545-56-3P 771545-57-4P 771545-58-5P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(trifluoromethyl)benzenesulfonamide hydrochloride 771545-59-6P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzenesulfonamide hydrochloride 771545-60-9P, 2-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzenesulfonamide hydrochloride 771545-61-0P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]thiophene-2-sulfonamide hydrochloride 771545-63-2P 771545-65-4P 771545-67-6P 771545-69-8P 771545-72-3P, N-[[(1R,3S)-3-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]-2-(4-fluorophenoxy)nicotinamide trifluoroacetate 771545-75-6P, N-[[(1R,3S)-3-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]-6-(2-methoxyphenoxy)nicotinamide 771545-76-7P, N-[[(1R,3S)-3-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]-6-(2-methoxyphenoxy)nicotinamide trifluoroacetate 771545-78-9P,

N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(3-fluorophenoxy)acetamide 771545-79-0P, 2-[(5-Chloropyridin-3-yl)oxy]-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]acetamide 771545-80-3P, N-[cis-4-[[4-(Dimethylamino)-5-ethylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide 771545-83-6P, N-[cis-4-[[4-[Ethyl(methyl)amino]-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide hydrochloride 771545-87-0P 771545-92-7P, N-[cis-4-[[4-(Dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide trifluoroacetate 771545-93-8P 771545-99-4P 771546-00-0P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-[[3-(trifluoromethyl)phenyl]sulfonyl]acetamide hydrochloride 771546-02-2P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(4-fluorophenoxy)nicotinamide hydrochloride 771546-05-5P, 2-(2-Bromophenoxy)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide hydrochloride 771546-06-6P, 2-(4-Bromophenoxy)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide hydrochloride 771546-07-7P, 2-(4-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide hydrochloride 771546-08-8P, 2-[(5-Chloropyridin-3-yl)oxy]-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide hydrochloride 771546-09-9P, 2-(tert-Butylthio)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide hydrochloride 771546-11-3P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(propylthio)nicotinamide hydrochloride 771546-12-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(isopropylthio)nicotinamide hydrochloride 771546-13-5P 771546-14-6P, 2-[(3,4-Difluorophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide hydrochloride 771546-18-0P 771546-20-4P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771546-22-6P 771546-26-0P 771546-28-2P, N-[[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771546-29-3P 771546-30-6P 771546-31-7P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide hydrochloride 771546-32-8P, N-[cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771546-33-9P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide hydrochloride 771546-35-1P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride 771546-37-3P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride 771546-39-5P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide hydrochloride 771546-41-9P, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride 771546-43-1P, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride 771546-45-3P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-furancarboxamide 771546-47-5P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(methylsulfonyl)benzamide 771546-49-7P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(methylsulfonyl)benzamide 771546-51-1P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(methylsulfonyl)benzamide 771546-53-3P, Methyl 2-[[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoate 771546-55-5P, Methyl

3-[[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoate 771546-57-7P, 2-[[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoic acid hydrochloride 771546-59-9P, 3-[[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoic acid hydrochloride 771546-61-3P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide hydrochloride 771546-63-5P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771546-65-7P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride 771546-67-9P, 3-Chloro-N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride 771546-69-1P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride 771546-71-5P, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride 771546-73-7P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide 771546-75-9P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide hydrochloride 771546-77-1P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide hydrochloride 771546-79-3P, 3-Bromo-4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride 771546-81-7P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771546-83-9P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-methylbenzamide 771546-85-1P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3,4-difluorobenzamide 771546-87-3P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-methoxybenzamide 771546-89-5P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-dimethoxybenzamide 771546-91-9P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-fluoro-4-methylbenzamide 771546-93-1P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-fluoro-3-methylbenzamide 771546-95-3P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-(trifluoromethyl)benzamide 771546-97-5P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-(trifluoromethyl)benzamide 771546-99-7P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-(trifluoromethoxy)benzamide 771547-02-5P, 4-Cyano-N-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771547-04-7P, 4-Bromo-N-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771547-06-9P, 4-Bromo-N-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-methylbenzamide 771547-08-1P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-fluorobenzamide 771547-10-5P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-fluoro-4-(trifluoromethyl)benzamide 771547-12-7P, 3,5-Dichloro-N-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771547-14-9P, 3,4-Dichloro-N-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771547-16-1P, N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-2,2-difluoro-1,3-benzodioxole-5-carboxamide 771547-18-3P,

N-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]biphenyl-4-carboxamide 771547-20-7P, 4-Chloro-N-[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771547-22-9P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-dimethoxybenzamide 771547-24-1P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]benzamide 771547-26-3P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-methylbenzamide 771547-28-5P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3,4-difluorobenzamide 771547-30-9P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-methoxybenzamide 771547-32-1P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3,5-dimethoxybenzamide 771547-34-3P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3-fluoro-4-methylbenzamide 771547-36-5P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-fluoro-3-methylbenzamide 771547-38-7P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3-(trifluoromethyl)benzamide 771547-40-1P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-(trifluoromethyl)benzamide 771547-42-3P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3-(trifluoromethoxy)benzamide 771547-44-5P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-(trifluoromethoxy)benzamide 771547-46-7P, 4-Cyano-N-[cis-4-[[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]benzamide 771547-48-9P, 4-Bromo-N-[cis-4-[[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]benzamide 771547-50-3P, 4-Bromo-N-[cis-4-[[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3-methylbenzamide 771547-52-5P, 3-Chloro-N-[cis-4-[[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-fluorobenzamide 771547-54-7P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3-fluoro-4-(trifluoromethyl)benzamide 771547-57-0P, 3,4-Dichloro-N-[cis-4-[[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]benzamide 771547-59-2P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-2,2-difluoro-1,3-benzodioxole-5-carboxamide 771547-61-6P, N-[cis-4-[[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide 771547-63-8P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]benzamide 771547-65-0P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-methylbenzamide 771547-67-2P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3,4-difluorobenzamide 771547-69-4P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-methoxybenzamide 771547-71-8P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3,5-dimethoxybenzamide 771547-73-0P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3-fluoro-4-methylbenzamide 771547-75-2P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-fluoro-3-methylbenzamide 771547-77-4P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3-(trifluoromethyl)benzamide 771547-79-6P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-(trifluoromethyl)benzamide 771547-81-0P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-

yl]amino]methyl]cyclohexyl]-3-(trifluoromethoxy)benzamide 771547-83-2P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-(trifluoromethoxy)benzamide 771547-85-4P, 4-Cyano-N-[cis-4-[[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]benzamide 771547-87-6P, 4-Bromo-N-[cis-4-[[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]benzamide 771547-89-8P, 4-Bromo-N-[cis-4-[[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3-methylbenzamide 771547-91-2P, 3-Chloro-N-[cis-4-[[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-4-fluorobenzamide 771547-93-4P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-3-fluoro-4-(trifluoromethyl)benzamide 771547-95-6P, 3,5-Dichloro-N-[cis-4-[[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]benzamide 771547-97-8P, 3,4-Dichloro-N-[cis-4-[[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]benzamide 771547-99-0P, N-[cis-4-[[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]methyl]cyclohexyl]-2,2-difluoro-1,3-benzodioxole-5-carboxamide 771548-01-7P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771548-03-9P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-methylbenzamide 771548-05-1P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3,4-difluorobenzamide 771548-07-3P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-methoxybenzamide 771548-09-5P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-fluoro-4-methylbenzamide 771548-11-9P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-fluoro-3-methylbenzamide 771548-13-1P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-(trifluoromethyl)benzamide 771548-15-3P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-(trifluoromethyl)benzamide 771548-17-5P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-(trifluoromethoxy)benzamide 771548-19-7P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-(trifluoromethoxy)benzamide 771548-21-1P, 4-Cyano-N-[[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771548-23-3P, 4-Bromo-N-[[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771548-25-5P, 4-Bromo-N-[[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-methylbenzamide 771548-27-7P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-4-fluorobenzamide 771548-29-9P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-3-fluoro-4-(trifluoromethyl)benzamide 771548-31-3P, 3,5-Dichloro-N-[[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771548-33-5P, 3,4-Dichloro-N-[[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 771548-35-7P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]-2,2-difluoro-1,3-benzodioxole-5-carboxamide 771548-37-9P, N-[[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]methyl]biphenyl-4-carboxamide 771548-40-4P 771548-42-6P 771548-44-8P 771548-46-0P 771548-48-2P 771548-50-6P 771548-52-8P 771548-54-0P 771548-56-2P 771548-58-4P 771548-60-8P 771548-62-0P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-N-(3-fluorophenyl)cyclohexanecarboxamide 771548-64-2P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-N-(4-propylphenyl)cyclohexanecarboxamide 771548-66-4P, cis-4-[[4-

(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-N-(4-methoxyphenyl)cyclohexanecarboxamide 771548-68-6P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-N-(3-methoxyphenyl)cyclohexanecarboxamide 771548-70-0P, cis-N-(3-Chlorophenyl)-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771548-72-2P, cis-N-(2-Bromophenyl)-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771548-74-4P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-N-((1S,2R)-2-phenylcyclopropyl)cyclohexanecarboxamide 771548-76-6P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-N-[4-(trifluoromethyl)phenyl]cyclohexanecarboxamide 771548-78-8P, cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-N-[2-(methylthio)phenyl]cyclohexanecarboxamide 771548-80-2P 771548-82-4P, cis-N-(4-Chlorophenyl)-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-N-methylcyclohexanecarboxamide 771548-84-6P 771548-86-8P 771548-88-0P 771548-90-4P, cis-N-Benzyl-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771548-92-6P, cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]-N-(4-fluorobenzyl)cyclohexanecarboxamide 771548-94-8P, cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]-N-(2-fluorobenzyl)cyclohexanecarboxamide 771548-96-0P, cis-N-(3,4-Difluorobenzyl)-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide 771548-98-2P 771549-00-9P 771549-02-1P 771549-04-3P 771549-06-5P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-methoxybenzamide 771549-08-7P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-2,6-dihydroxyisonicotinamide 771549-10-1P
, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]pyrazine-2-carboxamide 771549-12-3P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-6-hydroxynicotinamide 771549-14-5P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-5-methylisoxazole-3-carboxamide 771549-16-7P 771549-18-9P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-2-methyl-1,3-oxazole-4-carboxamide 771549-20-3P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-2-methylnicotinamide 771549-22-5P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-2,6-dimethoxynicotinamide 771549-24-7P, 3-Amino-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]pyrazine-2-carboxamide 771549-26-9P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-2-ethoxynicotinamide 771549-28-1P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]pyridine-2-carboxamide 771549-30-5P, 3-Cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771549-32-7P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 771549-34-9P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771549-36-1P, 3-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771549-38-3P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide 771549-40-7P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide 771549-42-9P, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771549-44-1P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide 771549-46-3P, 4-Cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771549-48-5P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-methylbenzamide 771549-50-9P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-

yl]amino]cyclohexyl]-4-fluorobenzamide 771549-52-1P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771549-54-3P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-2-methoxybenzamide 771549-56-5P, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771549-58-7P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide 771549-60-1P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-ethoxybenzamide 771549-62-3P, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 771549-64-5P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide 771549-66-7P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide 771549-68-9P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-ethylbenzamide 771549-70-3P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide 771549-72-5P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 771549-74-7P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-5-methylthiophene-2-carboxamide 771549-76-9P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-6-(trifluoromethyl)nicotinamide 771549-78-1P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,5-diethoxybenzamide 771549-80-5P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-ethoxybenzamide 771549-82-7P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-isopropoxybenzamide 771549-84-9P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-6-hydroxypyridine-2-carboxamide 771549-86-1P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide 771549-88-3P, 4-(Dimethylamino)-5,6-dimethyl-2-[[cis-4-[[3-(trifluoromethoxy)benzyl]amino]cyclohexyl]amino]pyrimidine 771549-90-7P, 2-[[cis-4-[(3,4-Difluorobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6-dimethylpyrimidine 771549-92-9P, N-(3,4-Dimethoxyphenyl)-N'-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]urea 771549-94-1P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-N'-(2-ethoxyphenyl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(melanin-concentrating hormone antagonist; preparation of quinolines, quinazolines,
and pyrimidines as melanin-concentrating hormone antagonist for treatment of
CNS disorders)

IT 771549-96-3P, N-[4-(Benzyloxy)phenyl]-N'-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]urea 771549-98-5P, 1-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]cyclopropanecarboxamide 771550-00-6P, 1-(2,4-Dichlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]cyclopropanecarboxamide 771550-02-8P, 2-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]acetamide 771550-04-0P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-1-(4-methylphenyl)cyclopropanecarboxamide 771550-06-2P 771550-08-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-1-(4-methoxyphenyl)cyclopropanecarboxamide 771550-10-8P 771550-12-0P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(3-methoxyphenoxy)acetamide 771550-14-2P, N-[cis-4-[[4-(Dimethylamino)-5-

methylpyrimidin-2-yl]amino]cyclohexyl]-2-[3-(trifluoromethyl)phenoxy]aceta
mide 771550-16-4P, 2-(3-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)-5-
methylpyrimidin-2-yl]amino]cyclohexyl]acetamide 771550-18-6P
771550-20-0P 771550-22-2P 771550-24-4P 771550-26-6P,
2-[(3,4-Difluorophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-5-
methylpyrimidin-2-yl]amino]cyclohexyl]acetamide 771550-28-8P,
N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-
[(3-methylphenyl)oxy]nicotinamide 771550-30-2P, N-[cis-4-[[4-
(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(3-
fluorophenoxy)nicotinamide 771550-32-4P, N-[cis-4-[[4-(Dimethylamino)-5-
methylpyrimidin-2-yl]amino]cyclohexyl]-2-(3-methoxyphenoxy)nicotinamide
771550-34-6P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]-2-(4-methoxyphenoxy)nicotinamide 771550-36-8P,
N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(4-
iodophenoxy)nicotinamide 771550-38-0P, N-[cis-4-[[4-(Dimethylamino)-5-
methylpyrimidin-2-yl]amino]cyclohexyl]-2-(2-methoxyphenoxy)nicotinamide
771550-40-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]-2-(2-fluorophenoxy)nicotinamide 771550-42-6P,
2-(2-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]nicotinamide 771550-44-8P, 2-(3-Chlorophenoxy)-N-
[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]nicotinamide 771550-46-0P, 2-(3-Bromophenoxy)-N-[cis-
4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide
771550-48-2P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]-2-[3-(trifluoromethyl)phenoxy]nicotinamide
771550-50-6P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide 771550-52-8P,
N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-
fluorobenzamide 771550-54-0P, 3-Bromo-N-[cis-4-[[4-(dimethylamino)-5-
methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771550-56-2P,
N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-
fluorobenzamide 771550-58-4P, N-[cis-4-[[4-(Dimethylamino)-5-
methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide
771550-60-8P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]-2,4-difluorobenzamide 771550-62-0P,
N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2,5-
difluorobenzamide 771550-64-2P, N-[cis-4-[[4-(Dimethylamino)-5-
methylpyrimidin-2-yl]amino]cyclohexyl]-2,3,4-trifluorobenzamide
771550-66-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]benzamide 771550-68-6P, 4-tert-Butyl-N-[cis-4-[[4-
(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771550-70-0P, 4-Butyl-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]benzamide 771550-72-2P, 4-Chloro-N-[cis-4-[[4-
(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771550-74-4P, 3-Cyano-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]benzamide 771550-76-6P, 4-Cyano-N-[cis-4-[[4-
(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771550-78-8P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]-2-methoxybenzamide 771550-80-2P,
4-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]benzamide 771550-82-4P, N-[cis-4-[[4-(Dimethylamino)-
5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide
771550-84-6P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]-4-methoxybenzamide 771550-86-8P,
2-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]benzamide 771550-88-0P, 2-Chloro-N-[cis-4-[[4-
(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771550-90-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-
yl]amino]cyclohexyl]-2-fluorobenzamide 771550-92-6P,
N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-

methylbenzamide 771550-94-8P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(trifluoromethyl)benzamide 771550-96-0P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)benzamide 771550-98-2P, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 771551-00-9P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-ethoxybenzamide 771551-02-1P, 3-(Dimethylamino)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771551-04-3P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide 771551-06-5P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide 771551-08-7P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethylbenzamide 771551-10-1P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2,2-difluoro-1,3-benzodioxole-5-carboxamide 771551-12-3P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethoxybenzamide 771551-14-5P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-isopropoxybenzamide 771551-16-7P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-diethoxybenzamide 771551-18-9P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)benzamide 771551-20-3P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)benzamide 771551-22-5P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 771551-24-7P, 3,5-Dibromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771551-26-9P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethylbenzamide 771551-28-1P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 771551-30-5P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)benzamide 771551-32-7P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methylbenzamide 771551-34-9P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771551-36-1P 771551-38-3P 771551-40-7P 771551-42-9P 771551-44-1P 771551-46-3P 771551-48-5P 771551-50-9P 771551-52-1P, 2-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-methylpropanamide 771551-54-3P, 2-[3,5-Bis(trifluoromethyl)phenyl]-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]acetamide 771551-56-5P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771551-58-7P, 4-Butyl-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771551-60-1P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluorobenzamide 771551-62-3P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide 771551-64-5P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-methoxybenzamide 771551-66-7P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methoxybenzamide 771551-68-9P, 3-Cyano-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771551-70-3P, 4-Cyano-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771551-72-5P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)benzamide 771551-74-7P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)benzamide 771551-76-9P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)benzamide 771551-78-1P, 3-Chloro-N-[cis-4-[[4-

(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 771551-80-5P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide 771551-82-7P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide 771551-84-9P, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771551-86-1P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide 771551-88-3P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-difluorobenzamide 771551-90-7P, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 771551-92-9P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethylbenzamide 771551-94-1P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-ethoxybenzamide 771551-96-3P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide 771551-98-5P, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771552-00-2P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-ethylbenzamide 771552-02-4P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-diethoxybenzamide 771552-04-6P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethoxybenzamide 771552-06-8P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-isopropoxybenzamide 771552-08-0P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 771552-10-4P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-furancarboxamide 771552-12-6P, 5-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-furancarboxamide 771552-14-8P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)benzamide 771552-16-0P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide 771552-18-2P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 771552-20-6P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4,5-trimethoxybenzamide 771552-22-8P, N-[4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-nitrobenzamide 771552-24-0P 771552-26-2P, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771552-28-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzenesulfonamide 771552-30-8P, 4-(Dimethylamino)-5-methyl-2-[[cis-4-[(4-methylbenzyl)amino]cyclohexyl]amino]pyrimidine 771552-32-0P, 2-[[cis-4-[(3,4-Difluorobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5-methylpyrimidine 771552-34-2P, 2-[[cis-4-[(3-Chlorobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5-methylpyrimidine 771552-36-4P, 2-[[cis-4-[(3-Bromobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5-methylpyrimidine 771552-38-6P, 2-[[cis-4-[(3,5-Dimethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5-methylpyrimidine 771552-41-1P, 2-[[cis-4-[(3,5-Dichlorobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5-methylpyrimidine 771552-43-3P, 2-[[cis-4-[(3,4-Dichlorobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5-methylpyrimidine 771552-45-5P, 2-[[cis-4-[(4-Methoxy-3-methylbenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5-methylpyrimidine 771552-47-7P, 4-(Dimethylamino)-5-methyl-2-[[cis-4-[[3-(trifluoromethoxy)benzyl]amino]cyclohexyl]amino]pyrimidine 771552-49-9P, 4-(Dimethylamino)-6-methyl-2-[[cis-4-[[3-(trifluoromethoxy)benzyl]amino]cyclohexyl]amino]pyrimidine 771552-51-3P, N-[cis-4-[[4-(Dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide 771552-53-5P, N-[[(1R,3S)-3-[[4-(Dimethylamino)-5-methylpyrimidin-2-

yl]amino]cyclopentyl]methyl]-6-(3-fluorophenoxy)nicotinamide 771552-55-7P, 6-(3-Chlorophenoxy)-N-[[(1R,3S)-3-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]nicotinamide 771552-57-9P, N-[[(1R,3S)-3-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]-6-(3-methoxyphenoxy)nicotinamide 771552-60-4P, N-[[(1R,3S)-3-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]-6-(2-fluorophenoxy)nicotinamide 771552-62-6P, 2-(4-Bromophenoxy)-N-[[(1R,3S)-3-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]nicotinamide 771552-64-8P, N-[[(1R,3S)-3-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]-2-(2-methoxyphenoxy)nicotinamide 771552-66-0P, 2-(2-Bromophenoxy)-N-[[(1R,3S)-3-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]nicotinamide 771552-68-2P, N-[[(1R,3S)-3-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]-2-(2-fluorophenoxy)nicotinamide 771552-70-6P, N-[[(1R,3S)-3-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]-2-(4-methoxyphenoxy)nicotinamide 771552-72-8P, N-[[(1R,3S)-3-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]-2-(3-fluorophenoxy)nicotinamide 771552-74-0P, 2-(3-Chlorophenoxy)-N-[[(1R,3S)-3-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]nicotinamide 771552-76-2P, 2-(3-Chloro-4-fluorophenoxy)-N-[[(1R,3S)-3-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]nicotinamide 771552-78-4P, 2-(4-Chloro-3-fluorophenoxy)-N-[[(1R,3S)-3-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclopentyl]methyl]nicotinamide 771552-80-8P, N-(3-Chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methylurea 771552-82-0P, N-(3,4-Dichlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methylurea 771552-84-2P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methyl-N-(3-methylphenyl)urea 771552-86-4P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methyl-N-(4-methylphenyl)urea 771552-88-6P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-(3-fluorophenyl)-N-methylurea 771552-90-0P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-(4-fluorophenyl)-N-methylurea 771552-93-3P, N-(4-Chlorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-methylurea 771552-95-5P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-(3-methoxyphenyl)-N-methylurea 771552-98-8P, N'-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-N-(4-methoxyphenyl)-N-methylurea 771553-00-5P, 3,4-Dichloro-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 771553-02-7P, 3,4-Difluoro-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771553-09-4P, 2-Phenoxy-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]nicotinamide hydrochloride 771553-14-1P, 3-Methyl-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771553-18-5P, 3-Methoxy-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771553-20-9P, 3-Chloro-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771553-22-1P 771553-24-3P, 2-Chloro-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]nicotinamide hydrochloride 771553-26-5P, 3-Chloro-4-fluoro-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771553-28-7P, 3,5-Dimethoxy-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771553-30-1P, 3,4-Dichloro-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771553-32-3P 771553-34-5P 771553-36-7P 771553-38-9P 771553-40-3P, 3-Nitro-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771553-42-5P, 4-Fluoro-3-methyl-N-[cis-4-(quinolin-2-

ylamino)cyclohexyl]benzamide hydrochloride 771553-44-7P, 3-Bromo-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771553-46-9P, 2-(2-Bromophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771553-50-5P, 3-Cyano-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771553-52-7P, N-[cis-4-(Quinolin-2-ylamino)cyclohexyl]-3-trifluoromethylbenzamide hydrochloride 771553-54-9P, N-[cis-4-(Quinolin-2-ylamino)cyclohexyl]-2-(m-tolyloxy)acetamide hydrochloride 771553-56-1P, 2,2-Diphenyl-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]acetamide hydrochloride 771553-58-3P 771553-60-7P, 2-(4-Fluorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771553-64-1P, 2-(3,4-Difluorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771553-67-4P, N-[cis-4-(Quinolin-2-ylamino)cyclohexyl]-2-(p-tolyloxy)nicotinamide hydrochloride 771553-70-9P, 2-(4-Chlorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771553-73-2P, 2-(4-Bromophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771553-76-5P, 2-(4-Methoxyphenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771553-80-1P, 2-(3-Chloro-4-fluorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771553-83-4P, N-[cis-4-(Quinolin-2-ylamino)cyclohexyl]-2-(m-tolyloxy)nicotinamide hydrochloride 771553-86-7P, 2-(3-Methoxyphenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide hydrochloride 771553-88-9P, 2-(3-Chlorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide hydrochloride 771553-91-4P, 2-(3-Chloro-4-fluorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide hydrochloride 771553-95-8P, 2-(3,4-Dichlorophenoxy)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide hydrochloride 771553-98-1P, 2-[Methyl(phenyl)amino]-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]acetamide dihydrochloride 771554-02-0P, 2-(3,4-Dichlorophenylamino)-N-[cis-4-[(quinolin-2-yl)amino]cyclohexyl]acetamide dihydrochloride 771554-06-4P, 3,4-Difluoro-N-[[cis-4-(quinolin-2-ylamino)cyclohexyl]methyl]benzamide hydrochloride 771554-13-3P, 2-Phenoxy-N-[[cis-4-(quinolin-2-ylamino)cyclohexyl]methyl]nicotinamide hydrochloride 771554-15-5P 771554-18-8P
, 3,4-Difluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771554-20-2P, N-(2,3-Dichlorophenyl)-N'-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]urea hydrochloride 771554-23-5P, 3-Chloro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771554-25-7P 771554-27-9P, 3-Methyl-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771554-29-1P, 3-Methoxy-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771554-31-5P, 4-Cyano-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771554-33-7P, 3,4-Dichloro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771554-35-9P, 3-Chloro-4-fluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771554-37-1P, 4-Fluoro-3-methyl-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771554-39-3P 771554-41-7P 771554-43-9P 771554-45-1P, N-[cis-4-(4-Methylquinolin-2-ylamino)cyclohexyl]-2-(m-tolyloxy)acetamide hydrochloride 771554-47-3P 771554-49-5P, 3-Bromo-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771554-51-9P, 3-Cyano-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771554-53-1P, N-[cis-4-(4-Methylquinolin-2-ylamino)cyclohexyl]-3-

trifluoromethylbenzamide hydrochloride 771554-55-3P
771554-57-5P, 2-(4-Fluorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771554-59-7P, 2-(3,4-Difluorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771554-61-1P, N-[cis-4-(4-Methylquinolin-2-ylamino)cyclohexyl]-2-(p-tolyloxy)nicotinamide hydrochloride 771554-63-3P, 2-(4-Chlorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771554-65-5P, 2-(4-Bromophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771554-67-7P, 2-(4-Methoxyphenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771554-69-9P, 2-(3-Chloro-4-fluorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771554-71-3P, N-[cis-4-(4-Methylquinolin-2-ylamino)cyclohexyl]-2-(m-tolyloxy)nicotinamide hydrochloride 771554-73-5P, 2-(3-Methoxyphenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide hydrochloride 771554-75-7P, 2-(3-Chlorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide hydrochloride 771554-77-9P, 2-(3-Chloro-4-fluorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide hydrochloride 771554-79-1P, 2-(3,4-Dichlorophenoxy)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide hydrochloride 771554-81-5P, 2-[Methyl(phenyl)amino]-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]acetamide dihydrochloride 771554-83-7P, 2-(3,4-Dichlorophenylamino)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]acetamide dihydrochloride 771554-85-9P, 3,4-Difluoro-N-[[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]methyl]benzamide hydrochloride 771554-89-3P 771554-91-7P, N-(2,3-Dichlorophenyl)-N'-[[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]methyl]urea hydrochloride 771554-93-9P 771554-98-4P, 3-Chloro-N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]-4-fluorobenzamide hydrochloride 771555-00-1P, N-[cis-4-(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]-4-fluoro-3-methylbenzamide hydrochloride 771555-02-3P, N-[cis-4-(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]-3,5-dimethoxybenzamide hydrochloride 771555-04-5P 771555-06-7P, N-[cis-4-(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]-3-nitrobenzamide hydrochloride 771555-08-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(melanin-concentrating hormone antagonist; preparation of quinolines, quinazolines,
and pyrimidines as melanin-concentrating hormone antagonist for treatment of
CNS disorders)

IT 771555-11-4P 771555-15-8P 771555-17-0P
771555-19-2P, 3,4-Difluoro-N-[cis-4-(4-methoxyquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771555-23-8P, N-[cis-4-(4-Chloroquinolin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771555-25-0P, N-[cis-4-(2-Chloroquinolin-4-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771555-27-2P 771555-33-0P 771555-36-3P, N-[cis-4-(4-Dimethylamino-5-methylpyrimidin-2-ylamino)cyclohexyl]-3-methoxybenzamide hydrochloride 771555-40-9P, N-(2,3-Dichlorophenyl)-N'-[[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]methyl]urea hydrochloride 771555-42-1P 771555-45-4P, 3-Chloro-N-[cis-4-(4-

dimethylamino-6-methylpyrimidin-2-ylamino)cyclohexyl]benzamide hydrochloride 771555-47-6P 771555-53-4P, 3,4-Difluoro-N-[cis-4-[(4-trifluoromethylpyrimidin-2-yl)amino]cyclohexyl]benzamide hydrochloride 771555-55-6P, 3,4-Difluoro-N-[cis-4-(4-methoxypyrimidin-2-ylamino)cyclohexyl]benzamide hydrochloride 771555-57-8P, N-[cis-4-[(4,6-Dimethoxypyrimidin-2-yl)amino]cyclohexyl]-3,4-difluorobenzamide hydrochloride 771555-59-0P, 2-Phenoxy-N-[cis-4-[(4-trifluoromethylpyrimidin-2-yl)amino]cyclohexyl]nicotinamide hydrochloride 771555-61-4P 771555-63-6P 771555-65-8P 771555-70-5P 771555-74-9P, N-[cis-4-(4-Dimethylamino-5-phenylpyrimidin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771555-76-1P, N-[cis-4-(5-Chloro-4-dimethylaminopyrimidin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771555-78-3P 771555-81-8P 771555-83-0P, N-[cis-4-(4,6-Dimethylpyrimidin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771555-85-2P 771555-87-4P, 3,4-Difluoro-N-[cis-4-(pyrimidin-2-ylamino)cyclohexyl]benzamide hydrochloride 771555-89-6P 771555-93-2P, 3-Hydroxy-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771555-94-3P, N-[cis-4-(Quinolin-2-ylamino)cyclohexyl]isophthalamic acid methyl ester hydrochloride 771555-95-4P, N-[cis-4-(Quinolin-2-ylamino)cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771555-96-5P, N-[cis-4-(Quinolin-2-ylamino)cyclohexyl]-3-trifluoromethoxybenzamide hydrochloride 771555-99-8P, 2-[Ethyl(phenyl)amino]-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]acetamide dihydrochloride 771556-00-4P, 3,5-Difluoro-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-01-5P, 4-Chloro-3-fluoro-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-02-6P 771556-03-7P, N-[cis-4-(Quinolin-2-ylamino)cyclohexyl]isophthalamide hydrochloride 771556-04-8P, 3,4-Difluoro-N-[cis-4-[(quinolin-2-ylmethyl)amino]cyclohexyl]benzamide dihydrochloride 771556-05-9P, N-[cis-4-(4-Methylquinolin-2-ylamino)cyclohexyl]-3-trifluoromethoxybenzamide hydrochloride 771556-06-0P, 2-[Ethyl(phenyl)amino]-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]acetamide dihydrochloride 771556-07-1P, 3-Hydroxy-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-08-2P, 2-Amino-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]nicotinamide dihydrochloride 771556-09-3P, 2,3-Difluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-10-6P, 2,4-Difluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-11-7P, 2,5-Difluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-12-8P, 2,6-Difluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-13-9P, 3,5-Difluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-14-0P 771556-15-1P, 4-Chloro-3-fluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-16-2P, 4-Fluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-17-3P, 3-Fluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-18-4P, 2-Fluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-19-5P, 4-Chloro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-20-8P, 2-Hydroxy-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]nicotinamide hydrochloride 771556-21-9P, N-[cis-4-(4-Methylquinolin-2-ylamino)cyclohexyl]isophthalamic acid methyl ester hydrochloride 771556-22-0P, 6-Chloro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]nicotinamide hydrochloride 771556-23-1P, 6-Dimethylamino-N-[cis-4-(4-methylquinolin-2-

ylamino)cyclohexyl]nicotinamide dihydrochloride 771556-25-3P, 3-Hydroxymethyl-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-27-5P, N-[cis-4-(4-Methylquinolin-2-ylamino)cyclohexyl]isophthalamide hydrochloride 771556-28-6P, 3-Chloro-5-fluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-29-7P 771556-30-0P 771556-31-1P, N-[cis-4-(4-Methylquinolin-2-ylamino)cyclohexyl]nicotinamide hydrochloride 771556-32-2P, N-[cis-4-(4-Methylquinolin-2-ylamino)cyclohexyl]isonicotinamide hydrochloride 771556-33-3P 771556-34-4P, 5-Bromo-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]nicotinamide dihydrochloride 771556-35-5P, N-[cis-4-(4-Methylquinolin-2-ylamino)cyclohexyl]-6-trifluoromethylnicotinamide hydrochloride 771556-36-6P, 6-(Imidazol-1-yl)-N-[cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl]nicotinamide dihydrochloride 771556-37-7P, N-[cis-4-(4-Dimethylaminoquinolin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771556-38-8P 771556-39-9P, N-[[cis-4-(4-Dimethylaminoquinolin-2-ylamino)cyclohexyl]methyl]-3,4-difluorobenzamide hydrochloride 771556-40-2P, N-(2,3-Dichlorophenyl)-N'-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]urea hydrochloride 771556-41-3P, N-[cis-4-(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771556-42-4P 771556-43-5P 771556-44-6P, N-[[cis-4-(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]methyl]-3,4-difluorobenzamide hydrochloride 771556-45-7P, N-(2,3-Dichlorophenyl)-N'-[[cis-4-[(4-dimethylamino-5,6,7,8-tetrahydroquinazolin-2-yl)amino]cyclohexyl]methyl]urea hydrochloride 771556-46-8P, N-[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771556-47-9P 771556-48-0P 771556-49-1P 771556-50-4P, N-[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]-2-(4-fluorophenoxy)nicotinamide hydrochloride 771556-51-5P, N-[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]-2-[ethyl(phenyl)amino]acetamide dihydrochloride 771556-52-6P, 2-[(4-Chlorophenyl)ethylamino]-N-[cis-4-[(4-dimethylaminopyrimidin-2-yl)amino]cyclohexyl]acetamide dihydrochloride 771556-53-7P, 2-(3,4-Difluorophenyl)-N-[cis-4-[(4-dimethylaminopyrimidin-2-yl)amino]cyclohexyl]acetamide hydrochloride 771556-54-8P, N-[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]-3,5-difluorobenzamide hydrochloride 771556-55-9P, 3-Chloro-N-[cis-4-(4-dimethylaminopyrimidin-2-ylamino)cyclohexyl]-4-fluorobenzamide hydrochloride 771556-56-0P, 4-Chloro-N-[cis-4-(4-dimethylaminopyrimidin-2-ylamino)cyclohexyl]-3-fluorobenzamide hydrochloride 771556-57-1P 771556-58-2P, N-[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]nicotinamide dihydrochloride 771556-59-3P, N-[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]isonicotinamide dihydrochloride 771556-60-6P, 5-Bromo-N-[cis-4-(4-dimethylaminopyrimidin-2-ylamino)cyclohexyl]nicotinamide hydrochloride 771556-61-7P, N-[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]-6-trifluoromethylnicotinamide hydrochloride 771556-62-8P 771556-63-9P, N-[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]-4-fluorobenzamide hydrochloride 771556-64-0P, 3-Chloro-N-[cis-4-(4-dimethylaminopyrimidin-2-ylamino)cyclohexyl]-5-fluorobenzamide hydrochloride 771556-65-1P, N-[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]-3,4,5-trifluorobenzamide hydrochloride 771556-66-2P, 3,5-Di-tert-butyl-N-[cis-4-(4-dimethylaminopyrimidin-2-ylamino)cyclohexyl]-4-hydroxybenzamide hydrochloride 771556-67-3P, N-(2,3-Dichlorophenyl)-N'-[cis-4-[(4-dimethylaminopyrimidin-2-yl)amino]cyclohexyl]urea hydrochloride 771556-68-4P, N-[[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]methyl]-3,4-difluorobenzamide hydrochloride

771556-69-5P, N-[[cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]methyl]-2-(2,3,6-trichlorophenyl)acetamide hydrochloride 771556-70-8P 771556-71-9P, N-(2,3-Dichlorophenyl)-N'-[[cis-4-[(4-dimethylaminopyrimidin-2-yl)amino]cyclohexyl]methyl]urea hydrochloride 771556-72-0P, 3,4-Difluoro-N-[cis-4-(4-methylaminopyrimidin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-80-0P, 3-Chloro-4-fluoro-N-[cis-4-(4-methylaminopyrimidin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-81-1P, N-[cis-4-(4-Ethylaminopyrimidin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771556-82-2P, N-[cis-4-[4-(Ethylmethylamino)pyrimidin-2-ylamino]cyclohexyl]-3,4-difluorobenzamide hydrochloride 771556-84-4P, 3,4-Difluoro-N-[cis-4-[[4-[(2-hydroxyethyl)(methyl)amino]pyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride 771556-86-6P, 3-Chloro-N-[cis-4-(4-dimethylamino-5-methylpyrimidin-2-ylamino)cyclohexyl]-4-fluorobenzamide hydrochloride 771556-88-8P, 3-Chloro-N-[cis-4-(4-dimethylamino-5-fluoropyrimidin-2-ylamino)cyclohexyl]-4-fluorobenzamide hydrochloride 771556-89-9P, 3-Chloro-N-[cis-4-(4-dimethylamino-6-methylpyrimidin-2-ylamino)cyclohexyl]-4-fluorobenzamide hydrochloride 771556-90-2P, N-[cis-4-(4-Dimethylamino-6-ethylpyrimidin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771556-93-5P, N-[cis-4-[[4,6-Bis(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide hydrochloride 771556-95-7P 771556-96-8P, N-[cis-4-(6-Chloro-4-dimethylaminopyrimidin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771556-97-9P, N-[cis-4-(4-Aminoquinolin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771556-98-0P, 2-[[cis-4-[[1-(3,4-Difluorophenyl)methanoyl]amino]cyclohexyl]amino]quinoline-4-carboxylic acid amide 771557-01-8P 771557-03-0P, 3,4-Difluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide methanesulfonate 771557-05-2P, 3-Chloro-4-fluoro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]benzamide methanesulfonate 771557-06-3P, 3-Methoxy-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide methanesulfonate 771557-07-4P, N-[cis-4-[(4-Amino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771557-09-6P, 2-[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]-1-[4-(trifluoromethoxy)phenyl]ethanone trifluoroacetate 771557-11-0P, N-[1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl]-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea trifluoroacetate 771557-14-3P 771557-16-5P, cis-N-[1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl]-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide trifluoroacetate 771557-18-7P, 3,4-Difluoro-N-[cis-4-[(4-methoxy-5-methylpyrimidin-2-yl)amino]cyclohexyl]benzamide trifluoroacetate 771557-21-2P, N-[cis-4-[[4-Methyl-6-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride 771557-23-4P, N-[[cis-4-[(4-Amino-5-methylpyrimidin-2-yl)amino]cyclohexyl]methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771557-25-6P, 2-[(2-Chlorophenyl)sulfonyl]-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide trifluoroacetate 771557-30-3P 771557-34-7P 771557-36-9P 771557-39-2P 771557-43-8P 771557-45-0P, N-(3,4-Difluorophenyl)-N'-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]urea trifluoroacetate 771557-46-1P, 2-[(3,4-Difluorophenyl)amino]-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]nicotinamide 771557-48-3P 771557-50-7P 771557-52-9P 775312-31-7P 775312-32-8P 775312-33-9P 775320-98-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(melanin-concentrating hormone antagonist; preparation of quinolines, quinazolines,
and pyrimidines as melanin-concentrating hormone antagonist for treatment of
CNS disorders)

IT 75-66-1, 2-Methyl-2-propanethiol 79-03-8, Propionyl chloride 85-41-6, Phthalimide 86-95-3, Quinoline-2,4-diol 90-05-1, 2-Methoxyphenol 95-56-7, 2-Bromophenol 98-80-6, Phenylboronic acid 100-61-8, Methyl(phenyl)amine, reactions 102-36-3, 1,2-Dichloro-4-isocyanatobenzene 104-88-1, 4-Chlorobenzaldehyde, reactions 105-36-2, Ethyl bromoacetate 108-12-3, Isovaleryl chloride 109-83-1, 2-Methylaminoethanol 121-90-4, 3-Nitrobenzoyl chloride 122-01-0, 4-Chlorobenzoyl chloride 150-19-6, 3-Methoxyphenol 288-32-4, Imidazole, reactions 367-12-4, 2-Fluorophenol 371-41-5, 4-Fluorophenol 372-20-3, 3-Fluorophenol 403-16-7, 3-Chloro-4-fluorobenzoic acid 454-89-7, 3-Trifluoromethylbenzaldehyde 455-84-5, 4-Fluoro-3-methylbenzoyl chloride 455-86-7, 3,4-Difluorobenzoic acid 501-53-1, Benzyl chloroformate 541-41-3, Ethyl chloroformate 609-71-2, 2-Hydroxynicotinic acid 612-62-4, 2-Chloroquinoline 618-46-2, 3-Chlorobenzoyl chloride 619-81-8, cis-Cyclohexane-1,4-dicarboxylic acid 624-78-2 634-47-9, 2-Chloro-4-methylquinoline 776-04-5, 2-Trifluoromethylbenzenesulfonyl chloride 785-56-8, 3,5-Bis(trifluoromethyl)benzoyl chloride 874-60-2, 4-Methylbenzoyl chloride 937-00-8, 3-Trifluoromethylbenzenethiol 1452-94-4, 2-Chloronicotinic acid ethyl ester 1546-80-1, 4-Hydroxy-2-trifluoromethylpyrimidine 1643-15-8, m-Tolyloxyacetic acid 1655-07-8, 2-Oxocyclohexanecarboxylic acid ethyl ester 1711-05-3, m-Anisoyl chloride 1711-06-4, 3-Methylbenzoyl chloride 1776-53-0, 4-Aminocyclohexanecarboxylic acid 1780-31-0, 2,4-Dichloro-5-methylpyrimidine 1877-71-0, Isophthalic acid monomethyl ester 2713-33-9, 3,4-Difluorophenol 2740-83-2, 3-Trifluoromethylbenzylamine 2905-62-6, 3,5-Dichlorobenzoyl chloride 3024-72-4, 3,4-Dichlorobenzoyl chloride 3685-23-2, cis-4-Aminocyclohexanecarboxylic acid 3764-01-0, 2,4,6-Trichloropyrimidine 3863-11-4, 3,4-Difluoroaniline 3932-97-6, 2,4-Dichloro-5-trifluoromethylpyrimidine 3934-20-1, 2,4-Dichloropyrimidine 4187-56-8, [(S)-1-(4-Chlorophenyl)ethyl]amine 4212-49-1, 5-Ethyluracil 4774-14-5, 2,6-Dichloropyrazine 5424-21-5, 2,4-Dichloro-6-methylpyrimidine 5467-57-2, 2-Chloroquinoline-4-carboxylic acid 5470-96-2, 2-Quinolinecarboxaldehyde 6320-03-2, 2-Chlorobenzenethiol 7311-34-4, 3,5-Dimethoxybenzaldehyde 13519-75-0, N-(4-Chlorophenyl)ethylamine 15827-56-2, cis-1,4-Diaminocyclohexane 18908-07-1, 3-Methoxyphenyl isocyanate 24358-62-1, 1-(4-Bromophenyl)ethylamine 25199-84-2, 4-(Trifluoromethyl)quinolin-2-ol 26177-43-5, 3-Nitrobenzylamine hydrochloride 26305-13-5, 2,4-Dihydroxy-5,6-dimethylpyrimidine 27298-98-2, [(S)-1-(4-Methylphenyl)ethyl]amine 33034-67-2, 2-Chloro-4-trifluoromethylpyrimidine 35620-71-4, 2-Phenoxynicotinic acid 36823-88-8, 4-Trifluoromethoxybenzoyl chloride 40357-96-8, 5-Nitrothiophene-3-carboxylic acid 40750-59-2, N-(3,4-Dichlorophenyl)-N-methylamine 41195-90-8 42601-04-7 45791-36-4, [(R)-1-(4-Bromophenyl)ethyl]amine 49609-84-9, 2-Chloronicotinoyl chloride 50921-39-6, 1-(4-Chlorophenyl)cyclobutanecarboxylic acid 51362-49-3, 2-Phenoxynicotinoyl chloride 52771-21-8, 3-Trifluoromethoxybenzaldehyde 53292-90-3, cis-4-(tert-Butoxycarbonylamino)cyclohexanecarboxylic acid 58757-38-3, 6-Chloronicotinoyl chloride 60811-24-7, 3,4-Difluorobenzenethiol 61367-17-7, cis-4-Aminocyclohexanecarboxylic acid ethyl ester hydrochloride 72220-50-9, 4-(Trifluoromethoxy)phenoxyacetic acid 72934-37-3, 1-(4-Chlorophenyl)cyclopropanecarboxylic acid 76903-88-3, 3,4-Difluorobenzoyl chloride 83594-83-6, 3,5-Difluorophenyl isocyanate 103962-10-3 127163-51-3, 2,2-Difluorobenzodioxole-5-carbonyl chloride 129986-67-0, N-Methoxy-N-methyl-2-

(triphenylphosphoranylidene)acetamide 132741-29-8 157373-08-5, 2,3,4-Trifluorobenzoyl chloride 220996-80-5, 4-Bromo-2-trifluoromethoxybenzaldehyde 274255-98-0, 3,5-Bis(trifluoromethyl)benzamide chloride 289686-70-0, 2-[3,5-Bis(trifluoromethyl)phenyl]-2-methylpropionic acid 347185-71-1 509143-00-4, cis-(4-Aminomethylcyclohexyl)carbamic acid tert-butyl ester 769175-38-4, 2-[(cis-4-Aminocyclohexyl)amino]-4-(methylamino)quinoline 771544-74-2, cis-N-(4-Aminocyclohexylmethyl)-3,5-bis(trifluoromethyl)benzamide 771546-19-1, 3,4-Difluorophenyl carbamate 771546-24-8, cis-4-(4-Dimethylamino-5-methylpyrimidin-2-ylamino)-1-aminocyclohexane hydrochloride 771553-48-1, 2-Chloro-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]nicotinamide 771555-38-5, 2-Chloro-N-[cis-4-(dimethylaminomethylpyrimidin-2-ylamino)cyclohexyl]nicotinamide 771556-24-2, 6-Chloro-N-[cis-4-(4-methylquinolin-2-ylamino)cyclohexyl]nicotinamide 771557-12-1 771557-22-3, cis-N-(4-Aminocyclohexyl)-4-trifluoromethoxybenzamide 771557-32-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating
hormone antagonist for treatment of CNS disorders)

IT 769175-46-4P, 2-[(cis-4-Aminocyclohexyl)amino]-4-(dimethylamino)quinoline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating hormone antagonist for treatment of CNS disorders)

RN 769175-46-4 ZCAPLUS
CN 2,4-Quinolinediamine, N2-(cis-4-aminocyclohexyl)-N4,N4-dimethyl- (CA INDEX NAME)

Relative stereochemistry.



L50 ANSWER 3 OF 3 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:822842 ZCAPLUS Full-text
DOCUMENT NUMBER: 141:314346
TITLE: Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders
INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.; Semple, Graeme; Zou, Ning
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co. Ltd., Japan; Arena Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 586 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
EP 1464335	A2	20041006	EP 2004-7651		20040330	<--
EP 1464335	A3	20070509				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK						
US 2005197350	A1	20050908	US 2004-812075		20040330	<--
AU 2004226049	A1	20041014	AU 2004-226049		20040331	<--
CA 2518913	A1	20041014	CA 2004-2518913		20040331	<--
WO 2004087669	A1	20041014	WO 2004-JP4624		20040331	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
JP 2004300156	A	20041028	JP 2004-107965		20040331	<--
BR 2004008910	A	20060321	BR 2004-8910		20040331	<--
CN 1798736	A	20060705	CN 2004-80014547		20040331	<--
IN 2005KN01805	A	20061201	IN 2005-KN1805		20050912	<--
MX 2005PA10475	A	20060525	MX 2005-PA10475		20050929	<--
NO 2005004999	A	20051107	NO 2005-4999		20051027	<--
PRIORITY APPLN. INFO.:			US 2003-458530P	P	20030331	<--
			US 2003-495911P	P	20030819	<--
			US 2003-510186P	P	20031009	<--
			US 2003-530360P	P	20031216	<--
			WO 2004-JP4624	W	20040331	

OTHER SOURCE(S): MARPAT 141:314346
GI



AB Title compds. I, II, and III [wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide IV•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data). This is part I of three in a series covering the patent.

IC ICM A61K031-4709
ICS C07D401-12; C07D403-12; C07D405-12; C07D409-12; C07D413-12; C07D417-12; C07D417-14; C07D215-38; A61K031-506; A61P003-04

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 769175-49-7P, Benzyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769175-69-1P, Benzyl [[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]carbamate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

IT 769175-36-2P, 2-[[cis-4-[(4-Bromo-2-trifluoromethoxybenzyl)amino]cyclohexyl]amino]-4-(methylamino)quinoline dihydrochloride 769175-40-8P, 2-[[cis-4-[[2-(4-Bromo-2-trifluoromethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(methylamino)quinoline dihydrochloride 769175-41-9P, 2-[[cis-4-[[(4-Bromo-2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(methylamino)quinoline dihydrochloride 769175-43-1P, 4-(Methylamino)-2-[[cis-4-[[(2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]quinoline dihydrochloride 769175-45-3P, 2-[[cis-4-[(4-Bromo-2-trifluoromethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline dihydrochloride 769175-47-5P, 2-[[cis-4-[[2-(4-Bromo-2-trifluoromethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline dihydrochloride 769175-48-6P, 2-[[cis-4-[[(4-Bromo-2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline dihydrochloride 769175-51-1P, 4-(Dimethylamino)-2-[[cis-4-[[(2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]quinoline dihydrochloride 769175-52-2P, 2-[[cis-4-[(4-Bromo-2-trifluoromethoxybenzyl)amino]cyclohexyl]amino]-4-(methylamino)-5,6,7,8-tetrahydroquinazoline dihydrochloride 769175-54-4P, 2-[[cis-4-[[2-(4-Bromo-2-trifluoromethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(methylamino)-5,6,7,8-tetrahydroquinazoline dihydrochloride 769175-55-5P, 2-[[cis-4-[[(4-Bromo-2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(methylamino)-5,6,7,8-tetrahydroquinazoline dihydrochloride 769175-57-7P, 4-(Methylamino)-2-[[cis-4-[[(2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline dihydrochloride 769175-58-8P, 2-[[cis-4-[(4-Bromo-2-trifluoromethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline dihydrochloride 769175-60-2P, 2-[[cis-4-[[2-(4-Bromo-2-trifluoromethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline dihydrochloride 769175-61-3P, 2-[[cis-4-[[(4-Bromo-2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline dihydrochloride 769175-62-4P, 4-(Dimethylamino)-2-[[cis-4-[[(2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline dihydrochloride 769175-63-5P, 2-[[cis-4-[(4-Bromo-2-trifluoromethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine dihydrochloride 769175-65-7P, 2-[[cis-4-[[2-(4-Bromo-2-trifluoromethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine dihydrochloride 769175-68-0P, 2-[[cis-4-[[(4-Bromo-2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine dihydrochloride 769175-72-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-methoxybenzamide 769175-73-7P, 3-Bromo-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769175-74-8P, 4-Bromo-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769175-75-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2,1,3-benzoxadiazole-5-carboxamide 769175-76-0P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769175-77-1P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769175-78-2P 769175-79-3P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-nitrobenzamide 769175-80-6P, 2-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769175-81-7P, 3-Cyano-N-[cis-4-[[4-(dimethylamino)quinolin-2-

yl]amino]cyclohexyl]benzamide 769175-82-8P, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769175-83-9P, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769175-84-0P, 2,2-Diphenyl-N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769175-85-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide 769175-86-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3,5-difluorobenzamide 769175-87-3P, 2-(2,5-Dimethoxyphenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769175-88-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(ethylthio)nicotinamide 769175-89-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 769175-90-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)benzamide 769175-91-9P, 2,4-Dichloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-fluorobenzamide 769175-92-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]hexanamide 769175-93-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-iodobenzamide 769175-94-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(methylthio)nicotinamide 769175-95-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-methyl-3-nitrobenzamide 769175-96-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-nitrobenzamide 769175-97-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-phenylacetamide 769175-98-6P 769175-99-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1,3-benzodioxole-5-carboxamide 769176-00-3P 769176-01-4P 769176-02-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-methylbenzamide 769176-03-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-methylbenzamide 769176-04-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769176-05-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(2-thienyl)acetamide 769176-06-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide 769176-07-0P, Benzyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769176-08-1P, 4-Nitrobenzyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769176-09-2P, 4-Bromo-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-methylbenzamide 769176-10-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-iodobenzamide 769176-11-6P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-fluorobenzamide 769176-12-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2,3-difluoro-4-methylbenzamide 769176-13-8P, 2-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 769176-14-9P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2,4-difluorobenzamide 769176-15-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(phenylthio)acetamide 769176-16-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-fluoro-3-(trifluoromethyl)benzamide 769176-17-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-fluoro-5-(trifluoromethyl)benzamide 769176-18-3P 769176-19-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(3-methoxyphenyl)acetamide 769176-20-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(4-fluorophenyl)acetamide

769176-21-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(4-methoxyphenyl)acetamide 769176-22-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-methyl-2-(trifluoromethyl)-3-furancarboxamide 769176-23-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2,5-dimethyl-3-furancarboxamide 769176-24-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-ethoxybenzamide 769176-25-2P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 769176-26-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide 769176-27-4P, 2-Cyclopentyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769176-28-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide 769176-29-6P, 4-Cyano-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769176-30-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide 769176-31-0P 769176-32-1P , 2-(2-Bromophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769176-33-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide 769176-34-3P, 2-[(Difluoromethyl)thio]-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769176-35-4P, 2,5-Dichloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiophene-3-carboxamide 769176-36-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(propylthio)nicotinamide 769176-37-6P, 1-Benzyl-3-tert-butyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1H-pyrazole-5-carboxamide 769176-38-7P, 3-tert-Butyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1-methyl-1H-pyrazole-5-carboxamide 769176-39-8P 769176-40-1P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]nicotinamide 769176-41-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(1-naphthyl)acetamide 769176-42-3P, 1-tert-Butyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-methyl-1H-pyrazole-3-carboxamide 769176-43-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1-benzothiophene-3-carboxamide 769176-44-5P 769176-45-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769176-46-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1-benzothiophene-2-carboxamide 769176-47-8P 769176-48-9P, 2-(4-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769176-49-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]cyclohexanecarboxamide 769176-50-3P, 3-(2-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-methylisoxazole-4-carboxamide 769176-51-4P, 1-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]cyclopentanecarboxamide 769176-52-5P, 3-(2-Chloro-6-fluorophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-methylisoxazole-4-carboxamide 769176-53-6P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-(isopropylsulfonyl)thiophene-2-carboxamide 769176-54-7P, 2-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-nitrobenzamide 769176-55-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide 769176-56-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3,4-dimethoxybenzamide 769176-57-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-

fluorobenzamide 769176-58-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)benzamide 769176-59-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide 769176-60-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(4-methoxyphenoxy)-5-nitrobenzamide 769176-61-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1-naphthalenecarboxamide 769176-62-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-naphthalenecarboxamide 769176-63-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-nitro-2-furancarboxamide 769176-64-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-phenoxyacetamide 769176-65-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(2-nitrophenoxy)acetamide 769176-66-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]quinoxaline-2-carboxamide 769176-67-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3,4,5-trimethoxybenzamide 769176-68-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide 769176-69-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide 769176-70-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(trifluoromethoxy)benzamide 769176-71-8P, 4,5-Dimethoxy-2-nitrobenzyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769176-72-9P, 4-Phenoxy-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]butanamide 769176-73-0P, 2-Bromo-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-methoxybenzamide 769176-74-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(2,3,4,5,6-pentafluorophenoxy)acetamide 769176-75-2P, 2-(3,4-Dimethoxyphenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769176-76-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2,3,4-trifluorobenzamide 769176-77-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]cyclopentanecarboxamide 769176-78-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2,4-difluorobenzamide 769176-79-6P, 3-Phenyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]propanamide 769176-80-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2,3,4,5-tetrafluorobenzamide 769176-81-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-ethoxy-1-naphthalenecarboxamide 769176-82-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2,3,4,5,6-pentafluorobenzamide 769176-83-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-[(trifluoromethyl)thio]benzamide 769176-84-3P, 3,4,5-Trichloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769176-85-4P, 2-(3-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769176-86-5P, 3-(2,6-Dichlorophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-methylisoxazole-4-carboxamide 769176-87-6P 769176-88-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(phenylthio)nicotinamide 769176-89-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-[(4-methylphenyl)oxy]nicotinamide 769176-90-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-[(dipropylamino)sulfonyl]benzamide 769176-91-2P, 2-(4-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)quinolin-2-

yl]amino]cyclohexyl]-2-methylpropanamide 769176-92-3P, 5-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(trifluoromethyl)-3-furancarboxamide 769176-93-4P, 2-(2,3-Dihydrobenzo[b]furan-5-yl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1,3-thiazole-4-carboxamide 769176-94-5P, 3-tert-Butyl-1-(2,4-dichlorobenzyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1H-pyrazole-5-carboxamide 769176-95-6P, 6-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2H-chromene-3-carboxamide 769176-96-7P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide 769176-97-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-[(4-methyl-2-oxo-2H-chromen-8-yl)oxy]acetamide 769176-98-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(2-thienyl)-1,3-thiazole-4-carboxamide 769176-99-0P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3-methoxybenzamide 769177-00-6P, 3-Bromo-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769177-01-7P, 4-Bromo-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769177-02-8P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2,1,3-benzoxadiazole-5-carboxamide 769177-03-9P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769177-04-0P
, 4-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769177-05-1P 769177-06-2P, 4-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3-nitrobenzamide 769177-07-3P, 2-(4-Chlorophenyl)-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]acetamide 769177-08-4P, 3-Cyano-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769177-09-5P, 3,5-Dichloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769177-10-8P, 3,4-Dichloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769177-11-9P, -2,2-Diphenyl-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]acetamide 769177-12-0P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3,4-difluorobenzamide 769177-13-1P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3,5-difluorobenzamide 769177-14-2P, 2-(2,5-Dimethoxyphenyl)-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]acetamide 769177-15-3P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-(ethylthio)nicotinamide 769177-16-4P
, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-4-fluorobenzamide 769177-17-5P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3-fluoro-5-(trifluoromethyl)benzamide 769177-18-6P, 2,4-Dichloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-5-fluorobenzamide 769177-19-7P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]hexanamide 769177-20-0P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-4-iodobenzamide 769177-21-1P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-(methylthio)nicotinamide 769177-22-2P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-4-methyl-3-nitrobenzamide 769177-23-3P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3-nitrobenzamide 769177-24-4P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-

yl]amino]cyclohexyl]methyl]-2-phenylacetamide 769177-25-5P
769177-26-6P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]-1,3-benzodioxole-5-carboxamide
769177-27-7P 769177-28-8P 769177-29-9P,
N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3-
methylbenzamide 769177-30-2P, N-[[cis-4-[[4-
(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-4-methylbenzamide
769177-31-3P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]thiophene-2-carboxamide 769177-32-4P,
N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-(2-
thienyl)acetamide 769177-33-5P, N-[[cis-4-[[4-
(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3-
(trifluoromethoxy)benzamide 769177-34-6P, [[4-(4-
Dimethylaminoquinolin-2-ylamino)cyclohexyl]methyl]carbamic acid benzyl
ester 769177-35-7P, [[4-(4-Dimethylaminoquinolin-2-
ylamino)cyclohexyl]methyl]carbamic acid 4-nitrobenzyl ester
769177-36-8P, 4-Bromo-N-[[cis-4-[[4-(dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]-3-methylbenzamide 769177-37-9P,
N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3-
iodobenzamide 769177-38-0P, 3-Chloro-N-[[cis-4-[[4-
(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-fluorobenzamide
769177-39-1P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]-2,3-difluoro-4-methylbenzamide
769177-40-4P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]-4-fluorobenzamide 769177-41-5P,
3-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]-2,4-difluorobenzamide 769177-42-6P,
N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-
(phenylthio)acetamide 769177-43-7P, N-[[cis-4-[[4-
(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-3-
(trifluoromethyl)benzamide 769177-44-8P, N-[[cis-4-[[4-
(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-5-
(trifluoromethyl)benzamide 769177-45-9P 769177-46-0P,
N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-(3-
methoxyphenyl)acetamide 769177-47-1P, N-[[cis-4-[[4-
(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-(4-
fluorophenyl)acetamide 769177-48-2P, N-[[cis-4-[[4-
(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-(4-
methoxyphenyl)acetamide 769177-49-3P, N-[[cis-4-[[4-
(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-5-methyl-2-
(trifluoromethyl)-3-furancarboxamide 769177-50-6P,
N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2,5-
dimethyl-3-furancarboxamide 769177-51-7P, N-[[cis-4-[[4-
(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-ethoxybenzamide
769177-52-8P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]-4-fluorobenzamide 769177-53-9P,
N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3-
fluoro-4-methylbenzamide 769177-54-0P, 2-Cyclopentyl-N-[[cis-4-
[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]acetamide
769177-55-1P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]-3,5-dimethoxybenzamide 769177-56-2P,
4-Cyano-N-[[cis-4-[[4-(dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]benzamide 769177-57-3P,
N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3,5-
bis(trifluoromethyl)benzamide 769177-58-4P 769177-59-5P
, 2-(2-Bromophenyl)-N-[[cis-4-[[4-(dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]acetamide 769177-60-8P,
N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-4-
fluoro-3-methylbenzamide 769177-61-9P, 2-[(Difluoromethyl)thio]-
N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzami

de 769177-62-0P, 2,5-Dichloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]thiophene-3-carboxamide 769177-63-1P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-(propylthio)nicotinamide 769177-64-2P, 1-Benzyl-3-tert-butyl-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-1H-pyrazole-5-carboxamide 769177-65-3P, 3-tert-Butyl-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-1-methyl-1H-pyrazole-5-carboxamide 769177-66-4P 769177-67-5P, 5-Bromo-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]nicotinamide 769177-68-6P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-(1-naphthyl)acetamide 769177-69-7P, 1-tert-Butyl-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-5-methyl-1H-pyrazole-3-carboxamide 769177-70-0P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-1-benzothiophene-3-carboxamide 769177-71-1P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]biphenyl-4-carboxamide 769177-72-2P , 2-Bromo-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769177-73-3P, 2,6-Dichloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769177-74-4P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-iodobenzamide 769177-75-5P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-methylbenzamide 769177-76-6P, 2,3-Dichloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769177-77-7P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-5-fluorobenzamide 769177-78-8P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-9-oxo-9H-fluorene-4-carboxamide 769177-79-9P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2,3,6-trifluorobenzamide 769177-80-2P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2,3-difluorobenzamide 769177-81-3P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2,6-difluorobenzamide 769177-82-4P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-6-(trifluoromethyl)benzamide 769177-83-5P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2,4,6-trimethylbenzamide 769177-84-6P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-6-fluorobenzamide 769177-85-7P, 2,4,6-Trichloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769177-86-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as MCH antagonist for treatment of CNS disorders)

IT 769177-87-9P, 6-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-3-methylbenzamide 769177-88-0P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3,6-difluorobenzamide 769177-89-1P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2,3-dimethylbenzamide 769177-90-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-methoxybenzamide 769177-91-5P, 3-Bromo-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769177-92-6P, 4-Bromo-N-[cis-4-[[4-

(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769177-93-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2,1,3-benzoxadiazole-5-carboxamide 769177-94-8P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769177-95-9P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769177-96-0P 769177-97-1P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-nitrobenzamide 769177-98-2P, 2-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769177-99-3P, 3-Cyano-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769178-00-9P, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769178-01-0P, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769178-02-1P, 2,2-Diphenyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769178-03-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide 769178-04-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,5-difluorobenzamide 769178-05-4P, 2-(2,5-Dimethoxyphenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769178-06-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(ethylthio)nicotinamide 769178-07-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 769178-08-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)benzamide 769178-09-8P, 2,4-Dichloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-fluorobenzamide 769178-10-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]hexanamide 769178-11-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-iodobenzamide 769178-12-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(methylthio)nicotinamide 769178-13-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-methyl-3-nitrobenzamide 769178-14-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-nitrobenzamide 769178-15-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-phenylacetamide 769178-16-7P 769178-17-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1,3-benzodioxole-5-carboxamide 769178-18-9P 769178-19-0P 769178-20-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 769178-21-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-methylbenzamide 769178-22-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769178-23-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(2-thienyl)acetamide 769178-24-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide 769178-25-8P, [4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]carbamic acid benzyl ester 769178-26-9P, [4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]carbamic acid 4-nitrobenzyl ester 769178-27-0P, 4-Bromo-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 769178-28-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-iodobenzamide 769178-29-2P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-fluorobenzamide 769178-30-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2,3-difluoro-4-methylbenzamide 769178-31-6P, 2-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 769178-32-7P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2,4-difluorobenzamide 769178-33-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(phenylthio)acetamide 769178-34-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-fluoro-3-(trifluoromethyl)benzamide 769178-35-0P, N-[cis-4-[[4-

(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-fluoro-5-(trifluoromethyl)benzamide 769178-36-1P 769178-37-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(3-methoxyphenyl)acetamide 769178-38-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(4-fluorophenyl)acetamide 769178-39-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(4-methoxyphenyl)acetamide 769178-40-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-methyl-2-(trifluoromethyl)-3-furancarboxamide 769178-41-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2,5-dimethyl-3-furancarboxamide 769178-42-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-ethoxybenzamide 769178-43-0P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 769178-44-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide 769178-45-2P, 2-Cyclopentyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769178-46-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide 769178-47-4P, 4-Cyano-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769178-48-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide 769178-49-6P 769178-50-9P, 2-(2-Bromophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769178-51-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide 769178-52-1P, 2-[(Difluoromethyl)thio]-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769178-53-2P, 2,5-Dichloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiophene-3-carboxamide 769178-54-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(propylthio)nicotinamide 769178-55-4P, 1-Benzyl-3-tert-butyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1H-pyrazole-5-carboxamide 769178-56-5P, 3-tert-Butyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1-methyl-1H-pyrazole-5-carboxamide 769178-57-6P 769178-58-7P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]nicotinamide 769178-59-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(1-naphthyl)acetamide 769178-60-1P, 1-tert-Butyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-methyl-1H-pyrazole-3-carboxamide 769178-61-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1-benzothiophene-3-carboxamide 769178-62-3P 769178-63-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769178-64-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1-benzothiophene-2-carboxamide 769178-65-6P 769178-66-7P, 2-(4-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769178-67-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]cyclohexanecarboxamide 769178-68-9P, 3-(2-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-methylisoxazole-4-carboxamide 769178-69-0P, 1-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]cyclopentanecarboxamide 769178-70-3P, 3-(2-Chloro-6-fluorophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-methylisoxazole-4-carboxamide 769178-71-4P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(isopropylsulfonyl)thiophene-2-carboxamide 769178-72-5P, 2-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-nitrobenzamide 769178-73-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide

769178-74-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,4-dimethoxybenzamide 769178-75-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-fluorobenzamide 769178-76-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)benzamide 769178-77-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide 769178-78-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(4-methoxyphenoxy)-5-nitrobenzamide 769178-79-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1-naphthalenecarboxamide 769178-80-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-naphthalenecarboxamide 769178-81-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-nitro-2-furancarboxamide 769178-82-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-phenoxyacetamide 769178-83-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(2-nitrophenoxy)acetamide 769178-84-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]quinoxaline-2-carboxamide 769178-85-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,4,5-trimethoxybenzamide 769178-86-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide 769178-87-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide 769178-88-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(trifluoromethoxy)benzamide 769178-89-4P, 4,5-Dimethoxy-2-nitrobenzyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769178-90-7P, 4-Phenoxy-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]butanamide 769178-91-8P, 2-Bromo-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-methoxybenzamide 769178-92-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(2,3,4,5,6-pentafluorophenoxy)acetamide 769178-93-0P, 2-(3,4-Dimethoxyphenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769178-94-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2,3,4-trifluorobenzamide 769178-95-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]cyclopentanecarboxamide 769178-96-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2,4-difluorobenzamide 769178-97-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-phenylpropanamide 769178-98-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2,3,4,5-tetrafluorobenzamide 769178-99-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-ethoxy-1-naphthalenecarboxamide 769179-00-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2,3,4,5,6-pentafluorobenzamide 769179-01-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-[(trifluoromethyl)thio]benzamide 769179-02-4P, 3,4,5-Trichloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769179-03-5P, 2-(3-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769179-04-6P, 3-(2,6-Dichlorophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-methylisoxazole-4-carboxamide 769179-05-7P 769179-06-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(phenylthio)nicotinamide 769179-07-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-[(4-methylphenyl)oxy]nicotinamide 769179-08-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-[(dipropylamino)sulfonyl]benzamide 769179-09-1P, 2-(4-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-methylpropanamide 769179-10-4P, 5-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(trifluoromethyl)-3-

furancarboxamide 769179-11-5P, 2-(2,3-Dihydrobenzo[b]furan-5-yl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1,3-thiazole-4-carboxamide 769179-12-6P, 3-tert-Butyl-1-(2,4-dichlorobenzyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1H-pyrazole-5-carboxamide 769179-13-7P, 6-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2H-chromene-3-carboxamide 769179-14-8P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide 769179-15-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-[(4-methyl-2-oxo-2H-chromen-8-yl)oxy]acetamide 769179-16-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(2-thienyl)-1,3-thiazole-4-carboxamide 769179-17-1P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-methoxybenzamide 769179-18-2P, 3-Bromo-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-19-3P, 4-Bromo-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-20-6P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2,1,3-benzoxadiazole-5-carboxamide 769179-21-7P, 3-Chloro-N-[[cis-4-[3-[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-22-8P, 4-Chloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-23-9P 769179-24-0P, 4-Chloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-nitrobenzamide 769179-25-1P, 2-(4-Chlorophenyl)-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]acetamide 769179-26-2P, 3-Cyano-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-27-3P, 3,5-Dichloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-28-4P, 3,4-Dichloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-29-5P, 2,2-Diphenyl-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]acetamide 769179-30-8P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3,4-difluorobenzamide 769179-31-9P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-difluorobenzamide 769179-32-0P, 2-(2,5-Dimethoxyphenyl)-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]acetamide 769179-33-1P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-(ethylthio)nicotinamide 769179-34-2P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-4-fluorobenzamide 769179-35-3P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-fluoro-5-(trifluoromethyl)benzamide 769179-36-4P, 2,4-Dichloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-5-fluorobenzamide 769179-37-5P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]hexanamide 769179-38-6P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-4-iodobenzamide 769179-39-7P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-(methylthio)nicotinamide 769179-40-0P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-4-methyl-3-nitrobenzamide 769179-41-1P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-nitrobenzamide 769179-42-2P, N-[[cis-4-[[4-(Dimethylamino)Pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-phenylacetamide 769179-43-3P 769179-44-4P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-1,3-benzodioxole-5-carboxamide 769179-45-5P 769179-46-6P 769179-47-7P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-methylbenzamide 769179-48-8P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-4-methylbenzamide 769179-49-9P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]thiophene-2-carboxamide 769179-50-2P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-

yl]amino]cyclohexyl]methyl]-2-(2-thienyl)acetamide 769179-51-3P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-(trifluoromethoxy)benzamide 769179-52-4P, 4-Nitrobenzyl [[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]carbamate 769179-53-5P, 4-Bromo-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-methylbenzamide 769179-54-6P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-iodobenzamide 769179-55-7P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-fluorobenzamide 769179-56-8P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2,3-difluoro-4-methylbenzamide 769179-57-9P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-4-fluorobenzamide 769179-58-0P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2,4-difluorobenzamide 769179-59-1P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-(phenylthio)acetamide 769179-60-4P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-3-(trifluoromethyl)benzamide 769179-61-5P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-5-(trifluoromethyl)benzamide 769179-62-6P 769179-63-7P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-(3-methoxyphenyl)acetamide 769179-64-8P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-(4-fluorophenyl)acetamide 769179-65-9P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-(4-methoxyphenyl)acetamide 769179-66-0P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-5-methyl-2-(trifluoromethyl)-3-furancarboxamide 769179-67-1P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2,5-dimethyl-3-furancarboxamide 769179-68-2P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-ethoxybenzamide 769179-69-3P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-4-fluorobenzamide 769179-70-6P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-fluoro-4-methylbenzamide 769179-71-7P, 2-Cyclopentyl-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]acetamide 769179-72-8P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-dimethoxybenzamide 769179-73-9P, 4-Cyano-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-74-0P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-bis(trifluoromethyl)benzamide 769179-75-1P 769179-76-2P, 2-(2-Bromophenyl)-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]acetamide 769179-77-3P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-4-fluoro-3-methylbenzamide 769179-78-4P, 2-[(Difluoromethyl)thio]-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-79-5P, 2,5-Dichloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]thiophene-3-carboxamide 769179-80-8P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-(propylthio)nicotinamide 769179-81-9P, 1-Benzyl-3-tert-butyl-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-1H-pyrazole-5-carboxamide 769179-82-0P, 3-tert-Butyl-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-1-methyl-1H-pyrazole-5-carboxamide 769179-83-1P 769179-84-2P, 5-Bromo-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]nicotinamide 769179-85-3P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-(1-naphthyl)acetamide 769179-86-4P, 1-tert-Butyl-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-

yl]amino]cyclohexyl]methyl]-5-methyl-1H-pyrazole-3-carboxamide 769179-87-5P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-1-benzothiophene-3-carboxamide 769179-88-6P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]biphenyl-4-carboxamide 769179-89-7P, 2-Bromo-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-90-0P, 2,6-Dichloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-91-1P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-iodobenzamide 769179-92-2P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-methylbenzamide 769179-93-3P, 2,3-Dichloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769179-94-4P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-5-fluorobenzamide 769179-95-5P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-9-oxo-9H-fluorene-4-carboxamide 769179-96-6P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2,3,6-trifluorobenzamide 769179-97-7P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2,3-difluorobenzamide 769179-98-8P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2,6-difluorobenzamide 769179-99-9P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-6-(trifluoromethyl)benzamide 769180-00-9P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2,4,6-trimethylbenzamide 769180-01-0P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-6-fluorobenzamide 769180-02-1P, 2,4,6-Trichloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769180-03-2P 769180-04-3P, 6-Chloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-3-methylbenzamide 769180-05-4P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3,6-difluorobenzamide 769180-06-5P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2,3-dimethylbenzamide 769180-07-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-methoxybenzamide 769180-08-7P, 3-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769180-09-8P, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769180-10-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2,1,3-benzoxadiazole-5-carboxamide 769180-11-2P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769180-12-3P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769180-13-4P 769180-14-5P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-nitrobenzamide 769180-15-6P, 2-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769180-16-7P, 3-Cyano-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769180-17-8P, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769180-18-9P, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769180-19-0P, 2,2-Diphenyl-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769180-20-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

IT 769180-21-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3,5-difluorobenzamide 769180-22-5P, 2-(2,5-Dimethoxyphenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769180-23-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(ethylthio)nicotinamide 769180-24-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 769180-25-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)benzamide 769180-26-9P, 2,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-fluorobenzamide 769180-27-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]hexanamide 769180-28-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-iodobenzamide 769180-29-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(methylthio)nicotinamide 769180-30-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-methyl-3-nitrobenzamide 769180-31-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-nitrobenzamide 769180-32-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-phenylacetamide 769180-33-8P 769180-34-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1,3-benzodioxole-5-carboxamide 769180-35-0P 769180-36-1P 769180-37-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-methylbenzamide 769180-38-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-methylbenzamide 769180-39-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769180-40-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(2-thienyl)acetamide 769180-41-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide 769180-42-9P, [4-(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]carbamic acid benzyl ester 769180-43-0P, [4-(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]carbamic acid 4-nitrobenzyl ester 769180-44-1P, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-methylbenzamide 769180-45-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-iodobenzamide 769180-46-3P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-fluorobenzamide 769180-47-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2,3-difluoro-4-methylbenzamide 769180-48-5P, 2-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 769180-49-6P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]-2,4-difluorobenzamide 769180-50-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(phenylthio)acetamide 769180-51-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-fluoro-3-(trifluoromethyl)benzamide 769180-52-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-fluoro-5-(trifluoromethyl)benzamide 769180-53-2P 769180-54-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-

yl]amino]cyclohexyl]-2-(3-methoxyphenyl)acetamide 769180-55-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(4-fluorophenyl)acetamide 769180-56-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(4-methoxyphenyl)acetamide 769180-57-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-methyl-2-(trifluoromethyl)-3-furancarboxamide 769180-58-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2,5-dimethyl-3-furancarboxamide 769180-59-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-ethoxybenzamide 769180-60-1P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-fluorobenzamide 769180-61-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide 769180-62-3P, 2-Cyclopentyl-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769180-63-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide 769180-64-5P, 4-Cyano-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769180-65-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide 769180-66-7P 769180-67-8P, 2-(2-Bromophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769180-68-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide 769180-69-0P, 2-[(Difluoromethyl)thio]-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769180-70-3P, 2,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiophene-3-carboxamide 769180-71-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(propylthio)nicotinamide 769180-72-5P, 1-Benzyl-3-tert-butyl-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1H-pyrazole-5-carboxamide 769180-73-6P, 3-tert-Butyl-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1-methyl-1H-pyrazole-5-carboxamide 769180-74-7P 769180-75-8P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]nicotinamide 769180-76-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(1-naphthyl)acetamide 769180-77-0P, 1-tert-Butyl-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-methyl-1H-pyrazole-3-carboxamide 769180-78-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1-benzothiophene-3-carboxamide 769180-79-2P 769180-80-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769180-81-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1-benzothiophene-2-carboxamide 769180-82-7P 769180-83-8P, 2-(4-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769180-84-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]cyclohexanecarboxamide 769180-85-0P, 3-(2-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-methylisoxazole-4-carboxamide 769180-86-1P, 1-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]cyclopentanecarboxamide 769180-87-2P, 3-(2-Chloro-6-fluorophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-methylisoxazole-4-carboxamide 769180-88-3P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-

tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-(isopropylsulfonyl)thiophene-2-carboxamide 769180-89-4P, 2-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-nitrobenzamide 769180-90-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide 769180-91-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3,4-dimethoxybenzamide 769180-92-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-fluorobenzamide 769180-93-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)benzamide 769180-94-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide 769180-95-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(4-methoxyphenoxy)-5-nitrobenzamide 769180-96-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1-naphthalenecarboxamide 769180-97-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-naphthalenecarboxamide 769180-98-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-nitro-2-furancarboxamide 769180-99-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-phenoxyacetamide 769181-00-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(2-nitrophenoxy)acetamide 769181-01-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]quinoxaline-2-carboxamide 769181-02-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3,4,5-trimethoxybenzamide 769181-03-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide 769181-04-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide 769181-05-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(trifluoromethoxy)benzamide 769181-06-8P, 4,5-Dimethoxy-2-nitrobenzyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769181-07-9P, 4-Phenoxy-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]butanamide 769181-08-0P, 2-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]-5-methoxybenzamide 769181-09-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(2,3,4,5,6-pentafluorophenoxy)acetamide 769181-10-4P, 2-(3,4-Dimethoxyphenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769181-11-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2,3,4-trifluorobenzamide 769181-12-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]cyclopentanecarboxamide 769181-13-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2,4-difluorobenzamide 769181-14-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-phenylpropanamide 769181-15-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2,3,4,5-tetrafluorobenzamide 769181-16-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-ethoxy-1-naphthalenecarboxamide 769181-17-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2,3,4,5,6-pentafluorobenzamide 769181-18-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-[(trifluoromethyl)thio]benzamide 769181-19-3P,

3,4,5-Trichloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769181-20-6P, 2-(3-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769181-21-7P, 3-(2,6-Dichlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-methylisoxazole-4-carboxamide 769181-22-8P 769181-23-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(phenylthio)nicotinamide 769181-24-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-[(4-methylphenyl)oxy]nicotinamide 769181-25-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-[(dipropylamino)sulfonyl]benzamide 769181-26-2P, 2-(4-Chlorophenoxy)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-methylpropanamide 769181-27-3P, 5-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(trifluoromethyl)-3-furancarboxamide 769181-28-4P, 3-tert-Butyl-1-(2,4-dichlorobenzyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1H-pyrazole-5-carboxamide 769181-29-5P, 6-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2H-chromene-3-carboxamide 769181-30-8P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide 769181-31-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-[(4-methyl-2-oxo-2H-chromen-8-yl)oxy]acetamide 769181-32-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(2-thienyl)-1,3-thiazole-4-carboxamide 769181-33-1P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-methoxybenzamide 769181-34-2P, 3-Bromo-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769181-35-3P, 4-Bromo-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769181-36-4P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2,1,3-benzoxadiazole-5-carboxamide 769181-37-5P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769181-38-6P, 4-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769181-39-7P 769181-40-0P, 4-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-nitrobenzamide 769181-41-1P, 2-(4-Chlorophenyl)-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]acetamide 769181-42-2P, 3-Cyano-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769181-43-3P, 3,5-Dichloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769181-44-4P, 3,4-Dichloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769181-45-5P, 2,2-Diphenyl-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]acetamide 769181-46-6P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3,4-difluorobenzamide 769181-47-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3,5-difluorobenzamide 769181-48-8P, 2-(2,5-Dimethoxyphenyl)-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]acetamide 769181-49-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-(ethylthio)nicotinamide 769181-50-2P,

N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-4-fluorobenzamide 769181-51-3P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-fluoro-5-(trifluoromethyl)benzamide 769181-52-4P, 2,4-Dichloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-5-fluorobenzamide 769181-53-5P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]hexanamide 769181-54-6P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-4-iodobenzamide 769181-55-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-(methylthio)nicotinamide 769181-56-8P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-4-methyl-3-nitrobenzamide 769181-57-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-nitrobenzamide 769181-58-0P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-phenylacetamide 769181-59-1P 769181-60-4P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-1,3-benzodioxole-5-carboxamide 769181-61-5P 769181-62-6P 769181-63-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-methylbenzamide 769181-64-8P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-4-methylbenzamide 769181-65-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]thiophene-2-carboxamide 769181-66-0P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-(2-thienyl)acetamide 769181-67-1P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-(trifluoromethoxy)benzamide 769181-68-2P, Benzyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769181-69-3P, 4-Nitrobenzyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769181-70-6P, 4-Bromo-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-methylbenzamide 769181-71-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-iodobenzamide 769181-72-8P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-fluorobenzamide 769181-73-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2,3-difluoro-4-methylbenzamide 769181-74-0P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-4-fluorobenzamide 769181-75-1P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2,4-difluorobenzamide 769181-76-2P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-(phenylthio)acetamide 769181-77-3P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-3-(trifluoromethyl)benzamide 769181-78-4P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-5-(trifluoromethyl)benzamide 769181-79-5P 769181-80-8P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-(3-methoxyphenyl)acetamide 769181-81-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-(4-fluorophenyl)acetamide 769181-82-0P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-(4-methoxyphenyl)acetamide 769181-83-1P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-5-methyl-2-(trifluoromethyl)-3-furancarboxamide 769181-84-2P, N-[[cis-4-[[4-

(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2,5-dimethyl-3-furancarboxamide 769181-85-3P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-ethoxybenzamide 769181-86-4P, 3-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-4-fluorobenzamide 769181-87-5P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-fluoro-4-methylbenzamide 769181-88-6P, 2-Cyclopentyl-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]acetamide 769181-89-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3,5-dimethoxybenzamide 769181-90-0P, 4-Cyano-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769181-91-1P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3,5-bis(trifluoromethyl)benzamide 769181-92-2P 769181-93-3P, 2-(2-Bromophenyl)-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]acetamide 769181-94-4P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-4-fluoro-3-methylbenzamide 769181-95-5P, 2-[(Difluoromethyl)thio]-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769181-96-6P , 2,5-Dichloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]thiophene-3-carboxamide 769181-97-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-(propylthio)nicotinamide 769181-98-8P, 1-Benzyl-3-tert-butyl-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-1H-pyrazole-5-carboxamide 769181-99-9P, 3-tert-Butyl-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-1-methyl-1H-pyrazole-5-carboxamide 769182-00-5P 769182-01-6P, 5-Bromo-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]methyl]nicotinamide 769182-02-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-(1-naphthyl)acetamide 769182-03-8P, 1-tert-Butyl-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-5-methyl-1H-pyrazole-3-carboxamide 769182-04-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-1-benzothiophene-3-carboxamide 769182-05-0P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]biphenyl-4-carboxamide 769182-06-1P, 2-Bromo-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769182-07-2P, 2,6-Dichloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769182-08-3P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-iodobenzamide 769182-09-4P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-methylbenzamide 769182-10-7P, 2,3-Dichloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769182-11-8P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]methyl]-5-fluorobenzamide 769182-12-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-9-oxo-9H-fluorene-4-carboxamide 769182-13-0P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2,3,6-trifluorobenzamide 769182-14-1P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2,3-difluorobenzamide 769182-15-2P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2,6-difluorobenzamide 769182-16-3P,

N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-6-(trifluoromethyl)benzamide 769182-17-4P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2,4,6-trimethylbenzamide 769182-18-5P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]methyl]-6-fluorobenzamide 769182-19-6P, 2,4,6-Trichloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769182-20-9P 769182-21-0P, 6-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]methyl]-2-fluoro-3-methylbenzamide 769182-22-1P, 2-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]methyl]-3,6-difluorobenzamide 769182-23-2P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2,3-dimethylbenzamide 769182-24-3P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769182-25-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(2,3,6-trichlorophenyl)acetamide 769182-26-5P, 2-(2-Chloro-4-fluorophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769182-27-6P, 5-(4-Chloro-2-nitrophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-furancarboxamide 769182-28-7P, 5-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769182-29-8P 769182-30-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-(2-hydroxyphenyl)propanamide 769182-31-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-iodo-2-furancarboxamide 769182-32-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(2-iodophenyl)acetamide 769182-33-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide 769182-34-5P 769182-35-6P 769182-36-7P, 2-Benzyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769182-37-8P, 2,2-Bis(4-chlorophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769182-38-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-(4-methyl-2-nitrophenyl)-2-furancarboxamide 769182-39-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-nitrothiophene-2-carboxamide 769182-40-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-methyl-4-nitrobenzamide 769182-41-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-methoxy-4-nitrobenzamide 769182-42-5P, 1-Benzyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1H-indole-3-carboxamide 769182-43-6P, 3-Acetyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769182-44-7P 769182-45-8P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-furancarboxamide 769182-46-9P, 3-Cyclohexyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]propanamide 769182-47-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-[(4-methylpyrimidin-2-yl)thio]acetamide 769182-48-1P, 5-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-furancarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

IT 769182-49-2P, 3-(3,4-Dichlorophenyl)-N-[cis-4-[[4-

(dimethylamino)quinolin-2-yl]amino]cyclohexyl]propanamide 769182-50-5P, 2-(3,4-Dichlorophenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769182-52-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(4-hydroxy-3,5-dimethoxyphenyl)acetamide 769182-54-9P, 4,5-Dibromo-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769182-56-1P, 2-(3,5-Dimethoxyphenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769182-58-3P, 2-(3,5-Di-tert-butyl-4-hydroxyphenyl)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769182-60-7P 769182-62-9P , 3-(Dimethylamino)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769182-64-1P, 4,5-Dibromo-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-furancarboxamide 769182-66-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-(4-fluorophenyl)-4-oxobutanamide 769182-68-5P 769182-70-9P 769182-72-1P 769182-74-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(1H-indol-3-yl)acetamide 769182-76-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)acetamide 769182-77-6P 769182-78-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-[1-[(4-methoxybenzyl)thio]cyclohexyl]acetamide 769182-79-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide 769182-80-1P 769182-81-2P 769182-82-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3,5-dimethyl-2-[[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]benzamide 769182-83-4P, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-[(3-phenylprop-2-ynoyl)amino]benzamide 769182-84-5P 769182-85-6P 769182-86-7P 769182-87-8P, N-(2,4-Dichlorophenyl)-2-[2-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]-2-oxoethyl]benzamide 769182-88-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-methyl-1-[3-(morpholin-4-yl)propyl]-5-phenyl-1H-pyrrole-3-carboxamide 769182-89-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-(4-nitrophenyl)butanamide 769182-90-3P 769182-91-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(3-phenoxyphenyl)acetamide 769182-92-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(4-phenoxyphenyl)acetamide 769182-93-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(2-phenyl-1H-indol-3-yl)acetamide 769182-94-7P 769182-95-8P 769182-96-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(2-phenylethyl)benzamide 769182-97-0P, 3-Benzoyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769182-98-1P, 2,2-Diphenyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(ethylthio)acetamide 769182-99-2P, 2-[(2-Cyanophenyl)thio]-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]benzamide 769183-00-8P, 2-[4-(Benzyloxy)-3-methoxyphenyl]-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769183-01-9P* ** ***769183-02-0P 769183-03-1P 769183-04-2P 769183-05-3P 769183-06-4P 769183-07-5P 769183-08-6P 769183-09-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-oxo-4-(2-thienyl)butanamide 769183-10-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-(2-thienyl)butanamide 769183-11-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-

yl]amino]cyclohexyl]-2-(2,4,6-trichlorophenoxy)acetamide 769183-12-2P, 2-[5-(Benzyloxy)-1H-indol-3-yl]-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769183-13-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(1-naphthoyl)benzamide 769183-14-4P, 3-(Benzyloxy)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-methoxybenzamide 769183-15-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide 769183-16-6P, 1-[2-[(2-Chloro-6-fluorobenzyl)thio]ethyl]-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide 769183-17-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]anthracene-9-carboxamide 769183-18-8P 769183-19-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]biphenyl-2-carboxamide 769183-21-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3,3-diphenylpropanamide 769183-22-4P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-phenylquinoline-4-carboxamide 769183-23-5P 769183-24-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(4-methylbenzoyl)benzamide 769183-25-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-(phenoxymethyl)benzamide 769183-26-8P, 2-[4-(4-Chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]acetamide 769183-27-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide 769183-28-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-(3-nitrophenyl)-2-furancarboxamide 769183-29-1P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-(methylsulfonyl)thiophene-2-carboxamide 769183-30-4P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide 769183-31-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-iodo-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide 769183-32-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-nitrothiophene-3-carboxamide 769183-33-7P , N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1-methyl-4-nitro-1H-pyrrole-2-carboxamide 769183-34-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1-(phenylsulfonyl)-1H-indole-3-carboxamide 769183-35-9P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-nitrobenzamide 769183-36-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-methoxy-4-nitrobenzamide 769183-37-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)benzamide 769183-38-2P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-fluoro-4-nitrobenzamide 769183-39-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3,5-dimethyl-4-nitrobenzamide 769183-40-6P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-mesityl-2-(oxo)acetamide 769183-41-7P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]quinoline-3-carboxamide 769183-42-8P 769183-43-9P 769183-44-0P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-1,3-benzothiazole-6-carboxamide 769183-45-1P, 5-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-hydroxybenzamide 769183-46-2P, 2-Chloro-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-5-(methylthio)benzamide 769183-47-3P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-7-methoxy-1-benzofuran-2-carboxamide 769183-48-4P, 2-Amino-N-[cis-4-[[4-

(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-3-methylbenzamide 769183-49-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-hydroxy-3,5-dimethoxybenzamide 769183-50-8P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]quinoline-4-carboxamide 769183-51-9P, 2-(Allylthio)-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]nicotinamide 769183-52-0P, 3,5-Di-tert-butyl-N-[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]-4-hydroxybenzamide 769183-53-1P, 5-Bromo-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]thiophene-2-carboxamide 769183-54-2P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-(2,3,6-trichlorophenyl)acetamide 769183-55-3P, 2-(2-Chloro-4-fluorophenyl)-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]acetamide 769183-56-4P, 5-(4-Chloro-2-nitrophenyl)-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-furancarboxamide 769183-57-5P, 5-Chloro-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]thiophene-2-carboxamide 769183-58-6P 769183-59-7P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3-(2-hydroxyphenyl)propanamide 769183-60-0P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-5-iodo-2-furancarboxamide 769183-61-1P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-(2-iodophenyl)acetamide 769183-62-2P 769183-63-3P 769183-64-4P, 2-Benzyl-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]benzamide 769183-65-5P, 2,2-Bis(4-chlorophenyl)-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]acetamide 769183-66-6P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-5-(4-methyl-2-nitrophenyl)-2-furancarboxamide 769183-67-7P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-5-nitrothiophene-2-carboxamide 769183-68-8P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3-methyl-4-nitrobenzamide 769183-69-9P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3-methoxy-4-nitrobenzamide 769183-70-2P, 1-Benzyl-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-1H-indole-3-carboxamide 769183-71-3P, 2-(Cyclohex-1-en-1-yl)-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]acetamide 769183-72-4P 769183-73-5P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide 769183-74-6P, 4-(Benzyloxy)-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-3,5-dimethylbenzamide 769183-75-7P, N-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]-9H-xanthene-9-carboxamide 769183-76-8P, 2-(Benzo[b]thien-3-yl)-N-[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]acetamide 769183-77-9P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769183-78-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(2,3,6-trichlorophenyl)acetamide 769183-79-1P, 2-(2-Chloro-4-fluorophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769183-80-4P, 5-(4-Chloro-2-nitrophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-furancarboxamide 769183-81-5P, 5-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769183-82-6P 769183-83-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-(2-hydroxyphenyl)propanamide 769183-84-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-iodo-2-furancarboxamide 769183-85-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-

2-(2-iodophenyl)acetamide 769183-86-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide 769183-87-1P 769183-88-2P 769183-89-3P, 2-Benzyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769183-90-6P, 2,2-Bis(4-chlorophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769183-91-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-(4-methyl-2-nitrophenyl)-2-furancarboxamide 769183-92-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-nitrothiophene-2-carboxamide 769183-93-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-methyl-4-nitrobenzamide 769183-94-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-methoxy-4-nitrobenzamide 769183-95-1P, 1-Benzyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1H-indole-3-carboxamide 769183-96-2P, 3-Acetyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769183-97-3P 769183-98-4P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-furancarboxamide 769183-99-5P, 3-Cyclohexyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]propanamide 769184-00-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-[(4-methylpyrimidin-2-yl)thio]acetamide 769184-01-2P, 5-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-furancarboxamide 769184-02-3P, 3-(3,4-Dichlorophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]propanamide 769184-03-4P, 2-(3,4-Dichlorophenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769184-04-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(4-hydroxy-3,5-dimethoxyphenyl)acetamide 769184-05-6P, 4,5-Dibromo-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769184-06-7P, 2-(3,5-Dimethoxyphenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769184-07-8P, 2-(3,5-Di-tert-butyl-4-hydroxyphenyl)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769184-08-9P 769184-09-0P, 3-(Dimethylamino)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769184-10-3P, 4,5-Dibromo-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-furancarboxamide 769184-11-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(4-fluorophenyl)-4-oxobutanamide 769184-12-5P 769184-13-6P 769184-14-7P 769184-15-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(1H-indol-3-yl)acetamide 769184-16-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)acetamide 769184-17-0P 769184-18-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-[1-[(4-methoxybenzyl)thio]cyclohexyl]acetamide 769184-19-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide 769184-20-5P 769184-21-6P 769184-22-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethyl-2-[[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]benzamide 769184-23-8P, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-[(3-phenylprop-2-ynoyl)amino]benzamide 769184-24-9P, 3-[2-(4-Bromophenyl)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl]-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769184-25-0P 769184-26-1P 769184-27-2P 769184-28-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-methyl-1-[3-(morpholin-4-yl)propyl]-5-phenyl-1H-pyrrole-3-carboxamide 769184-29-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(4-nitrophenyl)butanamide 769184-30-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-[(3-nitropyridin-2-yl)thio]acetamide 769184-31-8P 769184-32-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(3-

phenoxyphenyl)acetamide 769184-33-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(4-phenoxyphenyl)acetamide 769184-34-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(2-phenyl-1H-indol-3-yl)acetamide 769184-35-2P 769184-36-3P 769184-37-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(2-phenylethyl)benzamide 769184-38-5P, 3-Benzoyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769184-39-6P, 2,2-Diphenyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(ethylthio)acetamide 769184-40-9P, 2-[(2-Cyanophenyl)thio]-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 769184-41-0P, 2-[4-(Benzyloxy)-3-methoxyphenyl]-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769184-42-1P 769184-43-2P 769184-44-3P 769184-45-4P 769184-46-5P 769184-47-6P 769184-48-7P 769184-49-8P 769184-50-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-oxo-4-(2-thienyl)butanamide 769184-51-2P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(2-thienyl)butanamide 769184-52-3P, 2-[5-(Benzyloxy)-1H-indol-3-yl]-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769184-53-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(1-naphthoyl)benzamide 769184-54-5P, 3-(Benzyloxy)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-methoxybenzamide 769184-55-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide 769184-56-7P, 1-[2-[(2-Chloro-6-fluorobenzyl)thio]ethyl]-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide 769184-57-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]anthracene-9-carboxamide 769184-58-9P 769184-59-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]biphenyl-2-carboxamide 769184-60-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,3-diphenylpropanamide 769184-61-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-phenylquinoline-4-carboxamide 769184-62-5P 769184-63-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(4-methylbenzoyl)benzamide 769184-64-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-(phenoxymethyl)benzamide 769184-65-8P
, 2-[4-(4-Chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]acetamide 769184-66-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide 769184-67-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-(3-nitrophenyl)-2-furancarboxamide 769184-68-1P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(methylsulfonyl)thiophene-2-carboxamide 769184-69-2P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide 769184-70-5P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-iodo-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide 769184-71-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-nitrothiophene-3-carboxamide 769184-72-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1-methyl-4-nitro-1H-pyrrole-2-carboxamide 769184-73-8P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1-(phenylsulfonyl)-1H-indole-3-carboxamide 769184-74-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-nitrobenzamide 769184-75-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-methoxy-4-nitrobenzamide 769184-76-1P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)benzamide 769184-77-2P,

N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-fluoro-4-nitrobenzamide 769184-78-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethyl-4-nitrobenzamide 769184-79-4P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-mesityl-2-(oxo)acetamide 769184-80-7P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]quinoline-3-carboxamide 769184-81-8P 769184-82-9P 769184-83-0P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-1,3-benzothiazole-6-carboxamide 769184-84-1P, 5-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-hydroxybenzamide 769184-85-2P, 2-Chloro-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-(methylthio)benzamide 769184-86-3P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-7-methoxy-1-benzofuran-2-carboxamide 769184-87-4P, 2-Amino-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 769184-88-5P, 2-(Allylthio)-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]nicotinamide 769184-89-6P, 3,5-Di-tert-butyl-N-[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-hydroxybenzamide 769184-90-9P, 5-Bromo-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]thiophene-2-carboxamide 769184-91-0P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-(2,3,6-trichlorophenyl)acetamide 769184-92-1P, 2-(2-Chloro-4-fluorophenyl)-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]acetamide 769184-93-2P, 5-(4-Chloro-2-nitrophenyl)-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-furancarboxamide 769184-94-3P, 5-Chloro-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]thiophene-2-carboxamide 769184-95-4P 769184-96-5P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-(2-hydroxyphenyl)propanamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

IT 769184-97-6P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-5-iodo-2-furancarboxamide 769184-98-7P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide 769184-99-8P 769185-00-4P 769185-01-5P, 2-Benzyl-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]benzamide 769185-02-6P, 2,2-Bis(4-chlorophenyl)-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]acetamide 769185-03-7P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-5-(4-methyl-2-nitrophenyl)-2-furancarboxamide 769185-04-8P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-5-nitrothiophene-2-carboxamide 769185-05-9P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-methyl-4-nitrobenzamide 769185-06-0P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3-methoxy-4-nitrobenzamide 769185-07-1P, 1-Benzyl-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-1H-indole-3-carboxamide 769185-08-2P, 2-Cyclohex-1-en-1-yl-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]acetamide 769185-09-3P 769185-10-6P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide 769185-11-7P, 4-(Benzyloxy)-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-3,5-dimethylbenzamide 769185-12-8P, N-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]-9H-xanthene-9-carboxamide 769185-13-9P, 2-(Benzo[b]thien-3-yl)-N-[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]acetamide

769185-14-0P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769185-15-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(2,3,6-trichlorophenyl)acetamide 769185-16-2P, 2-(2-Chloro-4-fluorophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769185-17-3P, 5-(4-Chloro-2-nitrophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-furancarboxamide 769185-18-4P, 5-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769185-19-5P 769185-20-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-(2-hydroxyphenyl)propanamide 769185-21-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-iodo-2-furancarboxamide 769185-22-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(2-iodophenyl)acetamide 769185-23-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide 769185-24-2P 769185-25-3P 769185-26-4P, 2-Benzyl-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769185-27-5P, 2,2-Bis(4-chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769185-28-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-(4-methyl-2-nitrophenyl)-2-furancarboxamide 769185-29-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-nitrothiophene-2-carboxamide 769185-30-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-methyl-4-nitrobenzamide 769185-31-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-methoxy-4-nitrobenzamide 769185-32-2P, 1-Benzyl-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]-1H-indole-3-carboxamide 769185-33-3P, 3-Acetyl-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769185-34-4P 769185-35-5P, 5-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-furancarboxamide 769185-36-6P, 3-Cyclohexyl-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]propanamide 769185-37-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-[(4-methylpyrimidin-2-yl)thio]acetamide 769185-38-8P, 5-(4-Chlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-furancarboxamide 769185-39-9P, 3-(3,4-Dichlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]propanamide 769185-40-2P, 2-(3,4-Dichlorophenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769185-41-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(4-hydroxy-3,5-dimethoxyphenyl)acetamide 769185-42-4P, 4,5-Dibromo-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]thiophene-2-carboxamide 769185-43-5P, 2-(3,5-Dimethoxyphenyl)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769185-44-6P 769185-45-7P 769185-46-8P, 3-(Dimethylamino)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769185-47-9P, 4,5-Dibromo-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-furancarboxamide 769185-48-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-(4-fluorophenyl)-4-oxobutanamide 769185-49-1P 769185-50-4P 769185-51-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-

yl]amino]cyclohexyl]-2-(1H-indol-3-yl)acetamide 769185-52-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)acetamide 769185-53-7P 769185-54-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-[1-[(4-methoxybenzyl)thio]cyclohexyl]acetamide 769185-55-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide 769185-56-0P 769185-57-1P 769185-58-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3,5-dimethyl-2-[[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]benzamide 769185-59-3P, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-[(3-phenylprop-2-ynoyl)amino]benzamide 769185-60-6P, 3-[2-(4-Bromophenyl)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl]-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769185-61-7P 769185-62-8P 769185-63-9P 769185-64-0P, N-(2,4-Dichlorophenyl)-2-[2-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]-2-oxoethyl]benzamide 769185-65-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-methyl-1-[3-(morpholin-4-yl)propyl]-5-phenyl-1H-pyrrole-3-carboxamide 769185-66-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-(4-nitrophenyl)butanamide 769185-67-3P 769185-68-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(3-phenoxyphenyl)acetamide 769185-69-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(4-phenoxyphenyl)acetamide 769185-70-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(2-phenyl-1H-indol-3-yl)acetamide 769185-71-9P 769185-72-0P 769185-73-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(2-phenylethyl)benzamide 769185-74-2P, 3-Benzoyl-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769185-75-3P 769185-76-4P, 2-[(2-Cyanophenyl)thio]-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]benzamide 769185-77-5P, 2-[4-(Benzyloxy)-3-methoxyphenyl]-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769185-78-6P 769185-79-7P 769185-80-0P 769185-81-1P 769185-82-2P 769185-83-3P 769185-84-4P 769185-85-5P 769185-86-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-oxo-4-(2-thienyl)butanamide 769185-87-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-(2-thienyl)butanamide 769185-88-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(2,4,6-trichlorophenoxy)acetamide 769185-89-9P, 2-[5-(Benzyloxy)-1H-indol-3-yl]-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769185-90-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(1-naphthoyl)benzamide 769185-91-3P, 3-(Benzyloxy)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-methoxybenzamide 769185-93-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide 769185-95-7P, 1-[2-[(2-Chloro-6-fluorobenzyl)thio]ethyl]-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide 769185-97-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]anthracene-9-carboxamide 769185-99-1P 769186-00-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]biphenyl-2-carboxamide 769186-01-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-

yl]amino]cyclohexyl]-3,3-diphenylpropanamide 769186-02-9P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-phenylquinoline-4-carboxamide 769186-03-0P 769186-04-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(4-methylbenzoyl)benzamide 769186-05-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-(phenoxymethyl)benzamide 769186-06-3P, 2-[4-(4-Chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]acetamide 769186-07-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide 769186-08-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-(3-nitrophenyl)-2-furancarboxamide 769186-09-6P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]-4-(methylsulfonyl)thiophene-2-carboxamide 769186-10-9P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide 769186-11-0P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-iodo-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide 769186-12-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-5-nitrothiophene-3-carboxamide 769186-13-2P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1-methyl-4-nitro-1H-pyrrole-2-carboxamide 769186-14-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1-(phenylsulfonyl)-1H-indole-3-carboxamide 769186-15-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-nitrobenzamide 769186-16-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-methoxy-4-nitrobenzamide 769186-17-6P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)benzamide 769186-18-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-fluoro-4-nitrobenzamide 769186-19-8P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3,5-dimethyl-4-nitrobenzamide 769186-20-1P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-mesityl-2-(oxo)acetamide 769186-21-2P 769186-22-3P 769186-23-4P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-1,3-benzothiazole-6-carboxamide 769186-24-5P, 5-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]-2-hydroxybenzamide 769186-25-6P, 2-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]-5-(methylthio)benzamide 769186-26-7P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-7-methoxy-1-benzofuran-2-carboxamide 769186-27-8P, 2-Amino-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-3-methylbenzamide 769186-28-9P, 2-(Allylthio)-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]nicotinamide 769186-29-0P, 3,5-Di-tert-butyl-N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-4-hydroxybenzamide 769186-30-3P, 5-Bromo-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]thiophene-2-carboxamide 769186-31-4P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-(2,3,6-trichlorophenyl)acetamide 769186-32-5P, 2-(2-Chloro-4-fluorophenyl)-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]acetamide 769186-34-7P, 5-(4-Chloro-2-nitrophenyl)-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-furancarboxamide 769186-36-9P,

5-Chloro-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]methyl]thiophene-2-carboxamide 769186-38-1P 769186-40-5P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-(2-hydroxyphenyl)propanamide 769186-42-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-5-iodo-2-furancarboxamide 769186-44-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-(2-iodophenyl)acetamide 769186-46-1P 769186-48-3P 769186-50-7P, 2-Benzyl-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]benzamide 769186-52-9P, 2,2-Bis(4-chlorophenyl)-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]acetamide 769186-54-1P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-5-(4-methyl-2-nitrophenyl)-2-furancarboxamide 769186-56-3P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-5-nitrothiophene-2-carboxamide 769186-58-5P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-methyl-4-nitrobenzamide 769186-60-9P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3-methoxy-4-nitrobenzamide 769186-62-1P, 1-Benzyl-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-1H-indole-3-carboxamide 769186-64-3P, 2-Cyclohex-1-en-1-yl-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]acetamide 769186-66-5P 769186-68-7P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide 769186-70-1P, 4-(Benzyloxy)-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-3,5-dimethylbenzamide 769186-72-3P, N-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]-9H-xanthene-9-carboxamide 769186-74-5P, 2-(Benzo[b]thien-3-yl)-N-[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]acetamide 769186-76-7P, 2-[[cis-4-[(2,6-Dimethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769186-78-9P, 2-[[cis-4-[(2-Ethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769186-80-3P, 2-[[cis-4-[(1H-Indol-3-ylmethyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769186-82-5P, 2-[[cis-4-[(2,5-Dimethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769186-84-7P, 2-[[cis-4-[[(4-Methoxy-1-naphthyl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769186-85-8P, 2-[[cis-4-[[(5-Methoxy-1H-indol-3-yl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769186-87-0P, 2-[[cis-4-[[(2-Methoxy-1-naphthyl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769186-89-2P, 4-Bromo-2-[[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]methyl]-6-methoxyphenol 769186-90-5P, 2-[[cis-4-[[(5-Bromo-1H-indol-3-yl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769186-91-6P, 2-[[cis-4-[(2,4-Dimethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769186-92-7P, 4-(Dimethylamino)-2-[[cis-4-[(2,3,4-trimethoxybenzyl)amino]cyclohexyl]amino]quinoline 769186-93-8P, 4-[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]methyl]-2,6-dimethoxyphenol 769186-94-9P, 2-[[cis-4-[(3-Ethoxy-4-methoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769186-95-0P, 4-(Dimethylamino)-2-[[cis-4-[[[3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]methyl]amino]cyclohexyl]amino]quinoline 769186-96-1P, 4-(Dimethylamino)-2-[[cis-4-[(3,4,5-trimethoxybenzyl)amino]cyclohexyl]amino]quinoline 769186-97-2P, 4-(Dimethylamino)-2-[[cis-4-[(2,3,4,5,6-pentamethylbenzyl)amino]cyclohexyl]amino]quinoline 769186-98-3P, 2-[[cis-4-[(3,5-

Dimethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769186-99-4P, 4-[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]methyl]-2-iodo-6-methoxyphenol 769187-00-0P, 4-[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]methyl]-2,6-dimethylphenol 769187-01-1P, 2-[[cis-4-[(3-Methoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-02-2P, 2-[[cis-4-[(3-Bromo-4-fluorobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-04-4P 769187-06-6P, 3-[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]methyl]-6-methyl-4H-chromen-4-one 769187-07-7P, 3-[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]methyl]-6,8-dimethyl-4H-chromen-4-one 769187-09-9P, 2-[[cis-4-[[(2,5-Dimethyl-1-phenyl-1H-pyrrol-3-yl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-10-2P 769187-12-4P 769187-13-5P 769187-15-7P, 6-Chloro-3-[[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]methyl]-4H-chromen-4-one 769187-16-8P, 2-[[cis-4-[[[5-(4-Fluorophenyl)pyridin-3-yl]methyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-17-9P, Ethyl 4,6-dichloro-3-[[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]methyl]-1H-indole-2-carboxylate 769187-18-0P 769187-19-1P, 2-[[cis-4-[[[3-(4-Fluorophenyl)-1H-pyrazol-4-yl]methyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-20-4P, 4-(Dimethylamino)-2-[[cis-4-[[4-(methylthio)benzyl]amino]cyclohexyl]amino]quinoline 769187-21-5P, 4-(Dimethylamino)-2-[[cis-4-[(1-naphthylmethyl)amino]cyclohexyl]amino]quinoline 769187-22-6P, 4-[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]methyl]-2-methoxyphenol 769187-23-7P, 2-[[cis-4-[(3-Chloro-4-fluorobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-24-8P, 2-[[cis-4-[[(2,6-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-25-9P, 2-[[cis-4-[[(2-Ethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-26-0P, 2-[[cis-4-[[(1H-Indol-3-ylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-27-1P, 2-[[cis-4-[[(2,5-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-28-2P, 2-[[cis-4-[[[(4-Methoxy-1-naphthyl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-29-3P, 2-[[cis-4-[[[(5-Methoxy-1H-indol-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-30-6P, 2-[[cis-4-[[[(2-Methoxy-1-naphthyl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-31-7P, 4-Bromo-2-[[[[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-6-methoxyphenol 769187-32-8P, 2-[[cis-4-[[[(5-Bromo-1H-indol-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-33-9P
, 2-[[cis-4-[[(2,4-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-34-0P, 4-(Dimethylamino)-2-[[cis-4-[[(2,3,4-trimethoxybenzyl)amino]methyl]cyclohexyl]amino]quinoline 769187-35-1P, 4-[[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2,6-dimethoxyphenol 769187-36-2P, 2-[[cis-4-[[(3-Ethoxy-4-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-37-3P, 4-(Dimethylamino)-2-[[cis-4-[[[3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]methyl]amino]methyl]cyclohexyl]amino]quinoline 769187-38-4P, 4-(Dimethylamino)-2-[[cis-4-[[(3,4,5-trimethoxybenzyl)amino]methyl]cyclohexyl]amino]quinoline 769187-39-5P, 4-(Dimethylamino)-2-[[cis-4-[[(2,3,4,5,6-pentamethylbenzyl)amino]methyl]cyclohexyl]amino]quinoline

769187-40-8P, 2-[[cis-4-[[(3,5-Dimethoxybenzyl)amino]methyl]cycloh
exyl]amino]-4-(dimethylamino)quinoline 769187-41-9P,
4-[[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]amino
]methyl]-2-iodo-6-methoxyphenol 769187-42-0P,
4-[[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]amino
]methyl]-2,6-dimethylphenol 769187-43-1P, 2-[[cis-4-[[(4-
Methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline
769187-44-2P, 2-[[cis-4-[[(2,3-Dihydro-1,4-benzodioxin-6-
ylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline
769187-45-3P, 2-[[cis-4-[[(3-Bromobenzyl)amino]methyl]cyclohexyl]a
mino]-4-(dimethylamino)quinoline 769187-46-4P,
2-[[cis-4-[[(5-Bromo-2,4-dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-
(dimethylamino)quinoline 769187-47-5P, 2-[[cis-4-[[(5-Bromo-2-
methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline
769187-48-6P, 3-Chloro-4-[[[[cis-4-[[4-(dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]amino]methyl]phenol 769187-49-7P,
2-[[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]amino
]methyl]benzonitrile 769187-50-0P, 2-[[cis-4-[[(3-
Chlorobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline
769187-51-1P, 2-[[cis-4-[[(4-Chlorobenzyl)amino]methyl]cyclohexyl]
amino]-4-(dimethylamino)quinoline 769187-52-2P,
2-[[cis-4-[[[4-(Diethylamino)benzyl]amino]methyl]cyclohexyl]amino]-4-
(dimethylamino)quinoline 769187-53-3P, 2-[[cis-4-[[[4-
(Dimethylamino)benzyl]amino]methyl]cyclohexyl]amino]-4-
(dimethylamino)quinoline 769187-54-4P, 2-[[cis-4-[[[(9-Ethyl-9H-
carbazol-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-
(dimethylamino)quinoline 769187-55-5P, 2-[[cis-4-[[[2-Fluoro-5-
(trifluoromethyl)benzyl]amino]methyl]cyclohexyl]amino]-4-
(dimethylamino)quinoline 769187-56-6P, 4-[[[[cis-4-[[4-
(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]phenol
769187-57-7P, [5-[[[[cis-4-[[4-(Dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]amino]methyl]-2-furyl]methanol
769187-58-8P, 2-[[cis-4-[[(4-Isopropoxybenzyl)amino]methyl]cyclohe
xyl]amino]-4-(dimethylamino)quinoline 769187-59-9P,
2-[[cis-4-[[[(5-Ethyl-2-thienyl)methyl]amino]methyl]cyclohexyl]amino]-4-
(dimethylamino)quinoline 769187-60-2P, 2-[[cis-4-[[(3,3-
Diphenylprop-2-en-1-yl)amino]methyl]cyclohexyl]amino]-4-
(dimethylamino)quinoline 769187-61-3P, 4-[[[[cis-4-[[4-
(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-
ethoxyphenol 769187-62-4P, 2-[[cis-4-[[[[4-(Dimethylamino)-1-
naphthyl]methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline
769187-63-5P, 4-(Dimethylamino)-2-[[cis-4-[[(2,4,6-
trimethoxybenzyl)amino]methyl]cyclohexyl]amino]quinoline
769187-64-6P, 2-Bromo-4-chloro-6-[[[[cis-4-[[4-
(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]phenol
769187-65-7P, 3-[[[[cis-4-[[4-(Dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]amino]methyl]benzonitrile 769187-66-8P
, 2-[[cis-4-[[(2-Fluoro-5-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-
(dimethylamino)quinoline 769187-67-9P, 4-(Dimethylamino)-2-[[cis-
4-[[[2-[(trifluoromethyl)thio]benzyl]amino]methyl]cyclohexyl]amino]quinoli
ne
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines
as
MCH antagonist for treatment of CNS disorders)

IT 769187-68-0P, 2-[[cis-4-[[(5-Bromo-2-ethoxybenzyl)amino]methyl]cyc
lohexyl]amino]-4-(dimethylamino)quinoline 769187-69-1P,
2-[[cis-4-[[(2,4-Dimethoxy-3-methylbenzyl)amino]methyl]cyclohexyl]amino]-4-

(dimethylamino)quinoline 769187-70-4P, 4-(Dimethylamino)-2-[[cis-4-[[[2-(trifluoromethoxy)benzyl]amino]methyl]cyclohexyl]amino]quinoline 769187-71-5P, 2-[[cis-4-[[(2,5-Diethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-72-6P, 2-[[cis-4-[[(2,4-Diethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-73-7P, 2-[[cis-4-[[(3,5-Dibromo-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-74-8P, 2-[[cis-4-[[[2-(Difluoromethoxy)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-75-9P, 2-[[cis-4-[[(5-Fluoro-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-76-0P, 4-(Dimethylamino)-2-[[cis-4-[[(2,4,5-triethoxybenzyl)amino]methyl]cyclohexyl]amino]quinoline 769187-77-1P, 4-(Dimethylamino)-2-[[cis-4-[[(2,4,5-trimethoxybenzyl)amino]methyl]cyclohexyl]amino]quinoline 769187-78-2P, 2-[[cis-4-[[(2,3-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-79-3P, 2-[[cis-4-[[[2-(Allyloxy)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-80-6P, 2-[[cis-4-[[[(Benzo[b]thien-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-81-7P, 4-(Dimethylamino)-2-[[cis-4-[[[(1-methyl-1H-indol-3-yl)methyl]amino]methyl]cyclohexyl]amino]quinoline 769187-82-8P, 4-(Dimethylamino)-2-[[cis-4-[[[(5-methyl-2-thienyl)methyl]amino]methyl]cyclohexyl]amino]quinoline 769187-83-9P, 2-[[cis-4-[[(Mesitylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-84-0P, 2-[[cis-4-[[(1,3-Benzodioxol-5-ylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-85-1P, 4-(Dimethylamino)-2-[[cis-4-[[(3-thienylmethyl)amino]methyl]cyclohexyl]amino]quinoline 769187-86-2P, 4-(Dimethylamino)-2-[[cis-4-[[(3-methylbenzyl)amino]methyl]cyclohexyl]amino]quinoline 769187-88-4P, 4-(Dimethylamino)-2-[[cis-4-[[(2-methylbenzyl)amino]methyl]cyclohexyl]amino]quinoline 769187-89-5P, 4-(Dimethylamino)-2-[[cis-4-[[(4-methylbenzyl)amino]methyl]cyclohexyl]amino]quinoline 769187-90-8P, 2-[[cis-4-[[(3,5-Dichlorobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-91-9P, 2-[[cis-4-[[[(7-Methoxybenzodioxol-5-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-92-0P, 2-[[cis-4-[[(3-Bromo-4,5-dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-93-1P, 2-[[cis-4-[[(4-Methoxy-3-methylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-94-2P, 2-[[cis-4-[[(2-Bromo-4,5-dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-95-3P, 4-(Dimethylamino)-2-[[cis-4-[[[(2-methyl-5-phenyl-3-furyl)methyl]amino]methyl]cyclohexyl]amino]quinoline 769187-96-4P, 2-[[cis-4-[[(3,4-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-97-5P, 4-[[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-methylphenol 769187-98-6P, 2-[[cis-4-[[(4-Methoxy-2,5-dimethylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769187-99-7P, 2-[[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-6-methoxyphenol 769188-00-3P, 2-[[cis-4-[[[3-Chloro-2-fluoro-5-(trifluoromethyl)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769188-01-4P, 2-[[cis-4-[[[3-Fluoro-5-(trifluoromethyl)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769188-02-5P, 4-[[[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-fluoro-6-methoxyphenol 769188-03-6P, 2-[[cis-4-[[(2-Fluoro-4,5-dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769188-04-7P, 2-[[cis-4-[[(2-Ethylbenzyl)amino]methyl]cyclohexyl]a

mino]-4-(dimethylamino)quinoline 769188-05-8P,
3-[[[4-[[[[cis-4-[[4-(Dimethylamino)quinolin-2-
yl]amino]cyclohexyl]methyl]amino]methyl]phenyl]methyl]amino]propanenitrile
769188-06-9P, 2-[[cis-4-[[[4-[(4-Bromobenzyl)oxy]benzyl]amino]meth
yl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769188-07-0P,
2-[[cis-4-[[(3,5-Dibromo-2-ethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-
(dimethylamino)quinoline 769188-08-1P, 2-[[cis-4-[(2,6-
Dimethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine
769188-09-2P, 2-[[cis-4-[(2-Ethoxybenzyl)amino]cyclohexyl]amino]-4-
(dimethylamino)pyrimidine 769188-10-5P, 2-[[cis-4-[(1H-Indol-3-
ylmethyl)amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine
769188-11-6P, 2-[[cis-4-[(2,5-Dimethoxybenzyl)amino]cyclohexyl]amino]-4-
(dimethylamino)pyrimidine 769188-12-7P, 2-[[cis-4-[[(4-Methoxy-1-
naphthyl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine
769188-13-8P, 2-[[cis-4-[[(5-Methoxy-1H-indol-3-
yl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine
769188-14-9P, 2-[[cis-4-[[(2-Methoxy-1-naphthyl)methyl]amino]cyclohexyl]am
ino]-4-(dimethylamino)pyrimidine 769188-15-0P, 4-Bromo-2-[[[cis-4-[[4-
(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]amino]methyl]-6-
methoxyphenol 769188-16-1P, 2-[[cis-4-[[(5-Bromo-1H-indol-3-
yl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine
769188-17-2P, 2-[[cis-4-[(2,4-Dimethoxybenzyl)amino]cyclohexyl]amino]-4-
(dimethylamino)pyrimidine 769188-18-3P, 4-(Dimethylamino)-2-[[cis-4-
[(2,3,4-trimethoxybenzyl)amino]cyclohexyl]amino]pyrimidine 769188-19-4P,
4-[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]amino]methyl
]-2,6-dimethoxyphenol 769188-20-7P, 2-[[cis-4-[(3-Ethoxy-4-
methoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine
769188-21-8P, 4-(Dimethylamino)-2-[[cis-4-[[[3-[4-(trifluoromethyl)phenyl]-
1H-pyrazol-4-yl]methyl]amino]cyclohexyl]amino]pyrimidine 769188-22-9P,
4-(Dimethylamino)-2-[[cis-4-[(3,4,5-trimethoxybenzyl)amino]cyclohexyl]amin
o]pyrimidine 769188-23-0P, 4-(Dimethylamino)-2-[[cis-4-[(2,3,4,5,6-
pentamethylbenzyl)amino]cyclohexyl]amino]pyrimidine 769188-24-1P,
2-[[cis-4-[(3,5-Dimethoxybenzyl)amino]cyclohexyl]amino]-4-
(dimethylamino)pyrimidine 769188-25-2P, 4-[[[cis-4-[[4-
(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]amino]methyl]-2-iodo-6-
methoxyphenol 769188-26-3P, 4-[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-
yl]amino]cyclohexyl]amino]methyl]-2,6-dimethylphenol 769188-27-4P,
2-[[cis-4-[(3-Methoxybenzyl)amino]cyclohexyl]amino]-4-
(dimethylamino)pyrimidine 769188-28-5P, 2-[[cis-4-[(3-Bromo-4-
fluorobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine
769188-29-6P 769188-30-9P, 3-[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-
yl]amino]cyclohexyl]amino]methyl]-6-methyl-4H-chromen-4-one
769188-32-1P, 6-Chloro-3-[[[cis-4-[[4-(dimethylamino)pyrimidin-2-
yl]amino]cyclohexyl]amino]methyl]-7-methyl-4H-chromen-4-one
769188-33-2P, 3-[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-
yl]amino]cyclohexyl]amino]methyl]-6,8-dimethyl-4H-chromen-4-one
769188-35-4P, 2-[[cis-4-[[(2,5-Dimethyl-1-phenyl-1H-pyrrol-3-
yl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine
769188-36-5P 769188-37-6P 769188-39-8P 769188-40-1P,
6-Chloro-3-[[[cis-4-[[4-(dimethylamino)pyrimidin-2-
yl]amino]cyclohexyl]amino]methyl]-4H-chromen-4-one 769188-41-2P,
2-[[cis-4-[[[5-(4-Fluorophenyl)pyridin-3-yl]methyl]amino]cyclohexyl]amino]-
4-(dimethylamino)pyrimidine 769188-42-3P, Ethyl 4,6-dichloro-3-[[[cis-4-
[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]amino]methyl]-1H-indole-
2-carboxylate 769188-43-4P 769188-44-5P, 2-[[cis-4-[[[3-(4-
Fluorophenyl)-1H-pyrazol-4-yl]methyl]amino]cyclohexyl]amino]-4-
(dimethylamino)pyrimidine 769188-45-6P, 4-(Dimethylamino)-2-[[cis-4-[[4-
(methylthio)benzyl]amino]cyclohexyl]amino]pyrimidine 769188-46-7P,
4-(Dimethylamino)-2-[[cis-4-[(1-naphthylmethyl)amino]cyclohexyl]amino]pyri
midine 769188-47-8P, 4-[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-

yl]amino]cyclohexyl]amino]methyl]-2-methoxyphenol 769188-48-9P, 2-[[cis-4-[(3-Chloro-4-fluorobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-49-0P, 2-[[cis-4-[[(2,6-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-50-3P, 2-[[cis-4-[[(2-Ethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-51-4P, 2-[[cis-4-[[(1H-Indol-3-ylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-52-5P, 2-[[cis-4-[[(2,5-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-53-6P, 2-[[cis-4-[[[(4-Methoxy-1-naphthyl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-54-7P, 2-[[cis-4-[[[(5-Methoxy-1H-indol-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-55-8P, 2-[[cis-4-[[[(2-Methoxy-1-naphthyl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-56-9P, 4-Bromo-2-[[[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-6-methoxyphenol 769188-57-0P, 2-[[cis-4-[[[(5-Bromo-1H-indol-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-58-1P, 2-[[cis-4-[[(2,4-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-59-2P, 4-(Dimethylamino)-2-[[cis-4-[[(2,3,4-trimethoxybenzyl)amino]methyl]cyclohexyl]amino]pyrimidine 769188-60-5P, 4-[[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2,6-dimethoxyphenol 769188-61-6P, 2-[[cis-4-[[(3-Ethoxy-4-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-62-7P, 4-(Dimethylamino)-2-[[cis-4-[[[3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]methyl]amino]methyl]cyclohexyl]amino]pyrimidine 769188-63-8P, 4-(Dimethylamino)-2-[[cis-4-[[(3,4,5-trimethoxybenzyl)amino]methyl]cyclohexyl]amino]pyrimidine 769188-64-9P, 4-(Dimethylamino)-2-[[cis-4-[[(2,3,4,5,6-pentamethylbenzyl)amino]methyl]cyclohexyl]amino]pyrimidine 769188-65-0P, 2-[[cis-4-[[(3,5-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-66-1P, 4-[[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-iodo-6-methoxyphenol 769188-67-2P, 4-[[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2,6-dimethylphenol 769188-68-3P, 2-[[cis-4-[[(4-Methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-69-4P, 2-[[cis-4-[[(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-70-7P, 2-[[cis-4-[[(3-Bromobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-71-8P, 2-[[cis-4-[[(5-Bromo-2,4-dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-72-9P, 2-[[cis-4-[[(5-Bromo-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-73-0P, 3-Chloro-4-[[[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]phenol 769188-74-1P, 2-[[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]benzonitrile 769188-75-2P, 2-[[cis-4-[[(3-Chlorobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-76-3P, 2-[[cis-4-[[(4-Chlorobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-77-4P, 2-[[cis-4-[[[4-(Diethylamino)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-78-5P, 2-[[cis-4-[[[4-(Dimethylamino)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-79-6P, 2-[[cis-4-[[[(9-Ethyl-9H-carbazol-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-80-9P, 2-[[cis-4-[[[2-Fluoro-5-(trifluoromethyl)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-81-0P, 4-[[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]phenol 769188-82-1P, [5-[[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-

yl]amino]cyclohexyl]methyl]amino]methyl]-2-furyl]methanol 769188-83-2P, 2-[[cis-4-[[(4-Isopropoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-84-3P, 2-[[cis-4-[[[(5-Ethyl-2-thienyl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-85-4P, 2-[[cis-4-[[(3,3-Diphenylprop-2-en-1-yl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-86-5P, 4-[[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-ethoxyphenol 769188-87-6P, 2-[[cis-4-[[[[4-(Dimethylamino)-1-naphthyl]methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-88-7P, 4-(Dimethylamino)-2-[[cis-4-[[(2,4,6-trimethoxybenzyl)amino]methyl]cyclohexyl]amino]pyrimidine 769188-89-8P, 2-Bromo-4-chloro-6-[[[[cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]phenol 769188-90-1P, 3-[[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]benzonitrile 769188-91-2P, 2-[[cis-4-[[(2-Fluoro-5-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-92-3P, 4-(Dimethylamino)-2-[[cis-4-[[[2-[(trifluoromethyl)thio]benzyl]amino]methyl]cyclohexyl]amino]pyrimidine 769188-93-4P, 2-[[cis-4-[[(5-Bromo-2-ethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-94-5P, 2-[[cis-4-[[(2,4-Dimethoxy-3-methylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-95-6P, 4-(Dimethylamino)-2-[[cis-4-[[[2-(trifluoromethoxy)benzyl]amino]methyl]cyclohexyl]amino]pyrimidine 769188-96-7P, 2-[[cis-4-[[(2,5-Diethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-97-8P, 2-[[cis-4-[[(2,4-Diethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-98-9P, 2-[[cis-4-[[(3,5-Dibromo-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769188-99-0P, 2-[[cis-4-[[[2-(Difluoromethoxy)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-00-6P, 2-[[cis-4-[[(5-Fluoro-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-01-7P, 4-(Dimethylamino)-2-[[cis-4-[[(2,4,5-triethoxybenzyl)amino]methyl]cyclohexyl]amino]pyrimidine 769189-02-8P, 4-(Dimethylamino)-2-[[cis-4-[[(2,4,5-trimethoxybenzyl)amino]methyl]cyclohexyl]amino]pyrimidine 769189-03-9P, 2-[[cis-4-[[(2,3-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-04-0P, 2-[[cis-4-[[[2-(Allyloxy)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-05-1P, 2-[[cis-4-[[[(Benzo[b]thien-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-06-2P, 4-(Dimethylamino)-2-[[cis-4-[[[(1-methyl-1H-indol-3-yl)methyl]amino]methyl]cyclohexyl]amino]pyrimidine 769189-07-3P, 4-(Dimethylamino)-2-[[cis-4-[[[(5-methyl-2-thienyl)methyl]amino]methyl]cyclohexyl]amino]pyrimidine 769189-08-4P, 2-[[cis-4-[[(Mesitylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-09-5P, 2-[[cis-4-[[(1,3-Benzodioxol-5-ylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-10-8P, 4-(Dimethylamino)-2-[[cis-4-[[(3-thienylmethyl)amino]methyl]cyclohexyl]amino]pyrimidine 769189-11-9P, 4-(Dimethylamino)-2-[[cis-4-[[(3-methylbenzyl)amino]methyl]cyclohexyl]amino]pyrimidine 769189-12-0P, 4-(Dimethylamino)-2-[[cis-4-[[(2-methylbenzyl)amino]methyl]cyclohexyl]amino]pyrimidine 769189-13-1P, 4-(Dimethylamino)-2-[[cis-4-[[(4-methylbenzyl)amino]methyl]cyclohexyl]amino]pyrimidine 769189-14-2P, 2-[[cis-4-[[(3,5-Dichlorobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-15-3P, 2-[[cis-4-[[[(7-Methoxybenzodioxol-5-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-16-4P, 2-[[cis-4-[[(3-Bromo-4,5-dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-17-5P, 2-[[cis-4-[[(4-Methoxy-3-methylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-18-6P, 2-[[cis-4-[[(2-Bromo-4,5-

dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-19-7P, 4-(Dimethylamino)-2-[[cis-4-[[[(2-methyl-5-phenyl-3-furyl)methyl]amino]methyl]cyclohexyl]amino]pyrimidine 769189-20-0P, 2-[[cis-4-[[(3,4-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-21-1P, 4-[[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-methylphenol 769189-22-2P, 2-[[cis-4-[[(4-Methoxy-2,5-dimethylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-23-3P, 2-[[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-6-methoxyphenol 769189-24-4P, 2-[[cis-4-[[[3-Chloro-2-fluoro-5-(trifluoromethyl)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-25-5P, 2-[[cis-4-[[[3-Fluoro-5-(trifluoromethyl)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-26-6P, 4-[[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-fluoro-6-methoxyphenol 769189-27-7P, 2-[[cis-4-[[(2-Fluoro-4,5-dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-28-8P, 2-[[cis-4-[[(2-Ethylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-29-9P, 3-[[4-[[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]methyl]amino]methyl]phenyl](methyl)amino]propanenitrile 769189-30-2P, 2-[[cis-4-[[[4-[(4-Bromobenzyl)oxy]benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-31-3P, 2-[[cis-4-[[(3,5-Dibromo-2-ethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769189-32-4P, 2-[[cis-4-[(2,6-Dimethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-33-5P, 2-[[cis-4-[(2-Ethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-34-6P, 2-[[cis-4-[(1H-Indol-3-ylmethyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-35-7P, 2-[[cis-4-[(2,5-Dimethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-36-8P, 2-[[cis-4-[[(4-Methoxy-1-naphthyl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-37-9P, 2-[[cis-4-[[(5-Methoxy-1H-indol-3-yl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-39-1P, 2-[[cis-4-[[(2-Methoxy-1-naphthyl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-40-4P, 4-Bromo-2-[[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-quinazolin-2-yl]amino]cyclohexyl]amino]methyl]-6-methoxyphenol 769189-41-5P, 2-[[cis-4-[[(5-Bromo-1H-indol-3-yl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-42-6P, 2-[[cis-4-[(2,4-Dimethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-43-7P, 4-(Dimethylamino)-2-[[cis-4-[(2,3,4-trimethoxybenzyl)amino]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769189-44-8P, 4-[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]methyl]-2,6-dimethoxyphenol 769189-45-9P, 2-[[cis-4-[(3-Ethoxy-4-methoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-46-0P, 4-(Dimethylamino)-2-[[cis-4-[[[3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]methyl]amino]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769189-47-1P, 4-(Dimethylamino)-2-[[cis-4-[(3,4,5-trimethoxybenzyl)amino]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769189-48-2P, 4-(Dimethylamino)-2-[[cis-4-[(2,3,4,5,6-pentamethylbenzyl)amino]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769189-49-3P, 2-[[cis-4-[(3,5-Dimethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-50-6P, 4-[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]methyl]-2-iodo-6-methoxyphenol 769189-51-7P

, 4-[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]methyl]-2,6-dimethylphenol 769189-52-8P, 2-[[cis-4-[(3-Methoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-53-9P, 2-[[cis-4-[(3-Bromo-4-fluorobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-54-0P 769189-55-1P, 3-[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]methyl]-6-methyl-4H-chromen-4-one 769189-56-2P, 6-Chloro-3-[[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]methyl]-7-methyl-4H-chromen-4-one 769189-57-3P, 3-[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]methyl]-6,8-dimethyl-4H-chromen-4-one 769189-58-4P, 2-[[cis-4-[[(2,5-Dimethyl-1-phenyl-1H-pyrrol-3-yl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-59-5P 769189-60-8P 769189-61-9P 769189-62-0P, 6-Chloro-3-[[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]methyl]-4H-chromen-4-one 769189-63-1P, 2-[[cis-4-[[[5-(4-Fluorophenyl)pyridin-3-yl]methyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-64-2P, Ethyl 4,6-dichloro-3-[[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]methyl]-1H-indole-2-carboxylate 769189-65-3P 769189-66-4P, 2-[[cis-4-[[[3-(4-Fluorophenyl)-1H-pyrazol-4-yl]methyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-67-5P, 4-(Dimethylamino)-2-[[cis-4-[[4-(methylthio)benzyl]amino]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769189-68-6P, 4-(Dimethylamino)-2-[[cis-4-[(1-naphthylmethyl)amino]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769189-69-7P, 4-[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]methyl]-2-methoxyphenol 769189-70-0P, 2-[[cis-4-[(3-Chloro-4-fluorobenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-71-1P, 2-[[cis-4-[[(2,6-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-72-2P, 2-[[cis-4-[[(2-Ethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-73-3P, 2-[[cis-4-[[(1H-Indol-3-ylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-74-4P, 2-[[cis-4-[[(2,5-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-75-5P, 2-[[cis-4-[[[(4-Methoxy-1-naphthyl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-76-6P, 2-[[cis-4-[[[(5-Methoxy-1H-indol-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-77-7P, 2-[[cis-4-[[[(2-Methoxy-1-naphthyl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-78-8P, 4-Bromo-2-[[[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-6-methoxyphenol 769189-79-9P, 2-[[cis-4-[[[(5-Bromo-1H-indol-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-80-2P, 2-[[cis-4-[[(2,4-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-81-3P, 4-(Dimethylamino)-2-[[cis-4-[[(2,3,4-trimethoxybenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769189-82-4P, 4-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2,6-dimethoxyphenol 769189-83-5P, 2-[[cis-4-[[(3-Ethoxy-4-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-85-7P, 4-(Dimethylamino)-2-[[cis-4-[[[[3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]methyl]amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline

769189-86-8P, 4-(Dimethylamino)-2-[[cis-4-[[(3,4,5-trimethoxybenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769189-87-9P, 4-(Dimethylamino)-2-[[cis-4-[[(2,3,4,5,6-pentamethylbenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769189-88-0P, 2-[[cis-4-[[(3,5-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-89-1P, 4-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-iodo-6-methoxyphenol 769189-90-4P, 4-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2,6-dimethylphenol 769189-91-5P, 2-[[cis-4-[[(4-Methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-92-6P, 2-[[cis-4-[[(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-93-7P, 2-[[cis-4-[[(3-Bromobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-94-8P, 2-[[cis-4-[[(5-Bromo-2,4-dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-95-9P, 2-[[cis-4-[[(5-Bromo-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-96-0P, 3-Chloro-4-[[[[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]phenol 769189-97-1P, 2-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]benzonitrile 769189-98-2P, 2-[[cis-4-[[(3-Chlorobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769189-99-3P, 2-[[cis-4-[[(4-Chlorobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-00-3P, 2-[[cis-4-[[[4-(Diethylamino)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-01-4P, 2-[[cis-4-[[[4-(Dimethylamino)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-02-5P, 2-[[cis-4-[[[(9-Ethyl-9H-carbazol-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-03-6P, 2-[[cis-4-[[[2-Fluoro-5-(trifluoromethyl)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-04-7P, 4-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]phenol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

IT 769190-05-8P, [5-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-furyl]methanol 769190-06-9P, 2-[[cis-4-[[(4-Isopropoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-07-0P, 2-[[cis-4-[[[(5-Ethyl-2-thienyl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-08-1P, 2-[[cis-4-[[(3,3-Diphenylprop-2-en-1-yl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-09-2P, 4-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-ethoxyphenol 769190-10-5P, 2-[[cis-4-[[[[4-(Dimethylamino)-1-naphthyl]methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-11-6P, 4-(Dimethylamino)-2-[[cis-4-[[(2,4,6-trimethoxybenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-12-7P, 2-Bromo-4-chloro-6-[[[[cis-4-[[4-

(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]phenol 769190-13-8P, 3-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]benzonitrile 769190-14-9P, 2-[[cis-4-[[(2-Fluoro-5-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-15-0P, 4-(Dimethylamino)-2-[[cis-4-[[[2-[(trifluoromethyl)thio]benzyl]amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-16-1P, 2-[[cis-4-[[(5-Bromo-2-ethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-17-2P, 2-[[cis-4-[[(2,4-Dimethoxy-3-methylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-18-3P, 4-(Dimethylamino)-2-[[cis-4-[[[2-(trifluoromethoxy)benzyl]amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-19-4P, 2-[[cis-4-[[(2,5-Diethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-20-7P, 2-[[cis-4-[[(2,4-Diethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-21-8P, 2-[[cis-4-[[(3,5-Dibromo-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-22-9P, 2-[[cis-4-[[[2-(Difluoromethoxy)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-23-0P, 2-[[cis-4-[[(5-Fluoro-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-24-1P, 4-(Dimethylamino)-2-[[cis-4-[[(2,4,5-triethoxybenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-25-2P, 4-(Dimethylamino)-2-[[cis-4-[[(2,4,5-trimethoxybenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-26-3P, 2-[[cis-4-[[(2,3-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-27-4P, 2-[[cis-4-[[[2-(Allyloxy)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-28-5P, 2-[[cis-4-[[[(Benzo[b]thien-3-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-29-6P, 4-(Dimethylamino)-2-[[cis-4-[[[(1-methyl-1H-indol-3-yl)methyl]amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-30-9P, 4-(Dimethylamino)-2-[[cis-4-[[[(5-methyl-2-thienyl)methyl]amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-32-1P, 2-[[cis-4-[[(Mesitylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-33-2P, 2-[[cis-4-[[(1,3-Benzodioxol-5-ylmethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-34-3P, 4-(Dimethylamino)-2-[[cis-4-[[(3-thienylmethyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-35-4P, 4-(Dimethylamino)-2-[[cis-4-[[(3-methylbenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-36-5P, 4-(Dimethylamino)-2-[[cis-4-[[(2-methylbenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-37-6P, 4-(Dimethylamino)-2-[[cis-4-[[(4-methylbenzyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-38-7P, 2-[[cis-4-[[(3,5-Dichlorobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-39-8P, 2-[[cis-4-[[[(7-Methoxybenzodioxol-5-yl)methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-40-1P, 2-[[cis-4-[[(3-Bromo-4,5-dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-41-2P, 2-[[cis-4-[[(4-Methoxy-3-methylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-42-3P, 2-[[cis-4-[[(2-Bromo-4,5-dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-43-4P,

4-(Dimethylamino)-2-[[cis-4-[[[(2-methyl-5-phenyl-3-furyl)methyl]amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-44-5P, 2-[[cis-4-[[(3,4-Dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-45-6P, 4-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-methylphenol 769190-46-7P, 2-[[cis-4-[[(4-Methoxy-2,5-dimethylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-47-8P, 2-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-6-methoxyphenol 769190-48-9P, 2-[[cis-4-[[[3-Chloro-2-fluoro-5-(trifluoromethyl)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-49-0P, 2-[[cis-4-[[[3-Fluoro-5-(trifluoromethyl)benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-50-3P, 4-[[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]-2-fluoro-6-methoxyphenol 769190-51-4P, 2-[[cis-4-[[(2-Fluoro-4,5-dimethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-52-5P, 2-[[cis-4-[[(2-Ethylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-53-6P, 3-[[4-[[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]amino]methyl]phenyl](methyl)amino]propanenitrile 769190-54-7P, 2-[[cis-4-[[[4-[(4-Bromobenzyl)oxy]benzyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-55-8P, 2-[[cis-4-[[(3,5-Dibromo-2-ethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-56-9P, 2-[[cis-4-[[2-(4-Bromophenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-57-0P, 2-[[cis-4-[[2-(3-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-58-1P, 2-[[cis-4-[[2-(2-Chlorophenoxy)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-59-2P 769190-60-5P, 4-(Dimethylamino)-2-[[4-[(2,3,4,5,6-pentamethylphenylmethyl)amino]cyclohexyl]amino]quinoline 769190-61-6P, 2-[[cis-4-[(3-Ethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-62-7P 769190-63-8P, 2-[[cis-4-[[(3-Methoxy-2-naphthyl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-64-9P, 3-[[2-[[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]amino]ethyl](phenyl)amino]propanenitrile 769190-65-0P 769190-66-1P, [2-[[[4-(4-Dimethylaminoquinolin-2-ylamino)cyclohexyl]amino]methyl]cyclohexyl]phenylmethanol 769190-67-2P, 2-[[cis-4-[[2-(3,5-Dimethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-68-3P, 4-(Dimethylamino)-2-[[cis-4-[[2-(2-phenyl-1H-indol-3-yl)ethyl]amino]cyclohexyl]amino]quinoline 769190-69-4P, 2-[[cis-4-[[2,2-Bis(4-chlorophenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-70-7P 769190-71-8P, 2-[[cis-4-[[[1-(Diphenylmethyl)azetidin-3-yl]methyl]amino]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-72-9P, 2-[[cis-4-[[[2-(4-Bromophenyl)ethyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-73-0P, 2-[[cis-4-[[[4-(4-Methoxyphenyl)butyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-74-1P, 4-(Dimethylamino)-2-[[cis-4-[[(6-phenylhexyl)amino]methyl]cyclohexyl]amino]quinoline 769190-75-2P, 2-[[cis-4-[[(2-Mesitylethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-76-3P, 4-(Dimethylamino)-2-[[cis-4-[[(8-phenyloctyl)amino]methyl]cyclohexyl]amino]quinoline 769190-77-4P, 2-[[cis-4-[[[2-(4-tert-Butylphenyl)ethyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-78-5P, 4-(Dimethylamino)-2-[[cis-4-[[(5-phenyl-4-pentyn-1-yl)amino]methyl]cyclohexyl]amino]quinoline

769190-79-6P, 2-[[cis-4-[[[2-(2-Methoxyphenyl)ethyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-80-9P, 4-(Dimethylamino)-2-[[cis-4-[[(3-phenoxypropyl)amino]methyl]cyclohexyl]amino]quinoline 769190-81-0P, 4-(Dimethylamino)-2-[[cis-4-[[(2,3,5,6-tetrafluorobenzyl)amino]methyl]cyclohexyl]amino]quinoline 769190-82-1P, 2-[[cis-4-[[(2,5-Dichlorobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-83-2P, 2-[[cis-4-[[(5-Chloro-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-84-3P, 2-[[cis-4-[[(4-Chloro-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-85-4P, 2-[[cis-4-[[(3-Iodo-4-methylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-86-5P 769190-87-6P, 4-(Dimethylamino)-2-[[cis-4-[[[(1-phenyl-5-propyl-1H-pyrazol-4-yl)methyl]amino]methyl]cyclohexyl]amino]quinoline 769190-88-7P, 2-[[cis-4-[[[[1-(4-Chlorophenyl)-5-propyl-1H-pyrazol-4-yl]methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)quinoline 769190-89-8P, 4-(Dimethylamino)-2-[[cis-4-[[[4-(4-nitrophenyl)butyl]amino]methyl]cyclohexyl]amino]quinoline 769190-90-1P, 2-[[cis-4-[[2-(4-Bromophenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-91-2P, 2-[[cis-4-[[2-(3-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-92-3P 769190-93-4P, 2-[[4-(2-Methoxy-2-phenylethylamino)cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-94-5P, 4-(Dimethylamino)-2-[[4-[(2,3,4,5,6-pentamethylphenylmethyl)amino]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769190-95-6P, 2-[[cis-4-[(3-Ethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-96-7P 769190-97-8P, 2-[[cis-4-[[(3-Methoxy-2-naphthyl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769190-98-9P, 3-[[2-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]ethyl](3-methylphenyl)amino]propanenitrile 769190-99-0P, 3-[[2-[[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]amino]ethyl](phenyl)amino]propanenitrile 769191-00-6P 769191-01-7P, [2-[4-[[[4-[(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-yl)amino]cyclohexyl]amino]methyl]cyclohexyl]phenyl]methanol 769191-02-8P, 2-[[cis-4-[[2-(3,5-Dimethoxyphenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-03-9P, 4-(Dimethylamino)-2-[[cis-4-[[2-(2-phenyl-1H-indol-3-yl)ethyl]amino]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769191-04-0P, 2-[[cis-4-[[2,2-Bis(4-chlorophenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-05-1P 769191-06-2P, 2-[[cis-4-[[[1-(Diphenylmethyl)azetidin-3-yl]methyl]amino]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-07-3P, 2-[[cis-4-[[[2-(4-Bromophenyl)ethyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-08-4P, 2-[[cis-4-[[[4-(4-Methoxyphenyl)butyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-09-5P, 4-(Dimethylamino)-2-[[cis-4-[[(6-phenylhexyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769191-10-8P, 2-[[cis-4-[[(2-Mesitylethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-11-9P, 4-(Dimethylamino)-2-[[cis-4-[[(8-phenyloctyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769191-12-0P, 2-[[cis-4-[[[2-(4-tert-Butylphenyl)ethyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-13-1P, 2-[[cis-4-[[[2-(2-Methoxyphenyl)ethyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-14-2P, 4-(Dimethylamino)-2-[[cis-4-[[(3-phenoxypropyl)amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769191-15-3P, 2-[[cis-4-[[(5-Chloro-2-

methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-16-4P, 2-[[cis-4-[[(4-Chloro-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-17-5P, 2-[[cis-4-[[(3-Iodo-4-methylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-18-6P 769191-19-7P, 4-(Dimethylamino)-2-[[cis-4-[[[(1-phenyl-5-propyl-1H-pyrazol-4-yl)methyl]amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769191-20-0P, 2-[[cis-4-[[[(1-(4-Chlorophenyl)-5-propyl-1H-pyrazol-4-yl]methyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769191-21-1P, 4-(Dimethylamino)-2-[[cis-4-[[[4-(4-nitrophenyl)butyl]amino]methyl]cyclohexyl]amino]-5,6,7,8-tetrahydroquinazoline 769191-22-2P, 2-[[cis-4-[[2-(4-Bromophenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-23-3P, 2-[[cis-4-[[2-(3-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-24-4P, 2-[[cis-4-[[2-(2-Chlorophenoxy)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-25-5P 769191-26-6P, 2-[[4-(2-Methoxy-2-phenylethylamino)cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-27-7P, 2-[[cis-4-[[2-(4-Bromophenoxy)ethyl]amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-28-8P, 4-(Dimethylamino)-2-[[4-[(2,3,4,5,6-pentamethylphenylmethyl)amino]cyclohexyl]amino]pyrimidine 769191-29-9P, 2-[[cis-4-[(3-Ethoxybenzyl)amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-30-2P 769191-31-3P, 2-[[cis-4-[[(3-Methoxy-2-naphthyl)methyl]amino]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-32-4P, 3-[[2-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]amino]ethyl](3-methylphenyl)amino]propanenitrile 769191-33-5P, 3-[[2-[[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]amino]ethyl](phenyl)amino]propanenitrile 769191-34-6P, 2-[[cis-4-[[[4-(4-Methoxyphenyl)butyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-35-7P, 4-(Dimethylamino)-2-[[cis-4-[[(6-phenylhexyl)amino]methyl]cyclohexyl]amino]pyrimidine 769191-36-8P, 2-[[cis-4-[[(2-Mesitylethyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-37-9P, 4-(Dimethylamino)-2-[[cis-4-[[(8-phenyloctyl)amino]methyl]cyclohexyl]amino]pyrimidine 769191-38-0P, 2-[[cis-4-[[[2-(4-tert-Butylphenyl)ethyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-39-1P, 4-(Dimethylamino)-2-[[cis-4-[[(5-phenyl-4-pentyn-1-yl)amino]methyl]cyclohexyl]amino]pyrimidine 769191-40-4P, 2-[[cis-4-[[[2-(2-Methoxyphenyl)ethyl]amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-41-5P, 4-(Dimethylamino)-2-[[cis-4-[[(3-phenoxypropyl)amino]methyl]cyclohexyl]amino]pyrimidine 769191-42-6P, 4-(Dimethylamino)-2-[[cis-4-[[(2,3,5,6-tetrafluorobenzyl)amino]methyl]cyclohexyl]amino]pyrimidine 769191-43-7P, 2-[[cis-4-[[(2,5-Dichlorobenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-44-8P, 2-[[cis-4-[[(5-Chloro-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-45-9P, 2-[[cis-4-[[(4-Chloro-2-methoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-46-0P, 2-[[cis-4-[[(3-Iodo-4-methylbenzyl)amino]methyl]cyclohexyl]amino]-4-(dimethylamino)pyrimidine 769191-47-1P 769191-48-2P, 2-(Benzyloxy)ethyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-49-3P, 2,2-Dimethylpropyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-50-6P, [4-(4-Dimethylaminoquinolin-2-ylamino)cyclohexyl]carbamic acid 4,5-dimethoxy-2-nitrobenzyl ester 769191-51-7P, 3-(Trifluoromethyl)phenyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-52-8P, 4-Bromophenyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-53-9P, 2-Methoxyphenyl

[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-54-0P, 2-Methoxyethyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-55-1P, Octyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-56-2P, Ethyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-57-3P, [4-(4-Dimethylaminoquinolin-2-ylamino)cyclohexyl]carbamic acid 4-nitrobenzyl ester 769191-58-4P, Naphth-2-yl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-59-5P, Allyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-60-8P, [4-(4-Dimethylaminoquinolin-2-ylamino)cyclohexyl]carbamic acid benzyl ester 769191-61-9P
, Phenyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-62-0P 769191-63-1P, 4-Methylphenyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-64-2P, Methyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-65-3P, 2-Chlorobenzyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-66-4P, 9H-Fluoren-9-ylmethyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-67-5P, 2,2,2-Trichloroethyl [cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]carbamate 769191-68-6P, 2-(Benzyloxy)ethyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-69-7P, 2,2-Dimethylpropyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-70-0P, 4,5-Dimethoxy-2-nitrobenzyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-71-1P, 3-(Trifluoromethyl)phenyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-72-2P, 4-Bromophenyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-73-3P, 2-Methoxyphenyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-74-4P, 2-Methoxyethyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-75-5P, Octyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-76-6P, Ethyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-77-7P, 4-Nitrobenzyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-78-8P, Naphth-2-yl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-79-9P, Allyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-80-2P, Phenyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-81-3P 769191-82-4P, 4-Methylphenyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-83-5P, Methyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-84-6P, 2-Chlorobenzyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-85-7P, 9H-Fluoren-9-ylmethyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-86-8P, 2,2,2-Trichloroethyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate 769191-87-9P, 2-(Benzyloxy)ethyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769191-88-0P, 2,2-Dimethylpropyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769191-89-1P, [4-(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]carbamic acid

4,5-dimethoxy-2-nitrobenzyl ester 769191-90-4P, 3-(Trifluoromethyl)phenyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769191-91-5P, 4-Bromophenyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769191-92-6P, 2-Methoxyphenyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769191-93-7P, 2-Methoxyethyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769191-94-8P, Octyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769191-95-9P, Ethyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769191-96-0P, 4-Nitrobenzyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769191-97-1P, Naphth-2-yl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769191-98-2P, Allyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769191-99-3P, Benzyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769192-00-9P, Phenyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769192-01-0P 769192-02-1P, 4-Methylphenyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769192-03-2P, Methyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769192-04-3P, 2-Chlorobenzyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769192-05-4P, 9H-Fluoren-9-ylmethyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769192-06-5P, 2,2,2-Trichloroethyl [cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]carbamate 769192-07-6P, 2-(Benzyloxy)ethyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-08-7P, 2,2-Dimethylpropyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-09-8P, 4,5-Dimethoxy-2-nitrobenzyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-10-1P, 3-(Trifluoromethyl)phenyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-11-2P, 4-Bromophenyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-12-3P, 2-Methoxyphenyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-13-4P, 2-Methoxyethyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-14-5P, Octyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-15-6P, Ethyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-16-7P, [[4-(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]methyl]carbamic acid 4-nitrobenzyl ester 769192-17-8P, Naphth-2-yl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-18-9P, Allyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-19-0P, [[4-(4-Dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]methyl]carbamic acid benzyl ester 769192-20-3P, Phenyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-

yl]amino]cyclohexyl]methyl]carbamate 769192-21-4P 769192-22-5P, 4-Methylphenyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-23-6P, Methyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-24-7P, 2-Chlorobenzyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-25-8P, 9H-Fluoren-9-ylmethyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-26-9P, 2,2,2-Trichloroethyl [[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]methyl]carbamate 769192-27-0P, 2-(Benzyloxy)ethyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769192-28-1P, 2,2-Dimethylpropyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769192-30-5P, [4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]carbamic acid 4,5-dimethoxy-2-nitrobenzyl ester 769192-31-6P, 3-(Trifluoromethyl)phenyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769192-32-7P, 4-Bromophenyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769192-33-8P, 2-Methoxyphenyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769192-34-9P, 2-Methoxyethyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769192-35-0P, Octyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769192-36-1P, Ethyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769192-37-2P, 4-Nitrobenzyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769192-38-3P, Naphth-2-yl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769192-39-4P, Allyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate 769192-40-7P, Benzyl [cis-4-[[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]carbamate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

IT 703-61-7P, 2,4-Dichloroquinoline 1127-85-1P, 2,4-Dichloro-5,6,7,8-tetrahydroquinazoline 5652-13-1P, (2-Chloroquinolin-4-yl)dimethylamine 6041-50-5P, (4-Chloroquinolin-2-yl)dimethylamine 23631-02-9P, (4-Chloropyrimidin-2-yl)dimethylamine 31058-81-8P, (2-Chloropyrimidin-4-yl)dimethylamine 35042-48-9P, 5,6,7,8-Tetrahydroquinazoline-2,4-diol 76781-00-5P, N-(2-Chloro-5,6,7,8-tetrahydroquinazolin-4-yl)-N-methylamine 76781-03-8P, (2-Chloro-5,6,7,8-tetrahydroquinazolin-4-yl)dimethylamine 220996-80-5P, 4-Bromo-2-trifluoromethoxybenzaldehyde 223131-01-9P, (cis-4-Hydroxymethylcyclohexyl)carbamic acid tert-butyl ester 247570-24-7P, (cis-4-Aminocyclohexyl)carbamic acid tert-butyl ester 509142-45-4P, [cis-4-[(Benzyloxycarbonyl)amino]cyclohexyl]carbamic acid benzyl ester 509142-53-4P, [cis-4-[[(Benzyloxycarbonyl)amino]methyl]cyclohexyl]carbamic acid tert-butyl ester 509142-55-6P, [(cis-4-Aminocyclohexyl)methyl]carbamic acid benzyl ester 509142-62-5P, 2-(4-Bromo-2-trifluoromethoxyphenyl)acetaldehyde 769175-37-3P, N-(2-Chloroquinolin-4-yl)-N-methylamine 769175-38-4P, 2-[(cis-4-Aminocyclohexyl)amino]-4-(methylamino)quinoline 769175-39-5P, [cis-4-(4-Methylaminoquinolin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester 769175-42-0P, [[cis-4-(4-Methylaminoquinolin-2-ylamino)cyclohexyl]methyl]carbamic acid benzyl ester 769175-46-4P, 2-[(cis-4-Aminocyclohexyl)amino]-4-(dimethylamino)quinoline 769175-50-0P, 2-[(cis-4-Aminomethylcyclohexyl)amino]-4-(dimethylamino)quinoline 769175-53-3P, 2-[(cis-4-Aminocyclohexyl)amino]-4-(methylamino)-5,6,7,8-

tetrahydroquinazoline 769175-56-6P, [[cis-4-(4-Methylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)cyclohexyl]methyl]carbamic acid benzyl ester 769175-59-9P, 2-[(cis-4-Aminocyclohexyl)amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline 769175-64-6P, [cis-4-[(4-Bromo-2-trifluoromethoxybenzyl)amino]cyclohexyl]carbamic acid tert-butyl ester 769175-66-8P, [cis-4-(4-Dimethylaminopyrimidin-2-ylamino)cyclohexyl]carbamic acid tert-butyl ester 769175-67-9P, 2-[(cis-4-Aminocyclohexyl)amino]-4-(dimethylamino)pyrimidine 769175-70-4P, 2-[(cis-4-Aminomethylcyclohexyl)amino]-4-(dimethylamino)pyrimidine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinolines, quinazolines, and pyrimidines as MCH antagonist for treatment of CNS disorders)

IT 86-95-3, Quinoline-2,4-diol 619-81-8, cis-Cyclohexane-1,4-dicarboxylic acid 1655-07-8, 2-Oxocyclohexanecarboxylic acid ethyl ester 3685-23-2, cis-4-Aminocyclohexanecarboxylic acid 3934-20-1, 2,4-Dichloropyrimidine 175278-12-3, 4-Bromo-1-iodo-2-trifluoromethoxybenzene 769175-44-2, 2-[[cis-4-[[(4-Bromo-2-trifluoromethoxybenzyl)amino]methyl]cyclohexyl]amino]-4-(methylamino)quinoline 769175-71-5, 2-[(cis-4-Aminomethylcyclohexyl)amino]-4-(dimethylamino)-5,6,7,8-tetrahydroquinazoline
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinolines, quinazolines, and pyrimidines as MCH antagonist for treatment of CNS disorders)

IT 769175-49-7P, Benzyl [[cis-4-[[4-(dimethylamino)quinolin-2-yl]amino]cyclohexyl]methyl]carbamate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

RN 769175-49-7 ZCAPLUS

CN Carbamic acid, [[cis-4-[[4-(dimethylamino)-2-quinolinyl]amino]cyclohexyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



```
=> file registry
FILE 'REGISTRY' ENTERED AT 14:08:04 ON 19 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 FEB 2008  HIGHEST RN 1004360-55-7
DICTIONARY FILE UPDATES:  18 FEB 2008  HIGHEST RN 1004360-55-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 14:08:07 ON 19 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 19 Feb 2008  VOL 148 ISS 8
FILE LAST UPDATED: 18 Feb 2008  (20080218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L49
L3              STR
```



Structure attributes must be viewed using STN Express query preparation:
Uploading L3.str



ring nodes :
1 2 3 4 5 6 7 8 9 10
ring/chain nodes :
11 12 13
chain bonds :
9-11
ring/chain bonds :
11-13 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
9-11 11-13 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS

L5 STR



Structure attributes must be viewed using STN Express query preparation:
Uploading L5.str



ring nodes :
1 2
ring bonds :
1-2
exact bonds :
1-2

Match level :
1:Atom 2:Atom

L7 8933 SEA FILE=REGISTRY SSS FUL L3 AND L5
L29 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading L29.str





chain nodes :
11 13 14 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 33 34
35 36 38 39 40 41 43 45 46 47 49 50 52 53 54 67
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
9-67 11-13 13-16 14-16 14-17 18-19 19-20 20-21 22-23 23-24 24-25 26-27

```
27-28  29-30  30-31  31-33  33-34  35-36  36-38  38-39  40-41  41-43  43-45  46-47
47-49  50-52
53-54
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10
exact/norm bonds :
9-67  11-13  13-16  14-16  14-17  19-20  20-21  22-23  23-24  29-30  30-31  31-33
33-34  35-36  36-38  38-39  40-41  41-43  43-45  46-47  47-49  50-52  53-54
exact bonds :
18-19  24-25  26-27  27-28
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10


G1:CH2,O

G2:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  13:CLASS  14:CLASS  16:Atom  17:CLASS  18:CLASS  19:Atom  20:CLASS
21:CLASS  22:CLASS  23:CLASS
24:Atom  25:CLASS  26:CLASS  27:Atom  28:CLASS  29:CLASS  30:CLASS  31:Atom
33:CLASS  34:CLASS
35:CLASS  36:Atom  38:CLASS  39:CLASS  40:CLASS  41:CLASS  43:Atom  45:CLASS
46:CLASS  47:Atom
49:CLASS  50:Atom  52:CLASS  53:Atom  54:CLASS  67:CLASS
Generic attributes :
31:
Number of Hetero Atoms : Exactly 1
36:
Number of Hetero Atoms : Exactly 1
43:
Number of Hetero Atoms : Exactly 1
47:
Number of Hetero Atoms : Exactly 1
50:
Type of Ring System    : Polycyclic
53:
Type of Ring System    : Polycyclic

Element Count :
Node 31: Limited
    O,O1

Node 36: Limited
    O,O1

Node 43: Limited
    O,O1

Node 47: Limited
    O,O1

Node 50: Limited
    N,N1
    C,C2-9

Node 53: Limited
    N,N1
```

```
L31        1356 SEA FILE=REGISTRY SUB=L7 SSS FUL L29
L32          85 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L31
L33          17 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  MCH ANTAGONIST/TI
L34           4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L32 AND L33
L36             TRANSFER  PLU=ON  L34 1- RN :    3820 TERMS
L37        3820 SEA FILE=REGISTRY ABB=ON  PLU=ON  L36
L38        1043 SEA FILE=REGISTRY ABB=ON  PLU=ON  L37 AND L31
L39         313 SEA FILE=REGISTRY ABB=ON  PLU=ON  L31 NOT L38
L41          81 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L39
L42          42 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L32 AND P/DT
L43          43 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L32 NOT L42
L44          36 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L43 AND PY<2005
L45          25 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L42 AND PD<20040107
L46          33 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L42 AND PRD<20040107
L47          27 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L42 AND AD<20040107
L48          70 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  (L44 OR L45 OR L46 OR L47)
L49          67 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L41 AND L48


=> s L49 not (L50 or L65)
L66          67 L49 NOT (L50 OR L65)

=> s L49 not (L50 or L65 or L64)
L67          66 L49 NOT (L50 OR L65 OR L64)

=> d ibib abs hitstr L67 1-66

L67  ANSWER 1 OF 66  ZCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2005:638883  ZCAPLUS  Full-text
DOCUMENT NUMBER:          143:153408
TITLE:                    Preparation of pyrrolo[2,1-f][1,2,4]triazine
                          derivatives as HER1, HER2, and HER4 kinase inhibitors,
                          and antiproliferative agents
INVENTOR(S):              Fink, Brian E.; Gavai, Ashvinikumar V.; Vite, Gregory
                          D.; Chen, Ping; Mastalerz, Harold; Norris, Derek J.;
                          Tokarski, John S.; Zhao, Yufen; Han, Wen-Ching
PATENT ASSIGNEE(S):       Bristol-Myers Squibb Company, USA
SOURCE:                   PCT Int. Appl., 196 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2005066176         A1    20050721    WO 2004-US43169         20041223 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
```

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005182058	A1	20050818	US 2004-19901		20041222 <--
US 7141571	B2	20061128			
AU 2004312413	A1	20050721	AU 2004-312413		20041223 <--
CA 2552107	A1	20050721	CA 2004-2552107		20041223 <--
EP 1699797	A1	20060913	EP 2004-815269		20041223 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU					
CN 1922182	A	20070228	CN 2004-80042198		20041223 <--
BR 2004018231	A	20070427	BR 2004-18231		20041223 <--
JP 2007518721	T	20070712	JP 2006-547328		20041223 <--
NO 2006002763	A	20060911	NO 2006-2763		20060613 <--
IN 2006DN03471	A	20070831	IN 2006-DN3471		20060616 <--
MX 2006PA07038	A	20060831	MX 2006-PA7038		20060619 <--
US 2006264438	A1	20061123	US 2006-426479		20060626 <--
US 7297695	B2	20071120			
PRIORITY APPLN. INFO.:			US 2003-533335P	P	20031229 <--
			US 2004-19901	A1	20041222
			WO 2004-US43169	W	20041223

OTHER SOURCE(S): MARPAT 143:153408

GI



I



II

AB Title compds. I [R1 = (un)substituted cycloalkyl, aryl, heterocyclyl; R2 = (un)substituted hetero/aryl, heterocyclyl; R3 = H, (un)substituted alkyl; X = a direct bond, NR3, O; Y = a direct bond, (un)substituted alk(en/yn)yl; with the proviso that R2 is not (un)substituted indolyl; and their pharmaceutically acceptable salts and stereoisomers] were prepared as inhibitors tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases. For example, a 7-step synthesis of II, starting from 4-chloro-5-methylpyrrolo[2,1- f][1,2,4]triazine, is given. Most preferred compds. I had IC50 values between 0.001 and 0.1 μM in one or more HER1, HER2,

and HER4 assays. I are useful for treating other diseases associated with signal transduction pathways operating through growth factor receptors.

IT 859851-73-3P, N-[5-[(4-Amino-1-piperidinyl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]-2-quinolinamine monotrifluoroacetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrrolotriazines as HER1, HER2, and HER4 kinase inhibitors, and antiproliferative agents)

RN 859851-73-3 ZCAPLUS

CN 2-Quinolinamine, N-[5-[(4-amino-1-piperidinyl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859851-72-2
CMF C21 H23 N7



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 2 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:324156 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:392397
TITLE: Preparation of quinoline compounds containing isoxazole moiety as IgE receptor signaling cascade inhibitors
INVENTOR(S): Rajinder, Singh; Hui, Lin

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005033103	A1	20050414	WO 2004-US28411	20040901 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005113412	A1	20050526	US 2004-931481	20040901 <--
EP 1675850	A1	20060705	EP 2004-782827	20040901 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-502605P P 20030912 <--
WO 2004-US28411 W 20040901
OTHER SOURCE(S): CASREACT 142:392397; MARPAT 142:392397
GI



I

AB Title compds. I [R1 = (un)substituted alkyl; R2, R3, R5, R6, R7, R8 = H, ORd, SRd, etc.; Rd = protecting group; R9 = CF3, CH2CF3, CF2CF3, etc.; A = O, NH, CO; B = CO, NH, O; further details on A, B were provided.] and their pharmaceutically acceptable salts were prepared For example, acylation of 4-hydroxy-2-methylquinoline with 5-methyl-3-phenylisoxazole-4- carbonyl chloride, e.g., prepared from 5-methyl-3-phenylisoxazole-4- carboxylic acid, afforded 5-methyl-3-phenyl-4-isoxazolecarboxylic acid 2-methyl-4-quinolinyl ester (II). In IgE activation assays, compound II exhibited the IC50 value of <10 μM. Compound I are claimed useful for the treatment of allergic diseases, inflammation, etc.

IT 849936-94-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline compds. containing isoxazole moiety as IgE receptor
signaling cascade inhibitors)
RN 849936-94-3 ZCAPLUS
CN 4-Quinolinecarboxamide, 6-bromo-2-(1H-indol-5-ylamino)-N-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 3 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:216813 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:298122
TITLE: Preparation of pyrrolidinecarbonitrile compounds and analogs for DPP-IV enzyme inhibition
INVENTOR(S): Aranyi, Peter; Bata, Imre; Batori, Sandor; Boronkay, Eva; Bovy, Philippe; Kapui, Zoltan; Susan, Edit; Szabo, Tibor; Urban-szabo, Katalin; Varga, Marton
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Sanofi Aventis
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021536	A2	20050310	WO 2004-HU88	20040827 <--
WO 2005021536	A3	20051013		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG

HU 2003002788	A2	20070928	HU 2003-2788		20030829 <--
AU 2004268832	A1	20050310	AU 2004-268832		20040827 <--
CA 2537123	A1	20050310	CA 2004-2537123		20040827 <--
EP 1664031	A2	20060607	EP 2004-769087		20040827 <--
EP 1664031	B1	20071219			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
CN 1845921	A	20061011	CN 2004-80024974		20040827 <--
BR 2004013973	A	20061031	BR 2004-13973		20040827 <--
JP 2007504120	T	20070301	JP 2006-524430		20040827 <--
AT 381559	T	20080115	AT 2004-769087		20040827 <--
MX 2006PA02345	A	20060519	MX 2006-PA2345		20060228 <--
US 2006276487	A1	20061207	US 2006-364154		20060228 <--
IN 2006KN00637	A	20070803	IN 2006-KN637		20060320 <--
PRIORITY APPLN. INFO.:			HU 2003-2788	A	20030829 <--
			WO 2004-HU88	W	20040827

OTHER SOURCE(S): CASREACT 142:298122; MARPAT 142:298122
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A variety of compds. of the general formula R-B-NHCH2CO-Z-CN [R = mono or bicyclic (hetero)aryl, substituted Ph, R1aCH2, R1a = H, C1-C4 alkyl, Ph, PhCH2, pyridyl, quinolinyl, thienyl, C1-C4 alkoxy, cyano, etc.; R = R1aR2CH2, R2 = H, Me; R = R1bCO, R2 = C1-C4 alkyl, Ph, PhCH2, PhCH2CH2, naphthyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinolinyl, pyridyl, quinazolinyl, quinoxalinyl; R = 4-MeC6H4SO2; B = rings Q, Q1, Q2, Q3; Z = ring Q4, X = CF2, CHF, CH2, S, O] were prepared For example, 1,3-diaminoadamantane reacted with p-anisoyl chloride to give N-(3-amino-1-adamantyl)-4-methoxybenzamide which was condensed with (2S)-1-(chloroacetyl)-4,4-difluoropyrrolidine-2-carbonitrile to give one of the title compds. I. The compds. are intended to be used as DPP-IV enzyme inhibitors and to treat diseases related to DPP-IV enzyme concentration

IT 847796-24-1P 847796-25-2P 847797-00-6P
847797-01-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidinecarbonitriles and related compds. for DPP-IV enzyme inhibition)

RN 847796-24-1 ZCAPLUS

CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[3-(2-quinolinylamino)tricyclo[3.3.1.13,7]dec-1-yl]amino]acetyl]-, trihydrochloride (9CI) (CA INDEX NAME)



RN 847796-25-2 ZCAPLUS
CN 2-Pyrrolidinecarbonitrile, 4-fluoro-1-[[[3-(2-quinolinylamino)tricyclo[3.3.1.13,7]dec-1-yl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 847797-00-6 ZCAPLUS
CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[3-(2-quinolinylamino)tricyclo[3.3.1.13,7]dec-1-yl]amino]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847797-01-7 ZCAPLUS
CN 2-Pyrrolidinecarbonitrile, 4-fluoro-1-[[[3-(2-quinolinylamino)tricyclo[3.3.1.13,7]dec-1-yl]amino]acetyl]-, (2S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 847796-71-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolidinecarbonitriles and related compds. for DPP-IV enzyme inhibition)
RN 847796-71-8 ZCAPLUS
CN Tricyclo[3.3.1.13,7]decane-1,3-diamine, N-2-quinolinyl- (9CI) (CA INDEX NAME)



IT 847796-58-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolidinecarbonitriles and related compds. for DPP-IV enzyme inhibition)
RN 847796-58-1 ZCAPLUS
CN Carbamic acid, [3-(2-quinolinylamino)tricyclo[3.3.1.13,7]dec-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L67 ANSWER 4 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1154695 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:93821
TITLE: Processes for the preparation of 1-[(benzimidazol-1-yl)quinolin-8-yl]piperidin-4-ylamine derivatives
INVENTOR(S): Tom, Norma Jacqueline; Ripin, David Harold Brown; Castaldi, Michael James
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004113322	A1	20041229	WO 2004-IB1983		20040614 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004249511	A1	20041229	AU 2004-249511		20040614 <--
CA 2529032	A1	20041229	CA 2004-2529032		20040614 <--
EP 1641780	A1	20060405	EP 2004-736779		20040614 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
CN 1809556	A	20060726	CN 2004-80017570		20040614 <--
BR 2004011794	A	20060808	BR 2004-11794		20040614 <--
JP 2007516168	T	20070621	JP 2006-516552		20040614 <--
US 2005020625	A1	20050127	US 2004-875030		20040623 <--
US 7183414	B2	20070227			
IN 2005DN05390	A	20071130	IN 2005-DN5390		20051123 <--
MX 2005PA14203	A	20060224	MX 2005-PA14203		20051221 <--
KR 787649	B1	20071221	KR 2005-724593		20051222 <--
NO 2006000376	A	20060124	NO 2006-376		20060124 <--
US 2007088032	A1	20070419	US 2006-567071		20061205 <--
KR 2007092333	A	20070912	KR 2007-719713		20070829 <--
PRIORITY APPLN. INFO.:			US 2003-482176P	P	20030624 <--
			WO 2004-IB1983	W	20040614

US 2004-875030 A3 20040623
KR 2005-724593 A3 20051222

OTHER SOURCE(S): CASREACT 142:93821; MARPAT 142:93821

GI



I

AB The present invention relates to a process for preparing a compound of the formula (I) or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof [wherein R1, R2, R3 = independently H, C1-6 alkyl, C3-6 cycloalkyl, halo, cyano, CF3, F2CHO, CF3O, C1-6 alkoxy, C3-6 cycloalkoxy, cycloalkyl, or NR12R13 (wherein R12, R13 = independently H, C1-6 alkyl, or C3-6 cycloalkyl); R4 = (CR5R6)mH or (CR7R8)nQ (wherein Q = optionally substituted 4 to 10 membered aromatic or nonarom. heterocyclic containing one or more heteroatoms each selected from O, S and N; m = 1-5; n = 0-5; R5-R8 = independently H or C1-6 alkyl)], comprising reacting a compound of the formula (II) (wherein BOC = tert-butoxycarbonyl; R1-R4 = same as above) with a metal alkoxide in the presence of water. The compound I is useful in the treatment of abnormal cell growth such as cancer in mammals. Thus, mesylation of 3-methyl-3-oxetanemethanol by methanesulfonyl chloride in the presence of Et3N in MeCN followed by etherification with 4-amino-3-nitrophenol gave [4-(3-methyloxetan-3-ylmethoxy)-2- nitrophenyl]amine which underwent amination with 8-benzyloxyquinolin-2-ol in the presence of 1,2-bis(diphenylphosphino)ethane and Pd(OAc)2 in toluene at 100° for 24-30 h to give (8-benzyloxyquinolin-2-yl)[4-[(3-methyloxetan-3-yl)methoxy]-2-nitrophenyl]amine (III). Reductive cyclocondensation and debenzylation of III with formic acid in the presence of Pd(OH)2/C and Et3N in ethanol at 55° for 15-25 h gave 2-[5-(3-methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-ol which was triflated by N-phenyltrifluoromethanesulfonimide in the presence of Et3N in DMF at 20-30° for 20-30 h to give trifluoromethanesulfonic acid 2-[5-(3-methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl ester (IV). IV was coupled with piperidin-4-ylcarbamic acid tert-Bu ester in the presence of BINAP and tris(dibenzylideneacetone)dipalladium in PhMe at 85° for 24-32 h to give [1-[2-[5-(3-methyloxetan-3- ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]carbamic acid tert-Bu ester which was refluxed with sodium tert-butoxide and 1 equiv of H2O in 2-methyltetrahydrofuran for 24-30° and quenched by 20% aqueous citric acid, and basified with 50% aqueous NaOH to give, after workup, 86% [1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine.

IT 816463-37-3P, (8-Benzyloxyquinolin-2-yl)[4-[(3-methyloxetan-3-yl)methoxy]-2-nitrophenyl]amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; process for preparation of 1-[(benzimidazol-1-yl)quinolin-8-yl]piperidin-4-ylamine derivs. by deprotection of tert-butoxycarbonyl group with metal alkoxide and water)

RN 816463-37-3 ZCAPLUS

CN 2-Quinolinamine, N-[4-[(3-methyl-3-oxetanyl)methoxy]-2-nitrophenyl]-8-(phenylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 5 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:780540 ZCAPLUS Full-text
DOCUMENT NUMBER: 141:295872
TITLE: Preparation of heterocycles, in particular N-substituted quinolinecarboxamides, as kinase, especially ZAP-70 and Syk tyrosine kinase, and IL-2 production inhibitors
INVENTOR(S): Siddiqui, M. Arshad; Belanger, David; Dai, Chaoyang; Zhao, Lianyun
PATENT ASSIGNEE(S): Neogenesis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004080463	A1	20040923	WO 2004-US7286		20040310 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2518398	A1	20040923	CA 2004-2518398		20040310 <--
EP 1601357	A1	20051207	EP 2004-719237		20040310 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK					
CN 1784229	A	20060607	CN 2004-80012042		20040310 <--
JP 2006519846	T	20060831	JP 2006-507031		20040310 <--
MX 2005PA09722	A	20060309	MX 2005-PA9722		20050912 <--
PRIORITY APPLN. INFO.:			US 2003-453457P	P	20030310 <--
			US 2003-460910P	P	20030407 <--
			US 2003-463025P	P	20030415 <--
			US 2003-502710P	P	20030912 <--
			WO 2004-US7286	W	20040310

OTHER SOURCE(S): MARPAT 141:295872
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A forms a benzene, pyridine, pyrimidine, thiophene, pyrrole, imidazole, pyrazole, thiazole, or oxazole ring; X = O, NH and derivs., NHNH and derivs., CO, NHCO and derivs., CONH and derivs., or alkyl; Rx = H, (un)substituted cyclo/aryl/heteroaryl/akyl, heterocyclyl, hetero/aryl, aryl/heteroaryl/alkynyl, hetero/arylalkenyl, etc.; each R2 = H, NH and derivs., halo, (un)substituted cyclo/aryl/heteroaryl/alkyl, aryl/heteroaryl/alkenyl, aryl/heteroaryl/alkynyl, hetero/aryl, heterocyclyl, etc.; when X-Rx = Me and Q = NHaryl substituted with heterocyclyl, R2 is not Me; and when X-Rx = arylalkenyl, R2 is not acetyl; n = 0-3; Q = H, halo, C(:O)H and derivs., CONH2 and derivs., NH2 and derivs., etc.; including stereoisomers] were prepared as ZAP-70 and Syk tyrosine kinase, and IL-2 production inhibitors for treating autoimmune and inflammatory diseases. For example, II was prepared, in 5 steps, by ring expansion of 5-iodoisatin with malonic acid in glacial AcOH, Pd-cross coupling of the iodide with 3,4-(methylenedioxy)phenylboronic acid, chlorination of 2-quinolone with POCl3, acylation of the acid (no data) with (S)-N-[(pyrrolidin-2-yl)methyl]pyrrolidine, and amination of the chloride with benzylamine. Selected I inhibited ZAP-70 kinase with an IC50 < 1 μM in an in vitro DELFIA assay. I demonstrated inhibition of IL-2 production (no data). Thus, I are useful for treating autoimmune and inflammatory diseases, especially as lupus and arthritis.

IT 763134-13-0P 763134-57-2P 763134-58-3P
763138-63-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ZAP-70 tyrosine kinase inhibitor; preparation of heterocycles, in particular N-substituted quinolinecarboxamides, as kinase, especially ZAP-70
and Syk tyrosine kinase, and IL-2 production inhibitors for treating autoimmune and inflammatory disorders)

RN 763134-13-0 ZCAPLUS
CN Pyrrolidine, 1-[[2-(1H-indazol-6-ylamino)-4-quinolinyl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 763134-57-2 ZCAPLUS
CN Pyrrolidine, 1-[[6-(1,3-benzodioxol-5-yl)-2-(6-benzothiazolylamino)-4-quinolinyl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 763134-58-3 ZCAPLUS
CN Pyrrolidine, 1-[[6-(1,3-benzodioxol-5-yl)-2-(1H-indazol-6-ylamino)-4-quinolinyl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 763138-63-2 ZCAPLUS
CN Pyrrolidine, 1-[[2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(1,3-benzodioxol-5-yl)-4-quinolinyl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 6 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:504487 ZCAPLUS Full-text
DOCUMENT NUMBER: 141:277519
TITLE: Thieno[2,3-c]quinolines-synthesis and biological investigation
AUTHOR(S): Goerlitzer, K.; Gabriel, B.; Frohberg, P.; Wobst, I.; Drutkowski, G.; Wiesner, J.; Jomaa, H.
CORPORATE SOURCE: Institute Pharmazeutische Chemie, Braunschweig, D-38106, Germany
SOURCE: Pharmazie (2004), 59(6), 439-442
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 141:277519

AB PH-Dependent reduction of the Me 3-(2-nitrophenyl)thiophene-2-carboxylate, obtained by Suzuki cross-coupling of the Me 3-iodothiophene-2-carboxylate with 2-nitrophenyl boronic acid yields the cyclic hydroxamic acid 4 and the lactam 5, resp. The lactam 5 is also formed by reacting the compound Me 3-iodothiophene-2-carboxylate with pinacolato 2-aminophenylboronate. The 4-chlorothieno[2,3-c]quinoline 6 is formed from the lactam 5 by heating with POCl3/PCl5. Melting of 6 with the novaldiamine base in phenol gives the chloroquine analog 7, whereas the amodiaquine and the cycloquine analogs 8 and 9 are obtained using phenol Mannich bases. The hydroxamic acid 4 has a moderate effect on eicosanoid biosynthesis in human whole blood. The growth of the chloroquine resistant Plasmodium falciparum strain Dd2 is inhibited by the pyronaridine derivative 9 with an IC50-value of 650 nM.

IT 760189-88-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thieno[2,3-c]quinolines and their lipoxygenase-inhibitory and antimalarial activity)

RN 760189-88-6 ZCAPLUS
CN Phenol, 2-[(diethylamino)methyl]-4-(thieno[2,3-c]quinolin-4-ylamino)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 7 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:497359 ZCAPLUS Full-text
DOCUMENT NUMBER: 141:201822
TITLE: Selective binding and cleavage of DNA by stereoisomers of N,N'-bis(phenanthrolin-2-yl)-1,2-cyclohexanediamine conjugates, and their copper complexes
AUTHOR(S): Hayashi, Keigo; Nakajima, Ryouko; Kiyosawa, Isao; Ozaki, Hiroaki; Sawai, Hiroaki
CORPORATE SOURCE: Department of Applied Chemistry, Faculty of Engineering, Gunma University, Gunma, 376-8515, Japan
SOURCE: Chemistry Letters (2004), 33(6), 684-685
CODEN: CMLTAG; ISSN: 0366-7022
PUBLISHER: Chemical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Stereoisomers, trans-RR, trans-SS, and cis forms, of N,N'- bis(phenanthrolin-2-yl)-1,2-cyclohexanediamine conjugates were prepared, and their DNA binding activity was evaluated. The copper complexes of the conjugates (ligand:Cu(II) = 1:1 and 1:2) cleave DNA in the same order of the DNA binding activity of the conjugates, trans-RR > cis > trans-SS.

IT 742103-09-9 742103-12-4 742103-12-4D, copper complexes
RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(DNA cleavage by stereoisomers of N,N'-bis(phenanthrolin-2-yl)-1,2-cyclohexanediamine conjugates and their copper complexes)

RN 742103-09-9 ZCAPLUS
CN 1,2-Cyclohexanediamine, N,N'-di-1,10-phenanthrolin-2-yl-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 742103-12-4 ZCAPLUS
CN 1,2-Cyclohexanediamine, N,N'-di-1,10-phenanthrolin-2-yl-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 742103-12-4 ZCAPLUS
CN 1,2-Cyclohexanediamine, N,N'-di-1,10-phenanthrolin-2-yl-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 8 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:168587 ZCAPLUS Full-text
DOCUMENT NUMBER: 140:374934
TITLE: Chiral Proton Catalysis: A Catalytic Enantioselective Direct Aza-Henry Reaction
AUTHOR(S): Nugent, Benjamin M.; Yoder, Ryan A.; Johnston, Jeffrey N.
CORPORATE SOURCE: Department of Chemistry, Indiana University, Bloomington, IN, 47405, USA
SOURCE: Journal of the American Chemical Society (2004), 126(11), 3418-3419
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:374934
GI



I



II

AB Nonracemic β-aryl-β-aminonitroalkanes I (R = H, Me; R1 = H, 2-O2N, 3-O2N, 4-O2N, 4-Cl, 4-F3C, 4-F3CO) are prepared in 50-69% yields, 7:1-19:1 diastereoselectivities (for R = Me), and in 59-95% ee by the stereoselective aza-Henry reaction of nitroalkanes RCH2NO2 (R = H, Me) to the N-Boc imines RC6H4CH:NBoc (Boc = tert-butoxycarbonyl) in the presence of nonracemic di(quinolinylamino)cyclohexane triflic acid salt II•F3CSO3H. II is prepared by amination of 2-chloroquinoline with (1R-trans)-1,2-cyclohexanediamine in the presence of Pd(dba)2, racemic BINAP, and sodium tert-butoxide; II•F3CSO3H

is prepared as a bench-stable white solid by addition of triflic acid to II in methylene chloride. The free base II does not act as a catalyst for enantioselective Henry reactions in the absence of acid. II•F3CSO3H is proposed to act as a catalyst using polar ionic hydrogen bonds to accelerate the reaction while controlling its stereoselectivity; the catalyst is effective without either a Bronsted base additive or preactivation of the nitroalkane.

IT 685132-71-2P, HQuin-BAM
RL: CAT (Catalyst use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of a nonracemic trans-(quinolinylamino)cyclohexane and its lack of activity as a catalyst for enantioselective aza-Henry reactions of nitroalkanes with N-Boc imines in the absence of a proton source)

RN 685132-71-2 ZCAPLUS
CN 1,2-Cyclohexanediamine, N,N'-di-2-quinolinyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 685132-72-3P
RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(preparation of a nonracemic trans-(quinolinylamino)cyclohexane and the use of its triflate salt as a catalyst for the preparation of nonracemic β-aryl-β-aminonitroalkanes by enantioselective aza-Henry reactions of nitroalkanes with N-Boc imines)

RN 685132-72-3 ZCAPLUS
CN Methanesulfonic acid, 1,1,1-trifluoro-, compd. with (1R,2R)-N1,N2-di-2-quinolinyl-1,2-cyclohexanediamine (1:1) (CA INDEX NAME)

CM 1

CRN 685132-71-2
CMF C24 H24 N4

Absolute stereochemistry. Rotation (+).



CM 2

CRN 1493-13-6
CMF C H F3 O3 S



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 9 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:719461 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:245893
TITLE: Preparation of aminoacetylpyrrolidinecarbonitriles as inhibitors of DPP-IV
INVENTOR(S): Aranyi, Peter; Balazs, Laszlo; Bata, Imre; Batori, Sandor; Boronkay, Eva; Bovy, Philippe; Kanai, Karoly; Kapui, Zoltan; Susan, Edit; Szabo, Tibor; Nagy, Lajos T.; Urban-Szabo, Katalin; Varga, Marton
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; et al.
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074500	A2	20030912	WO 2003-HU17	20030304 <--
WO 2003074500	A3	20031218		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
HU 2002000849	A2	20040830	HU 2002-849	20020306 <--
CA 2475312	A1	20030912	CA 2003-2475312	20030304 <--
AU 2003209514	A1	20030916	AU 2003-209514	20030304 <--
EP 1487807	A2	20041222	EP 2003-743452	20030304 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007960	A	20050215	BR 2003-7960	20030304 <--
CN 1639159	A	20050713	CN 2003-805263	20030304 <--
JP 2005529078	T	20050929	JP 2003-572969	20030304 <--
NZ 535662	A	20070531	NZ 2003-535662	20030304 <--

CN 1990486	A	20070704	CN 2006-10164020		20030304 <--
TW 250978	B	20060311	TW 2003-92104743		20030306 <--
IN 2004KN01079	A	20060127	IN 2004-KN1079		20040728 <--
ZA 2004006467	A	20050622	ZA 2004-6467		20040813 <--
MX 2004PA08613	A	20050608	MX 2004-PA8613		20040906 <--
NO 2004004221	A	20041206	NO 2004-4221		20041005 <--
US 2005130981	A1	20050616	US 2005-507005		20050131 <--
PRIORITY APPLN. INFO.:			HU 2002-849	A	20020306 <--
			CN 2003-805263	A3	20030304 <--
			WO 2003-HU17	W	20030304 <--

OTHER SOURCE(S): MARPAT 139:245893

GI



I



II

AB Title compds. I [R1 = (un)substituted N heteroarom., thienyl, furyl, CH2Ph, tosyl, acyl; B = N heterocyclic; R2 = H, F] were prepared for use as dipeptidyl peptidase IV (DPP-IV) inhibitors with IC50 ≤ 100 nM, useful in the treatment of diabetes. Thus, the title compound II was prepared from 8-(2-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl-exo-amine and (2S)-1-chloroacetyl-4,4-difluoro-2-pyrrolidinecarbonitrile, each prepared in several steps.

IT 596817-25-3P 596817-81-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminoacetylpyrrolidinecarbonitriles as inhibitors of DPP-IV)

RN 596817-25-3 ZCAPLUS

CN Carbamic acid, [(3-exo)-8-(2-quinolinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 596817-81-1 ZCAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(2-quinolinyl)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



IT 596816-43-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoacetylpyrrolidinecarbonitriles as inhibitors of DPP-IV)
RN 596816-43-2 ZCAPLUS
CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[(3-exo)-8-(2-quinolinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

L67 ANSWER 10 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:570986 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:133579
TITLE: Preparation of fused pyrimidines as Rho-kinase inhibitors useful for inhibiting tumor growth and treating disorders such as erectile dysfunction
INVENTOR(S): Nagarathnam, Dhanapalan; Khire, Uday; Asgari, Davoud; Shao, Jianxing; Liu, Xiao-Gao; Wang, Chunguang; Hart, Barry; Weber, Olaf; Lynch, Mark; Zhang, Lei; Wang, Lei
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059913	A1	20030724	WO 2003-US606	20030110 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2472619	A1	20030724	CA 2003-2472619		20030110 <--
AU 2003202263	A1	20030730	AU 2003-202263		20030110 <--
US 2004014755	A1	20040122	US 2003-339393		20030110 <--
EP 1465900	A1	20041013	EP 2003-701278		20030110 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005523251	T	20050804	JP 2003-560016		20030110 <--
US 2007238741	A1	20071011	US 2007-733045		20070409 <--
PRIORITY APPLN. INFO.:			US 2002-346628P	P	20020110 <--
			US 2003-339393	B1	20030110 <--
			WO 2003-US606	W	20030110 <--

OTHER SOURCE(S): MARPAT 139:133579

GI



I



II

AB Disclosed are (shown as I; variables defined below; e.g. 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine (shown as II)), their synthesis, and their use as Rho-kinase inhibitors (no data). These compds. of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease. For I: X is -(CH2)x-, -O-(CH2)n-, -S-(CH2)n-, -NR7-CO-(CH2)n-, -NR7-SO2-(CH2)n-, -NR7-(CH2)n-, or -(O)C-NR7- (n = 0-3; x = 0-3); p = 0-3; a and c = -CR5=, -N=, or -NR6-, wherein one of a or c is -NR6-, and b is -CR5= or -N=; A is H, halogen, -CO-OR8, -CO-R8, cyano, -OR8, -NR8R9, -CO-NR8R9, -NR8-CO-R9, -NR8-CO-OR9, -NR8-SO2-R9, -SR8, -SO2-R8, -SO2-NR8R9, NR8-CO-NHR9, or A is cyclohexyl or C5-12-aryl or C5-12-heteroaryl. Ring B = a fused 5- or 6-membered heterocyclic ring containing 1-2 O, N, and/or S atoms and 1-5 C atoms; R1, and R6-R11 are each independently H and C1-6 alkyl; R2-R5 = C1-10-alkyl, C2-10-alkenyl, C3-C10 cycloalkyl, C3-10-

cycloalkenyl, partially unsatd. C5-10-heterocyclyl, aryl, heteroaryl, halogen, -CO-OR10, -OCOR10, -OCO2R10, -CHO, cyano, -OR16, -NR10R15, nitro, -CO-NR10R11, -NR10-CO-R12, -NR10-CO-OR11, -NR10-SO2-R12, -SR16, -SOR16, -SO2-R16, -SO2-NR10R11, NR10-CO-NHR11, amidino, guanidino, sulfo, -B(OH)2, -OCON(R10)2, or -NR10CON(R10)2. R12 is H, C1-6-alkyl or C5-10-aryl, R13 is H, C1-6-alkyl or C1-6-alkoxy, R14 is lower alkyl or phenyl; R15 is lower alkyl, halogen, amino, N-lower alkyl amino, N,N-dilower alkylamino, N-lower alkanoylamino, OH, CN, COOR10, -COR14 or -OCOR14; R16 is H, C1-6-alkyl (un)substituted by halogen, up to perhalo, or C5-10 heteroaryl; with the provisos that A is not H when x is 0; -X-A is not CH3 when B = a thieno[3,2-b] fused ring, and b and c are -CR5=, and a is NH; and A is not Ph when X is NH, B forms an imidazo fused ring, and -a-b-c- is -CR5:N-NR6- or -NR6:N-CR5-; addnl. details are given in the claims. Although the methods of preparation are not claimed, .apprx.10 example prepns. and characterization data for many I are included.

IT 568581-71-5P, N-(Quinolin-2-yl)-4-(1H-indazol-5-ylamino)thieno[3,2-d]pyrimidin-2-amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of fused pyrimidines as Rho-kinase inhibitors useful for inhibiting tumor growth and treating disorders such as erectile dysfunction)

RN 568581-71-5 ZCAPLUS

CN Thieno[3,2-d]pyrimidine-2,4-diamine, N4-1H-indazol-5-yl-N2-2-quinolinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 11 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:236029 ZCAPLUS Full-text

DOCUMENT NUMBER: 139:81899

TITLE: Conformational restriction of methionyl tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent gram-Positive antibacterial activity

AUTHOR(S): Jarvest, Richard L.; Berge, John M.; Brown, Pamela; Houge-Frydrych, Catherine S. V.; O'Hanlon, Peter J.; McNair, David J.; Pope, Andrew J.; Rittenhouse, Stephen

CORPORATE SOURCE: GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(7), 1265-1268
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:81899

AB Conformationally restricted analogs of the central linker unit of bacterial methionyl tRNA synthetase inhibitors were prepared The (1S,2R)-cyclopentylmethyl moiety was identified as the preferred cyclic linker, with significant diastereo- and enantioselectivity of activity. Combination of this linker with an optimal substituted aryl right-hand side has resulted in a compound with exceptionally good antibacterial activity against staphylococci and enterococci, including antibiotic resistant strains.

IT 248607-90-1P 248607-91-2P 552859-24-2P
552859-25-3P 552859-26-4P 552859-31-1P
552859-32-2P 552859-38-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(conformational restriction of methionyl tRNA synthetase inhibitors leading to analogs with potent inhibition and excellent gram-Pos. antibacterial activity)

RN 248607-90-1 ZCAPLUS
CN Carbamic acid, (4-ethoxy-2-quinolinyl)[[(1R,2S)-2-[[(1S)-1-phenylethyl](phenylmethyl)amino]cyclopentyl]methyl]-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 248607-91-2 ZCAPLUS
CN 2-Quinolinamine, N-[[(1R,2S)-2-aminocyclopentyl]methyl]-4-ethoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 552859-24-2 ZCAPLUS
CN D-erythro-Pentitol, 1,4-anhydro-3-azido-2,3,5-trideoxy-5-[(4-ethoxy-2-quinolinyl)[(2,2,2-trichloroethoxy)carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 552859-25-3 ZCAPLUS
CN D-erythro-Pentitol, 3-amino-1,4-anhydro-2,3,5-trideoxy-5-[(4-ethoxy-2-quinolinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 552859-26-4 ZCAPLUS
CN D-erythro-Pentitol, 1,4-anhydro-2,3,5-trideoxy-3-[[(3,4-dichlorophenyl)methyl]amino]-5-[(4-ethoxy-2-quinolinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 552859-31-1 ZCAPLUS
CN 2-Quinolinamine, N-[(5-azido-1-cyclopenten-1-yl)methyl]-4-ethoxy- (CA INDEX NAME)



RN 552859-32-2 ZCAPLUS
CN 2-Quinolinamine, N-[(5-amino-1-cyclopenten-1-yl)methyl]-4-ethoxy- (CA INDEX NAME)



RN 552859-38-8 ZCAPLUS
CN Carbamic acid, [[2-[[(3,4-dichlorophenyl)methyl]amino]cyclobutyl]methyl](4-ethoxy-2-quinolinyl)-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 12 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:173587 ZCAPLUS Full-text
DOCUMENT NUMBER: 138:221475
TITLE: Preparation of quinoline-2,4-diamines as N-type calcium channel antagonists for the treatment of pain
INVENTOR(S): D'amico, Derin
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018560	A1	20030306	WO 2002-SE1520	20020823 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

AU 2002324407 A1 20030310 AU 2002-324407 20020823 <--
EP 1430029 A1 20040623 EP 2002-759045 20020823 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
JP 2005505541 T 20050224 JP 2003-523223 20020823 <--
US 2004266819 A1 20041230 US 2004-488066 20040809 <--
US 7060834 B2 20060613
PRIORITY APPLN. INFO.: SE 2001-2857 A 20010827 <--
WO 2002-SE1520 W 20020823 <--
OTHER SOURCE(S): CASREACT 138:221475; MARPAT 138:221475
GI



AB The title compds. [I; R1 = alkyl, alkenyl, (un)substituted Ph, etc.; A = CH2, a bond; R4 = alkyl, alkoxyalkyl; R5 = H, alkyl; R6 = H, halo, alkyl, etc.; R7 = H, halo, alkyl, etc.; R8 = H, Me] such as the quinoline II, useful for the treatment of pain, were prepared by coupling 2-chloroquinoline intermediates with amines using a ChemSpeed robot. The compound II showed IC50 of 2.82 nM in the FLIPR assay.

IT 500780-21-2P 500780-26-7P 500780-28-9P
500780-31-4P 500780-38-1P 500780-43-8P
500780-52-9P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of quinoline-2,4-diamines as N-type calcium channel antagonists
for the treatment of pain)

RN 500780-21-2 ZCAPLUS

CN 2,4-Quinolinediamine, N2-6-benzothiazolyl-N4-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 500780-26-7 ZCAPLUS
CN 2,4-Quinolinediamine, N2-6-benzothiazolyl-N4-(2,2-dimethylpropyl)-8-(trifluoromethyl)- (CA INDEX NAME)



RN 500780-28-9 ZCAPLUS
CN 2,4-Quinolinediamine, N2-6-benzothiazolyl-N4-(2,2-dimethylpropyl)-8-fluoro- (CA INDEX NAME)



RN 500780-31-4 ZCAPLUS
CN 2,4-Quinolinediamine, N2-6-benzothiazolyl-8-bromo-N4-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 500780-38-1 ZCAPLUS
CN 2,4-Quinolinediamine, N2-6-benzothiazolyl-6-bromo-N4-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 500780-43-8 ZCAPLUS
CN 2,4-Quinolinediamine, N2-6-benzothiazolyl-N4-(2,2-dimethylpropyl)-6-fluoro- (CA INDEX NAME)



RN 500780-52-9 ZCAPLUS
CN 2,4-Quinolinediamine, N2-6-benzothiazolyl-N4-(2,2-dimethylpropyl)-8-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 13 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:849627 ZCAPLUS Full-text
DOCUMENT NUMBER: 137:370084
TITLE: Preparation of 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine-4,6-dione derivatives as inhibitors of production of tumor necrosis factor-α (TNF-α)
INVENTOR(S): Tanaka, Yasuhiro; Fujita, Kohichi; Chujoh, Yoshitomo; Fukuda, Syunsuke; Ikenoue, Yuka; Tagami, Tomoyuki; Chiba, Akira; Kodaira, Ariko; Matsumoto, Hideki; Nakagawa, Tadakiyo; Yamada, Tatsuhiro; Suzuki, Manabu; Murata, Masahiro
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088122	A1	20021107	WO 2002-JP4206	20020426 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002251553	A1	20021111	AU 2002-251553	20020426 <--
EP 1396493	A1	20040310	EP 2002-720620	20020426 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004147546	A1	20040729	US 2004-475097	20040224 <--
PRIORITY APPLN. INFO.:			JP 2001-130438 A	20010426 <--
			WO 2002-JP4206 W	20020426 <--

OTHER SOURCE(S): MARPAT 137:370084

GI



I

AB Pharmaceutical compns. containing as the active ingredient heterocyclic compds. represented by the general formula (I), isomers or solvates thereof, or pharmaceutically acceptable salts of them [R1 = each (un)substituted alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, heteroaryl, heteroarylalkyl, or cycloalkyl or cycloalkylalkyl each optionally containing a heteroatom in the ring; R2, R3 = H, HO, or each (un)substituted alkyl or aralkyl; or R2 and R3 together represent cycloalkyl optionally containing a heteroatom in the ring, :CR5R6, :N+(O-)R7, :NR8, or oxo [wherein R5, R6 = H, alkoxyl, alkoxycarbonyl, each (un)substituted alkyl, cycloalkyl, aralkyl, aryl, heteroaryl, or cycloalkyl; R7 = (un)substituted aryl; R8 = HO, alkoxy, each (un)substituted aryl or heteroaryl; R9 = (un)substituted aryl or heteroaryl, acyl, CONH2]; R4 = H, each (un)substituted alkyl or aralkyl; X = H, halo, HO, each (un)substituted alkyl, aralkyl, alkoxy, aryl, heteroaryl, NH2, alkylthio, aralkylthio, arylthio, heteroarylthio, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, etc.; Y = O, S] are disclosed. These compds. exhibit excellent TNF-α production inhibiting activity and are therefore useful in the prevention and treatment of various diseases caused by abnormal production of TNF-α such as Crohn's disease, ulcerative colitis, septicemia, chronic articular rheumatism, or autoimmune disease. Thus, 3-amino-2-phenyl-2H-4,5,6,7- tetrahydropyrazolo[4,3-c]pyridine-4,6-dione and pentafluorobenzaldehyde were refluxed in the presence of a catalytic amount of AcOH in ethanol overnight to give 3-amino-7-(2,3,4,5,6-pentafluorobenzylidene)-2-phenyl-2H- 4,5,6,7-tetrahydropyrazolo[4,3-

c]pyridine-4,6-dione (II). II showed IC50 of 0.4 μM for inhibiting the lipopolysaccharide-stimulated production of TNF-α in mouse i.p. macrophage.

IT 475093-19-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydropyrazolo[4,3-c]pyridinedione derivs. as TNF-α production inhibitors for prevention and treatment of various diseases caused by abnormal production of TNF-α)

RN 475093-19-7 ZCAPLUS
CN 2H-Pyrazolo[4,3-c]pyridine-4,6(5H,7H)-dione, 3-amino-2-(2-quinolinyl)- (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 14 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:574932 ZCAPLUS Full-text
DOCUMENT NUMBER: 137:140443
TITLE: Preparation of N-(2-quinolinyl)propane-1,3-diamines as urotensin-II receptor antagonists
INVENTOR(S): Dhanak, Dashyant; Knight, Steven D.; Warren, Gregory L.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, UK
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058702	A1	20020801	WO 2002-US2007	20020125 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002235453	A1	20020806	AU 2002-235453	20020125 <--
EP 1359915	A1	20031112	EP 2002-702068	20020125 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004524295	T	20040812	JP 2002-559036	20020125 <--

CA 2488968	A1	20031120	CA 2003-2488968		20030312	<--
JP 2006502096	T	20060119	JP 2004-503490		20030312	<--
US 2004063757	A1	20040401	US 2003-470115		20030725	<--
US 6818655	B2	20041116				
PRIORITY APPLN. INFO.:			US 2001-264439P	P	20010126	<--
			WO 2002-US2007	W	20020125	<--
			US 2002-63046	A	20020508	<--
			WO 2003-US7683	W	20030312	<--

OTHER SOURCE(S): MARPAT 137:140443

GI



I

AB The title compds. [I; R1 = (un)substituted 1,1,-diphenylmethyl, Ph, benzimidazolyl, etc.; R2 = H, alkyl; R3 = H, alkyl, (un)substituted Ph, CH2Ph; or both R3 together with the carbon they are attached to, form cycloalkyl; R4 = H, alkyl; R5 = H, alkoxy, CONR6R7; R6 = H, alkyl; R7 = H, alkyl; NR6R7 = 5-6 membered ring; X = CR8R9, CO; R8 = H, alkyl; R9 = H, alkyl; or CR8R9 = cycloalkyl] and their pharmaceutically acceptable salts, useful as antagonists of urotensin II, were prepared and formulated. E.g., a multi-step synthesis of I [R1 = 1-benzyl-1H-indol-3-yl; R2-R4 = H; R5 = OMe; X = CH2], starting with 2,4-dihydroxyquinoline, was given. Activity for the compds. I against h-U-II range from 1 nM to 10000 nM (Ki).

IT 444683-03-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(2-quinolinyl)propane-1,3-diamines as urotensin-II receptor antagonists)

RN 444683-03-8 ZCAPLUS

CN 1,1-Cyclohexanedimethanamine, N-(4-methoxy-2-quinolinyl)-N'-[[1-(phenylmethyl)-1H-indol-3-yl]methyl]- (CA INDEX NAME)



IT 444683-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(2-quinolinyl)propane-1,3-diamines as urotensin-II receptor antagonists)
RN 444683-29-8 ZCAPLUS
CN 1,1-Cyclohexanedimethanamine, N-(4-methoxy-2-quinolinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 15 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:465720 ZCAPLUS Full-text
DOCUMENT NUMBER: 137:33226
TITLE: Preparation of quinolones as urotensin-II receptor antagonists
INVENTOR(S): Dhanak, Dashyant; Knight, Steven D.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002047456	A2	20020620	WO 2001-US46370		20011205 <--
WO 2002047456	A3	20030123			
W: AE, AG, AL, BA, BB, BR, CA, CH, CU, CZ, EC, ES, FI, GB, HU, ID, IS, JP, KP, KR, LS, LT, MA, MD, MW, RO, RU, SK, TR, TT, UA, UG, YU, ZA, RU, TJ, TM					
RW: AT, BE, CH, CY, ES, FI, FR, GB, GR, IT, NL, BF, CI, GA, NE, SN, TD, TG					
AU 2002039506	A5	20020624	AU 2002-39506		20011205 <--
EP 1351687	A2	20031015	EP 2001-987271		20011205 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004515507	T	20040527	JP 2002-549045		20011205 <--
US 2004053963	A1	20040318	US 2003-450281		20030611 <--
PRIORITY APPLN. INFO.:			US 2000-254594P	P	20001211 <--
			WO 2001-US46370	W	20011205 <--

OTHER SOURCE(S): MARPAT 137:33226
GI



I

AB The title compds. [I; R1 = (un)substituted Ph, thienyl, indolyl, etc.; R2 = H, Me; R3 = H, I, F, etc.; X = CHR4; R4 = H, CO, alkyl, Ph; Y = CH2CR5R6CH2; R5 = H, alkyl, CH2Ph, etc.; R6 = cycloalkyl, (un)substituted CH2Ph, Ph; or R5 and R6 together with the carbon they are attached to may form a cycloalkyl], useful as urotensin antagonists, were prepared and formulated. E.g., a multi-step synthesis of the quinolone I [R1 = 1-benzyl-1H-indol-3-yl; R2, R3 = H; X = CH2; Y = CH2CHPhCH2] was given. The compds. I show activity against h-U-II in the range from 8 nM to 1 μM.

IT 437708-62-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinolones as urotensin-II receptor antagonists)

RN 437708-62-8 ZCAPLUS

CN Cyclohexanedimethanamine, N-(4-methoxy-2-quinolinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L67 ANSWER 16 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:283021 ZCAPLUS Full-text

DOCUMENT NUMBER: 137:185392

TITLE: Synthesis of pyrrolo[a]- and pyrrolo[c]phenanthridine derivatives and indolinyl and indolyl-substituted 6-phenanthridines

AUTHOR(S): Baberkina, E. P.; Buyanov, V. N.; Zhukova, M. E.; Shchekotikhin, A. E.; Zhigachev, V. E.; Suvorov, N. N.

CORPORATE SOURCE: Russian University of Chemical Technology, Moscow, 125190, Russia

SOURCE: Chemistry of Heterocyclic Compounds (New York, NY, United States)(Translation of Khimiya Geterotsiklicheskikh Soedinenii) (2001), 37(10), 1234-1237
CODEN: CHCCAL; ISSN: 0009-3122

PUBLISHER: Kluwer Academic/Consultants Bureau

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:185392

AB The corresponding Mannich bases have been synthesized by the aminomethylation of 6-methyl-1H-pyrrolo[2,3-a]- and 4-methyl-3H- pyrrolo[3,2-c]phenanthridinium iodides. The interaction of 6-chlorophenanthridine with indoline and with 5-amino-N-acetylindoline gave the corresponding derivs. of phenanthridine. 6-(1- Indolyl)phenanthridine has been obtained by the dehydrogenation of 6-(1-indolinyl)phenanthridine with manganese dioxide.

IT 450414-94-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of pyrrolo[a]- and pyrrolo[c]phenanthridine derivs. and indolinyl and indolyl-substituted 6-phenanthridines via condensation, alkylation, and dehydrogenation reactions)

RN 450414-94-5 ZCAPLUS

CN 1H-Indol-5-amine, 1-acetyl-2,3-dihydro-N-6-phenanthridinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 17 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:15647 ZCAPLUS Full-text

DOCUMENT NUMBER: 132:85730

TITLE: Electroluminescent devices using boron chelates of 8-aminoquinoline derivatives

INVENTOR(S): Heuer, Helmut Werner; Wehrmann, Rolf; Elschner, Andreas

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Ger. Offen., 50 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19829949	A1	20000105	DE 1998-19829949	19980704 <--
US 2002006528	A1	20020117	US 1999-345253	19990630 <--
US 6368731	B2	20020409		
JP 2000138096	A	20000516	JP 1999-187870	19990701 <--
KR 2000011463	A	20000225	KR 1999-26748	19990703 <--
EP 1074602	A1	20010207	EP 1999-115097	19990806 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: DE 1998-19829949 A 19980704 <--

OTHER SOURCE(S): MARPAT 132:85730

AB Electroluminescent devices are described which employ boron complexes of 8-aminoquinoline derivs. in the active structure of the device. The devices may addnl. comprise hole-injecting regions formed from polythiophene derivs. or

hole-injecting and/or transporting regions formed from aromatic tertiary amine compds.

IT 253780-71-1 253780-72-2
RL: DEV (Device component use); USES (Uses)
(electroluminescent devices using boron complexes of 8-aminoquinoline derivs.)

RN 253780-71-1 ZCAPLUS
CN Boron, [μ-[[N,N'-[(butylimino)di(2,8-quinolinediyl-κN)]bis[pentanamidato-κN]](2-)]]tetraphenyldi- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 253780-72-2 ZCAPLUS
CN Boron, [μ-[[diethyl [(methylimino)di(2,8-quinolinediyl-κN)]bis[carbamato-κN]](2-)]]tetraphenyldi- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L67 ANSWER 18 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:12784 ZCAPLUS Full-text
DOCUMENT NUMBER: 132:85983
TITLE: Electroluminescent devices with boron chelates
INVENTOR(S): Heuer, Helmut-Werner; Wehrmann, Rolf; Elschner, Andreas
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: Eur. Pat. Appl., 59 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 969531	A2	20000105	EP 1999-111855	19990621 <--
EP 969531	A3	20000223		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
DE 19829947	A1	20000105	DE 1998-19829947	19980704 <--
TW 419929	B	20010121	TW 1999-88110272	19990621 <--
US 6287713	B1	20010911	US 1999-342952	19990629 <--
JP 2000150163	A	20000530	JP 1999-187807	19990701 <--
KR 2000011462	A	20000225	KR 1999-26746	19990703 <--
PRIORITY APPLN. INFO.:			DE 1998-19829947 A	19980704 <--

OTHER SOURCE(S): MARPAT 132:85983

AB The electroluminescent device comprises on a substrate, an anode, an electroluminescent element, comprised of a hole injection layer, hole transport layer, light-emitting layer, electron transport layer, and electron injection layer, and a cathode, wherein the electroluminescent element contains boron complex with 8-hydroxyquinoline derivative The hole injection layer contains a specific polythiophene compound The specific aromatic tertiary amino compound is located in the hole injection layer and/or the hole transport layer. The electroluminescent device shows improved illumination d.

IT 253672-97-8
RL: DEV (Device component use); USES (Uses)
(boron hydroxyquinoline complex in electroluminescent device)
RN 253672-97-8 ZCAPLUS
CN Boron, [μ-[[2,2'-(methylimino)bis[8-quinolinolato-

κN1,κO8]](2-)]]tetraphenyldi- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 253672-88-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of boron chelates for electroluminescent devices)
RN 253672-88-7 ZCAPLUS
CN Boron, [μ-[[2,2'-(butylimino)bis[8-quinolinolato-κN,κO8]](2-)]]tetraphenyldi- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 19 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:708742 ZCAPLUS Full-text
DOCUMENT NUMBER: 131:322546

TITLE: Preparation of 2-aminoquinolin-4-ones as inhibitors of methionyl tRNA synthase.

INVENTOR(S): Berge, John Michael; Brown, Pamela; Elder, John Stephen; Forrest, Andrew Keith; Hamprecht, Dieter Wolfgang; Jarvest, Richard Lewis; Mcnair, David Jonathan; Sheppard, Robert John

PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK

SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9955677	A1	19991104	WO 1999-EP2648		19990415 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2330564	A1	19991104	CA 1999-2330564		19990415 <--
AU 9935235	A	19991116	AU 1999-35235		19990415 <--
BR 9909994	A	20001226	BR 1999-9994		19990415 <--
TR 200003170	T2	20010122	TR 2000-3170		19990415 <--
EP 1084110	A1	20010321	EP 1999-916927		19990415 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI					
HU 2001003093	A2	20020228	HU 2001-3093		19990415 <--
HU 2001003093	A3	20020328			
JP 2002513005	T	20020508	JP 2000-545837		19990415 <--
ZA 2000005781	A	20010604	ZA 2000-5781		20001018 <--
NO 2000005400	A	20001026	NO 2000-5400		20001026 <--
MX 2000PA10551	A	20010507	MX 2000-PA10551		20001026 <--
US 6320051	B1	20011120	US 2000-674102		20001026 <--
PRIORITY APPLN. INFO.:			GB 1998-9050	A	19980429 <--
			GB 1998-24571	A	19981109 <--
			WO 1999-EP2648	W	19990415 <--

OTHER SOURCE(S): MARPAT 131:322546

GI



I

AB Title compds. [I; R1 = (substituted) aryl, heteroaryl; R2 = H, alkyl, aralkyl, aralkenyl, alkylcarbonyl; R3 = halo, cyano, OH, (substituted) alkyl, cycloalkyl, alkoxy, amino, acylamino, CO2H, etc.; X = CHR4, alkylene, alkenylene, CO; R4 = H, alkyl, aryl; Y = (substituted) alkylene, etc.; Z = NH,

O; R1X or R1R2 = (substituted) alkylene; XR2, XY, or YR2 = atoms to form a 4-7 membered ring; m = 0-3], were prepared Thus, 2-chloro-4-ethoxyquinoline and 1,3-diaminopropane were heated at 60° for 48 h to give 77% 2-(3-aminoprop-1-ylamino)-4- ethoxyquinoline. This was refluxed with concentrate HCl for 24 h to give 100% 2-(3-aminoprop-1-ylamino)-1H-quinolin-4-one dihydrochloride. The latter was stirred 40 min. with quinoline-3-carboxaldehyde and NaOAc in DMF/HOAc; Na(OAc)3BH was added and the mixture was stirred 2 h to give 2-[3-(3-quinolylmethylamino)prop-1-ylamino]-1H-quinolin-4-one. I inhibited S. aureus methionyl tRNA synthase with IC50's of <3nM to 700 nM.

IT 248607-48-9P 248607-73-0P 248607-86-5P
248607-88-7P 248607-90-1P 248607-92-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-aminoquinolin-4-ones as inhibitors of methionyl tRNA synthase)

RN 248607-48-9 ZCAPLUS
CN 1,3-Cyclohexanediamine, N-(4-methoxy-2-quinolinyl)-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 248607-73-0 ZCAPLUS
CN 2-Quinolinamine, N-[(2-aminocyclopentyl)methyl]-4-methoxy- (CA INDEX NAME)



RN 248607-86-5 ZCAPLUS
CN Carbamic acid, (4-ethoxy-2-quinolinyl)[[(1R,2R)-2-[[(1R)-1-phenylethyl](phenylmethyl)amino]cyclopentyl]methyl]-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 248607-88-7 ZCAPLUS
CN Formic acid, compd. with N-[[(1R,2R)-2-aminocyclopentyl]methyl]-4-ethoxy-2-quinolinamine (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 248607-87-6
CMF C17 H23 N3 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 248607-90-1 ZCAPLUS
CN Carbamic acid, (4-ethoxy-2-quinolinyl)[[(1R,2S)-2-[[(1S)-1-phenylethyl](phenylmethyl)amino]cyclopentyl]methyl]-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 248607-92-3 ZCAPLUS
CN Formic acid, compd. with N-[[(1R,2S)-2-aminocyclopentyl]methyl]-4-ethoxy-2-quinolinamine (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 248607-91-2
CMF C17 H23 N3 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 20 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:317279 ZCAPLUS Full-text
DOCUMENT NUMBER: 131:5197
TITLE: Preparation of N-heterocyclic compounds as 5-HT receptor antagonists
INVENTOR(S): Ito, Kiyotaka; Spears, Glen W.; Yamanaka, Toshio; Harada, Kyoko; Noda, Yuka; Kato, Masayuki
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11130750	A	19990518	JP 1998-234962	19980805 <--
PRIORITY APPLN. INFO.:			AU 1997-8631 A	19970818 <--

OTHER SOURCE(S): MARPAT 131:5197
AB R1NHAC6H4NHCOR2 [I; R1 = quinolyl, quinazolinyl, isoquinolyl, pyridyl; R2 = YR4 (R3 = Ph, lower cycloalkyl, indolyl, lower alkylindazolyl, 2,3-dihydroindolyl; Y = direct bond, lower alkylene, lower alkenylene), NHR4 (R4 = lower alkylindolyl, Ph which may be substituted with lower alkoxy, phenyl-lower alkyl); A = lower alkylene] and their salts are prepared I show 5HT2C antagonistic effect and are useful for treatment of anxiety, depression, migraine, Alzheimer's disease, polyphagia, panic, withdrawal due to drugs of

abuse such as cocaine, EtOH, nicotine, and benzazepines, schizophrenia, disorders due to bone marrow injury, hydrocephalus, etc. N-[3-[(isoquinolin-1-yl)aminomethyl]phenyl]-N'-(1- methylindol-5-yl)urea (preparation given) showed 100% replacement for [3H]-mesulergine bound to a membrane preparation of rat frontal cortex.

IT 225371-91-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heterocycle-containing anilides or phenylureas as 5-HT receptor antagonists for central nervous system diseases)

RN 225371-91-5 ZCAPLUS

CN Urea, N-(1-methyl-1H-indol-5-yl)-N'-[3-[(2-quinolinylamino)methyl]phenyl]- (CA INDEX NAME)



L67 ANSWER 21 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:31977 ZCAPLUS Full-text

DOCUMENT NUMBER: 130:81523

TITLE: Preparation of quinolines and quinazolines useful in the treatment of benign prostatic hyperplasia

INVENTOR(S): Fox, David Nathan Abraham; Mantell, Simon John; Collis, Alan John

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 887344	A1	19981230	EP 1998-303897	19980518 <--
EP 887344	B1	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6048864	A	20000411	US 1998-67588	19980428 <--
AT 255563	T	20031215	AT 1998-303897	19980518 <--
PT 887344	T	20040227	PT 1998-303897	19980518 <--
ES 2210673	T3	20040701	ES 1998-303897	19980518 <--
CA 2239603	A1	19981205	CA 1998-2239603	19980603 <--
CA 2239603	C	20030722		
JP 11012274	A	19990119	JP 1998-156107	19980604 <--
JP 3163281	B2	20010508		
BR 9801778	A	20000321	BR 1998-1778	19980604 <--
US 6417194	B1	20020709	US 2000-499623	20000207 <--
PRIORITY APPLN. INFO.:			GB 1997-11650 A	19970605 <--
			US 1998-67588 A3	19980428 <--

OTHER SOURCE(S): MARPAT 130:81523

GI



I



II



III

AB The title compds. [I; R1 = C1-4 alkoxy optionally substituted by one or more F atoms; R2, R3 = H, (un)substituted C1-6 alkoxy; R4 = (un)substituted 4-7 membered heterocyclic ring containing at least one heteroatom selected from N, O and S which may be optionally fused to a benzene ring or a 5-6 membered heterocyclic ring; X = CH, N; L = absent, II (wherein A is attached to R4; A = CO, SO2; Z = CH, N; m = 1-2, and in addition, when Z = CH, m = 0; n = 1-3; provided that m + n = 2-5), -N(R5)(CH2)pZ(R6)A- (wherein A and Z as defined above; R5, R6 = H, C1-4 alkyl; p = 1-3, and in addition, when Z = CH, p = 0)], useful in therapy, in particular in the treatment of benign prostatic hyperplasia, were prepared Thus, reaction of 4-amino-6-hydroxy-7-methoxy-2-[4-(4-morpholinecarbonyl)- 1,4-diazepan-1-yl]quinazoline (preparation given) with (iodomethyl)cyclobutane afforded III which showed pA2 of 9.2 in "Contractile responses of human prostate" screening.

IT 218962-09-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolines and quinazolines useful in the treatment of benign prostatic hyperplasia)

RN 218962-09-5 ZCAPLUS

CN Methanesulfonamide, N-[2-[4-amino-5-(cyclobutyloxy)-6,7-dimethoxy-2-quinolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 22 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:721497 ZCAPLUS Full-text
DOCUMENT NUMBER: 130:3852
TITLE: Quinoline and quinazoline compounds useful in therapy of benign prostatic hyperplasia
INVENTOR(S): Collis, Alan John; Fox, David Nathan Abraham
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 875506	A1	19981104	EP 1998-302968	19980416 <--
EP 875506	B1	20030226		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 233242	T	20030315	AT 1998-302968	19980416 <--
ES 2190809	T3	20030816	ES 1998-302968	19980416 <--
CA 2236239	A1	19981101	CA 1998-2236239	19980429 <--
CA 2236239	C	20030318		
BR 9801506	A	20000208	BR 1998-1506	19980429 <--
JP 10316664	A	19981202	JP 1998-121990	19980501 <--
JP 3076786	B2	20000814		
MX 9803607	A	20000131	MX 1998-3607	19980504 <--
US 2003045525	A1	20030306	US 2002-252852	20020923 <--
US 6649620	B2	20031118		
US 2004034032	A1	20040219	US 2003-640314	20030813 <--
PRIORITY APPLN. INFO.:			GB 1997-8917 A	19970501 <--
			US 1998-67608 B1	19980428 <--
			US 2000-591195 B1	20000609 <--
			US 2002-252852 A3	20020923 <--

OTHER SOURCE(S): MARPAT 130:3852
GI



I



II

AB Title compds. I [wherein R1 = C1-4 alkoxy (un)substituted by 1 or more F atoms; R2 = aryl or heteroaryl, (un)substituted by C1-4 alkyl or SO2NH2; R3 = 4-, 5-, 6-, or 7-membered heterocyclic ring containing at least 1 heteroatom selected from N, O, and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing at least 1 heteroatom selected from N, O, and S, the ring system as a whole being (un)substituted by OH, C1-4 alkyl, C1-4 alkoxy, halo, and/or NHSO2-(C1-4 alkyl); X = CH or N; L = certain cyclic or chain amino groups; or L may be absent] and their pharmaceutically acceptable salts are useful in the treatment of a variety of disorders including benign prostatic hyperplasia (no data). Examples include syntheses of approx. 20 compds. I and a variety of intermediates. For instance, 5-hydroxy-4-methoxy-2- nitrobenzoic acid was converted to the Me ester (87%), followed by conversion to the 5-triflate (85%), Pd-catalyzed phenylation of the latter (99%), reduction of the nitro group to amino (99%), and 2-step cyclization with sodium cyanate (91%), to give 7-methoxy-6-phenylquinazoline-2,4- dione. Treatment of this with POCl3 and then methanolic NH3 gave 55% 4-amino-2-chloro-7-methoxy-6-phenylquinazoline, which was condensed with 1-(4-morpholinesulfonyl)-1,4-diazepane HCl (16%) to give title compound II.HCl.

IT 215659-37-3P, 4-Amino-7-methoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-6-(2-pyridinyl)quinoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(product; preparation of quinoline and quinazoline derivs. for therapy of benign prostatic hyperplasia)

RN 215659-37-3 ZCAPLUS

CN Methanesulfonamide, N-[2-[4-amino-7-methoxy-6-(2-pyridinyl)-2-quinolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 23 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:490639 ZCAPLUS Full-text
DOCUMENT NUMBER: 129:136176
TITLE: Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
INVENTOR(S): Fox, David Nathan Abraham
PATENT ASSIGNEE(S): Pfizer Ltd., UK; Pfizer Inc.; Fox, David Nathan Abraham
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9830560	A1	19980716	WO 1998-EP143	19980106 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 444013	B	20010701	TW 1997-86117203	19971118 <--
CA 2277473	A1	19980716	CA 1998-2277473	19980106 <--
CA 2277473	C	20030812		
EP 968208	A1	20000105	EP 1998-904058	19980106 <--
EP 968208	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AP 819	A	20000403	AP 1998-1175	19980106 <--
W: BW, GM, KE, MW, UG, ZM, ZW				
JP 2000507966	T	20000627	JP 1998-530565	19980106 <--
JP 3357677	B2	20021216		
NZ 336302	A	20000825	NZ 1998-336302	19980106 <--
HU 2000000942	A2	20010428	HU 2000-942	19980106 <--
HU 2000000942	A3	20020628		
CN 1093858	B	20021106	CN 1998-801748	19980106 <--
AT 242238	T	20030615	AT 1998-904058	19980106 <--
PT 968208	T	20030930	PT 1998-904058	19980106 <--
ES 2198695	T3	20040201	ES 1998-904058	19980106 <--
CZ 295580	B6	20050817	CZ 1999-2436	19980106 <--
SK 284779	B6	20051103	SK 1999-907	19980106 <--
IL 130762	A	20051218	IL 1998-130762	19980106 <--
HR 980010	B1	20020630	HR 1998-10	19980108 <--
BG 63918	B1	20030630	BG 1999-103560	19990707 <--
NO 9903396	A	19990709	NO 1999-3396	19990709 <--
NO 318609	B1	20050418		
US 6365599	B1	20020402	US 2000-586503	20000602 <--
HK 1025327	A1	20030711	HK 2000-104585	20000724 <--
US 2002040028	A1	20020404	US 2001-7753	20011113 <--
US 6521629	B2	20030218		
CN 1403453	A	20030319	CN 2001-143291	20011226 <--

US 2003130259	A1	20030710	US 2002-318902		20021213 <--
US 6653302	B2	20031125			
HK 1054389	A1	20051014	HK 2003-106677		20030917 <--
PRIORITY APPLN. INFO.:			GB 1997-504	A	19970111 <--
			WO 1998-EP143	W	19980106 <--
			US 1999-341228	A3	19990707 <--
			US 2000-586503	A3	20000602 <--
			US 2001-7753	A3	20011113 <--

OTHER SOURCE(S): MARPAT 129:136176
GI



I

AB I [R1 = C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 = H, C1-6 alkoxy optionally substituted by one or more fluorine atoms; R3 = 5- or 6-membered heterocyclic ring, the ring being optionally substituted; R4 = 4-, 5-, 6- or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted; X = CH, N; L is absent or represents a N-containing cyclic group or chain], useful in treatment of benign prostatic hyperplasia, were prepared E.g., 4-amino-6,7-dimethoxy-2-[4-(4-morpholinecarbonyl)-1,4- diazepan-1-yl]-5-(oxazol-2-yl)quinoline was prepared

IT 210538-49-1P 210538-60-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline and quinazoline derivs. useful in treatment of benign prostatic hyperplasia)

RN 210538-49-1 ZCAPLUS
CN Methanesulfonamide, N-[2-[4-amino-6-ethoxy-7-methoxy-5-(2-pyridinyl)-2-quinolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)



RN 210538-60-6 ZCAPLUS
CN Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]-, monohydrochloride (9CI)

(CA INDEX NAME)



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 24 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:394386 ZCAPLUS Full-text
DOCUMENT NUMBER: 129:54291
TITLE: Preparation of carbamoylindolines as 5-hydroxytryptamine antagonists
INVENTOR(S): Ito, Kiyotaka; Spears, Glen W.; Yamanaka, Toshio; Harata, Kyoko; Noda, Yuka; Kato, Masayuki
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
JP 10158241	A	19980616	JP 1997-337896		19971121	<--
PRIORITY APPLN. INFO.:			AU 1996-3797	A	19961122	<--

OTHER SOURCE(S): MARPAT 129:54291
GI



I

AB Carbamoylindolines I [R1 = lower alkyl; (R2, R3) = (lower alkyl, H) or R2R3 = vinylene; R4 = (substituted) Ph, heterocyclyl; X = CH2, NHCH2; Y = bond, CO, CH2, NHCH2; n = 0, 1] or their salts are prepared A PhMe solution of 80 mg I [R1 = Me, R2R3 = vinylene, X(NH)nYR4 = 3-CH2NH2] (preparation given) was treated with PhCHO under reflux for 3 h and treated with AcOH to give 94 mg I acetate [R1 = Me, R2R3 = vinylene, X(NH)nYR4 =3-CH2NHCH2Ph], which (at 10-5M) showed 98% replacement with [3H]-mesulergine bound to 5-HT2c receptor in vitro.

IT 208598-67-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carbamoylindolines as 5-HT antagonists)

RN 208598-67-8 ZCAPLUS

CN Benzo[1,2-b:4,5-b']dipyrrole-1(2H)-carboxamide, 3,5-dihydro-5-methyl-N-[3-[(2-quinolinylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



L67 ANSWER 25 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:385684 ZCAPLUS Full-text

DOCUMENT NUMBER: 129:195368

TITLE: Phase relaxation of Frankel exciton migration in the nanostructure mixed molecular aggregates

AUTHOR(S): Liu, Junye; Zheng, Zhiren; Liu, Chunxu; Dou, Kai; Huang, Shihua; Yu, Jiaqi

CORPORATE SOURCE: Laboratory of Excited State Processes, Changchun Institute of Physics, The Chinese Academy of Sciences, Changchun, 130021, Peop. Rep. China

SOURCE: Guangxue Xuebao (1997), 17(5), 539-544
CODEN: GUXUDC; ISSN: 0253-2239

PUBLISHER: Kexue Chubanshe

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

AB Energy barriers were formed in PIC-I dye doped with azaPIC-I, changing the phys. sizes of PIC-I J-aggregates. Dephasing processes of coherent Frenkel excitons were studied using accumulated photon echo with double modulation and heterodyne detection technique. The lengthening of dephasing time T2, from 60 to 224 ps, were observed with increasing the molar fractions of azaPIC-I. It is contrary to the shortening of T2 in the mixed aggregates with traps. The coherence lengths of excitons in the mixed aggregates were investigated theor. and exptl.

IT 14303-33-4
RL: PRP (Properties)
(phase relaxation of Frenkel exciton migration in nanostructure mixed mol. aggregate)

RN 14303-33-4 ZCAPLUS

CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, iodide (9CI) (CA INDEX NAME)



L67 ANSWER 26 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:168348 ZCAPLUS Full-text
DOCUMENT NUMBER: 128:289961
TITLE: Synthesis of some pyridinethione derivatives and their biological activity
AUTHOR(S): Miky, Jehane A. A.; Zahkoug, Samir A. M.
CORPORATE SOURCE: Chemistry Department, Faculty of Science (Girls), Nasr City, 11884, Egypt
SOURCE: Natural Product Sciences (1997), 3(2), 89-99
CODEN: NPSCFB; ISSN: 1226-3907
PUBLISHER: Korean Society of Pharmacognosy
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Aminolysis, hydrazinolysis and alkylation of 4-methoxy- and 4,9-dimethoxy-6-cyano-7-thione-5-methyl-7H-furo[3,2-g]benzopyridine (I, R = H, OMe) gave 7-N-substituted furobenzopyridine derivs. Hydrolysis of I (R = H) with acetic acid gave the corresponding pyridone derivative Furobenzopyridinyl-7-thioacetyl hydrazides were prepared via alkylation of I (R = H, OMe) with Et chloroacetate followed by condensation with hydrazine hydrate. Schiff base II was prepared by reacting the furobenzopyridinyl-7- thioacetyl hydrazine with p-N,N-di-methylaminobenzaldehyde in boiling ethanol. Treatment of the furobenzopyridinyl-7-thioacetic acid with anthranilic acid gave the corresponding 7-substituted-4H-3,1-benzoxazine-4- one. Compound II increased bleeding, coagulating time, the total count of white blood cells, blood glucose level (cause hyperglycemia), enzymes (GOT, GPT) activities, concentration of urea and creatinine. II also decreased red blood cell number, Hb content and haematocrite value.

IT 206128-22-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of pyridinethione derivs. and their biol. activity)
RN 206128-22-5 ZCAPLUS
CN Furo[3,2-g]quinoline-6-carbonitrile, 4,9-dimethoxy-5-methyl-7-[(4-nitrophenyl)amino]- (CA INDEX NAME)



IT 206128-21-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyridinethione derivs. and their biol. activity)
RN 206128-21-4 ZCAPLUS
CN Furo[3,2-g]quinoline-6-carbonitrile, 4-methoxy-5-methyl-7-[(4-nitrophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 27 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:787194 ZCAPLUS Full-text
DOCUMENT NUMBER: 128:62835
TITLE: Electronic properties of polymethine systems. Part 4. Vinylene shift
AUTHOR(S): Kachkovski, A. D.; Kovalenko, N. M.
CORPORATE SOURCE: Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Kiev, 253 660, Ukraine
SOURCE: Dyes and Pigments (1997), 35(2), 131-148
CODEN: DYPIDX; ISSN: 0143-7208
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Features of the electron transitions in a vinylogous series of polymethine dyes and α,ω-disubstituted polyenes are considered. The vinylene shift of the long wave length band on chain lengthening by one vinylene group depends on the degree of π-bond equalization within the chromophore. In polymethines with end groups characterized by the highest or lowest basicity, the vinylene shift essentially decreases. In polyenes, the magnitude of the vinylene shift is determined by both the topol. indexes of residues and the polyene form,

neutral or charged. On chain lengthening, the difference between the transition energies in different forms increases regularly. Theor. conclusions are illustrated by both quantum-chemical calcns. and exptl. data.

IT 47292-23-9
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(vinylene shift and electronic properties of polymethine systems)

RN 47292-23-9 ZCAPLUS
CN Quinolinium, 1-methyl-2-[(1-methyl-2(1H)-quinolinylidene)amino]- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 28 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:596487 ZCAPLUS Full-text
DOCUMENT NUMBER: 125:342588
TITLE: The effect of J-aggregate size on photoinduced charge transfer processes for dye-sensitized silver halides
AUTHOR(S): Lanzafame, Joseph M.; Muenter, Annabel A.; Brumbaugh, Donald V.
CORPORATE SOURCE: Center for Photoinduced Charge Transfer, Department of Chemistry, University of Rochester, Rochester, NY, 14627, USA
SOURCE: Chemical Physics (1996), 210(1,2), 79-89
CODEN: CMPHC2; ISSN: 0301-0104
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The excited state dynamics of J-aggregated cyanine dyes adsorbed to silver halide microcrystals as spectral sensitizers were investigated. The rates of charge transfer, fluorescence, and non-radiative relaxation were studied as a function of surface morphol., halide, and degree of dye aggregation. The dye aggregation was controlled using a statistical dilution method: the sensitizing dyes studied (pseudoisocyanine [PIC] and a thiacarbocyanine [RTHC]) were diluted with structural homologues that do not absorb light at the wavelength of interest. As a general rule, the rate of charge transfer was observed to increase as the aggregate size increased. In spite of this trend, a strong enhancement in the rate of non-radiative relaxation as the aggregates become larger causes the net photog. efficiency of J-aggregate sensitization to decrease with increasing aggregate size.

IT 134440-21-4
RL: NUU (Other use, unclassified); USES (Uses)
(diluent compound; effect of J-aggregate size on photoinduced charge transfer processes for dye-sensitized silver halides studied by statistical dilution technique)

RN 134440-21-4 ZCAPLUS
CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 23664-31-5
CMF C22 H22 N3



CM 2

CRN 16722-51-3
CMF C7 H7 O3 S



L67 ANSWER 29 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:310840 ZCAPLUS Full-text
DOCUMENT NUMBER: 125:44073
TITLE: Dephasing processes of coherent exciton migration in mixed aggregates with barriers of PIC-I and azaPIC-I
AUTHOR(S): Liu, Junye; Chen, Yimin; Zhao, Jialong; Dou, Kai; Hang, Shihua; Yu, Jiaqi
CORPORATE SOURCE: Changchun Institute of Physics, Chinese Academy of Sciences, Changchun, 130021, Peop. Rep. China
SOURCE: Journal of Luminescence (1995), Volume Date 1996, 66&67(1-6), 337-340
CODEN: JLUMA8; ISSN: 0022-2313
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Coherence decay processes of Frenkel excitons in the mixed aggregates with barriers at low temperature were studied using an accumulated photon echo technique. The lengthening of the dephasing times T2 with increase of the molar fraction of azaPIC-I was observed, which is contrary to the shortening of T2 in the mixed aggregate with traps. Exciton coherence lengths were studied theor. and exptl. The effective distance, passed through by excitons, is less than the exciton coherence length.
IT 23664-31-5
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(dephasing processes of coherent exciton migration in mixed aggregates with barriers of PIC-I and azaPIC-I)
RN 23664-31-5 ZCAPLUS
CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]- (CA INDEX

NAME)



L67 ANSWER 30 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:239903 ZCAPLUS Full-text
DOCUMENT NUMBER: 124:279179
TITLE: Ribosylpurine derivatives for treatment of cerebrovascular disorders by vascular permeability enhancer inhibition
INVENTOR(S): Nagaoka, Akinobu; Imamoto, Tetsuji; Asano, Tsuneo; Sugiura, Yoshihiro; Goto, Giichi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Can. Pat. Appl., 52 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2150780	A1	19951203	CA 1995-2150780	19950601 <--
EP 704215	A2	19960403	EP 1995-108322	19950530 <--
EP 704215	A3	19980401		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08048631	A	19960220	JP 1995-134618	19950601 <--
US 5604210	A	19970218	US 1995-456723	19950601 <--
PRIORITY APPLN. INFO.:			JP 1994-120947 A	19940602 <--

OTHER SOURCE(S): MARPAT 124:279179
GI



I

AB A composition is disclosed for preventing or treating brain edema, intracranial hemorrhage, and cerebral infarction by inhibiting a vascular permeability enhancer. The composition comprises I [A = halo, XR3 (X = O, S,

NH, NHNH; R3 = H, acyl, (substituted) hydrocarbyl, (substituted) aromatic heterocyclyl), Y:R4 (Y = N:, NHN:; R4 = (substituted) divalent hydrocarbyl); R1 = H, halo, (substituted) hydrocarbyl, (substituted) heterocyclyl, ZR5 (Z = O, S, NH; R5 = H, (substituted) hydrocarbyl, (substituted) aromatic heterocyclyl); R2 = H, halo, (substituted) hydrocarbyl, (substituted) heterocyclyl; B = WR6 (W = CH2, C:O, C:S; R6 = OH, (substituted) alkoxy, acyloxy, alkylsulfinyl, alkylsulfonyl, O-phosphono, amino, or B together with E form cyclic phosphoric ester); D, E = H, (substituted) amino, azido, halo, (protected) OH] or a pharmaceutically acceptable salt thereof. Inhibitory activity of 42 compds. to a vascular permeability enhancer was determined 2',3'-O-(1-ethoxyethylidene)adenosine-5'-(N- ethylcarboxyamide) was shown to have efficacy in preventing stroke in an animal model. Tablet and injection formulations of 6-[2-(9H-purin-6- yl)hydrazino]nebularine are included.

IT 175552-69-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ribosylpurine derivs. for treatment of cerebrovascular disorders by vascular permeability enhancer inhibition)

RN 175552-69-9 ZCAPLUS

CN Adenosine, 2-(2-quinolinylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L67 ANSWER 31 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:233743 ZCAPLUS Full-text

DOCUMENT NUMBER: 118:233743

TITLE: Synthesis of 2-quinolyl derivatives of adenine and guanine

AUTHOR(S): Meegalla, Sanath K.; Defauw, Jean; Zhong, Wenge; LaVoie, Edmond J.

CORPORATE SOURCE: Coll. Pharm., Rutgers, State Univ. New Jersey, Piscataway, NJ, 08855, USA

SOURCE: Synlett (1993), (1), 61-2
CODEN: SYNLES; ISSN: 0936-5214

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The prepns. of N6-(2-quinolyl)adenine, N9-(2-quinolyl)adenine, N6-acetyl-N9-(2-quinolyl)adenine and N2-(2-quinolyl)guanine by N-alkylation with 2-fluoroquinoline are described.

IT 147665-58-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and acetylation of)

RN 147665-58-5 ZCAPLUS

CN 9H-Purin-6-amine, 9-(2-quinolinyl)- (CA INDEX NAME)



IT 147665-60-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deethoxyethylation of)
RN 147665-60-9 ZCAPLUS
CN 2-Quinolinamine, N-[9-(1-ethoxyethyl)-9H-purin-6-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
IT 147665-62-1P 147665-63-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 147665-62-1 ZCAPLUS
CN 2-Quinolinamine, N-[6-chloro-9-(phenylmethyl)-9H-purin-2-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 147665-63-2 ZCAPLUS
CN 2-Quinolinamine, N-[6-chloro-9-(methoxymethyl)-9H-purin-2-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
IT 147665-59-6P 147665-61-0P 147665-64-3P
147665-65-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 147665-59-6 ZCAPLUS
CN Acetamide, N-[9-(2-quinolinyl)-9H-purin-6-yl]- (CA INDEX NAME)



RN 147665-61-0 ZCAPLUS
CN 9H-Purin-6-amine, N-2-quinolinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 147665-64-3 ZCAPLUS
CN 6H-Purin-6-one, 1,9-dihydro-9-(phenylmethyl)-2-(2-quinolinylamino)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 147665-65-4 ZCAPLUS
CN 6H-Purin-6-one, 1,7-dihydro-2-(2-quinolinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L67 ANSWER 32 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:29818 ZCAPLUS Full-text
DOCUMENT NUMBER: 118:29818
TITLE: Silver halide photographic material containing oxonol dye
INVENTOR(S): Kawashima, Yasuhiko; Kagawa, Nobuaki; Yamauchi, Reiko; Kojima, Tamotsu
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04128835	A	19920430	JP 1990-251109	19900920 <--
JP 2892804	B2	19990517		
PRIORITY APPLN. INFO.:			JP 1990-251109	19900920 <--

GI



I

AB The title material contains an oxonol dye I (R1-R4 = aryl, aromatic group, heterocyclic group; R5, R6 = H, alkyl, aryl, alkenyl, heterocyclic group; L1-L5 = methine group; n, m = 0-2). The oxonol dye, used as a light-absorbing substance in the title photog. material, is water soluble, inactive to photog. emulsions, and easily removed from photog. materials (decolorized and/or flows out of photog. materials) during photog. development and leaves very little stains after processing.
IT 145206-92-4
RL: USES (Uses)
(light-absorbing dye, for photog. materials)
RN 145206-92-4 ZCAPLUS

CN 1,4-Benzenedisulfonic acid, 2-[3-[(di-2-quinolinylamino)carbonyl]-4-[3-[3-[(di-2-quinolinylamino)carbonyl]-1-(2,5-disulfophenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-1-propenyl]-5-hydroxy-1H-pyrazol-1-yl]-, tetrapotassium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L67 ANSWER 33 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:162312 ZCAPLUS Full-text
DOCUMENT NUMBER: 116:162312
TITLE: Size dependence of excited-state dynamics for J-aggregates at silver bromide interfaces
AUTHOR(S): Muenter, A. A.; Brumbaugh, D. V.; Apolito, J.; Horn, L. A.; Spano, F. C.; Mukamel, S.
CORPORATE SOURCE: Cent. Photoinduced Charge Transfer, Univ. Rochester, Rochester, NY, 14627, USA
SOURCE: Journal of Physical Chemistry (1992), 96(7), 2783-90
CODEN: JPCHAX; ISSN: 0022-3654
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The dependence of the fluorescence lifetime and relative quantum yield on the temperature and aggregate size was investigated for the J-aggregate of pseudoisocyanine on an AgBr surface, varying the average phys. size of the aggregate in a statistical sense by diluting it with a close structural analog. The dominant feature controlling the excited-state dynamics is energy

transfer to a defect state which is nonradiative at room temperature The rate of this transfer process increases with aggregate size. At large aggregate sizes, a weak superradiant enhancement of the J-aggregate radiative rate is also observed, with a temperature dependence which suggests strong coupling of the J-aggregate exciton to a low-frequency phonon. Since both the energy transfer to the defect state and the radiative decay compete with the desired process of electron transfer from the aggregate excited state to the AgBr conduction band, the sensitizing efficiency of the J-aggregate is expected to decrease with increasing aggregate size. Measurement of this size-dependent sensitizing efficiency shows a smaller loss than expected, indicating that the electron-transfer rate from the aggregate excited state to the AgBr conduction band increases with increasing aggregate size.

IT 134440-21-4
RL: USES (Uses)
(fluorescence lifetime and quantum yield for aggregates of, adsorbed on silver bromide, size-dependent electron- and energy-transfer deactivation processes in, photog. sensitization in relation to)

RN 134440-21-4 ZCAPLUS

CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 23664-31-5
CMF C22 H22 N3



CM 2

CRN 16722-51-3
CMF C7 H7 O3 S



L67 ANSWER 34 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:50274 ZCAPLUS Full-text
DOCUMENT NUMBER: 116:50274
TITLE: Synthesis and characterization of cobalt(II), nickel(II) and copper(II) complexes of isatin mono((4-methylquinolinyl)hydrazone)
AUTHOR(S): Garg, B. S.; Singh, P. K.; Garg, S. K.
CORPORATE SOURCE: Dep. Chem., Univ. Delhi, Delhi, 110 007, India

SOURCE: Indian Journal of Chemistry, Section A: Inorganic, Bio-inorganic, Physical, Theoretical & Analytical Chemistry (1991), 30A(11), 979-81
CODEN: ICACEC; ISSN: 0376-4710
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Complexes of Co(II), Ni(II), and Cu(II) with isatin mono((4-methylquinolin- 2-yl)hydrazone) (IMH) were synthesized and characterized using elemental anal., magnetic moment measurement, IR, electronic and EPR spectral data. The magnetic and spectral data indicate that [Co(IMH)2X2] (X = Cl,Br, NO3) are octahedral while [No(IMH)X2] and [Cu(IMH)X2] are square planar.

IT 138136-63-7P 138136-64-8P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and ESR of)

RN 138136-63-7 ZCAPLUS
CN Copper, dibromo[1H-indole-2,3-dione 3-(2-quinolinylhydrazone)]-, (SP-4-3)-(9CI) (CA INDEX NAME)



RN 138136-64-8 ZCAPLUS
CN Copper, [1H-indole-2,3-dione 3-(2-quinolinylhydrazone)]bis(nitrato-O)-, (SP-4-3)- (9CI) (CA INDEX NAME)





IT 138136-59-1P 138136-60-4P 138136-61-5P
138136-62-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 138136-59-1 ZCAPLUS
CN Nickel, dichloro[1H-indole-2,3-dione 3-(2-quinolinylhydrazone)]-, (SP-4-3)- (9CI) (CA INDEX NAME)



RN 138136-60-4 ZCAPLUS
CN Nickel, dibromo[1H-indole-2,3-dione 3-(2-quinolinylhydrazone)]-, (SP-4-3)-
(9CI) (CA INDEX NAME)



RN 138136-61-5 ZCAPLUS
CN Nickel, [1H-indole-2,3-dione 3-(2-quinolinylhydrazone)]bis(nitrato-O)-,
(SP-4-3)- (9CI) (CA INDEX NAME)



RN 138136-62-6 ZCAPLUS
CN Copper, dichloro[1H-indole-2,3-dione 3-(2-quinolinylhydrazone)]-,
(SP-4-3)- (9CI) (CA INDEX NAME)



L67 ANSWER 35 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:583333 ZCAPLUS Full-text
DOCUMENT NUMBER: 115:183333
TITLE: Benzoxazine derivatives, their preparation and pharmaceutical compositions containing them as antihypertensives or coronary vasodilators
INVENTOR(S): Matsuhisa, Akira; Asano, Masaharu; Matsumoto, Yuzo; Takayama, Kazuhisa; Yoden, Toru; Tsuzuki, Ryuji; Uchida, Wataru; Yanagisawa, Isao
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 89 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
EP 432893	A2	19910619	EP 1990-312102		19901105	<--
EP 432893	A3	19910710				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE						
NO 9004839	A	19910510	NO 1990-4839		19901107	<--
JP 04178375	A	19920625	JP 1990-301416		19901107	<--
JP 07074208	B	19950809				
CA 2029569	A1	19910509	CA 1990-2029569		19901108	<--
CN 1051910	A	19910605	CN 1990-109074		19901108	<--
CN 1029479	B	19950809				
AU 9065947	A	19910606	AU 1990-65947		19901108	<--
AU 641953	B2	19931007				
US 5420126	A	19950530	US 1992-982034		19921124	<--
CN 1100422	A	19950322	CN 1994-102737		19940312	<--
CN 1100423	A	19950322	CN 1994-102738		19940312	<--
PRIORITY APPLN. INFO.:			JP 1989-290727	A	19891108	<--
			JP 1989-315926	A	19891205	<--
			JP 1989-342937	A	19891228	<--
			JP 1990-208548	A	19900806	<--
			US 1990-607291	B2	19901030	<--
			US 1992-823256	B1	19920121	<--

OTHER SOURCE(S): MARPAT 115:183333
GI



I

AB Certain 1,4-benzoxazine derivs. and benzoxazinylpyridine N-oxides and their pharmaceutically acceptable salts are claimed. Some of the compds. were tested for their coronary vasodilating and hypotensive effects. A mixture of 3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine (2.66 g) and HCONMe2 (10

mL) was treated with NaH and 2-bromopyridine 1-oxide hydrochloride (2.77 g) to give 2.0 g 2-(3,4-dihydro-2,2-dimethyl-6-nitro- 2H-benzoxazin-4-yl)pyridine 1-oxide (I). The LD50 in mice was 30 mg/kg p.o., compared to 300 mg/kg p.o. for cromkalim. The IC50 for a coronary vasodilating effect was 0.01 μM compared to 0.39 μM for cromkalim; I induced a 16% reduction of the mean blood pressure in dogs upon coronary arterial administration of I and cromkalim induced a 28% reduction

IT 136544-20-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 136544-20-2 ZCAPLUS
CN 2H-1,4-Benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(1-oxido-2-quinolinyl)- (CA INDEX NAME)



L67 ANSWER 36 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:418417 ZCAPLUS Full-text
DOCUMENT NUMBER: 115:18417
TITLE: Coherence domains in the radiative dynamics of molecular aggregates
AUTHOR(S): Spano, F. C.; Kuklinski, J. R.; Mukamel, S.; Brumbaugh, D. V.; Burberry, M.; Muenter, A. A.
CORPORATE SOURCE: Dep. Chem., Univ. Rochester, Rochester, NY, USA
SOURCE: Molecular Crystals and Liquid Crystals (1991), 194, 331-6
CODEN: MCLCA5; ISSN: 0026-8941
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Theor. evidence of the existence of excited-state coherence domains in mol. aggregates is presented. The domain size is a function of exciton-phonon coupling and temperature, and dets. the radiative decay rate of the entire aggregate. A series of supporting expts. involving statistical control of the aggregate phys. size, are proposed.

IT 134440-21-4
RL: USES (Uses)
(fluorescence lifetime and quantum yield of mixed aggregates containing, on silver bromide microcrystals)
RN 134440-21-4 ZCAPLUS
CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 23664-31-5
CMF C22 H22 N3



CM 2

CRN 16722-51-3
CMF C7 H7 O3 S



L67 ANSWER 37 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:497296 ZCAPLUS Full-text
Correction of: 1987:67359
DOCUMENT NUMBER: 111:97296
Correction of: 106:67359
TITLE: Benzodiazepine derivatives and their pharmaceutical use
INVENTOR(S): Freidinger, Roger M.; Bock, Mark G.; Evans, Ben E.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: Eur. Pat. Appl., 290 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 167919	A2	19860115	EP 1985-107842	19850625 <--
EP 167919	A3	19861105		
EP 167919	B1	19930505		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
CA 1332410	C	19941011	CA 1985-484488	19850619 <--
NO 8502558	A	19851227	NO 1985-2558	19850625 <--
NO 173651	B	19931004		
NO 173651	C	19940112		
AU 8544152	A	19860102	AU 1985-44152	19850625 <--
DK 8502872	A	19860225	DK 1985-2872	19850625 <--
DK 175264	B1	20040802		
ES 544523	A1	19870416	ES 1985-544523	19850625 <--
AT 88998	T	19930515	AT 1985-107842	19850625 <--
ZA 8504764	A	19860226	ZA 1985-4764	19850626 <--
JP 61063666	A	19860401	JP 1985-138064	19850626 <--
ES 551504	A1	19870601	ES 1986-551504	19860131 <--

US 5004741	A	19910402	US 1988-269212		19881109 <--
AU 8944563	A	19900405	AU 1989-44563		19891110 <--
AU 640113	B2	19930819			
AU 9211171	A	19920514	AU 1992-11171		19920221 <--
AU 9471615	A	19941222	AU 1994-71615		19940831 <--
AU 679085	B2	19970619			
PRIORITY APPLN. INFO.:			US 1984-624854	A	19840626 <--
			US 1985-705272	A	19850225 <--
			US 1985-741972	A	19850610 <--
			EP 1985-107842	A	19850625 <--
			US 1987-26420	A3	19870316 <--

OTHER SOURCE(S): MARPAT 111:97296
GI



I



II

AB 1,4-Benzodiazepines I [n = 1,2; R = H, NO2, CF3, cyano, etc.; R1 = alkyl, alkenyl, carboxyalkyl, aminoalkyl, etc.; Z = O, S, H2, NH, etc.; R2, R6 = H, OH, Me; R3 = substituted alkyl; R4 = H, alkyl, acyl, etc.; R5 = H, alkyl, (un)substituted Ph, etc.], which are cholecystokinin (CCK) inhibitors, were prepared 2-Amino-2'-fluorobenzophenone was treated with tryptophan acid chloride-HCl and NaOH to give benzodiazepinone (R)-II. (R)-II inhibited CCK binding in isolated rat pancreas with an IC50 of o.40 μM.

IT 103407-27-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cholecystokinin inhibitor)

RN 103407-27-8 ZCAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-(2-fluorophenyl)-1,3-dihydro-3-(2-quinolinylamino)- (CA INDEX NAME)



L67 ANSWER 38 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:570452 ZCAPLUS Full-text
DOCUMENT NUMBER: 109:170452

TITLE: Preparation of 3-amino-2-(heteroaryl)amino-4(3H)-quinazolinones as potential drugs
INVENTOR(S): Kottke, Karl; Kuehmstedt, Hans; Graefe, Ingolf; Wehlan, Helmut; Knoke, Dagmar
PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
SOURCE: Ger. (East), 4 pp.
CODEN: GEXXA8
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 253622	A1	19880127	DD 1986-295764	19861030 <--

PRIORITY APPLN. INFO.: DD 1986-295764 19861030 <--
OTHER SOURCE(S): CASREACT 109:170452; MARPAT 109:170452
GI


I


II

AB The title compds. (I; R1, R2 = H, alkyl, alkoxy, halo; R3 = heteroaryl) potentially useful as cardiotonics, antihistaminics, and sedatives, were prepared Oxothioxotetrahydroquinolines II in MeOH containing NaOMe were treated with, e.g., EtBr or MeBr at reflux and the resulting alkylthio compds. were refluxed with N2H4.H2O in Me2CHOH to give 50-80% I.
IT 116896-06-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as potential drug)
RN 116896-06-1 ZCAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-(2-quinolinylamino)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L67 ANSWER 39 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:156362 ZCAPLUS Full-text
DOCUMENT NUMBER: 106:156362
TITLE: Synthesis of new quinoline derivatives as antimicrobial agents
AUTHOR(S): Zayed, Abdel Hadi A.; Zayed, Salem; Harb, Abdel Fattah

A.; Manhi, Fatma M.
CORPORATE SOURCE: Natl. Res. Cent., Dokki, Egypt
SOURCE: Polish Journal of Pharmacology and Pharmacy (1986), 38(1), 99-106
CODEN: PJPPAA; ISSN: 0301-0244
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 106:156362
GI



AB 2-Hydroxyquinoline-4-hydrazide was condensed with aromatic aldehydes and acetophenones to give the hydrazones I (R = Ph, 4-MeOC6H4, 4-H2NC6H4, etc.; R1 = H, Me). It was also treated with HCO2H, BzCl and 4-MeOC6H4COCl to afford II (R = H, Ph, 4-MeOC6H4). Cyclization of II (R = Ph) was completed by using PPA, POCl3 or P2S5, which gave azoles III (R = OH, Cl, R1 = Ph, X = O; R = OH, R1 = Ph, X = S). Reaction of III (R = Cl, R1 = Ph; X = O) with amines gave III (R = NHPh, NHC6H4OMe-4, NHC6H4Cl-4, etc.; R1 = Ph, X = O). III (R = NHC6H4Me-3, R1 = Ph, X = O; R = OH, R1 = NH2, X = S) showed bactericidal activity when tested against Bacillus mycoides and Sarcina lutea.
IT 107734-43-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 107734-43-0 ZCAPLUS
CN 2-Quinolinamine, N-(4-nitrophenyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)



L67 ANSWER 40 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:148782 ZCAPLUS Full-text

DOCUMENT NUMBER: 104:148782
ORIGINAL REFERENCE NO.: 104:23549a,23552a
TITLE: The reaction of cycloalkanonhydrazones with mercaptoacetic acid. Synthesis of novel N-aminospirothiazolidinones
AUTHOR(S): Reddy, R. Raji; Iyengar, D. S.; Bhalerao, U. T.
CORPORATE SOURCE: Reg. Res. Lab., Hyderabad, India
SOURCE: Journal of Heterocyclic Chemistry (1985), 22(2), 321-3
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 104:148782
GI



I



II

AB Spirothiazolidinones I (R = Ph, 2-pyridyl, 2-quinolyl, Me, PhSO2; n = 1, 2; X = CH2, NMe) were prepared by addition of hydrazones II (X1 = NNHR) and HSCH2CO2H or by addition of II (X1 = O), H2NNHR, and HSCH2CO2H. I have bactericidal and fungicidal activity (no data).

IT 99907-53-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of, with Me iodide)

RN 99907-53-6 ZCAPLUS
CN 1-Thia-4,8-diazaspiro[4.5]decan-3-one, 8-methyl-4-(2-quinolinylamino)- (CA INDEX NAME)



L67 ANSWER 41 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:87232 ZCAPLUS Full-text
DOCUMENT NUMBER: 100:87232
ORIGINAL REFERENCE NO.: 100:13227a,13230a
TITLE: Halochromic molecules. Part 4. Chromogenic compounds by cyclization of [2-(2-benzothiazolylamino)-4-(diethylamino)phenyl]heteroarylium salts: synthesis and acidobasic behavior
AUTHOR(S): Ziegler, Hugo; Balli, Heinz
CORPORATE SOURCE: Inst. Farbenchem., Univ. Basel, Basel, CH-4056, Switz.
SOURCE: Helvetica Chimica Acta (1983), 66(7), 2165-81
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal

LANGUAGE: German
OTHER SOURCE(S): CASREACT 100:87232
GI For diagram(s), see printed CA Issue.
AB Colored [2-(2-benzothiazolylamino)-4-(diethylamino)phenyl]heteroarylium salts (I; A = 2,6-diphenylpyrylium-4-yl, 2,6-diphenylthiopyrylium, 3-ethylbenzothiazolium-2-yl, 1-ethylquinolinium-2 (and 4-yl) are deprotonated to colorless spiro compds. (II; A = 2,6-diphenylpyran-4- ylidene, etc.). The synthesis of I and II from 2-[3- (diethylamino)anilino]benzothiazole [88760-92-3] is described, and their structures were elucidated by 1H-NMR and UV-visible spectroscopy. The halochromic properties were studied by spectrophotometric determination of εpH* and εHo* curves in buffered MeOH-H2O solution PK* values were also determined and the complex protonation equilibrium discussed. A tautomer of I (A = 5-phenyl-1,2-dithiolium-3-yl) did not form the corresponding II when deprotonated but instead was stabilized by σ-bond resonance.
IT 88851-41-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 88851-41-6 ZCAPLUS
CN Quinolinium, 2-[2-benzothiazolyl[3-(diethylamino)phenyl]amino]-1-methyl-, tetrafluoroborate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 88851-40-5
CMF C27 H27 N4 S



CM 2

CRN 14874-70-5
CMF B F4
CCI CCS



L67 ANSWER 42 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:8520 ZCAPLUS Full-text
DOCUMENT NUMBER: 100:8520

ORIGINAL REFERENCE NO.: 100:1443a,1446a
TITLE: Unsymmetrical quinoline azacyanine dyes
INVENTOR(S): Vavrova, Jaroslava
PATENT ASSIGNEE(S): Czech.
SOURCE: Czech., 3 pp.
CODEN: CZXXA9
DOCUMENT TYPE: Patent
LANGUAGE: Czech
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
CS 197695	B1	19800530	CS 1977-7545		19771116	<--
CS 202980	B1	19810227	CS 1979-4555		19790629	<--
PRIORITY APPLN. INFO.:			CS 1977-7545	A	19771116	<--

GI



I



IV

AB Quinoline azacyanine dyes I (R = H, MeO; R1 = Me, OMe), suitable as optical sensitizers of Ag halide color photog. layers for the blue region, are prepared in high yield (>50%) and purity from 6-(R-substituted)-2-aminobenzothiazoles (II) and 1,3-propane sultone (III) [1120-71-4] via IV, which reacts without isolation with 6-(R1-substituted)-1-ethyl-2-(ethylthio)quinolinium (V) halides in the presence of pyridine and/or Et3N. Thus, 1.65 g II (R = Me) [2536-91-6] and 1.3 g III were heated to 130-140°, then with 30 mL pyridine, 3.5 g V iodide (R1 = H) [50745-64-7], and 2 mL Et3N to 120-130°, and crystallized from aqueous MeOH to give 2.2 g I (R = Me, R1 = H) [88108-68-3].

IT 88108-68-3P 88108-69-4P 88108-70-7P
RL: PREP (Preparation)
(photog. sensitizer, manufacture of)

RN 88108-68-3 ZCAPLUS
CN Quinolinium, 1-ethyl-2-[[6-methyl-3-(3-sulfopropyl)-2(3H)-benzothiazolylidene]amino]-, inner salt (CA INDEX NAME)



RN 88108-69-4 ZCAPLUS
CN Quinolinium, 1-ethyl-6-methoxy-2-[[6-methoxy-3-(3-sulfopropyl)-2(3H)-benzothiazolylidene]amino]-, inner salt (CA INDEX NAME)



RN 88108-70-7 ZCAPLUS
CN Quinolinium, 1-ethyl-6-methoxy-2-[[6-methyl-3-(3-sulfopropyl)-2(3H)-benzothiazolylidene]amino]-, inner salt (CA INDEX NAME)



L67 ANSWER 43 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:420446 ZCAPLUS Full-text
DOCUMENT NUMBER: 93:20446
ORIGINAL REFERENCE NO.: 93:3419a,3422a
TITLE: Molecular models of induced DNA premutational damage and mutational pathways for the carcinogen 4-nitroquinoline 1-oxide and its metabolites
AUTHOR(S): Ornstein, Rick L.; Rein, Robert
CORPORATE SOURCE: Dep. Biophys. Sci., State Univ. New York, Buffalo, NY, 14226, USA
SOURCE: Chemico-Biological Interactions (1980), 30(1), 87-103
CODEN: CBINA8; ISSN: 0009-2797
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The covalent reaction products between 4-nitroquinoline 1-oxide (I) [56-57-5] and its metabolites with DNA minihelices based on chemical properties and key short-contacts after energy-minimization in 21 different intercalative-like complexes were studied. Ninety percent of the quinoline-bound DNAs in vivo involved guanine with the remaining 10% involving adenine residues. This trend was not due to the greater affinity of the quinolines for guanine, but instead resulted from secondary processes involving the preferential formation of apurinic sites at aralkyl-adenine residues over that of aralkyl-guanine residues. In addition, observed mutational patterns could be rationalized in terms of the proposed reaction products. The role of DNA repair mechanisms in the removal and correction of the different proposed reaction products are discussed. The binding pattern of several other aromatic carcinogens were similar to those depicted for I; hence the present study may be of some general significance.

IT 73980-88-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 73980-88-8 ZCAPLUS

CN 6H-Purin-6-one, 2-[(4-amino-1-oxido-2-quinolinyl)amino]-1,7-dihydro- (9CI) (CA INDEX NAME)



L67 ANSWER 44 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1977:486313 ZCAPLUS Full-text

DOCUMENT NUMBER: 87:86313

ORIGINAL REFERENCE NO.: 87:13735a,13738a

TITLE: Application of free electron molecular orbital model. Part II: absorption spectra of azacyanines

AUTHOR(S): Rout, Mahendra Kumar; Patnaik, Lalit Narayan; Bhuyan, Brhamanand

CORPORATE SOURCE: Dep. Chem., Ravenshaw Coll., Cuttack, India

SOURCE: Zeitschrift fuer Physikalische Chemie (Leipzig) (1977), 258(3), 601-4
CODEN: ZPCLAH; ISSN: 0323-4479

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB The use of the free electron mol. orbital model in calculating the light absorption of azacyanine dyes (I, A = benzothiazole, 6-substituted benzothiazole, 4-phenylthiazole, α-naphthothiazole, β-naphthothiazole, 2-quinoline residue, n = 0, 1) gives in all cases, except where A = 2-quinoline, unsatifactory agreement between the observed and calculated values. A correction of one parameter in the free electron model gives reasonable agreement between cald. and observed results for A = 6-substituted benzothiazole, n = 1.

IT 47292-23-9
RL: PRP (Properties)
(calcn. of absorption spectra of, using free electron mol. orbital

model)
RN 47292-23-9 ZCAPLUS
CN Quinolinium, 1-methyl-2-[(1-methyl-2(1H)-quinolinylidene)amino]- (CA INDEX NAME)



L67 ANSWER 45 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:91752 ZCAPLUS Full-text
DOCUMENT NUMBER: 86:91752
ORIGINAL REFERENCE NO.: 86:14504h,14505a
TITLE: Condensation products
INVENTOR(S): Ikeda, Tadashi; Iwamoto, Atsuo; Shishido, Tadao; Adachi, Keiichi; Fuseya, Yoshiharu
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Ger. Offen., 70 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 2617345	A1	19761104	DE 1976-2617345		19760421 <--
JP 51123223	A	19761027	JP 1975-48435		19750421 <--
GB 1541936	A	19790314	GB 1976-16225		19760421 <--
PRIORITY APPLN. INFO.:			JP 1975-48435	A	19750421 <--

GI



I

AB Cyanine dyes and related compds. were prepared in high yield and purity by dethiolation of a [(sulfoalkyl)thio]heterocyclic onium hydroxide with a compound containing an active amino, methylene, or methyl group. For example, a mixture of 3-methylbenzothiazole-2-thione [2254-94-6] and propanesultone [1120-71-4] was heated to give anhydrous 3-methyl-2-[(3-sulfopropyl)thio]benzothiazolium hydroxide [61680-83-9] which when condensed with 5-aminobenzotriazole dihydrochloride [3663-27-2] gave 80% I [61681-34-3].
IT 61681-19-4P 61681-20-7P
RL: IMF (Industrial manufacture); PREP (Preparation)

(preparation of)
RN 61681-19-4 ZCAPLUS
CN Quinolinium, 2-[(1-ethyl-2(1H)-quinolinylidene)amino]-1-methyl-, iodide (9CI) (CA INDEX NAME)



RN 61681-20-7 ZCAPLUS
CN Quinolinium, 1-methyl-2-[(3-methyl-2(3H)-benzothiazolylidene)amino]-, iodide (9CI) (CA INDEX NAME)



L67 ANSWER 46 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:551436 ZCAPLUS Full-text
DOCUMENT NUMBER: 85:151436
ORIGINAL REFERENCE NO.: 85:24183a,24186a
TITLE: The triplet state of 1,1'-diethyl-2,2'-cyanine iodide in neat and mixed crystals
AUTHOR(S): Marchetti, A. P.; Scozzafava, M.
CORPORATE SOURCE: Res. Lab., Eastman Kodak Co., Rochester, NY, USA
SOURCE: Journal of Chemical Physics (1976), 65(6), 2382-6
CODEN: JCPSA6; ISSN: 0021-9606
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The singlet-triplet absorption spectrum of crystalline 1,1'-diethyl-2,2'-cyanine iodide was obtained. The absorption origin consists of 2 lines separated by .apprx.4.0 cm-1. Zeeman spectra were used to assign the higher energy more intense line to the Au factor group state and the lower energy line to the Bu factor group state. Emission spectra were obtained from both dilute and concentrated solid solns. of the dye. The results from the concentrated samples indicate that the largest excitation-transfer interaction between translationally inequiv. mols. is <1 cm-1.
IT 14303-33-4
RL: PRP (Properties)
(electronic singlet-triplet absorption spectrum of diethylcyanine

iodide in matrix of)
RN 14303-33-4 ZCAPLUS
CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, iodide (9CI) (CA INDEX NAME)



L67 ANSWER 47 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:533185 ZCAPLUS Full-text
DOCUMENT NUMBER: 85:133185
ORIGINAL REFERENCE NO.: 85:21277a,21280a
TITLE: The mixed crystal absorption spectra of 1,1'-diethyl-2,2'-cyanine iodide
AUTHOR(S): Marchetti, A. P.; Scozzafava, M.
CORPORATE SOURCE: Res. Lab., Eastman Kodak Co., Rochester, NY, USA
SOURCE: Chemical Physics Letters (1976), 41(1), 87-90
CODEN: CHPLBC; ISSN: 0009-2614
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The optical absorption emission spectra of 1,1'-diethyl-2,2'-cyanine iodide as a guest in 1,1'-diethyl-9-aza-2,2'-cyanine iodide were obtained at 1.8°K. Several site origins were identified, the most intense of which showed very strong guest-lattice coupling.
IT 14303-33-4
RL: PRP (Properties)
(electronic spectrum and fluorescence of diethylcyanine iodide in)
RN 14303-33-4 ZCAPLUS
CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, iodide (9CI) (CA INDEX NAME)



L67 ANSWER 48 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:513609 ZCAPLUS Full-text
DOCUMENT NUMBER: 81:113609

ORIGINAL REFERENCE NO.: 81:17895a,17898a
TITLE: Structure of the J-aggregates of pseudoisocyanine
AUTHOR(S): Daltrozzo, E.; Scheibe, G.; Gschwind, K.; Haimerl, F.
CORPORATE SOURCE: Fachbereich Chem., Univ. Konstanz, Constance, Fed. Rep. Ger.
SOURCE: Photographic Science and Engineering (1974), 18(4), 441-50
CODEN: PSENAC; ISSN: 0031-8760
DOCUMENT TYPE: Journal
LANGUAGE: English

AB J-Aggregation (bathochromic shift of the 1st electronic transition of a dye on aggregation) can be observed only if the slipping of adjacent monomer units is large. This statement follows from all theor. treatment, independent of the approx. used. Accounting for this requirement, exptl. results and their consequences on both the mechanism of J-aggregation and the structure of the J-aggregates of pseudoisocyanine are discussed. In detail, the dependences of J-aggregation on temperature and solvent as well as on the dye anion, added organic and inorg. salts, and polyanion matrices are shown. Likewise, results of mol. weight, conductivity, and circular dichroism measurements are reported. From the exptl. data a strong similarity between the phase transition "soluted monomer dye ↔ J-aggregate" and the process of crystallization; follows. As in the case of crystallization a 2-step mechanism [(a) nucleation and (b) growth] could be detected. The finally formed J-aggregates-contrary to a normal crystal-remains homogeneously in solution; it shows marked similarity to properties of a liquid crystal. The interpretability of all exptl. results in terms of a new structure model is demonstrated.

IT 14303-33-4
RL: USES (Uses)
(J-aggregation of, in aqueous soluble, pentosane polysulfate effect on)

RN 14303-33-4 ZCAPLUS
CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, iodide (9CI) (CA INDEX NAME)



L67 ANSWER 49 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1970:446696 ZCAPLUS Full-text
DOCUMENT NUMBER: 73:46696
ORIGINAL REFERENCE NO.: 73:7709a,7712a
TITLE: Blue sensitizing azacyanins for silver halide emulsions containing dye couplers
INVENTOR(S): Riester, Oskar; Hase, Marie
PATENT ASSIGNEE(S): Agfa-Gevaert A.-G.
SOURCE: Ger. Offen., 21 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1808041	A	19700604	DE 1968-1808041	19681109 <--
DE 1808041	B2	19761014		
DE 1808041	C3	19770526		
US 3697282	A	19721010	US 1969-866520	19691015 <--
BE 741393	A	19700508	BE 1969-741393	19691107 <--
FR 2022971	A5	19700806	FR 1969-38498	19691107 <--
GB 1285078	A	19720809	GB 1969-1285078	19691107 <--

PRIORITY APPLN. INFO.: DE 1968-1808041 A 19681109 <--

GI For diagram(s), see printed CA Issue.

AB Ag(Cl, Br, F) emulsions containing dye couplers are sensitized in the blue region by addition of I [where X = CH:CH, S, or Se; and R or R1 = (CH2)3SO3-, CH2CH2CO2-, or (CH2)4SO2N-Ac] prepared by condensing the corresponding heterocyclic compds. and subsequent alkylation. Thus, a mixture of 2-methylthio-5-chloro-N-methylbenzothiazolium Me sulfate and 2-aminoquinoline in pyridine-NEt3 was refluxed for 4 hr to give a product which, on reaction for 20 min at 170° with propane sultone gave I (X = S, R = (CH2)3SO3-, R1 = Me, R2 = 5-Cl, R3 = H). Similarly 17 other I were prepared

IT 28532-41-4P 28532-42-5P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)

RN 28532-41-4 ZCAPLUS
CN Quinoline, 1,2-dihydro-1-methyl-2-(2-quinolylimino)- (8CI) (CA INDEX NAME)



RN 28532-42-5 ZCAPLUS
CN Quinoline, 6-chloro-1-ethyl-1,2-dihydro-2-(2-quinolylimino)- (8CI) (CA INDEX NAME)



IT 28532-25-4 28532-32-3 28532-33-4
28532-34-5 28532-35-6 28532-36-7
28532-37-8 28532-38-9 28532-39-0
28620-66-8
RL: PRP (Properties)
(spectra of)

RN 28532-25-4 ZCAPLUS
CN Quinolinium, 1-methyl-2-[[3-(3-sulfopropyl)-2(3H)-benzothiazolylidene]amino]-, inner salt (CA INDEX NAME)



RN 28532-32-3 ZCAPLUS
CN 1(2H)-Quinolinepropanesulfonic acid, 2-(2-quinolylimino)- (8CI) (CA INDEX NAME)



RN 28532-33-4 ZCAPLUS
CN Quinolinium, 1-methyl-2-[[1-(3-sulfopropyl)-2(1H)-quinolylidene]amino]-, hydroxide, inner salt (8CI) (CA INDEX NAME)



RN 28532-34-5 ZCAPLUS
CN Quinolinium, 2-[[1-[4-(acetylsulfamoyl)butyl]-2(1H)-quinolylidene]amino]-1-methyl-, hydroxide, inner salt (8CI) (CA INDEX NAME)



RN 28532-35-6 ZCAPLUS

CN Quinolinium, 2-[(1-allyl-2(1H)-quinolylidene)amino]-1-(3-sulfopropyl)-, hydroxide, inner salt (8CI) (CA INDEX NAME)



RN 28532-36-7 ZCAPLUS

CN Quinolinium, 1,6-dimethyl-2-[[1-(3-sulfopropyl)-2(1H)-quinolylidene]amino]-, hydroxide, inner salt (8CI) (CA INDEX NAME)



RN 28532-37-8 ZCAPLUS

CN Quinolinium, 6-methoxy-1-methyl-2-[[1-(3-sulfopropyl)-2(1H)-quinolylidene]amino]-, hydroxide, inner salt (8CI) (CA INDEX NAME)



RN 28532-38-9 ZCAPLUS

CN Quinolinium, 6-chloro-1-ethyl-2-[[1-(3-sulfopropyl)-2(1H)-quinolylidene]amino]-, hydroxide, inner salt (8CI) (CA INDEX NAME)



RN 28532-39-0 ZCAPLUS

CN Quinolinium, 6-methoxy-2-[[6-methoxy-1-(4-sulfobutyl)-2(1H)-quinolylidene]amino]-1-methyl-, hydroxide, inner salt (8CI) (CA INDEX

NAME)



RN 28620-66-8 ZCAPLUS
CN Quinolinium, 1-(3-sulfopropyl)-2-[[1-(3-sulfopropyl)-2(1H)-quinolylidene]amino]-, hydroxide, inner salt, monosodium salt (8CI) (CA INDEX NAME)



L67 ANSWER 50 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1969:434795 ZCAPLUS Full-text
DOCUMENT NUMBER: 71:34795
ORIGINAL REFERENCE NO.: 71:6431a,6434a
TITLE: Franck-Condon principle and the light absorption of merocyanines
AUTHOR(S): Scheibe, Guenter; Daltrozzo, E.; Woerz, O.; Heiss, J.
CORPORATE SOURCE: Tech. Hochsch., Munich, Fed. Rep. Ger.
SOURCE: Zeitschrift fuer Physikalische Chemie (Muenchen, Germany) (1969), 64(1-4), 97-114
CODEN: ZPCFAX; ISSN: 0044-3336
DOCUMENT TYPE: Journal
LANGUAGE: German

AB In open-chain cyanines (polymethines) the intensity ratio of 0 → 0', 0 → 1', 0 → 2' vibrational bands of the longest-wave electron transition is independent of the chain length. If this fact is explained by assuming that the distance of the potential curve min. between ground and excited state becomes smaller with increasing chain length, good conformity is found with the "extensions" which are obtained by L.C.A.O.-M.O. calcns. (Hueckel M.O. and Pople-Pariser-Parr approximation). In merocyanines (polyenes), considerably greater "extensions" result in the application of the Franck-Condon principle due to the comparatively strong intensity shift towards higher vibrational transitions. If no vibrational structure can be observed in the electron spectrum, the absorption maximum of the enveloping curve may appear at shorter wavelengths, although the 0 → 0' transition may even lie at longer wavelengths than in the resp. sym. cyanine. The solvent may shift the symmetry of the dyes in merocyanines more towards the C2v or more towards the

Cσ symmetry and thus also cause shifts of the absorption maximum of the enveloping curve which need not be identical with shifts of the 0 → 0' transition.

IT 23664-31-5 25705-67-3
RL: PRP (Properties)
(spectrum of, Franck-Condon factor in relation to electronic)

RN 23664-31-5 ZCAPLUS
CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]- (CA INDEX NAME)



RN 25705-67-3 ZCAPLUS
CN 2-Quinolinamine, N-[1-(difluoroboryl)-2(1H)-quinolinylidene]- (9CI) (CA INDEX NAME)



L67 ANSWER 51 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:411402 ZCAPLUS Full-text
DOCUMENT NUMBER: 69:11402
ORIGINAL REFERENCE NO.: 69:2191a,2194a
TITLE: Pentaazapentamethinecyanines. II.
AUTHOR(S): Quast, Helmut; Huenig, Siegfried
CORPORATE SOURCE: Univ. Marburg, Marburg, Fed. Rep. Ger.
SOURCE: Justus Liebigs Annalen der Chemie (1968), 711, 157-73
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB Title compds. of the bis(3-methyl-2-benzothiazole)pentaazapentamethinecyan ine perchlorate (I) type lost one or two N mols. upon heating. Upon reduction, I cleaved to form the 2-azido-3-methylbenzothiazolium salt and 3-methyl-2-benzothiazolone hydrazone. Nucleophiles such as reactive CH2 compds. and phenols attacked I at N-2 of the chain to yield heterocyclic azino dyes identical with those obtained by oxidative azo coupling. Correspondingly, the cleavage of I with PhSO2Li gave 2-(phenylsulfonylazo)- 3-methylbenzothiazolium derivs.

IT 19205-03-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 19205-03-9 ZCAPLUS
CN Quinolinium, 1-methyl-2-[(1-methyl-2(1H)-quinolylidene)amino]-, perchlorate (8CI) (CA INDEX NAME)

CM 1

CRN 47292-23-9
CMF C20 H18 N3



CM 2

CRN 14797-73-0
CMF Cl O4



L67 ANSWER 52 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1967:421728 ZCAPLUS Full-text
DOCUMENT NUMBER: 67:21728
ORIGINAL REFERENCE NO.: 67:4115a,4118a
TITLE: Anionoid substitution reactions of diethyl 2-acetamido-6-bromazulene-1,3-dicarboxylate
AUTHOR(S): Tada, Masao
CORPORATE SOURCE: Tohoku Univ., Sendai, Japan
SOURCE: Bulletin of the Chemical Society of Japan (1966), 39(9), 1954-61
CODEN: BCSJA8; ISSN: 0009-2673
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Azulene derivs. (VIII-IX, XII-XXXVI) were synthesized from I by nucleophilic substitution reactions. II (5.0 g.) was refluxed with 8 ml. Ac2O 8 hrs., and the residue obtained by evaporation of excess Ac2O was dissolved in 60 ml. EtOH. The insol. compound was recrystd. from EtOAc to yield 4.0 g. III, m. 212-13°. Crystals obtained from EtOH solution, recrystd. from EtOH gave 0.5 g. VII, m. 141-2°. Refluxing 5.0 g. II in Ac2O for 12 hrs. gave 0.6 g. III and 4.1 g. VII, while refluxing 50 mg. III in Ac2O 1.5 hrs. gave 45 mg. VII. Refluxing 50 mg. III in 8 ml. EtOH with 2 ml. 6N H2SO4 1.5 hrs., on cooling, gave 20 mg. II. Also refluxing 100 mg. III, 6 ml. EtOH, and 6 ml. 10% alc. KOH 30 min., on cooling, gave 20 mg. II. VII was hydrolyzed by refluxing 150

mg. VII, 5 ml. EtOH, and 1.5 ml. 6N H_2SO_4 30 min. to give 130 mg. III. IV was partially acetylated to V, m. 141-2° (MeOH). IV was fully acetylated by refluxing 0.6 g. IV 10 hrs. in 3 ml. Ac_2O to give VI, m. 138-8.5° (MeOH). A solution of 0.2 g. III in 30 ml. EtOH was added to 5 ml. 10% KOH and stirred 1 hr. to precipitate 20 mg. II overnight. The filtrate diluted with 20 ml. H_2O and acidified gave 0.1 g. VIII, m. 217-18° (decomposition) (aqueous EtOH). Refluxing VIII in Ac_2O 15 min. gave the acetate of VIII, m. 137-8°. III (500 mg.) was added to excess liquid NH_3, the residue obtained on standing 1 week with evaporation dissolved in Et acetate, the solution passed through an alumina column and eluted with EtOAc to give as the 1st effluent 30 mg. II, and as the 2nd effluent 310 mg. IX, m. 225-5.5° (EtOH); IX picrate (X) m. 155° (decomposition). Alternatively adding 300 mg. III and 1 g. NaN_3 to 10 ml. Me_2SO, heating the mixture on a water bath 15 hrs., diluting with H_2O, extracting with EtOAc, and chromatog. gave 100 mg. IX. IX (25 mg.), 6 ml. EtOH, and 1.5 ml. 6N H_2SO_4 were refluxed to give 10 mg. di-Et 2,6-diaminoazulene-1,3-dicarboxylate (XI), m. 206-7° (C_6H_6). III was treated with a variety of reagents to yield products XII-XXXVI. Thus 200 mg. III added to 20 mg. Na in 6 ml. EtOH, the mixture stirred 5 hrs. and diluted with H_2O yielded 150 mg. XII, m. 116-17° (aqueous EtOH). III (50 mg.) and 10 ml. EtOH treated with 3 ml. 27% NaSH 3 hrs., the solution diluted with H_2O, acidified, and extracted with EtOAc gave, on evaporation, 20 mg. XIII, m. 220-1° (C_6H_6). III (100 mg.) and 10 ml. MeOH treated with 5 ml. 80% $N_2H_4.H_2O$ 3 hrs., the mixture concentrated, and H_2O added yielded 60 mg. XIV, m. 203-4° (decomposition) (EtOH); XIV acetate m. 234.5-35°. III (300 mg.) added to 3 ml. $PhNHNH_2$ in 10 ml. EtOH, refluxed 1 hr., the solution concentrated, and 50 ml. H_2O and 5 ml. 2N AcOH added yielded 190 mg. XV, m. 218-19° (EtOH). III (500 mg.) added to a mixture of 10 ml. 40% $Me_2NH.H_2O$ and 20 ml. MeOH and refluxed 30 min. gave, on addition of H_2O, 300 mg. XVI, m. 179-80° (MeOH). Similarly were prepared from the corresponding amines XVII, m. 165-6° (EtOH); XVIII, m. 163-4° (aqueous EtOH); XIX, m. 207-8° (aqueous EtOH); XX, m. 210-11° (aqueous MeOH); XXI, m. 105-6° (aqueous EtOH); XXII, m. 136-8° (aqueous EtOH); XXIII, m. 144-5° (EtOH); XXIV, m. 158-9° (MeOH); XXV, m. 164.5-5.5° (MeOH); XXVI, m. 182-3° (decomposition) (aqueous EtOH); XXVII, m. 141-2° (EtOH); XXVIII, m. 205.5-206° (MeOH); XXIX, m. 157-8° (aqueous EtOH); XXX, m. 67-8° (aqueous EtOH); XXXI, m. 233-4° (aqueous EtOH); XXXII, m. 185-6° (EtOH); XXXIII, m. 110-12° (aqueous EtOH); XXXIV, m. 145-6° (EtOH); XXXV, m. 220-1° (EtOH); XXXVI, m. 234-5° (EtOH); acid hydrolysis of XVII, XIX, XX, XXIV, and XXVIII gave the corresponding 2-amino compds. XXXVII, m. 153-4° (EtOH); m. 184-5° (EtOH); m. 146-7° (aqueous MeOH); m. 123-4° (C_6H_6-cyclohexane); m. 134-5° (MeOH); diethyl 6-diethylaminoazulene-1,3-dicarboxylate was obtained from both XXXVII and XVII. All compds. are fully defined by chemical analysis and ir and uv spectral analysis.

IT 15071-21-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 15071-21-3 ZCAPLUS

CN 1,3-Azulenedicarboxylic acid, 2-acetamido-6-(2-quinolylamino)-, diethyl ester (8CI) (CA INDEX NAME)



L67 ANSWER 53 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1967:407725 ZCAPLUS Full-text
DOCUMENT NUMBER: 67:7725
ORIGINAL REFERENCE NO.: 67:1431a,1434a
TITLE: Palladium(II) complex of picolinaldehyde 2-quinolylhydrazone
AUTHOR(S): Jensen, Richard Erling; Pflaum, Ronald T.
CORPORATE SOURCE: Univ. of Iowa, Iowa City, IA, USA
SOURCE: Analytica Chimica Acta (1967), 37(3), 397-400
CODEN: ACACAM; ISSN: 0003-2670
DOCUMENT TYPE: Journal
LANGUAGE: English

AB cf. Heit and Ryan, CA 64: 18399f. To determine Pd, 14-37.2 ppm., in Pd/C and in Pd/CaCO3 catalysts, appropriately dissolve the sample containing Pd. To a 5-ml. aliquot containing 0.6-13 ppm. Pd2+, add ≥2-fold excess of 8 × 10-3M picolinaldehyde 2-quinolylhydrazone (PAQH)-0.1N HCl (CA 65: 14427d), 10 ml. of pH 8 buffer (add HCl dropwise to 0.5M (CH2OH)3CNH2 until a pH of 8.0 is obtained), and dilute to .apprx.75 ml. with H2O. Extract the aqueous solution with 3 5-ml. vols. of CHCl3, and filter the exts. through a small pad of cotton. Dilute the combined organic exts. to 50 ml. with CHCl3, measure the absorbance of the solution at 589 mμ, and compare the absorbance with that of a prepared calibration curve. For the SCN- derivative, add 10 ml. of 0.1% KSCN solution after the addition of the buffer. Extract with CHCl3 as described, and measure the absorbance of the solution at 592 mμ. The Pd(PAQH)Cl2 (I) and Pd(PAQH)(SCN)2 (II) complexes obey Beer's law for 6.2 × 10-6 -1.24 × 10-4M Pd2+; the molar absorptivities and Kd values are I, 1.28 × 104, 589, 23; and II, 1.58 × 104, 592 mμ, .apprx.500. Extraction and color formation of I and II are constant for pH 6.3-8.9. CHCl3 is the preferred extracting solvent; I and II can also be extracted from aqueous solution into C6H6, CCl4, EtOAc, iso-AmOH and PhNO2. Pt4+ in Pt4+/Pd2+ ratios of 10 and 20, resp., in the I and II systems, and NO3-, PO43-, and F- do not interfere; Ru3+, Rh3+, Os3+, Ir4+, Fe2+, Co2+, Ni2+, Cu2+, Au3+, Mn2+, Zn2+, V5+, Cr3+, Al3+, and S2O32- did. The Pd values determined as I and II are: for Pd/C, 14.0, 13.6; for Pd/CaCO3, 37.2, 35.6 ppm.

IT 16634-18-7 17084-82-1
RL: PRP (Properties)
(spectrum of)

RN 16634-18-7 ZCAPLUS
CN Palladium, dichloro(picolinaldehyde 2-quinolylhydrazone)- (8CI) (CA INDEX NAME)



RN 17084-82-1 ZCAPLUS
CN Palladium, (picolinaldehyde 2-quinolylhydrazone)bis(thiocyanato)- (8CI) (CA INDEX NAME)



L67 ANSWER 54 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1967:76910 ZCAPLUS Full-text
DOCUMENT NUMBER: 66:76910
ORIGINAL REFERENCE NO.: 66:14467a,14470a
TITLE: Electrochemical oxidation potentials of some cyanine dyes
AUTHOR(S): Stanienda, Alfred
CORPORATE SOURCE: Humboldt Univ., Berlin, Germany
SOURCE: Zeitschrift fuer Wissenschaftliche Photographie, Photophysik und Photochemie (1966), 59(5-8), 76-86
CODEN: ZPPPAQ; ISSN: 0372-9788
DOCUMENT TYPE: Journal
LANGUAGE: German

AB The anodic half-step potentials of some cyanine dyes were determined as a function of structure using a rotating Pt electrode in a 0.1M LiClO4-MeCN solution In the concentration range investigated (2 × 10-5 to 4 × 10-4M) the half-step potentials are proportional to and linearly dependent upon the sq. root of the speed of rotation of the electrode. The inclination of the steps was 0.058 v. for n = 1, 2, or 3 but not for n = 0. A H2O-saturated calomel electrode was used as reference. All measurements were carried out at 20° under Ar.

IT 14303-33-4
RL: PRP (Properties)
(elec. potential of)

RN 14303-33-4 ZCAPLUS
CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, iodide (9CI) (CA INDEX NAME)



L67 ANSWER 55 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1966:438498 ZCAPLUS Full-text
DOCUMENT NUMBER: 65:38498
ORIGINAL REFERENCE NO.: 65:7165f-h,7166a-h,7167a-c
TITLE: Problem of nucleophilic carbenes
AUTHOR(S): Quast, Helmut; Huenig, Siegfried
CORPORATE SOURCE: Univ. Wuerzburg, Germany
SOURCE: Chemische Berichte (1966), 99(6), 2017-38
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German

AB Ethylenes tetrasubstituted by electron donors and their formal dissociation products, the corresponding nucleophilic carbenes, reacted with electrophiles to yield the same type of products. By the use of reactive azides, such as p-tosyl azide, differentiation between ethylene and carbene reaction can be made unequivocally as demonstrated by the example of the corresponding benzothiazole derivs. Redox reactions have to be taken into account as side reactions. 3-Methylbenzothiazolium methosulfate with HClO4 in MeOH gave the perchlorate (I), m. 145-6° (MeOH containing a little HClO4). Benzothiazole (54 g.) in 200 cc. (CH2Cl)2 refluxed 0.5 hr. with 62 g. [Me3O] [BF4] gave 80.3 g. 3- methylbenzothiazolium tetrafluoroborate (II), m. 119-20° (MeOH-HClO4). II or I (0.04 mole) added to excess NaH (50% mineral oil paste) in about 100-150 cc. dry dioxane under N, stirred 2-3 hrs., and filtered under N yielded 4.20-4.44 g. light yellow III, m. from 128° with sintering from about 120° and partial change to colorless prisms which were completely melted at about 195°; III was stored under N at -25°/0.1 mm. III heated at 150-60° gave 3,3'-dimethyl-2,2'-spirobibenzothiazoline. IV (R = H) (V) (556 mg.) in 5 cc. MeCN treated with stirring with 10 cc. saturated p-MeC6H4SO2Na in MeOH yielded 600 mg. orange-yellow VI (R = p-MeC6H4SO2, n = 1) (VII) which changed at 140-50° with N evolution to VI (R = p-MeC6H4SO2, n = 0) (VIII). 3-Methyl-2-benzothiazolone imide (IX) (1.64 g.) in 2 cc. dioxane shaken 15 min. with 2.85 g. p-MeC6H4SO2Cl and 10 cc. 2N NaOH yielded 2.68 g. VIII, m. 204-5° (MeCN). 4-Chloro-1-methylquinolinium tetrafluoroborate (531 mg.) and 657 mg. IX refluxed 15 min. in MeCN, kept overnight, and diluted with H2O yielded 685 mg. yellow X (n = 0, X = BF4) (XI), m. 222-4° (10:1 MeOH-MeCN). 2 -Azido- 1,3 - dimethylbenzimidazolium tetrafluoroborate (XII) (2.2 g.) in 10 cc. MeCN treated dropwise during 1 hr. simultaneously with 5.0 cc. 0.8M I and 10 cc. 0.4M isoPr2NEt (XII) in MeCN, stirred 5 min., treated with 10 cc. saturated NaClO4-MeOH, and refrigerated overnight yielded 555 mg. orange-yellow XIII (n = 1, X = ClO4), m. 309-11° (MeCN-HClO4). I with 2-azido-1-methylquinolinium tetrafluoroborate yielded 641 mg. XIV (n = 1, X = ClO4) (XV) containing XIV (n = 0, X = ClO4) (XVI) which recrystd. from MeCN-HClO4 gave light red XV, m. 290-4°. IX (1.64 g.) and 3.35 g. 2-methylmercapto-1,3-dimethylbenzimidazolium methosulfate in 50 cc. dry C5H5N refluxed 0.5 hr., cooled, diluted with a little H2O, and poured into 250 cc. N NaClO4 yielded 3.09 g. XIII (n = 0, X =

ClO4) (XVII), m. 313-15° (HCO2H). 2-Chloro-1-methylquinolinium tetrafluoroborate (266 mg.) in 2.5 cc. MeCN refluxed 15 min. with 328 mg. IX, kept overnight, and diluted with 10 cc. H2O yielded 353 mg. pale yellow XVI, m. 256-8° (MeOH-HBF4). III (300 mg.) and 0.002 mole powdered V in 5 cc. MeCN mixed at 5.0° in a closed system evolved during 0.5-1 hr. 115% N, 19% XVIII (R = H, X = BF4, n = 1) (XIX), and 41% XVIII (R = H, X = BF4, n = 0) (XX). A similar run with 0.002 mole IV (R = MeO) (XXI) treated after completion of the N evolution with 2 cc. HClO3 yielded 109% N, 11% XVIII (R = MeO, X = ClO4, n = 1) (XXII), and 47% XVIII (R = MeO, X = ClO4, n = 0) (XXIII). 4-Azido-1-methylquinolinium tetrafluoroborate in 10 cc. MeCN yielded similarly during 137 min. 151% N and 327 mg. XI (perchlorate), red crystals with a blue luster. III (300 mg.) in 5 cc. MeCN treated 20-30 min. with 14 or 19 millimoles p-MeC6H4SO2N3 at 5.0 and 11.5°, resp. yielded 107 and 102% N, resp., 46 and 32% VII, resp., m. 198-205°, and 79 and 78% VIII, resp., m. 194-203°. III (0.001 mole) with 0.003 mole p-nitro- and p-methylbenzenediazonium tetrafluoroborate in 10 and 5 cc. MeCN, resp., gave during 0.5-1 hr. 160 mg. XXIV (X = BF4) (XXV), m. 297-312°, and 90 mg. XXV, m. 286-96°, resp. III (600 mg.) in 5 cc. MeCN treated 0.5-1 hr. with N and then 1-2 hrs. with 20 cc. 0.2M [p-O2NC6H4N2] [BF4] or 5 cc. 0.8M [p-MeC6H4N2][BF4] or [p-Me2NC6H4N2][BF4], treated with 5 cc. saturated NaClO4-HCO2H, and kept at -25° overnight yielded 431 mg. XXIV (X = ClO4) (XXVI), 318-23° (decomposition), 258 mg. XXVI, m. 286->350° (decomposition), and 215 mg. XXVI, m. 270-88° (decomposition), resp. 3-Methylbenzothiazolium tetrafluoroborate (XXVII) with 1, 2, and 5 millimoles V in 15, 15, and 20 cc. MeCN, resp. treated rapidly at about 20° with 0.343 cc. XII (d21, 0.754), stirred 1-2 min., acidified with 10 cc. HBF4 or HClO4, and filtered after 5 min. yielded 59, 72, and 77% XIX, resp.; method A. A similar run with 948 mg. XXVII and 0.008 mole V in 20 cc. MeCN in which 10 cc. 0.4M XII-MeCN was added during 1 hr. with stirring gave 72-8% XIX; method B. Less than 1% XX were formed by method A or B. XXVII with 2 mole equivs. XXI in 15 cc. MeCN gave 73 and 66-70% XXII by methods A and B, resp., and less than 1% XXIII. XXVII with 2 mole equivs. XII in 10 cc. MeCN yielded by methods A and B, 24 and 23% XIII (n = 1, X = ClO4), resp., and 11 and 15% XVII, resp. XXVII with 2 equivs. 2-azido-1-methylquinolinium perchlorate yielded similarly by methods A and B 18 and 19% XV and 11 and 15% XVI, resp. XXVII with 7.5 mole equivs. PhSO2N3 yielded by method B 44% VI (R = Bz, n = 0). XXVII with 1 and 8 mole equivs. p-MeC6H4SO2N3 yielded less than 1% VII and 56-62 and 53% VIII, m. 201.5°, resp. XXVII with 4 mole equivs. 4-azido-1-methylquinolinium tetrafluoroborate in 20 cc. MeCN yielded 24 and 47% XI by methods A and B, resp. XXVII treated with 2 mole equivs. by method B yielded 411 mg. XXVI, m. 297-300°. XXI (0.004 mole) with XXVII and 0.28 cc. Et3N in 15 cc. MeCN by method A treated after 1 min. with 5 cc. HClO4 and kept at -5° overnight yielded 1.038 g. XXII and unreacted XXI; XXIII could only be detected in the mother liquor. V (1.112 g.) in 15 cc. MeCN treated during 1.5 hrs. with 10 cc. 0.4M XII and kept 17 hrs. gave 80% N and 165 mg. solid, m. 334->350°, which recrystd. from HCO2H-HCONMe2 containing a little LiClO4 yielded 123 mg. light yellow crystals, m. 337-47° (decomposition). XXVII (948 mg.) and 1.89 g. [p-Me2NC6H4N2] [BF4] (XXVIII) in 10 cc. MeCN treated 0.5 hr. with N and then dropwise during 10 min. at 25.0 ± 0.1° with 5 cc. 0.8M XII-MeCN and kept 1 hr. yielded 49% N; the mixture treated with 10 cc. AcOH and 5 cc. saturated NaClO4-HCO2H and kept 5 hrs. at -25° yielded 7-8% 2-(p-dimethylaminobenzeneazo)-3-methylbenzothiazolium perchlorate; the mother liquor contained a yellow dye, λmaximum 413 mμ. XXVIII (470 mg.) in 5 cc. MeCN with 2.5 cc. 0.8M XII-MeCN gave during 0.5 hr. 62% N. XXVIII (948 mg.) and 4.4 g. BzN3 in 5 cc. MeCN treated during 25 min. dropwise with 10 cc. 0.4M XII-MeCN yielded during 1500 min. 4.09 millimoles N; the red mixture kept 1 day at -25° yielded 470 mg. VI (R = Bz, n = 0), m. 150-4°. 3-Methylbenzothiazolium perchlorate (1.000 g.) in 5 cc. MeCN and 5 cc. p-MeC6H4SO2N3 treated 3-4 hrs.

at 25.0 ± 0.1° with 10 cc. 0.4M XII-MeC yielded 764-88 mg. VIII, m. 201-5°, by method A.

IT 7267-72-3, Quinolinium, 1-methyl-2-[(3-methyl-2-benzothiazolinylidene)amino]-, tetrafluoroborate
(spectrum of)

RN 7267-72-3 ZCAPLUS

CN Quinolinium, 1-methyl-2-[(3-methyl-2-benzothiazolinylidene)amino]-, tetrafluoroborate (8CI) (CA INDEX NAME)

CM 1

CRN 47220-56-4
CMF C18 H16 N3 S



CM 2

CRN 14874-70-5
CMF B F4
CCI CCS



L67 ANSWER 56 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1965:454058 ZCAPLUS Full-text
DOCUMENT NUMBER: 63:54058
ORIGINAL REFERENCE NO.: 63:9788c-d
TITLE: Vinylamines. V. Stereochemistry of reactions with ethyl azodicarboxylate
AUTHOR(S): Risaliti, Amerigo; Marchetti, Leonardo
CORPORATE SOURCE: Univ. Trieste, Italy
SOURCE: Annali di Chimica (Rome, Italy) (1965), 55(7), 635-44
CODEN: ANCRAI; ISSN: 0003-4592
DOCUMENT TYPE: Journal
LANGUAGE: Italian

AB cf. CA 60, 9243c. The product of the reaction of 1-morpholinocyclohexene with ethyl azodicarboxylate (in Et2O, room temperature, 24 hrs.) is assigned the structure of 1-morpholino-6-(N,N'-dicarbethoxy)hydrazinocyclohexene from N.M.R. spectra. The reaction mechanism is discussed and cis-2,6-bis(N,N'-dicarbethoxy)hydrazinocyclohexanone is stipulated as an intermediate, which upon treatment with EtONa or organic acids rearranges into the more stable

trans isomer. The two stereoisomers are characterized by N.M.R. Partial resolution of dl trans-2,6-bis(N,N'- dicarbethoxy)hydrazinocyclohexanone is reported.

IT 3956-16-9
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 3956-16-9 ZCAPLUS

CN Bicarbamic acid, [3-[2-carboxy-1-(2-quinolyl)hydrazino]-2-oxocyclohexyl]-, triethyl ester (7CI, 8CI) (CA INDEX NAME)



L67 ANSWER 57 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1965:454057 ZCAPLUS Full-text

DOCUMENT NUMBER: 63:54057

ORIGINAL REFERENCE NO.: 63:9788b-c

TITLE: Cyclobutadieneiron tricarbonyl. A new aromatic system

AUTHOR(S): Fitzpatrick, J. D.; Watts, L.; Emerson, G. F.; Pettit, R.

CORPORATE SOURCE: Univ. of Texas, Austin

SOURCE: Journal of the American Chemical Society (1965), 87(14), 3254-5
CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 63:54057

AB The stable Fe tricarbonyl complex of cyclobutadiene was aromatic in the sense that it underwent electrophilic substitution reactions to yield a series of new cyclobutadiene complexes. These reactions find a close parallel in the well-known substitution reactions of ferrocene. Reactions which gave acetyl, benzoyl, formyl, and chloromethyl products of the complex were reported.

IT 3956-16-9
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 3956-16-9 ZCAPLUS

CN Bicarbamic acid, [3-[2-carboxy-1-(2-quinolyl)hydrazino]-2-oxocyclohexyl]-, triethyl ester (7CI, 8CI) (CA INDEX NAME)



L67 ANSWER 58 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1963:479202 ZCAPLUS Full-text
DOCUMENT NUMBER: 59:79202
ORIGINAL REFERENCE NO.: 59:14738b-e
TITLE: Influence of the steric effect on infrared absorption in cyanines
AUTHOR(S): Friedrich, Hans Joachim
CORPORATE SOURCE: Univ. Wuerzburg, Germany
SOURCE: Zeitschrift fuer Naturforschung (1963), 18b(8), 635-8
CODEN: ZNTFA2; ISSN: 0372-9516
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB The infrared absorption spectrum of cyanines in the out-of-plane vibration (γ-vibration) range of H atoms of the aromatic rings (700-900 cm.-1) depends on the steric characteristics of the mols. Only the frequency range of γ-vibrations for 4 adjacent H atoms on the carbocyclic ring (γ4 vibrations) and for 2 adjacent H atoms on the heterocyclic ring (γ2 vibrations) are considered in this study of salts and bases of the quinocyanine type and of cyanines. All measurements were made on KBr briquets of finely pulverized solid substances. The infrared spectra of tetra-2-quinolylethylene, di-2-quinolylmethane (X), tri-2- quinolylmethanol, di-2-quinolyl ketone, and X-di-HCl showed considerably more splitting of the bands than did I-IV and X ZnCl2 salt, and the cyanines V-IX. The vibration frequencies expected from the literature were 730-770 cm.-1 for γ4 and 800-860 cm.-1 for γ2. The values found for γ4 and γ2 are given.
IT 99870-55-0, 1-Methyl-2-[(1-methyl-2(1H)-quinolylidene)amino]quinolinium iodide
(spectrum of, steric effects in)
RN 99870-55-0 ZCAPLUS
CN 1-Methyl-2-[(1-methyl-2(1H)-quinolylidene)amino]quinolinium iodide (7CI) (CA INDEX NAME)



L67 ANSWER 59 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1963:446065 ZCAPLUS Full-text
DOCUMENT NUMBER: 59:46065
ORIGINAL REFERENCE NO.: 59:8297d-e
TITLE: Kendall's desensitization law and electronic state of dyes
AUTHOR(S): Tamura, Mikio; Hada, Hiroshi
CORPORATE SOURCE: Univ. Kyoto, Japan
SOURCE: Sci. Phot., Proc. Intern. Colloq., Liege (1962), Volume Date 1959 572-8

DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB The energy changes of the lowest vacant π-electronic levels of cyanine or hemicyanine dyes, caused by replacing a .tplbond.CH- group with a N atom in the methene or polymethene chain connecting the 2 terminal N atoms, are estimated by the quantum mech. perturbation method. The lowering of the lowest vacant level is large for dyes with even nos. of C atoms between the replacing N atom and the 2 terminal N atoms and small for dyes with odd nos. of C atoms. Kendall's law is explained by considering that the lower the lowest vacant level, the stronger the desensitizing action will be. Strong desensitizing action is produced by lowering the lowest vacant level of a carbocyanine dye by 0.6 e.v.

IT 14303-33-4, Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, iodide
(electronic state of, photographic desensitizing action and)

RN 14303-33-4 ZCAPLUS

CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, iodide (9CI) (CA INDEX NAME)



L67 ANSWER 60 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1962:480523 ZCAPLUS Full-text
DOCUMENT NUMBER: 57:80523
ORIGINAL REFERENCE NO.: 57:15999i,16000a
TITLE: Effect of pressure on cyanine spectra
AUTHOR(S): Samara, G. A.; Riggleman, B. M.; Drickamer, H. G.
CORPORATE SOURCE: Univ. of Illinois, Urbana
SOURCE: Journal of Chemical Physics (1962), 37, 1482-8
CODEN: JCPSA6; ISSN: 0021-9606
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB The effect of high pressure was measured on the electronic spectra of a number of cyanine dyes dissolved in cellulose acetate. In general, a red shift was observed with pressure, which varied in magnitude with the chain length and electroneg. of the end group. The results are discussed in terms of Olszewski's resonance barrier model (CA 52, 4306g). The peaks tended to broaden with increasing pressure, and to decrease in height. There was no significant change in the total area under the peak. For a few cyanines the spectra of the crystals were also measured to study the effect of pressure on the Davydoff splitting (CA 43, 4575f). The degree of splitting increased with increasing pressure, as was expected. There was a redistribution of intensity among the different branches with increasing splitting.

IT 14303-33-4, Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, iodide 105863-31-8, 1-Ethyl-2-[(3-ethyl-6-methyl-2-benzothiazolinylidene)amino]quinolinium iodide

(spectrum of, pressure effect on)
RN 14303-33-4 ZCAPLUS
CN Quinolinium, 1-ethyl-2-[(1-ethyl-2(1H)-quinolinylidene)amino]-, iodide (9CI) (CA INDEX NAME)



RN 105863-31-8 ZCAPLUS
CN 1-Ethyl-2-[(3-ethyl-6-methyl-2-benzothiazolinylidene)amino]quinolinium iodide (7CI) (CA INDEX NAME)



L67 ANSWER 61 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1962:66870 ZCAPLUS Full-text
DOCUMENT NUMBER: 56:66870
ORIGINAL REFERENCE NO.: 56:12863g-i,12864a-e
TITLE: Bislepidines
INVENTOR(S): Schock, Richard U., Jr.; Hasbrouck, Richard B.; Dickson, Donald E.
PATENT ASSIGNEE(S): Abbott Laboratories
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3020283		19620206	US 1958-768064	19581020 <--

PRIORITY APPLN. INFO.: US 19581020 <--
GI For diagram(s), see printed CA Issue.
AB The title compds. (I) were prepared by the reaction of a diamine with a 2-chlorolepidine (in 1:2 ratio) in the presence of a phenol at 125-75°, the product being isolated as dihydrochloride. The bases could be converted into quaternary salts in the usual way. Thus, 35 g. 2-chlorolepidine, 11.5 g. 72% 1,6-diaminohexane (II) and 23.4 g. PhOH was heated slowly to 150° at which

point the reaction became exothermic and the temperature increased rapidly to 260°; the mixture was allowed to cool to 60° and poured into 400 ml. acetone with stirring. Concentrated HCl (2 ml.) was added to the acetone mixture, which was cooled with ice. The precipitate was filtered off and washed with H2O and acetone to give N,N'-di(2-lepidyl)-1,6-diaminohexane-2HCl (III), m. 278-82° (H2O). III (9.5 g.) in 100 ml. dry PhCH3 and 50 ml. PhNO2 was refluxed, the solution treated with 6.5 ml. Me2SO4 during 1 hr., the mixture cooled, and poured into 200 ml. acetone. The crude dimethosulfate salt which was precipitated was dissolved in 100 ml. hot H2O and 15 g. NaI added to the solution to give N,N'-di(2-lepidyl)-1,6-diaminobenzene dimethiodide (crystallized from hot H2O). A mixture of 31.9 g. 2-chloro-6-methoxylepidine, 12.3 g. II, and 40 g. PhOH was heated 6 hrs. at 165° and the mixture worked up as for III to give N,N'-bis(6-methoxy-2-lepidyl)-1,6-diaminohexane dihydrochloride, m. 282-86°. Similarly, 23.0 g. 2-chloro-6,8-dimethyllepidine, 9.1 g. II, and 30 g. PhOH gave N,N'-bis(6,8-dimethyl-2-lepidyl)-1,6-diaminohexane dihydrochloride, m. 336-38°. 2-Chloro-8-methyllepidine (19 g.), 8.05 g. II, and 30 g. PhOH gave N,N'-bis(8-methyl-2-lepidyl)-1,6- diaminohexane dihydrochloride, m. 297-300°. The following I were prepared (Y, R1, R2, moles H2O of hydration, and m.p. given): (CH2)2, H, H, 2.0, 321-23°; (CH2)3, H, H, 3.0, 249.5-50.5°; (CH2)4, H, H, 0.75, 268-69°; (CH2)5, H, H, 1.75, 154-55.5°; p-phenylene, H, H, 4.0, 345°; 1,4-cyclohexylene, H, H, 3.5, 324-26°; (CH2)7, H, H, 0.25, 270-74°; (CH2)8, H, H, 2.0, 176-78°; 1,4-xylylene, H, H, 3.25, 317°; (CH2)9, H, H, 0.5, 93-5°; (CH2)10, H, H, 0, 157-58°; CH2CH2C6H4CH2CH2, H, H, 0, 320-25°; (CH2)11, H, H, 2.0, 132°; (CH2)12, H, H, 2.25, 210°; (CH2)6, 6-Me, H, 1.5, 285-88°; (CH2)6, 7-Me, H, 0.5, 346-49°; (CH2)6, H, 8-Et, 0, 298.5-99.5°; (CH2)6, 6-OH, H, 0, 260°; (CH2)6, 5-OMe, 8-OMe, 1.25, 238.5-39.5°; (CH2)6, 6-OC5H11, H, 0, 248.5-49.5°; (CH2)6, H, 7-Cl, 0, 136-38°; and (CH2)6, 5-Cl, 8-Me, 0, 279-81°. The diamines employed as starting materials were all known compds. The new bislepidine products were effective parasiticides and were useful for the control of pinworms such as Syphacia obvelta (IV) and tapeworms such as Hymenolepis nana (V), Dipylidium caninum and Taenia pisiformis. In representative operations, substantially complete controls of IV and V were obtained by oral administration to mice of 25-300 mg./kg. of body weight of N,N'-di(2-lepidyl)-1,7-diaminoheptane-2HCl.

IT 102324-50-5
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 102324-50-5 ZCAPLUS

CN Lepidine, 2,2'-(1,4-cyclohexylenediimino)di-, dihydrochloride (7CI) (CA INDEX NAME)



L67 ANSWER 62 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1962:66869 ZCAPLUS Full-text

DOCUMENT NUMBER: 56:66869
ORIGINAL REFERENCE NO.: 56:12863f-g
TITLE: Derivatives of pyridine or quinoline
INVENTOR(S): Hayashi, Eisaku; Yamanaka, Hiroshi
PATENT ASSIGNEE(S): Sankyo Co., Ltd.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 36015616	B4	19610000	JP	19571229 <--
PRIORITY APPLN. INFO.:			JP	19571229 <--

AB Catalytic reduction of 6 g. 4-benzyloxypyridine 1-oxide in 30 cc. MeOH using 3.0 g. Raney Ni prepared from Ni-Al alloy gives 5 g. 4-benzyloxypyridine, m. 55-6° (hexane). Similarly are prepared 4-methoxypyridine (b32 92°; picrate m. 170-2°), 4-aminopyridine (m. 152-5°; picrate m. 215-17°), 4-pyridone (monohydrate m. 59-61°), and 4-chloropyridine (b30 100°; picrate m. 170-2°), from the corresponding 1-oxides.

IT 102324-50-5
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 102324-50-5 ZCAPLUS
CN Lepidine, 2,2'-(1,4-cyclohexylenediimino)di-, dihydrochloride (7CI) (CA INDEX NAME)



●2 HCl

L67 ANSWER 63 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1953:2807 ZCAPLUS Full-text
DOCUMENT NUMBER: 47:2807
ORIGINAL REFERENCE NO.: 47:434g-i,435a
TITLE: 3-Azo derivatives of 1-substituted 1,3-dihydro-2,5-diketo-7-methylpyrazolo[2,3-a]pyrimidine
INVENTOR(S): Kellog, Henry B.
PATENT ASSIGNEE(S): General Aniline & Film Corp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2569418		19510925	US 1948-37974	19480709 <--

AB Azo dyes are prepared by coupling 1-substituted 1,3-dihydro-2,5-diketo-7-methylpyrimidopyrazoles (1-substituted 1,3-dihydro-2,5-diketo-7-methylpyrazolo-[2,3-a]pyrimidine) with any diazotized amine. Thus, 1-phenyl-1,3-dihydro-2,5-diketo-3-(o-methoxyphenylazo)-7- methylpyrimidopyrazole was prepared by mixing 0.6 g. of o-anisidine, 10 ml. H2O, 20 g. of ice, and 5 ml. of 6 N HCl, diazotizing with a solution of 0.4 g. of NaNO2 in 5 ml. H2O, and adding this mixture to a solution of 1.2 g. of 1-phenyl-1,3-di-hydro-2,5-diketo-7-methylpyrimidopyrazole in 10 ml. of MeOH. Nine ml. of 6 N NaOH solution were added, the solid which separated was filtered off and washed with H2O. In like manner 1-(p-tolyl)-1,3-dihydro- 2,5-diketo-3-(p-methylphenylazo)-7-methylpyrimidopyrazole, 1-(2-quinolyl)-1,3-dihydro-2,5-diketo-3-(6-ethoxy-2-benzothiazolylazo)-7- methylpyrimidopyrazole, p,p'-bis(1,7-dimethyl-1,3-dihydro-2,5- diketopyrimidopyrazolyl-3-azo)stilbene, and 1-methyl-1,3-dihydro-2,5- diketo-3-(o-methoxyphenylazo)-7-methylpyrimidopyrazole were prepared. These dyes, both water soluble and water insol., may be used in the Ag dye bleach color process where dye images are formed by selective destruction of the dyes in the presence of Ag images, and as filter and antihalation dyes. Since these dyes contain an azo substituent in the reactive coupling position of the pyrimido-pyrazole nucleus, they will react in color forming development with the oxidation product of the developer to form colored images.

IT 857989-38-9P, Pyrazolo[1,5-a]pyrimidine-2,5(1H,3H)dione, 3-(6-ethoxy-2-benzothiazolylazo)-7-methyl-1-(2-quinolyl)-
RL: PREP (Preparation)
(preparation of)

RN 857989-38-9 ZCAPLUS

CN Pyrazolo[1,5-a]pyrimidine-2,5(1H,3H)dione, 3-(6-ethoxy-2-benzothiazolylazo)-7-methyl-1-(2-quinolyl)- (5CI) (CA INDEX NAME)



L67 ANSWER 64 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1939:17167 ZCAPLUS Full-text

DOCUMENT NUMBER: 33:17167

ORIGINAL REFERENCE NO.: 33:2524a-i

TITLE: Preparation of simple cyanines

AUTHOR(S): Beilenson, Bernard; Hamer, Frances M.

SOURCE: Journal of the Chemical Society (1939) 143-51
CODEN: JCSOA9; ISSN: 0368-1769

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB A critical review is given of the known methods for preparing monomethinecyanines. The present study deals mostly with the method covered by Kendall's British patents 424,559 (C. A. 29, 4596.6) and 425,609 (C. A. 29, 5670.9.) 2-Thiolquinoline (I) and 2 mols. Me2SO4 in 5% NaOH give 56% of 2-methylthiolquinoline (II), b22 182-3°, m. 55°; I and Et2SO4 give 78% of the 2-

Et analog (III), pale yellow oil, b26 177-8°. II and MeI, heated at 100° for 24 hrs., give 87% of II.MeI, m. 193°; II metho-p-toluenesulfonate, m. 160° (25% yield). II reacts abnormally with EtI (100° for 24 hrs.) and gives III.MeI, m. 185° (decomposition), which also results from III and MeI (100° for 2 days). III.EtI, canary-yellow, m. 165° (decomposition), 49%. III etho-p-toluenesulfonate, m. 116°, 68%. II.MeI or III.MeI, 2-aminoquinoline.EtI and K2CO3 in EtOH, refluxed 3 hrs., give 31% of 1-methyl-1'-ethyl-2,2'-azacyanine iodide [(1-methyl-2-quinoline) 1-ethyl-2-quinoline)azamethinecyanine iodide)], m. 235° (decomposition). II.MeI, 2-aminoquinoline.MeI and K2CO3 in EtOH, refluxed 1 hr., give 43% of 1,1'-dimethyl-2,2'-azacyanine iodide, bright yellow, m. 273-5° (decomposition). 1-Methylthiolbenzothiazole (IV) yields 75% of a methiodide, bright yellow, m. 146° (decomposition); ethiodide (V), pale yellow, m. 135-7° (decomposition), 61%. 1-Ethylthiolbenzothiazole.EtI, m. 95-6°, 33%. V and 1-methyl-α-naphthathiazole.EtI with K2CO3 in EtOH, refluxed 20 min., give 75% of 2,2'-diethyl-5,6-benzothiacyanine iodide [(2-ethyl-1-benzothiazole) (2-ethyl-5,6-benzo-1-benzothiazole)methinecyanineiodide], canary-yellow, m. 299° (decomposition); 1-methylbenzoselenazole.EtI and V give 65% of 2,2'-diethylselenathiacyanine iodide [(2-ethyl-1- benzothiazole) (2-ethyl-5,6-benzo-1-benzoselenazole)methinecyanine iodide], bright yellow, m. 284° (decomposition); 2-methyl-β- naphthoxazole.EtI gives 17% of 2,2'-diethyl-3,4-benzoxathiacyanine iodide [(2-ethyl-3,4-benzo-1-benzoxazole) (2-ethyl-1-benzothiazole)methinecyanine iodide], m. 288° (decomposition). IV, 1-methyl-α-naphthoxazole and p-MeC6H4SO3Et, heated at 160° for 3.5 hrs., treated with K2CO3 and heated 15 min., and then with KI, give 28% of 2,2'-diethyl-5,6-benzoxathiacyanine iodide [(2-ethyl-5,6-benzo-1-benzoxazole) (2-ethyl-1-benzothiazole)methinecyanine iodide], bright yellow, m. 278° (decomposition). 1-Thiolbenzoxazole and 2 moles of Me2SO4 give 80% of the 1-Me derivative (VI), b21 139-41°; 2-thiol-β-naphthoxazole gives 45% of the 2-Me derivative (VII), amber, b2 214°, b18 225°, m. 73°; 1-methylthiol-α-naphthoxazole (VIII), b9 222-30°, m. 64°, 50% yield. VI, lepidine and p-MeC6H4SO3Et, heated 3.5 hrs. at 150-60°, followed by KI, give 11% of 2,1'-diethyloxa-4'-cyanine iodide [(1-ethyl-4-quinoline) (2-ethyl-1-benzoxazole)methinecyanine iodide] m. 233° (decomposition); VII and β-naphthaquinaldine, as above, give 15% of 2,1'-diethyl-5,6,5',6'-dibenzoxa-2'-cyanine iodide [(1-ethyl-5,6-benzo-2-quinoline) (2-ethyl-5,6-benzo-1-benzoxazole)methinecyanine iodide], m. 288° (decomposition); VIII and MeI, heated at 100° for 2 days, give 78% of 2-thio-1-methyl-1,2-dihydro-β-naphthoxazole (IX), m. 185-7°; VII and MeI give 63% of 1-thio-2-methyl-1,2-dihydro-α- naphthoxazole, m. 226°, solubility in MeOH less than 1 g. per 500 cc.; 2-Et analog, with EtI, m. 215°, 32% yield. VI and MeI give 1-thio-2-methyl-1,2-dihydrobenzoxazole, m. 133°, 28% yield. IX, 1-methylbenzothiazole (X) and p-MeC6H4SO3Me, heated for 1 hr. at 150°, give 58% of 2,2'-dimethyl-3,4-benzoxathiacyanine p-toluenesulfonate[(2-methyl-3,4-benzo-1-benzoxazole) (2-methyl-1- benzothiazole)methinecyanine p-toluenesulfonate], m. 262° (decomposition). 2-Thio-1-methyl-1,2-dihydroquinoline and p-MeC6H4SO3Me, heated 1 hr. at 150°, give 62% of the salt, m. 160-1°; heating this salt with X.MeI and K2CO3 in EtOH for 3 min. gives 65% of 2,1'-dimethylthia-2'-cyanine iodide.

IT 99870-55-0P, Quinolinium, 1-methyl-2-(1-methyl-2(1)-quinolylideneamino)-, iodide 855871-71-5P, Quinolinium, 1-ethyl-2-(1-methyl-2(1)-quinolylideneamino)-, iodide
RL: PREP (Preparation)
(preparation of)

RN 99870-55-0 ZCAPLUS

CN 1-Methyl-2-[(1-methyl-2(1H)-quinolylidene)amino]quinolinium iodide (7CI) (CA INDEX NAME)



RN 855871-71-5 ZCAPLUS
CN Quinolinium, 1-ethyl-2-(1-methyl-2(1)-quinolylideneamino)-, iodide (4CI) (CA INDEX NAME)



L67 ANSWER 65 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1924:20150 ZCAPLUS Full-text
DOCUMENT NUMBER: 18:20150
ORIGINAL REFERENCE NO.: 18:2707h-i,2708a-d
TITLE: Synthesis of an azocyamine
AUTHOR(S): Hamer, Frances M.
SOURCE: Journal of the Chemical Society, Transactions (1924), 125, 1348-57
CODEN: JCHTA3; ISSN: 0368-1645
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB 4-Cyanoquinoline, m. 103-4° (not 95° as reported by Meyer, Monatsh. 23, 897). Hydrolysis with boiling 70% H_2SO_4 for 1 hr. gives a 76% yield of cinchonic acid. 2-Aminoquinoline (I), m. 131.5°, is obtained in 76% yield by gradually adding 5 g. quinaldinamide to a 100 cc. of a solution of HBrO (4.65 g. Br and 8 g. KOH) and boiling 10 min. Condensation of 4 g. I and 5 g. 2-chloroquinoline by heating 8 hrs. in a sealed tube at 240-60° gave 60% of 2,2'-diquinolylamine (II) (cf. Diepolder, C. A. 17, 3877), which exists in 2 forms, straw-colored needles, m. 151-4° to a cloudy drop which clears at 168-9°, and compact orange crystals, m. 170°; conversion of the former into the latter occurs on heating at 140-50°. The former is the more soluble and crysts. from concentrated solns. quickly cooled. The mono-HCl salt is bright yellow, does not m. 300°; the mono-HI salt is pale yellow, does not m. 300°; the dinitrate pale yellow, m. about 240° (decomposition). The action of MeI upon II gives a mixture of the HI salt, and the methiodide (III), of V, m. 278°. The Ac derivative of II, m. 192-3°, is obtained in 74% yield; the

dimethosulfate (IV), m. indefinitely, depending on the rate of heating and is stable towards concentrated HCl or 70% H_2SO_4; the monomethiodide, orange, m. about 260°. IV in hot, very dilute H_2SO_4, poured into an excess of ice-cold 10% NaOH gives 1-methyldihydroquinolenyl-2-quinolyl-2'-imine (V), canary-yellow, m. 116°. V in hot EtOH acidified with HI gives 2,2'-diquinolylamine methiodide, yellow, m. indefinitely, which with 10% NaOH yields V. The action of HCl on V gives the corresponding methochloride, pale yellow, m. 110-25°. V, heated with MeI in a sealed tube at 100° for 24 hrs., gives III, also termed 1,1'-dimethyl-2,2'-azocyanine iodide, usually obtained as a mixture of yellow with orange crystals showing a blue reflex. The yellow form is monoclinic, holohedral, a:b:c = 1.897:1:1.0913; β 129° 8'. The absorption spectrum (same for both forms) has 3 very narrow bands, with maximum at λ 4240, 4020 and 2850, where the mol. extinction coefficient e is 80,000, 70,000 and 40,000 resp. Absorption spectra were also examined for p-dimethylaminobenzylidenequinaldine-EtI (1 band, 5320), the p-dimethylaminoanil of quinaldinaldehyde-EtI (1 band 5680), p-dimethylaminobenzylidene-β-naphthaquinaldine-EtI (1 band, 5250) and the p-dimethylaminoanil of β-naphthoquinaldinaldehyde-EtI (1 band, 5600). If the linking is by a :CH- group, the substance is a photographic sensitizer, but if by a :N- atom, it possesses desensitizing properties.

IT 28532-41-4P, Quinoline, 1,2-dihydro-1-methyl-2-(2-quinolylimino)-
879663-81-7P, Quinoline, 1,2-dihydro-1-methyl-2-(2-quinolylimino)-
, methiodide
RL: PREP (Preparation)
(preparation of)

RN 28532-41-4 ZCAPLUS
CN Quinoline, 1,2-dihydro-1-methyl-2-(2-quinolylimino)- (8CI) (CA INDEX NAME)



RN 879663-81-7 ZCAPLUS
CN Quinoline, 1,2-dihydro-1-methyl-2-(2-quinolylimino)-, methiodide (2CI) (CA INDEX NAME)



L67 ANSWER 66 OF 66 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1923:25990 ZCAPLUS Full-text
DOCUMENT NUMBER: 17:25990

ORIGINAL REFERENCE NO.: 17:3877d-g
TITLE: Dipyridyl-, diquinolyl-, and pyridylquinolylamines
AUTHOR(S): Deuerlein, With E.
SOURCE: Journal fuer Praktische Chemie (Leipzig) (1923), 106, 53-65
CODEN: JPCEAO; ISSN: 0021-8383
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB Dipyridylamine (C. A. 17, 3261) is conveniently isolated by concentrating the steam distillate, after adding HCl, and liberating the base with NH3- HgCl2-HCl salt, C10H10N3Cl3Hg, sinters 113°, m.,225°. Methiodide, yellow, m. 288-91°. 2-Aminoquinoline is readily prepared by heating the Cl derivative with 5 parts ZnCl2-NH4OH and some NH4Cl in a tube at 210° for 8 hrs. Above 220° considerable amts. of carbostyril is obtained. Heating the 2-Cl and 2-NH2 derivs. with BaO 8 hrs. at 200-210° gives diguinolylamine, pale yellow, m. 161°. HCl salt, does not m. 305°. AuCl3 salt, orange-yellow, sinters 261°, m. 306°. HgCl2 salt, pale yellow, m. 272°. Monopicrate, yellow, m. 286° (decomposition). Dipicrate, yellow, m. 297° (decomposition). Nitrosamine, pale yellow, m. 238° (decomposition). Methiodide, yellow, sinters 246°, m. 278°. 4,4'Dimethyldiquino-lylamine, canary-yellow, m. 167.5°. HCl salt, pale yellow; m. 292-7°. HgCl2 salt, m. 249°. Chloroplatinate, pale yellow, m. 280° (decomposition). Monopicrate, yellow, decompose 286-299°. Dipicrate, dark yellow, darkens 265°, decomps. 289°. Nitrosoamine, pale yellow, decomps. 238°. Methiodide, yellow, darkens 245°, m. 290°. Pyri- dylquinolylamine, pale yellow, m. 108°. HCl salt, yellow, decomps. 215-6°. Monopicrate, darkens 223°, m. 242-4°. HgCl2: salt of base, pale yellow, m. 210°. HgCl2-HCl salt, pale yellow, m. 245°. Methiodide, light yellow, m. 208°. Pyridyl-4-methylquinolylamine, pale yellow, sinters 158°, m. 174°. HCl salt, darkens 190°, m. 241°. Methiodide, bright yellow, m. 208°. 4-Methyldiquinolylamine, yellow, m. 129°. HCl salt, pale yellow, m. 275° (decomposition). Monopicrate, yellow, sinters 279°, decompose 287°. Methiodide, yellow, darkens 217°, m. 247-53° (decomposition).

IT 861368-74-3P, Quinoline, 1,2-dihydro-1-nitroso-2-(2-quinolylimino)-
861385-70-8P, Quinoline, 1,2-dihydro-4-methyl-2-(4-methyl-2-quinolylimino)-1-nitroso-
RL: PREP (Preparation)
(preparation of)

RN 861368-74-3 ZCAPLUS
CN Quinoline, 1,2-dihydro-1-nitroso-2-(2-quinolylimino)- (2CI) (CA INDEX NAME)



RN 861385-70-8 ZCAPLUS
CN Quinoline, 1,2-dihydro-4-methyl-2-(4-methyl-2-quinolylimino)-1-nitroso- (2CI) (CA INDEX NAME)


NO
N
N
N
Me
Me

```
=>  d his full

     (FILE 'HOME' ENTERED AT 11:41:35 ON 19 FEB 2008)

     FILE 'REGISTRY' ENTERED AT 11:41:48 ON 19 FEB 2008

     FILE 'STNGUIDE' ENTERED AT 11:41:59 ON 19 FEB 2008

     FILE 'ZCAPLUS' ENTERED AT 11:42:38 ON 19 FEB 2008
                  E US2006-596994/APPS
L1             1 SEA ABB=ON  PLU=ON  US2006-596994/AP
                  D SCA
                  SEL RN

     FILE 'REGISTRY' ENTERED AT 11:43:07 ON 19 FEB 2008
L2           196 SEA ABB=ON  PLU=ON  (100-46-9/BI OR 1000417-94-6/BI OR
                  1000490-56-1/BI OR 10102-94-0/BI OR 106792-38-5/BI OR 1192-58-1
                  /BI OR 1215-59-4/BI OR 131237-81-5/BI OR 132706-12-8/BI OR
                  13523-92-7/BI OR 13669-42-6/BI OR 141-82-2/BI OR 141-97-9/BI
                  OR 143679-80-5/BI OR 147-71-7/BI OR 154737-90-3/BI OR 156496-64
                  -9/BI OR 1578-96-7/BI OR 15861-36-6/BI OR 171919-36-1/BI OR
                  17380-18-6/BI OR 175202-93-4/BI OR 175204-81-6/BI OR 1810-72-6/
                  BI OR 18529-12-9/BI OR 19012-03-4/BI OR 1953-54-4/BI OR
                  20507-53-3/BI OR 233-88-5/BI OR 2338-71-8/BI OR 238756-47-3/BI
                  OR 238756-48-4/BI OR 2388-32-1/BI OR 25016-12-0/BI OR 25233-47-
                  0/BI OR 271-29-4/BI OR 271-63-6/BI OR 271241-24-8/BI OR
                  271241-25-9/BI OR 272-49-1/BI OR 27257-15-4/BI OR 274-76-0/BI
                  OR 27421-51-8/BI OR 27643-15-8/BI OR 276862-85-2/BI OR
                  29969-57-1/BI OR 30198-01-7/BI OR 3385-21-5/BI OR 349447-08-1/B
                  I OR 371-40-4/BI OR 372-19-0/BI OR 3779-27-9/BI OR 4002-83-9/BI
                   OR 40053-37-0/BI OR 406204-74-8/BI OR 43192-31-0/BI OR
                  439095-43-9/BI OR 441715-30-6/BI OR 444683-23-2/BI OR 455-14-1/
                  BI OR 477848-00-3/BI OR 477886-95-6/BI OR 482585-36-4/BI OR
                  498-62-4/BI OR 501-53-1/BI OR 50634-05-4/BI OR 50890-83-0/BI
                  OR 5170-68-3/BI OR 52173-35-0/BI OR 52606-02-7/BI OR 52771-21-8
                  /BI OR 536-90-3/BI OR 541-41-3/BI OR 542-92-7/BI OR 5467-57-2/B
                  I OR 5652-13-1/BI OR 58630-07-2/BI OR 6041-50-5/BI OR 6188-43-8
                  /BI OR 6340-55-2/BI OR 636-61-3/BI OR 645400-43-7/BI OR
                  645400-44-8/BI OR 645400-49-3/BI OR 645400-50-6/BI OR 67509-84-
                  6/BI OR 67999-51-3/BI OR 6953-22-6/BI OR 703-61-7/BI OR
                  79-44-7/BI OR 79200-56-9/BI OR 814-68-6/BI OR 827-01-0/BI OR
                  83783-33-9/BI OR 860296-28-2/BI OR 860296-29-3/BI OR 860296-30-
                  6/BI OR 860296-31-7/BI OR 860296-32-8/BI OR 860296-33-9/BI OR
                  860296-34-0/BI OR 860296-35-1/BI OR 860296-37-3/BI OR 860296-39
                  -5/BI OR 860296-41-9/BI OR 860296-42-0/BI OR 860

     FILE 'STNGUIDE' ENTERED AT 11:50:06 ON 19 FEB 2008

     FILE 'REGISTRY' ENTERED AT 12:02:49 ON 19 FEB 2008
L3                STRUCTURE UPLOADED
L4             50 SEA SSS SAM L3
L5                STRUCTURE UPLOADED
L6             50 SEA SSS SAM L3 AND L5
                  D STAT QUE L6
                  D STAT QUE
L7           8933 SEA SSS FUL L3 AND L5
                  SAVE TEMP CHA9943L5L/A L7
L8                STRUCTURE UPLOADED
```

```
L9           50 SEA SUB=L7 SSS SAM L8
L10        3365 SEA SUB=L7 SSS FUL L8
L11           9 SEA ABB=ON  PLU=ON  C27 H34 N6 S/MF
L12           3 SEA ABB=ON  PLU=ON  L10 AND L11
                D RSD 1
                D SCA
                D RSD 2
L13      489184 SEA ABB=ON  PLU=ON  591.79.52/RID
L14       17611 SEA ABB=ON  PLU=ON  >1 591.79.52/RID
L15         119 SEA ABB=ON  PLU=ON  L7 AND L14
L16          32 SEA ABB=ON  PLU=ON  L15 AND L10
                D SCA
L17        5568 SEA ABB=ON  PLU=ON  L7 NOT L10
L18             STRUCTURE UPLOADED
L19          50 SEA SUB=L7 SSS SAM L18
L20        3929 SEA SUB=L7 SSS FUL L18
                SAVE TEMP L20 CHA994STR18L/A
L21        2293 SEA ABB=ON  PLU=ON  L20 NOT L10

     FILE 'ZCAPLUS' ENTERED AT 13:09:25 ON 19 FEB 2008
L22         284 SEA ABB=ON  PLU=ON  L21
L23             ANALYZE PLU=ON  L22 1- RN HIT :    1953 TERMS
                D

     FILE 'REGISTRY' ENTERED AT 13:10:49 ON 19 FEB 2008
L24          39 SEA ABB=ON  PLU=ON  L21 AND L2

     FILE 'ZCAPLUS' ENTERED AT 13:11:20 ON 19 FEB 2008
L25           2 SEA ABB=ON  PLU=ON  L24

     FILE 'REGISTRY' ENTERED AT 13:11:49 ON 19 FEB 2008
L26          62 SEA ABB=ON  PLU=ON  L7 AND L2
L27          23 SEA ABB=ON  PLU=ON  L26 NOT L24
                D SCA

     FILE 'ZCAPLUS' ENTERED AT 13:12:57 ON 19 FEB 2008
L28           2 SEA ABB=ON  PLU=ON  L27

     FILE 'REGISTRY' ENTERED AT 13:13:20 ON 19 FEB 2008
L29             STRUCTURE UPLOADED
L30          50 SEA SUB=L7 SSS SAM L29
L31        1356 SEA SUB=L7 SSS FUL L29
                SAVE TEMP L31 CHA994STR29L/A

     FILE 'ZCAPLUS' ENTERED AT 13:50:02 ON 19 FEB 2008
L32          85 SEA ABB=ON  PLU=ON  L31
L33          17 SEA ABB=ON  PLU=ON  MCH ANTAGONIST/TI
L34           4 SEA ABB=ON  PLU=ON  L32 AND L33
                D SCA

     FILE 'REGISTRY' ENTERED AT 13:54:08 ON 19 FEB 2008
L35        1356 SEA ABB=ON  PLU=ON  L31 NOT L10

     FILE 'ZCAPLUS' ENTERED AT 13:56:53 ON 19 FEB 2008
L36             TRA PLU=ON  L34 1- RN :    3820 TERMS

     FILE 'REGISTRY' ENTERED AT 13:56:56 ON 19 FEB 2008
L37        3820 SEA ABB=ON  PLU=ON  L36
L38        1043 SEA ABB=ON  PLU=ON  L37 AND L31
L39         313 SEA ABB=ON  PLU=ON  L31 NOT L38
```

```
     FILE 'ZCAPLUS' ENTERED AT 13:57:30 ON 19 FEB 2008
L40            4 SEA ABB=ON  PLU=ON  L38
L41           81 SEA ABB=ON  PLU=ON  L39
L42           42 SEA ABB=ON  PLU=ON  L32 AND P/DT
L43           43 SEA ABB=ON  PLU=ON  L32 NOT L42
L44           36 SEA ABB=ON  PLU=ON  L43 AND PY<2005
L*** DEL      33 S L43 AND PY<2004
L45           25 SEA ABB=ON  PLU=ON  L42 AND PD<20040107
L46           33 SEA ABB=ON  PLU=ON  L42 AND PRD<20040107
L47           27 SEA ABB=ON  PLU=ON  L42 AND AD<20040107
L48           70 SEA ABB=ON  PLU=ON  (L44 OR L45 OR L46 OR L47)
L49           67 SEA ABB=ON  PLU=ON  L41 AND L48
L50            3 SEA ABB=ON  PLU=ON  L40 AND L48
L51            4 SEA ABB=ON  PLU=ON  EVERTSSON E?/AU
L52           34 SEA ABB=ON  PLU=ON  INGHARDT T?/AU
L53          536 SEA ABB=ON  PLU=ON  LINDBERG J?/AU
L54           23 SEA ABB=ON  PLU=ON  LINUSSON A?/AU
L55           30 SEA ABB=ON  PLU=ON  GIORDANETTO F?/AU
L56            3 SEA ABB=ON  PLU=ON  L51 AND (L52 OR L53 OR L54 OR L55)
L57           10 SEA ABB=ON  PLU=ON  L52 AND (L53 OR L54 OR L55)
L58            4 SEA ABB=ON  PLU=ON  L53 AND (L54 OR L55)
L59            2 SEA ABB=ON  PLU=ON  L54 AND L55
L60           10 SEA ABB=ON  PLU=ON  (L56 OR L57 OR L58 OR L59)
L61            2 SEA ABB=ON  PLU=ON  (L51 OR L52 OR L53 OR L54 OR L55) AND L25
L62            0 SEA ABB=ON  PLU=ON  (L51 OR L52 OR L53 OR L54 OR L55) AND L50
L63            1 SEA ABB=ON  PLU=ON  (L51 OR L52 OR L53 OR L54 OR L55) AND L49

     FILE 'REGISTRY' ENTERED AT 14:03:30 ON 19 FEB 2008

     FILE 'CAPLUS' ENTERED AT 14:03:32 ON 19 FEB 2008

     FILE 'REGISTRY' ENTERED AT 14:03:58 ON 19 FEB 2008

     FILE 'ZCAPLUS' ENTERED AT 14:04:02 ON 19 FEB 2008
                D STAT QUE L60
                D STAT QUE L61
                D STAT QUE L63
L64           10 SEA ABB=ON  PLU=ON  L60 OR L61 OR L63
                D IBIB ABS HITSTR L64 1-10

     FILE 'REGISTRY' ENTERED AT 14:05:10 ON 19 FEB 2008

     FILE 'ZCAPLUS' ENTERED AT 14:05:16 ON 19 FEB 2008
                D STAT QUE L25
L65            0 SEA ABB=ON  PLU=ON  L25 NOT L64

     FILE 'REGISTRY' ENTERED AT 14:05:54 ON 19 FEB 2008

     FILE 'ZCAPLUS' ENTERED AT 14:05:59 ON 19 FEB 2008
                D STAT QUE L50
                D IBIB ABS HITIND FHITSTR L50 1-3

     FILE 'REGISTRY' ENTERED AT 14:08:04 ON 19 FEB 2008

     FILE 'ZCAPLUS' ENTERED AT 14:08:07 ON 19 FEB 2008
                D STAT QUE L49
L66           67 SEA ABB=ON  PLU=ON  L49 NOT (L50 OR L65)
L67           66 SEA ABB=ON  PLU=ON  L49 NOT (L50 OR L65 OR L64)
                D IBIB ABS HITSTR L67 1-66
```

FILE HOME

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 FEB 2008 HIGHEST RN 1004360-55-7
DICTIONARY FILE UPDATES: 18 FEB 2008 HIGHEST RN 1004360-55-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 15, 2008 (20080215/UP).

FILE ZCAPLUS

FILE COVERS 1907 - 19 Feb 2008 VOL 148 ISS 8
FILE LAST UPDATED: 18 Feb 2008 (20080218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE CAPLUS

FILE COVERS 1907 - 19 Feb 2008 VOL 148 ISS 8
FILE LAST UPDATED: 18 Feb 2008 (20080218/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=>